Health and Labour Sciences Research Grants 2015 Research on Regulatory Science of Pharamaceuticals and Medical Devices: (H27-Iyaku A-Ippan-001)

2015 Nationwide General Population Survey on Drug Use in Japan

Principal Investigator: Takuya SHIMANE Department of Drug Dependence Research, National Institute of Mental Health, National Center of Neurology and Psychiatry

March 2017

Annual Report 2015 Nationwide General Population Survey on Drug Use in Japan

Health and Labour Sciences Research Grants 2015 Research on Regulatory Science of Pharamaceuticals and Medical Devices H27-Iyaku A-Ippan-001

Annual Report of Ministry of Health, Labour and Welfare

2015 Nationwide General Population Survey on Drug Use in Japan

Principal Investigator: Takuya SHIMANE (National Center of Neurology and Psychiatry) Research Collaborators: Megumi OMAGARI (National Center of Neurology and Psychiatry), Kiyoshi WADA (Saitama Psychiatric Medical Center), and Dongmei QIU (National Center of Neurology and Psychiatry)

Abstract

[Objective] This survey was conducted to examine the current situation of drug use, including alcohol, tobacco, and medications, in Japan. The findings will be provided as basic data for a drug abuse prevention strategy. This survey is the only monitoring survey on drug use conducted for the general population in Japan. Since the first nationwide survey in 1995, this series of surveys has been conducted every other year, and this survey is the 11th one.

[Methods] A total of 5,000 individuals aged 15–64 years were sampled from the Basic Resident Register using a two-stage stratified random sampling method (number of survey spots: 350). A self-administered questionnaire (anonymous) was handed out to each individual selected and was then collected from September to October 2015. The study protocol was reviewed and approved by the Ethics Committee of the National Center of Neurology and Psychiatry.

[Results] The questionnaires were collected from a total of 3,085 respondents (response rate: 61.7%). The following findings were obtained from valid responses from a total of 3,076 individuals (52.3% of which were females, with a mean age of 43.3 years):

- The lifetime prevalence of new psychoactive substance (NPS) use decreased from 0.4% (2013) to 0.3% (2015), and the past-year prevalence decreased from 0.1% (2013) to 0% (2015).
- 2. The number of individuals in the population with lifetime use of NPSs decreased from approximately 400,000 (2013) to 310,000 (2015).
- 3. The proportion of respondents having knowledge of harmful effects of NPSs increased from 61.5% (2013) to 85.8% (2015), with 56.9% of respondents having knowledge of Japan's regulations for designated substances and measures to prevent NPS use.
- 4. The lifetime prevalence of drug use was 1.5% for organic solvents, 1.0% for cannabis, 0.5% for methamphetamine, 0.1% for MDMA, 0.1% for cocaine, 0.3% for NPSs, and 2.4% for any drug. The rate for heroin was within the range of statistical errors.
- The mean age of drug users was 47.9 years for organic solvents, 41.3 years for cannabis, 44.1 years for methamphetamine, 40.0 years for MDMA, 45.4 years for cocaine, 45.7 years for heroin, 40.8 years for NPSs, and 45.5 years for any drug.

- 6. The number of individuals in the population with lifetime drug use was approximately 1.38 million for organic solvents, 0.95 million for cannabis, 0.50 million for methamphetamine, 0.12 million for cocaine, 0.12 million for MDMA, and 0.31 million for NPSs. All these figures decreased from those of 2013.
- 7. In general, the number of individuals in the population who have ever had someone try to tempt them with illegal drugs was also decreasing, except for methamphetamine (increasing from approximately 0.93 million to 0.94 million) and MDMA (increasing from approximately 0.42 million to 0.58 million).
- The past-year prevalence of analgesic use increased from 34.3% (1995) to 62.9% (2015).
 The rate of chronic use of analgesics (≥3 times/week) increased from 1.6% (1999) to 2.5% (2015).
- 9. The past-year prevalence of hypnotic use increased between 1995 (4.0%) and 2007 (7.7%), followed by a decrease, and then by a re-increase in 2015 (6.1%). Similarly, the rate of chronic use of hypnotics reached its peak in 2007 (2.7%) and subsequently decreased in 2011 (1.9%), but it increased again in 2015 (2.9%).

[Discussion] The number of respondents with lifetime use of NPSs decreased, and the past-year prevalence of the use of such was 0%. Behind this may lie the expansion of designated substances (2,297 substances as of May 2015) and the reinforcement of regulations regarding such designated substances (including orders of scientific testing, sales suspension, and advertisement suspension), which eliminated shops and websites selling NPSs and led to reduced opportunities for obtaining NPSs. The social issue regarding NPSs is considered to be calming down. However, approximately 20% of respondents answered that NPSs are "available," suggesting the necessity of continuous measures to prevent NPS abuse.

Based on the estimated number of individuals in the population with lifetime drug use, the use of organic solvents, cannabis, methamphetamine, cocaine, and MDMA have all decreased from the 2013 survey. It should be noted, however, that the number of individuals in the population who have ever had someone try to tempt them with illegal drugs is increasing both for methamphetamine and MDMA.

A. Objective

As shown in the Fourth Five-Year Drug Abuse Prevention Strategy (2013), the annual number of persons arrested for methamphetamine-related crimes is more than 10,000, and the proportion of repeat methamphetamine offenders has been more than 60%. Also, as indicated in "Emergency Countermeasures to Eradicate New Psychoactive Substance Abuse (2014)," in recent years the widespread use of new psychoactive substances (NPSs) sold as "legal herbs" has been leading to the continual occurrence of crimes and serious fatal traffic accidents caused by abusers, posing a significant social problem.

As the issue of drug abuse is constantly in flux along with the times and with social change, measures against drug abuse should be in line with actual conditions. For this purpose, a monitoring survey to understand the actual circumstances of drug abuse and dependence over time is necessary. In addition, the fact where not only illegal drugs, including narcotics and methamphetamine, but also some medications are subject to abuse requires the monitoring of the use of medications as well as illegal drugs.

This survey is the only monitoring survey on drug use conducted on the general population in Japan. The history of general population surveys on drug use dates back to the 1990s. Such were Ichikawa conducted in City. Chiba Prefecture (n = 1,100) in 1992, in the Tokyo and Osaka areas (n = 3,000) in 1993, and in the Tokyo, Osaka, and Kita-Kyushu areas (n = 3,300) in 1994. This servey was conducted as the first nationwide survey in 1995, followed by surveys conducted every two years. To date, a total of 11 surveys, including this report, have been conducted.

The findings from the study will be provided as basic data for the drug abuse prevention strategy in Japan. They will also be useful for the evaluation of various drug abuse prevention strategies and the process of planning for future countermeasures. Furthermore, it should be emphasized that the study findings can be used as basic data for the consideration of the proper use of alcohol, tobacco, and medications.

When considering the trend of drug abuse in recent years, abuse of NPSs cannot be ignored. According to a Nationwide Mental Hospital Survey on Drugrelated Psychiatric Disorders (from September to October in 2014), among patients who had used any drug in the past one year, NPS abusers accounted for the largest portion. exceeding that of methamphetamine abusers. To deal with the social issue regarding NPSs, the scope of designated substances was expanded (2,297 substances as of May 2015), and the minister of the Ministry of Health, Labour and Welfare and prefectural governors were granted the right to issue orders for scientific testing and the suspension of sales and/or advertisement to manufacturers (revised in December 2014), under the Law on Securing Quality, Efficacy and Safety of Products Including Pharmaceuticals and Medical Devices (the former Pharmaceutical Law).

These measures have led to the elimination of NPS dealers, and it is expected that the number of NPS abusers is decreasing. Yet, no evidence of such a decrease in abusers has been obtained. In this report, we particularly focused on the trend of NPS abuse. B. Methods

1. Target population and sampling

Sample size: 5,000 individuals (number of survey spots: 350)

Sampling method: Two-stage stratified random sampling method

Duration of survey: From September 10 to October 4, 2015

Sampling: In this study, a total of 5,000 individuals aged 15–64 years living in Japan were sampled using a two-stage stratified random sampling method. The sampling method is outlined as follows.

1) All 47 prefectures of Japan were divided into the following 11 geographic areas:

- ① Hokkaido area: Hokkaido
- ② Tohoku area: Aomori, Iwate, Miyagi, Akita, Yamagata, and Fukushima
- ③ Kanto area: Ibaraki, Tochigi, Gunma, Saitama, Chiba, Tokyo, and Kanagawa
- ④ Hokuriku area: Niigata, Toyama, Ishikawa, and Fukui
- (5) Tousan area: Yamanashi, Nagano, and Gifu
- (6) Tokai area: Shizuoka, Aichi, and Mie
- ⑦ Kinki area: Shiga, Kyoto, Osaka, Hyogo, Nara, and Wakayama
- (8) Chugoku area: Tottori, Shimane, Okayama, Hiroshima, and Yamaguchi
- (9) Shikoku area: Tokushima, Kagawa, Ehime, and Kochi
- 10 Kita-Kyushu area: Fukuoka, Saga, Nagasaki, and Oita
- Minami-Kyushu area: Kumamoto, Miyazaki, Kagoshima, and Okinawa

2) Each of the 11 areas was further stratified into five community sizes with a total of 65 strata (Table A).

 Large cities: 23 wards of Tokyo metropolitan, Yokohama City, Kawasaki City, Kyoto City, Chiba City, Nagoya City, Osaka City, Saitama City, Shizuoka City, Kobe City, Hiroshima City, Kita-Kyushu City, and other ordinance-designated cities (a total of 21 strata)

- ② Cities with a population of ≥0.2 million (11 strata in total)
- ③ Cities with a population of ≥0.1 million (11 strata in total)
- ④ Cities with a population of <0.1 million (11 strata in total)
- (5) Suburban districts (11 strata)

A "city" refers to a geographical area as per the implementation of the granting of city status as of April 1, 2015. The classification of community sizes based on population size was performed according to the *Basic Resident Register Population Handbook* based on the Basic Resident Register as of January 1, 2014 (population of individuals aged 15–64 years: 80,038,406).

3) The 5,000 individuals sampled were distributed to each of the above 65 strata proportional to the population density so as to have 10–16 samples per survey spot.

4) The survey spots selected to conduct the 2010 National Census were used as a primary sampling unit, and survey spots (enumeration districts) were selected according to the following procedures.

- If the number of survey spots (enumeration districts) within each stratum was 1, one spot was randomly selected using a random number table.
- If the number of survey spots (enumeration districts) was ≥2, the sampling interval was calculated, and survey spots (enumeration districts) were randomly selected using equal-interval sampling. The procedure of selecting survey spots (enumeration districts) is referred to as the "first

stage."

Sampling interval = (Sum of the population aged 15–64 years for each stratum at the time of conducting the national census) / (Number of survey spots calculated for each stratum)

5) During the selection of survey spots, the sequence of municipalities was arranged within each stratum according to the municipality codes used for the conduct of the 2010 National Census.

6) After calculating the sampling interval, the target population for each survey spot (enumeration district) was randomly selected from the Basic Resident Register or the pollbook using equal-interval sampling. The procedure of selecting the target population from each survey spot (enumeration district) is referred to as the "second stage."

Sampling interval = (Population aged 15– 64 years for each survey spot at the time of conducting the national census) / (Number of samples selected from each enumeration district for each stratum)

2. Methods of survey and ethical considerations

Each individual selected using the above-mentioned procedures was informed of the conduct of the survey in advance via postcard. Trained staffs visited each individual in his/her home to explain the survey both in writing and orally. When there was more than one member in a household. staff made the direct explanation to the subject. After obtaining consent, the staff selected the date and time for the collection of the questionnaire with the individual, and gave him/her an envelope containing the questionnaire and a ballpoint pen. A few days later, the staff collected the questionnaire. Before being collected, the envelope was to be sealed by the respondent to ensure that the staff was unable to see the content during the collection. If the respondent and his/her family were not home at the time of visit, the staff left a notice in the mailbox and came back at different days and times.

The questionnaire was to be anonymous self-administered, containing and no personally identifiable questions. It included a description to explain that the subject can voluntarily choose whether to respond to the survey or not. The study protocol was reviewed and approved by the Ethics Committee of the National Center of Neurology and Psychiatry (approval number: A2014-149).

3. Survey items

The survey items consisted of the following four parts.

1) Basic demographics: Sex, age, occupation, final academic background, time spent on the Internet, etc.

2) Acohol and/or tobacco use: Lifetime use, age of first use, past-year use, past 30-day use, etc.

3) Medications: Past-year use of analgesics, tranquilizers, and/or hypnotics; how obtained; reason for use; past 30-day use (name of the medications used); etc.

4) Drug use: Knowledge on and/or perception of drug abuse/dependence, presence or absence of peer abusers, accessibility (on a scale of four levels from "completely inaccessible" to "easily accessible"), experience of having someone try to tempt them with drugs, use experience, type of the NPS used (e.g., herbal), hospital visit associated with NPS use, etc. 4. Statistical analysis

Statistical analysis consisted of the following 12 parts.

1) Prevalence of drug use: For each drug, the prevalence was calculated for lifetime use, experience of having someone try to tempt them with the drug, accessibility, and the presence of peer drug users. Of the four response categories on the Likert scale for accessibility, responses of "barely accessible" and "easily accessible" were reclassified as "accessible." The prevalence was also calculated for analgesics, tranquilizers, hypnotics, and alcohol and/or tobacco use (Tables 1–6)

2) Cross tabulation for basic demographics (Tables 7–11)

3) Cross tabulation for alcohol and/or tobacco use (Tables 12–16)

4) Cross tabulation for the medications use (Tables 17–21)

5) Cross tabulation for analgesic use (Tables 22–26)

6) Cross tabulation for tranquilizer use (Tables 27–31)

7) Cross tabulation for hypnotic use (Tables 32–36)

8) Cross tabulation for knowledge on and/or perception of drug abuse (Tables 37–41)

9) Cross tabulation for NPSs use (Tables 42–46)

10) Cross tabulation for presence of peer drug users and the experience of having someone try to tempt them with drugs (Tables 47–51)

11) Cross tabulation for drug accessibility (Tables 52–56)

12) Cross tabulation for drug use experience (Tables57–61)

13) Monitoring of trend changes (Figures

2-33 and Tables 62-69)

In the cross tabulation for the above-mentioned items 2-12.cross tabulation with each item was conducted in terms of residence area (11 areas), sex, age group (15 to 64 [here in after, "teens" refers to those aged 15 to 19, and "60s" refers to those aged 60 to 64]), occupation (seven categories), and drug use experience (yes/no). For the detection of significant differences, Pearson's chi-square test was used for categorical variables, and a t-test and one-way analysis of variance (ANOVA) were used for a two-group and a three or more-group comparisons of continuous variables, respectively. For items such as lifetime prevalence, estimates (point and interval estimates), which were adjusted based on the total number of survey spots included in each stratum and in the population aged 15 years or older in each survey spot, were calculated. In the text, tables, and figures included in the report, these figures are shown as "estimates" as applicable.

C. Results

1. Response rate

Valid questionnaires were collected from 3,085 out of 5,000 targeted individuals (response rate: 61.7%). There were 1,915 individuals who did not respond to the survey. Overall, the most common reason for not responding to the survey was refusal (45.8%), followed by temporary absence (31.3%), and change of home address (10.9%).

The reasons for not responding to the survey are shown in Table B by sex. The proportion of individuals who refused to respond (refusal rate) was higher in women (49.1%) than in men (42.9%), and the

proportion of those who have changed address was higher in men (13.2%) than in women (8.2%). The reasons for not responding to the survey are shown in Table C by age group. The proportion of individuals who refused to respond (refusal rate) was highest in those in their 60s (63.2%) among all age groups, and such proportion was lowest in those in their 20s (31.5%). The proportion of individuals who were temporarily absent was highest in those in their 20s (38.7%) and lowest in those in their 60s (18.9%). Also, the proportion of individuals who have changed address was highest in those in their 20s (18.1%) and lowest in people in their 60s (5.7%). The reasons for not responding to the survey are shown in by geographic Table D area. The proportions of individuals who refused to respond (refusal rate) were high in those from the Hokuriku (61.2%) and Tokai (58.7%) areas, and such proportions were low in individuals from the Shikoku (35.0%) and Tousan (35.7%) areas. The proportions of individuals who were temporarily absent were high in those from the Kanto (37.2%), Tousan (35.7%), and Kinki (35.6%) areas, and such proportions were low in individuals from the Chugoku (14.6%) and Kita-Kyushu (17.2%) areas.

Figure 1 shows the change in response rate (1995–2015). In 1995, when the study was initiated, the response rate was 78.9%. It stayed in the 70% range until 2003, but decreased to the 60% range after 2005. In 2007 and 2013, the response rate further decreased to the 50% range, but it returned to the 60% range in this survey.

Responses were considered valid if the respondent answered to at least 40 out of a total of 76 questions. A total of 3,076

respondents met these criteria and were thus included in the analysis population of the study. The questionnaire contains 52 questions (Questions 1–52). If questions asked for each type of drugs (Questions 47– 50) are considered independent questions, however, the total number of questions will be 76.

2. Basic demographics

results regarding The the basic demographics of the respondents are presented in Tables 7-11. Responses were obtained from all 47 prefectures of Japan, with the highest proportion of responses being obtained from the Kanto area (30.8%). Of all the respondents, 52.3% and 47.7% were women and men, respectively, and the mean age was 43.3 years. The most common age group was 40s (24.4%), followed by 50s (22.6%) and 30s (18.0%). The most common occupation was "full-time employee" (45.7%), followed by "housewife" (14.2%) and "non-full-time employee" (12.8%). The most common final academic background was "high school" (38.6%),followed by "junior college/university" (30.2%) and "vocational school" (13.2%). The most common cellular phone owned was "smartphone" (68.1%), with only 2.7% of respondents having no cellular phone. Time spent on the Internet (not for work) given by the highest proportion of respondents was <1 hour (25.6%), but some respondents spend ≥ 5 hours (13.8%).

3. Alcohol and/or tobacco use

The results regarding alcohol and/or tobacco use are presented in Tables 6 and 12–16. For alcohol use, the lifetime prevalence was 93.8%, the past-year

prevalence was 80.2%, and the past 30-day prevalence was 67.0% (all these figures past being estimates). The 30-day prevalence was high in the Minami-Kyushu area (70.9%) with the lowest in the Chugoku area (61.3%). The past 30-day prevalence was higher in men (75.0%) than in women (59.7%). The past 30-day prevalence was highest in those in their 20s (76.7%). By occupation, the said prevalence was highest in workers engaged in "self-employed business" (79.4%), and by classification by time spent on the Internet, the prevalence was highest in the group of "1 to <2 hours" (72.0%).

For tobacco use, the lifetime prevalence was 59.8%, the past-year prevalence was 26.2%, and the past 30-day prevalence was 23.2% (all these figures being estimates). The past 30-day prevalence was highest in the Hokkaido area (33.6%) and lowest in the Tousan area (21.3%). As with alcohol use, the past 30-day prevalence was higher in men (37.9%) than in women (11.8%). The past 30-day prevalence was highest in those in their 30s (29.1%). By occupation, as with alcohol use, the said prevalence was highest in workers engaged in "self-employed business" (36.3%), and by time spent on the Internet, the prevalence was highest in the group of "zero" (31.2%).

4. Medications use

The results regarding the use of household medicines and medications are presented in Tables 17–21. The most common household medicine was "cold medicine" (71.3%), followed by "gastrointestinal medicine" (55.6%) and "antipyretic analgesic" (55.3%). The most common medications used within the past year was "cold medicine" (64.7%), followed by "antipyretic analgesic" (63.0%) and "gastrointestinal medicine" (37.1%).

5. Analgesic use

The results regarding analgesic use are shown in Tables 5 and 22-26. For analgesics use, the past-year prevalence was 62.9%, the past 30-day prevalence was 26.9%, and the rate of chronic use (defined as ≥three times a week) was 2.3% (all these figures being estimates). The rate of chronic use was highest in the Shikoku area (4.5%) and low in the Hokkaido (1.5%)and Tokai (1.5%) areas. The said rate was higher in women (3.0%) than in men (2.0%). The age group with the highest rate was 60s (3.6%). For occupation, the rate was high in the groups of "other" (5.1%) and "housewife" (3.4%). By time spent on the Internet, the rate was highest in the group responding "zero" (3.3%).

The most common source of analgesics "pharmacies/drugstores" (39.3%).was followed by "clinics/hospitals" (25.7%) and "household medicines" (12.9%)."Friends/acquaintances" (0.9%)or "romantic partners" (0.1%) were not common. Common reasons for the use of analgesics included "headache" (39.5%) and "menstrual pain" (10.9%), and no respondent selected "recreation (pleasure)."

6. Tranquilizer use

The results regarding tranquilizer use are shown in Tables 5 and 27–31. For tranquilizer use, the past-year prevalence was 5.6%, the past 30-day prevalence was 4.2%, and the rate of chronic use (defined as \geq three times a week) was 3.0% (all these figures being estimates). The rate of chronic use was highest in the Shikoku area (5.7%) and low in the Hokuriku (1.3%) and Tousan (1.3%) areas. The rate of chronic use was higher in women (3.4%) than in men (2.8%). The rate was highest in the age group of 60s (4.0%). For occupation, the rate was highest in the group of "unemployed" (12.3%). By time spent on the Internet, the said rate was highest in the group of "zero" (5.1%).

The most common source of tranquilizers was "clinics/hospitals" (4.4%). "friends" (0.1%) was not common, and no respondent selected "romantic partners." The most common reason for the use of tranquilizers was "to eliminate anxiety" (3.2%), followed by "to improve insomnia" (2.2%) and "to reduce stress" (1.5%). Only one respondent selected "recreation (pleasure)" (0.03%).

7. Hypnotic use

The results regarding hypnotic use are presented in Tables 5 and 32–36.

For hypnotic use, the past-year prevalence was 6.1%, the past 30-day prevalence was 4.3%, and the rate of chronic use (defined as ≥three times a week) was 2.8% (all these figures being estimates). The rate of chronic use was highest in the Hokkaido area (3.8%) and low in the Hokuriku area (0.6%). The rate of chronic use was higher in women (3.4%) than in men (2.4%). The age group with the highest rate was 60s (5.1%), and the occupation with the highest rate was "unemployed" (11.2%). By time spent on the Internet, the rate of chronic use was highest in the group responding "zero" (5.1%).

The most common source of hypnotics was "clinics/hospitals" (4.5%). "friends" (0.1%) was not common, and no respondent selected "romantic partners." "To improve insomnia" (5.1%) was a common reason for the use of hypnotics, and only one respondent selected "recreation (pleasure)" (0.03%).

8. Knowledge on and/or perception of drug abuse

The results regarding knowledge on and/or perception of drug abuse are presented in Tables 37-41. Common familiar harmful effects associated with drug abuse included drug dependence (97.9%), hallucinations (96.0%), delusion (92.3%),flashbacks (78.5%),cannabis-induced hallucinations/delusion (78.0%), cannabis-induced amotivational syndrome (60.8%),and methamphetamine-induced hallucinations/delusion (89.9%).

The common view on cannabis use was mostly "under no situation should it be used" (82.7%), but a few respondents answered that "it is not necessary to legally prohibit" (1.2%). Similarly, the common view on methamphetamine use was mostly "under no situation should it be used" (89.9%), but a few respondents answered that "it is an individual freedom and should not be legally prohibited" (0.7%).

9. New psychoactive substances (NPSs)

The results regarding NPSs are shown in Tables 1 and 42–46. The lifetime prevalence of NPS use was 0.4% (adjusted value: 0.3%), and no respondent used any NPS within the past year. Types of NPSs used included herbal (0.3%), powder (0.2%), and liquid (0.1%). No hospital visit associated with NPS use was observed.

The lifetime prevalence was highest in the Hokkaido area (1.5%), whereas it was 0% in the Tohoku, Hokuriku, and Tousan areas. The lifetime prevalence was higher in men (0.5%) than in women (0.2%). By age, the rate was highest in the age group of 30–39 (0.7%). For occupation, it was highest in the group of "Full-time employee" (0.5%), and by time spent on the Internet, the rate was highest in those responding " \geq 5 hours" (0.9%).

The harmful effects of NPSs and the regulations regarding designated substances were known to 85.8% and 56.9% of the respondents, respectively. While there were almost no differences in the proportion of respondents familiar with the harmful effects of NPSs in terms of sex, group. or residence area. the age proportion of respondents familiar with the harmful effects of NPSs was slightly low in unemployed respondents (76.5%).

On the other hand, the proportion of respondents familiar with the regulations for designated substances was higher in men (61.9%) than in women (52.3%), and it increased with age (49.1% for teens and 62.6% for those who were in their 60s). The proportion of respondents familiar with the regulations for designated substances was highest in the Kita Kyushu area (60.7%), whereas it was low in the Shikoku area (50.0%). By occupation, the proportion was high in the group of "self-employed business" (66.5%), whereas it was low in the group of "student" (46.9%). The most common answer to a question on the perceived number of NPS users was "increasing (57.2%)," followed by "do not know" (35.5%), "not changing" (5.8%), and "decreasing" (1.1%).

10. Drug use (presence of peer drug users and the experience of ever having someone try to tempt them with drugs)

The results regarding drug use (presence

of peer drug users and the experience of ever having someone try to tempt them with drugs) are shown in Tables 2, 4, and 47–51. The proportion of respondents who have ever had someone try to tempt them with illegal drugs was 2.4% for organic solvents, 2.0% for cannabis, 1.0% for methamphetamine, 0.6% for MDMA, 0.2% for cocaine, 0.2% for heroin, 0.6% for NPSs, and 4.1% for any drug (all these figures being adjusted values).

The proportion of respondents who have ever had someone try to tempt them with NPSs was highest in the Hokkaido area (3.1%) and higher in men (0.7% [adjustedvalue]) than in women (0.5% [adjustedvalue]). That proportions were highest in the age group of 30–39 (1.4%), the group of "non-full-time employee" (1.0%), and the group of "2 to <3 hours" (1.1%).

The proportion of respondents with a peer drug abuser was 4.5% for organic solvents, 2.7% for cannabis, 2.5% for methamphetamine, 1.4% for MDMA, 1.3% for cocaine, 1.2% for heroin, 1.6% for NPSs, and 5.9% for any drug (all these figures being adjusted values).

The proportion of respondents with a peer NPS abuser was highest in the Chugoku area (3.1%) and higher in men (2.1%) than in women (1.0%). The age groups with high proportions were 20–29 and 30–39 (2.4% each). By occupation, the proportion was highest in the group of "self-employed business" (2.4%), and by time spent on the Internet, it was highest in those responding "3 to <5 hours" (2.5%).

11. Drug use (accessibility)

The results regarding drug use (accessibility) are shown in Tables 3 and 52–56. The proportion of respondents who

answered that drugs were accessible (combined with "barely accessible" and "easily accessible") was 52.4% for organic solvents, 14.6% for cannabis, 13.1% for methamphetamine, 13.0% for MDMA, 11.5% for cocaine, 11.1% for heroin, 21.8% for NPSs, and 53.5% for any drug (all these figures being adjusted values).

The proportion of respondents who answered that NPSs were accessible was high in the Kanto area (25.0%), higher in men (22.2%) than in women (18.2%), higher in those in their 30s (24.1%) than those in their 60s (11.2%), and higher in students (23.2%) than those who were unemployed (13.4%). By time spent on the Internet, the said proportion was highest in the group of " \geq 5 hours" (25.3%).

12. Drug use (use experience)

The results regarding drug use (use experience) are presented in Tables 1 and 57–61 and Table E. The lifetime prevalence (i.e., the proportion of respondents who have used an illegal drug at least once) was 1.5% for organic solvents, 1.0% for cannabis, 0.5% for methamphetamine, 0.1% for MDMA, 0.1% for cocaine, 0.3% for NPSs, and 2.4% for any drug (all these figures being adjusted values). The proportion for heroin was within the range of statistical errors. The mean age of drug users was 47.9 years for organic solvents, 41.3 years for cannabis, 44.1 years for methamphetamine, 40.0 years for MDMA, 45.4 years for cocaine, 45.7 years for heroin, 40.8 years for NPSs, and 45.5 years for any drug.

The past-year prevalence of drug use was 0.1% for organic solvents, 0.1% for cannabis, 0.0% for methamphetamine, 0.0% for MDMA, 0.0% for cocaine, 0.0% for

heroin, 0.0% for NPSs, and 0.1% for any drug.

13. Monitoring of trend changes

Changes in the past-year prevalence of alcohol use over time are shown in Figures 2 and 3 and Table 62. The past-year prevalence of alcohol use has been decreasing (85.0%, 81.9%, and 79.8% for 2011, 2013, and 2015, respectively). Particularly, the decrease in the past-year prevalence of alcohol use is significant in teens. The past-year prevalence of alcohol use in teens reached its peak in 2007 (50.6%) and subsequently decreased to 25.2% in 2015.

Changes in the lifetime prevalence of tobacco use over time are shown in Figures 4 and 5. After reaching its peak in 2009 (66.4%), the lifetime prevalence of tobacco use decreased to 65.0%, 64.0%, and 59.8%, in 2011, 2013, and 2015, respectively. Especially, the decrease in the lifetime prevalence of tobacco use is significant in those in their 20s. The lifetime prevalence of tobacco use in those in their 20s reached its peak in 2001 (71.2%) and subsequently decreased to 42.9% in 2015.

Changes in the past-year prevalence of tobacco use over time are shown in Figures 6 and 7 and Table 62. The past-year prevalence of tobacco use has been gradually decreasing from 2001 (36.0%) to 2015 (26.9%). It has been decreasing in all age groups except for teens, whose past-year prevalence increased from 2013 (2.6%) to 2015 (4.5%).

Changes in analgesic use over time are shown in Figures 8 and 9 and Table 63. The past-year prevalence of analgesic use has been increasing every year in both men and women. Overall, it increased from 34.3% (1995) to 62.9% (2015). The chronic use of analgesics (\geq three times a week) has also been increasing in both men and women. Overall, it increased from 1.6% (1999) to 2.5% (2015).

Changes in tranquilizer use over time are shown in Figures 10 and 11 and Table 63. After reaching its peak in 2007, the past-year prevalence of tranquilizer use has been decreasing in both men and women. The chronic use of tranquilizers slightly increased to 2.6%, 2.9%, and 3.1% in 1999, 2013, and 2015, respectively.

Changes in hypnotic use over time are shown in Figures 12 and 13 and Table 63. The past-year prevalence of hypnotic use increased between 1995 (4.0%) and 2007 (7.7%), followed by a decrease in 2011 (5.6%), and then by a re-increase in 2015 (6.1%). Similarly, the rate of chronic use of hypnotics reached its peak in 2007 (2.7%) and subsequently decreased in 2011 (1.9%), but it increased again in 2015 (2.9%).

Changes in views on cannabis use over time are shown in Figures 14 and 15. The figure shown is the sum of the proportion of respondents who answered that "a little use should be allowed although legally prohibited" or "it is an individual freedom and should not be legally prohibited" (i.e., those who accept cannabis use). Overall, this has been decreasing (2.9%, 2.8%, 2.4%, and 1.5% in 2009, 2011, 2013, and 2015, respectively). It has been decreasing in all age groups, with no increase from 2013 to 2015 in any of these age groups.

Changes in views on methamphetamine use over time are shown in Figures 16 and 17. The figure shown is the sum of the proportion of respondents who answered that "a little use should be allowed although legally prohibited "or "it is an individual freedom and should not be legally prohibited" (i.e., those who accept methamphetamine use). Overall, it has been decreasing (1.7%, 1.4%, 0.9%, and 0.8% in 2009, 2011, 2013, and 2015, respectively). It decreased in those in their 20s, 50s, and 60s from 2013 to 2015, whereas it increased in teens and those in their 30s.

Changes over time in the proportion of respondents with a peer drug abuser within the past year are shown in Figure 18. The proportion increased from 2013 to 2015 for all drugs.

Changes in drug accessibility over time are shown in Figure 19. The figure shown is the sum of the proportion of respondents who answered that drugs were "barely accessible" or "easily accessible." Although little change in drug accessibility was observed over time, NPS accessibility (20.1%), which was investigated for the first time in this survey, was the second most common next to organic solvents (51.5%). Figures 20–31 show changes in the accessibility of each drug over time by age group.

Figure 32 and Tables 64 and 65 show changes over time in the lifetime experience of having someone try to tempt them with illegal drugs. While the lifetime experience of having someone try to tempt them with illegal drugs has generally remained unchanged, it increased from 2013 to 2015 only for methamphetamine $(0.9\% \rightarrow 1.0\%)$ and MDMA $(0.4\% \rightarrow 0.6\%)$.

Figure 33 and Tables 67 and 68 show changes in the lifetime prevalence of drug abuse over time. The lifetime prevalence of NPS abuse decreased from 0.4% (2013) to 0.3% (2015). The lifetime prevalence of drug abuse also decreased for organic solvents $(1.9\% \rightarrow 1.5\%)$, cannabis $(1.1\% \rightarrow 1.0\%)$, and MDMA $(0.3\% \rightarrow 0.1\%)$. No change was observed for methamphetamine and cocaine.

14. Estimated population with drug use

Table 65 shows changes in the population of individuals with lifetime experience of having someone try to tempt them with illegal drugs. This is an estimate of the number of people who have had someone try to tempt them with illegal drugs in Japan, and it was 2.29 million for organic solvents, 1.91 million for cannabis, 0.94 million for methamphetamine, 0.16 million for heroin, 0.20 million for cocaine, 0.58 million for MDMA, and 0.52 million for NPSs (all figures approximate). As compared with 2013,the estimate increased only for methamphetamine $(\sim 0.93 \rightarrow \sim 0.94 \text{ million})$ and MDMA (~ 0.42) \rightarrow ~0.58 million) and decreased for other drugs.

Table 68 shows changes in the population of individuals with lifetime experience of drug use. This is an estimate of the number of people with the experience of illegal drug use in Japan, and it was 1.38 million for organic solvents, 0.95 million for cannabis, 0.50 million for methamphetamine, 0.12 million for cocaine, 0.12 million for MDMA, and 0.31 million for NPSs (all figures approximate). As compared with the 2013 survey, the estimate decreased for all these drugs.

D. Discussion

1. Summary of the 2015 survey

Although the response rate decreased to the 50% range in the 2013 survey, it increased back to 61.7% in this survey. Behind this rise in the response rate may lie an increase in residents' awareness of drug abuse as brought about by media coverage on the social issue regarding "NPS-related accidents," including the runaway car accident in Ikebukuro, Tokyo (2014). Still, the response rate has remained low compared to the rate seen at the initial conduct of the study. To avoid a further drop in the response rate, it is necessary to continue to patiently explain to target individuals the detailed purposes and necessity of the study, and to solicit their understanding. At any rate, we would like to express our gratitude to the 3,085 respondents in 47 prefectures of Japan for understanding and cooperation their regarding the survey.

One of objectives of this study is to understand the actual circumstances of drug abuse in Japan. To approach this goal from a variety of angles, we aimed to play a "role of dictionary." In other words, we tried to obtain a picture of the current situation of drug abuse via analyzation not only by sex and age group but also by other different variables, including residence occupation, and educational area. background. In addition, this study has been conducted every other year since 1995 as a series of "monitoring surveys." Over the years, all these surveys have been conducted using the same sampling and study methods, which allows us to monitor the trend of drug abuse. In addition to the trend of drug abuse, a wide range of health-related information, including data on the use of alcohol, tobacco, and medications has been collected, which can be used as basic data for the consideration of related health issues. It is a tremendous amount of data, and it is impossible to discuss all of them; but we will discuss

some of important issues below.

2. Trend regarding new psychoactive substances (NPSs)

The lifetime prevalence of NPS use decreased from 0.4% (2013) to 0.3% (2015), and the past-year prevalence decreased from 0.1% (2013) to 0% (2015). Our estimates suggest that the number of individuals in the population with lifetime experience of NPS use is approximately 0.31 million, showing a decrease from the figure of the 2013 survey (approximately 0.40 million). It is likely that this decrease and the absence of past-year users are related to the recent inaccessibility of NPSs itself. In December 2014, The Law on Securing Quality, Efficacy and Safety of Products Including Pharmaceuticals and Medical Devices (the former *Pharmaceutical Law*) was revised, and the minister of the Ministry of Health, Labour and Welfare and prefectural governors were granted the right to issue orders for scientific testing and the suspension of advertisements sales and/or to manufacturers. Since then, drug retail outlets known as "head shops" and websites selling drugs on the Internet have been eliminated. apparently This strengthening of the regulations on NPSs may have been effective to a certain degree, contributing to the decrease in the accessibility of NPSs. This may have resulted in the disappearance of past-year users. These results suggest that the social issue regarding NPSs is calming down.

The proportion of respondents having knowledge of harmful effects of NPSs increased from 61.5% (2013) to 85.8% (2015), with 56.9% of respondents having knowledge of Japan's regulations for designated substances as measures to prevent NPS use. It is speculated that this increase in knowledge has resulted from media coverage of NPS-related crimes, anti-drug abuse activities led by each local government, and education for the prevention of drug abuse as provided by schools, through all of which the harmful effects of NPSs became more widely recognized by the general population. As for familiarity with the regulations for designated substances. this survey revealed that more than half of the general population were familiar with such regulations, although the future trend needs to be monitored because this was assessed for the first time in this survey.

Despite the increased awareness of the harmful effects of NPSs and the decrease in NPS users, the accessibility of NPSs is still higher than that of other drugs. The proportion of respondents who answered that drugs were "available" exceeded 20%, indicating that these respondents see NPSs as more accessible drugs compared with methamphetamine and cannabis. Continuous measures to prevent NPS use are required. Especially, the proportion of respondents who answered that NPSs were "available" was high in those spending ≥ 5 hours on the Internet, warranting an ongoing strengthening of the measures against websites selling drugs on the Internet.

3. Trend regarding illegal drugs

Based on the estimated number of individuals in the population with lifetime drug use, the use of organic solvents, cannabis, methamphetamine, cocaine, and MDMA have all decreased from the 2013 survey. It should be noted, however, that the number of individuals in the population who had ever had someone try to tempt them with illegal drugs is increasing both for methamphetamine and MDMA. The majority of the respondents were obviously conscious of methamphetamine use, with nearly 90% of respondents answering that "under no situation should it be used." However, it is also true that there were a small number of respondents who answered that "a little use should be allowed although legally prohibited" or "it is an individual freedom and not necessary to legally prohibit," namely we would call the "accepters." The increase in the proportion of accepters in young respondents, including teens and those in their 30s, from 2013 to 2015 suggests that there is a need to further enhance preventative measures against drug abuse targeting the younger generation.

As for MDMA, on the other hand, the amount seized has been decreasing in recent years, indicating that opportunities for abuse are decreasing. The future trend should be carefully monitored.

4. Trend regarding analgesic/hypnotic use

The survey showed that opportunities for using analgesics and hypnotics are clearly increasing. The past-year prevalence of analgesic use was 62.9%, the highest figure ever. While the past-year prevalence of hypnotic use reached its peak in 2007 and then decreased, this survey revealed that it is increasing again.

Some analgesics and hypnotics have dependence-forming potential. Such dependence-forming medications include opioid analgesics (e.g., tramadol) and benzodiazepines. It is known that there some patients abuse or heavily depend on benzodiazepines. The Nationwide Mental Hospital Survey on Drugrelated Psychiatric Disorders has reported that etizolam, flunitrazepam, and triazolam are often abused. This study, in which the use of drugs \geq three times a week was defined as "chronic use," showed that the chronic use of analgesics and hypnotics has also obviously been increasing.-It is difficult to predict the risk of drug abuse/dependence in drug users from the frequency of drug use. However, there is a certain proportion of individuals who use drugs having dependency-forming potential. It is therefore continuously important for physicians and pharmacists to promote the "proper use" of these drugs.

E. Conclusion

The number of respondents with lifetime use of NPSs decreased, and the past-year prevalence of their use was 0%. Behind this lie the reinforcement of may the regulations for designated substances (including orders for scientific testing and suspension of sales and/or advertisements) to eliminate shops and websites selling NPSs, which led to reduced opportunities for obtaining NPSs. In addition, the social issue regarding NPSs is considered to be calming down. However, approximately 20% of respondents answered that NPSs are "available," suggesting the necessity of continuous measures to prevent NPS abuse.



Map of Japan (All 47 prefectures of Japan were divided into the 11 geographic areas)

			Large	e cities			Cities	Cities	Cities	Suburba	Total
	23 wards	Yokoham	Kawasak	Chiba	Saitama	Other	with a	with a	with a	n	
	of Tokyo	a City	i City	City,	City,	ordinanc	populatio	populatio	populatio	districts	
	metropoli		and	Nagoya	Shizuoka	e-	n of ≥0.2	n of ≥0.1	n of ${<}0.1$		
	tan		Kyoto	City and	City,	designate	million	million	million		
			City,	Osaka	Kobe	d cities					
				City	City,						
					Hiroshi						
					ma City						
					and Kita-						
					Kyushu						
					City						
Hokkaido area						79	23	34	36	37	209
m 1 1						(5)	(2)	(3)	(3)	(3)	(16)
Tohoku area						44	91	44	106	64	349
TZ	000	151	01		F1	(3)	(6)	(3)	(7)	(5)	(24)
Kanto area	382	151	61	38	51	29	408	311	225	(7) (7)	1731
TT.1'1	(26)	(10)	(4)	(3)	(4)	(2)	(29)	(21)	(15)	(5)	(119)
Hokuriku area						(2)	62	23	(5)	16	204
Tousan area						(2)	(4)	(2)	(3)	33	(14)
i ousaii area							(3)	(3)	(5)	(3)	(14)
Tokai area				90	27	31	124	110	98	33	513
				(6)	(2)	(2)	(8)	(7)	(7)	(3)	(35)
Kinki area			56	107	61	33	257	101	154	44	813
			(4)	(7)	(4)	(3)	(18)	(7)	(10)	(3)	(56)
Chugoku area					47	27	63	69	54	21	281
					(3)	(2)	(4)	(5)	(4)	(2)	(20)
Shikoku area							60	20	45	23	148
							(4)	(2)	(3)	(2)	(11)
Kita-Kyushu area					37	62	66	36	89	39	329
					(3)	(4)	(5)	(3)	(6)	(3)	(24)
Minami-Kyushu area						29	53	40	70	39	231
						(2)	(4)	(3)	(5)	(3)	(17)
Total	382	151	117	235	223	365	1247	829	1027	424	5000
	(26)	(10)	(8)	(16)	(16)	(25)	(87)	(59)	(70)	(33)	(350)

Table A. Number of samples and numer of survey spot by each strata

*Upper data is numer of samples, lower data is numer of survey spot



Fig1. The change in response rate (1995–2015)

			-			
	Ν	Ien	W	omen	Тс	otal
Change of home address	134	13.2%	74	8.2%	208	10.9%
Long term absence	50	4.9%	28	3.1%	78	4.1%
Temporary absence	306	30.1%	293	32.6%	599	31.3%
Unknown address	33	3.3%	17	1.9%	50	2.6%
Refusal	435	42.9%	442	49.1%	877	45.8%
Answered by familes	11	1.1%	9	1.0%	20	1.0%
Other reasons	46	4.5%	37	4.1%	83	4.3%
Total	1015	100.0%	900	100.0%	1,915	100.0%

Table B. The reasons for not responding to the survey by sex

Table C. The reasons for not responding to the survey by age group

		10s		20s	30	Ds		40s
Change of home address	14	13.1%	65	18.1%	49	13.4%	39	8.0%
Long term absence	3	2.8%	18	5.0%	13	3.5%	20	4.1%
Temporary absence	22	20.6%	139	38.7%	129	35.1%	168	34.6%
Unknown address	1	0.9%	12	3.3%	12	3.3%	15	3.1%
Refusal	60	56.1%	113	31.5%	153	41.7%	220	45.4%
Answered by familes	1	0.9%	1	0.3%	2	0.5%	6	1.2%
Other reasons	6	5.6%	11	3.1%	9	2.5%	17	3.5%
Total	107	100.0%	359	100.0%	367	100.0%	485	100.0%

	1	50s	(60s	То	otal
Change of home address	29	7.9%	12	5.7%	208	10.9%
Long term absence	16	4.4%	8	3.8%	78	4.1%
Temporary absence	101	27.7%	40	18.9%	599	31.3%
Unknown address	6	1.6%	4	1.9%	50	2.6%
Refusal	197	54.0%	134	63.2%	877	45.8%
Answered by familes	6	1.6%	4	1.9%	20	1.0%
Other reasons	10	2.7%	10	4.7%	83	4.3%
Total	365	100.0%	212	100.0%	1,915	100.0%

Table D. The reasons for not responding to the survey by geographic area

	Hol	kaido	Т	ohoku	K	anto	Ho	kuriku	Tou	san	To	kai
Change of home address	3	3.8%	9	9.3%	65	8.3%	6	12.2%	8	19.0%	15	8.2%
Long term absence	7	9.0%	$\overline{7}$	7.2%	29	3.7%	1	2.0%	1	2.4%	6	3.3%
Temporary absence	23	29.5%	16	16.5%	291	37.2%	10	20.4%	15	35.7%	46	25.0%
Unknown address	2	2.6%	3	3.1%	22	2.8%	1	2.0%	3	7.1%	2	1.1%
Refusal	39	50.0%	56	57.7%	340	43.4%	30	61.2%	15	35.7%	108	58.7%
Answered by familes	1	1.3%	1	1.0%	4	0.5%	0	0.0%	0	0.0%	4	2.2%
Other reasons	3	3.8%	5	5.2%	32	4.1%	1	2.0%	0	0.0%	3	1.6%
Total	78	100.0%	97	100.0%	783	100.0%	49	100.0%	42	100.0%	184	100.0%
	K	inki	Ch	ugoku	Sh	ikoku	Kita	-Kyusyu	Minami	Kyusyu	To	tal
Change of home address	39	10.6%	19	21.3%	13	21.7%	23	23.2%	8	12.1%	208	10.9%
Long term absence	10	2.7%	5	5.6%	1	1.7%	6	6.1%	5	7.6%	78	4.1%
Temporary absence	131	35.6%	13	14.6%	17	28.3%	17	17.2%	20	30.3%	599	31.3%
Unknown address	8	2.2%	2	2.2%	5	8.3%	2	2.0%	0	0.0%	50	2.6%
Refusal	152	41.3%	44	49.4%	21	35.0%	41	41.4%	31	47.0%	877	45.8%
Answered by familes	6	1.6%	2	2.2%	2	3.3%	0	0.0%	0	0.0%	20	1.0%
Other reasons	22	6.0%	4	4.5%	1	1.7%	10	10.1%	2	3.0%	83	4.3%
Total	368	100.0%	89	100.0%	60	100.0%	99	100.0%	66	100.0%	1,915	100.0%

Table 1	Lifetime	Drovalanco	of Dung	Uso by	Dung	n = 2076
Table 1.	Lifetime	Prevalence	of Drug	Use by	Drug	n = 3076

			Prevalence	e of drug u	use (lifetin	me)		
	Organic	Cannabis	Methamph	MDMA	Cocaine	Heroin	NPSs	Any
	solvents		etamine					drug
Total	1.6	1.1	0.5	0.2	0.2	0.1	0.4	2.5
	(1.5)	(1.0)	(0.5)	(0.1)	(0.1)	(-)	(0.3)	(2.4)
Residence area								
Hokkaido	1.5	3.1	1.5	0.8	0.8	0.0	1.5	4.6
Tohoku	1.2	0.4	0.0	0.0	0.0	0.0	0.0	1.6
Kanto	1.5	1.6	0.7	0.1	0.3	0.3	0.2	2.6
Hokuriku	1.9	0.0	0.0	0.0	0.0	0.0	0.0	1.9
Tousan	0.7	1.3	0.7	0.0	0.0	0.0	0.0	1.3
Tokai	2.7	1.2	0.9	0.0	0.3	0.0	0.3	3.0
Kinki	1.4	1.4	0.2	0.5	0.0	0.0	0.5	2.9
Chugoku	2.1	0.5	0.5	0.5	0.0	0.0	0.5	3.1
Shikoku	0.0	0.0	0.0	0.0	0.0	0.0	1.1	1.1
Kita-Kyusyu	1.3	0.9	0.4	0.4	0.0	0.0	0.4	1.3
Minami-Kyusyu	2.4	0.0	0.0	0.0	0.0	0.0	0.6	3.0
Sex								
Men	23	19	1.0	0.3	0.3	0.2	0.5	4.0
11011	(2.1)	(1.6)	(1.0)	(0.2)	(0.3)	(-)	(0.5)	(3.6)
Women	0.9	0.4	0.1	0.1	0.0	0.0	0.2	1.2
	(0.8)	(0.4)	(-)	(-)	(-)	(-)	(-)	(1.2)
Age group	(0.0)	(011)						(1.2)
10s	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
20s	0.8	1.0	0.0	0.0	0.0	0.0	0.5	2.1
30s	1.1	2.0	0.9	0.5	0.2	0.0	0.7	2.7
40s	2.4	1.5	0.8	0.3	0.4	0.4	0.3	3.1
50s	1.9	1.3	0.6	0.1	0.1	0.0	0.4	3.3
60s	1.9	0.0	0.2	0.0	0.0	0.0	0.0	1.9
Occupation								
Self-employed business	2.8	2.8	1.2	0.4	0.4	0.4	0.4	5.6
Full-time employee	1.6	1.1	0.6	0.1	0.2	0.1	0.5	2.6
Non-full-time employee	2.0	2.0	0.0	0.0	0.0	0.0	0.3	3.6
Student	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Housewife (househusband)	0.7	0.0	0.0	0.2	0.0	0.0	0.2	1.1
Unemployed	3.4	1.7	1.7	0.6	0.6	0.6	0.0	3.4
Other	1.4	1.4	0.7	0.7	0.0	0.0	0.7	2.2
No response/unknown	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Final academic background								
Junior high school	9.3	5.7	4.1	1.0	1.5	1.0	3.1	11.9
High school	2.0	0.6	0.4	0.2	0.1	0.0	0.3	2.9
Vocational school	1.2	1.7	0.5	0.0	0.2	0.2	0.2	2.2
Junior college/university	0.2	0.9	0.1	0.2	0.0	0.0	0.1	1.1
Graduate school	0.0	1.5	0.0	0.0	0.0	0.0	0.0	1.5
Other	0.0	6.3	0.0	0.0	0.0	0.0	0.0	6.3
In school	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
No response/unknown	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Time spent on the Internet								
None	1.6	0.0	0.0	0.0	0.0	0.0	0.0	1.6
<1 hour	2.3	1.3	0.8	0.3	0.1	0.1	0.5	3.2
1 to <2 hours	1.1	1.2	0.5	0.2	0.0	0.0	0.2	2.6
2 to <3 hours	1.3	1.3	0.4	0.0	0.2	0.0	0.2	2.2
3 to <5 hours	0.9	0.9	0.3	0.3	0.3	0.3	0.3	1.6
≥5 hours	1.9	1.9	0.9	0.5	0.5	0.2	0.9	3.3
No response/unknown	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0

The values in parentheses for the total and sex are estimates, and "–" represents within the range of statistical "10s" refers to those aged 15 to 19, and "60s" refers to those aged 60 to 64.

Time spent on the Internet: Average hours spent per day not for work

Table 2. Experience of ever having try to tempt with illegal drugs (n = 3076)

		Experie	nce of ever l	naving try	to tempt ille	egal drugs (1	lifetime)	
	Organic	Cannabis	Methamp	MDMA	Cocaine	Heroin	NPSs	Any drug
	solvents		hetamine					
Total	2.6	2.1	1.0	0.7	0.3	0.2	0.5	4.3
	(2.4)	(2.0)	(1.0)	(0.6)	(0.2)	(0.2)	(0.6)	(4.1)
Residence area								
Hokkaido	3.1	3.8	1.5	2.3	0.8	0.0	3.1	7.6
Tohoku	2.4	2.4	0.4	0.8	0.0	0.0	0.4	4.0
Kanto	3.1	3.1	1.4	0.7	0.5	0.4	0.7	5.5
Hokuriku	2.6	0.0	0.0	0.0	0.0	0.0	0.0	2.6
Tousan	1.3	2.0	1.3	0.0	0.0	0.0	0.0	2.7
Tokai	4.3	1.8	1.5	0.6	0.0	0.0	0.0	5.5
Kinki	1.8	1.8	0.5	0.2	0.0	0.0	0.2	3.2
Chugoku	1.0	1.0	1.0	0.0	0.5	0.5	0.5	2.6
Shikoku	4.5	1.1	1.1	1.1	0.0	0.0	0.0	4.5
Kita-Kyusyu	1.7	0.9	0.4	0.9	0.4	0.4	0.4	1.7
Minami-Kyusyu	2.4	1.2	1.2	1.2	0.0	0.0	0.6	3.6
Sex								
Men	3.6	2.9	1.3	0.8	0.4	0.3	0.5	5.5
	(3.4)	(2.9)	(1.2)	(0.7)	(0.4)	(0.3)	(0.7)	(5.2)
Women	1.7	1.3	0.7	0.5	0.1	0.1	0.6	3.2
	(1.6)	(1.2)	(0.8)	(0.5)	(-)	(-)	(0.5)	(3.1)
Age group								
10s	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
20s	2.6	3.1	0.5	0.5	0.3	0.0	0.8	6.0
30s	5.1	4.9	2.5	2.0	0.2	0.2	1.4	8.0
40s	3.5	2.3	0.8	0.7	0.5	0.5	0.4	4.7
50s	1.9	1.0	0.9	0.1	0.1	0.0	0.3	3.0
60s	0.8	0.2	0.6	0.2	0.2	0.2	0.0	1.7
Occupation								
Self-employed business	4.0	3.2	0.8	0.8	0.8	0.8	0.4	5.2
Full-time employee	3.4	2.1	1.3	0.9	0.1	0.1	0.6	4.7
Non-full-time employee	2.0	3.6	1.0	0.5	0.8	0.5	1.0	5.3
Student	0.0	0.4	0.0	0.0	0.0	0.0	0.0	0.4
Housewife (househusband)	1.1	0.9	1.1	0.5	0.0	0.0	0.5	3.2
Unemployed	3.4	2.2	1.1	1.1	0.6	0.6	0.0	5.0
Other	2.9	2.2	0.0	0.0	0.0	0.0	0.7	5.1
No response/unknown	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Final academic background								
Junior high school	11.9	6.2	4.6	3.1	1.0	1.0	1.5	13.9
High school	3.5	2.0	1.2	0.6	0.3	0.2	0.7	5.3
Vocational school	2.7	2.5	1.2	0.7	0.5	0.5	0.5	3.9
Junior college/university	0.6	1.6	0.3	0.3	0.1	0.0	0.3	2.4
Graduate school	0.0	1.5	0.0	0.0	0.0	0.0	0.0	1.5
Other	0.0	6.3	0.0	6.3	0.0	0.0	0.0	6.3
In school	0.0	0.4	0.0	0.0	0.0	0.0	0.0	0.4
No response/unknown	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Time spent on the Internet								
None	1.2	0.2	0.5	0.0	0.0	0.0	0.2	1.9
<1 hour	3.0	2.0	1.0	0.8	0.5	0.4	0.5	4.1
1 to <2 hours	2.2	2.6	0.9	0.6	0.2	0.2	0.3	4.9
2 to <3 hours	3.1	2.4	0.9	0.9	0.2	0.0	1.1	5.1
3 to <5 hours	2.5	2.8	0.9	0.9	0.3	0.3	0.0	4.1
≥5 hours	3.8	2.4	1.9	0.7	0.2	0.2	0.9	5.4
No response/unknown	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0

				Drug ace	cessibility			
	Organic	Cannabis	Methamp	MDMA	Cocaine	Heroin	NPSs	Any drug
	solvents		hetamine					
Total	51.5	14.1	12.7	12.8	11.1	10.5	20.1	52.6
	(52.4)	(14.6)	(13.1)	(13.0)	(11.5)	(11.1)	(21.8)	(53.5)
Residence area								
Hokkaido	43.5	18.3	11.5	12.2	9.9	9.2	20.6	45.8
Tohoku	48.8	15.6	14.0	14.0	11.2	10.8	18.8	49.6
Kanto	55.9	17.8	15.7	15.5	14.1	13.8	25.0	57.0
Hokuriku	45.5	5.8	6.5	6.5	5.2	5.2	15.6	50.0
Tousan	46.0	5.3	5.3	6.7	4.7	4.7	8.0	46.7
Tokai	51.8	12.8	11.9	12.8	10.4	9.8	22.0	52.4
Kinki	51.6	12.7	11.3	11.8	9.0	8.1	18.6	52.5
Chugoku	56.0	12.6	14.1	11.5	11.5	10.5	18.8	56.5
Shikoku	48.9	12.5	11.4	12.5	9.1	9.1	19.3	48.9
Kita-Kyusyu	47.6	14.4	13.5	14.4	13.1	12.2	18.3	48.0
Minami-Kyusyu	47.9	10.9	10.3	10.3	10.3	9.1	13.9	49.1
Sex								
Men	61.8	14.8	12.7	13.1	11.1	10.8	22.2	62.8
Women	42.1	13.4	12.7	12.6	11.1	10.3	18.2	43.3
Age group								
10s	32.4	18.5	17.6	15.3	16.2	15.8	20.3	33.8
20s	43.5	20.4	17.8	16.0	16.2	15.2	23.0	45.3
30s	51.4	19.0	16.5	17.2	13.7	13.2	24.1	52.8
40s	58.6	13.6	12.6	14.1	10.9	10.5	22.4	59.5
50s	55.5	10.6	10.1	10.2	8.9	8.1	19.0	56.5
60s	49.9	7.0	5.9	5.9	4.9	4.9	11.2	50.1
Occupation								
Self-employed business	64.1	12.9	11.7	12.9	10.1	10.1	20.6	64.5
Full-time employee	57.8	14.6	12.4	12.7	10.9	10.4	21.7	58.8
Non-full-time employee	48.0	16.8	16.0	17.0	13.5	12.9	23.1	49.7
Student	35.8	19.9	18.8	16.2	18.1	17.3	23.2	37.3
Housewife (househusband)	41.7	9.4	8.7	9.2	6.9	6.0	13.5	42.7
Unemployed	44.7	10.1	10.6	9.5	8.4	7.8	13.4	45.8
Other	44.9	12.3	11.6	11.6	11.6	10.9	18.8	45.7
No response/unknown	50.0	0.0	25.0	0.0	0.0	0.0	0.0	50.0
Final academic background								
Junior high school	49.0	17.5	16.0	18.0	14.9	14.4	20.6	49.5
High school	50.7	12.4	11.4	11.9	9.7	8.9	18.4	51.4
Vocational school	52.0	14.8	13.3	12.1	11.1	11.1	18.0	52.7
Junior college/university	56.1	13.6	11.9	12.4	10.2	9.8	21.5	57.6
Graduate school	78.8	15.2	12.1	13.6	10.6	9.1	33.3	80.3
Other	31.3	12.5	6.3	12.5	6.3	6.3	18.8	37.5
In school	35.8	19.9	18.8	16.2	18.1	17.3	23.2	37.3
No response/unknown	25.0	0.0	0.0	0.0	0.0	0.0	0.0	25.0
Time spent on the Internet								
None	39.2	8.9	9.1	8.4	7.7	7.2	11.7	39.9
<1 hour	53.7	12.2	10.0	10.0	9.3	8.5	18.8	54.9
1 to <2 hours	51.9	13.3	11.4	12.3	9.6	9.4	21.1	53.0
2 to <3 hours	55.0	17.1	15.7	15.3	14.4	13.7	22.4	56.3
3 to < 5 hours	51.3	15.9	15.0	16.6	13.4	12.8	23.4	52.2
≥5 hours	56.5	19.9	18.7	18.2	15.1	14.4	25.3	57.4
No response/unknown	31.3	6.3	6.3	6.3	6.3	6.3	6.3	31.3

Drug accessibility: The proportion of respondents who answered that drug were "barely accessible" or "easily accessible" when a question about drug accessibility was asked on a scale of four levels.

Table 4. Rate of Having a Close Drug Abuser by Drug (n = 3076)

Organic Cannabis Methamp MMAA Cocaine Heroin NEss Any drug solvenis http://hethamp 1.1 1.5 6.0 Total 4.5 2.8 2.6 1.4 1.2 1.1 1.5 6.0 Residence area Hotkaido 3.1 6.1 5.8 3.1 0.8 0.8 2.3 8.4 Tohoko 4.4 2.8 2.4 1.2 1.6 1.2 2.0 4.8 Kanto 4.6 2.3 2.0 0.8 0.8 0.9 1.4 5.9 Hokaniku 5.2 2.6 1.9 1.3 0.6 0.6 0.6 5.8 Tokai 6.4 3.4 3.4 2.4 1.8 1.5 1.8 7.9 Shikohu 9.1 2.3 5.7 2.3 1.1 1.1 1.1 1.1 1.1 1.1 1.1 1.1 1.1 1.1 1.1 1.1 1.1 1.1 1				Rate of	close drug a	abuser			
Interame Netamine Total 4.5 2.8 2.6 1.4 1.2 1.1 1.5 6.0 Besidence area N Hokkaido 3.1 6.1 3.8 3.1 0.8 0.8 2.3 8.4 Tohoku 4.4 2.8 2.4 1.2 1.6 1.2 2.0 4.8 Kanto 4.6 2.3 2.0 0.8 0.8 0.9 1.4 5.9 Hokuriku 5.2 2.6 1.9 1.3 0.6 0.6 0.6 5.8 Tokai 6.44 3.4 3.4 2.4 1.8 1.5 1.8 7.6 Kinki 2.9 2.9 2.3 0.7 0.7 0.11 1.4 1.1 1.1 1.1 1.1 1.1 1.1 1.1 1.1 1.1 1.1 1.1 1.1 1.1 1.1 1.1 1.1 1.1 1.1 1.1 1.1 <th></th> <th>Organic</th> <th>Cannabis</th> <th>Methamp</th> <th>MDMA</th> <th>Cocaine</th> <th>Heroin</th> <th>NPSs</th> <th>Any drug</th>		Organic	Cannabis	Methamp	MDMA	Cocaine	Heroin	NPSs	Any drug
Intal 4.5 2.8 2.6 1.4 1.2 1.1 1.5 0.0 Rosidence area (4.5) (2.7) (2.5) (1.4) (1.3) (1.2) (1.6) (5.9) Rosidence area 3.1 0.1 3.8 3.1 0.8 0.8 0.9 1.4 5.9 Hokkrädo 4.6 2.3 2.0 0.8 0.8 0.9 1.4 5.9 Iokuriku 5.2 2.6 1.9 1.3 0.66 0.66 5.8 Tokai 6.4 3.4 3.4 2.4 1.8 1.5 1.8 7.6 Kinki 2.9 2.3 0.7 0.7 0.1 1.1 1.1 1.1 1.1 1.1 1.1 1.1 1.1 1.1 1.1 1.1 1.1 1.1 1.1 1.1 1.1 1.1 1.1 1.1 1.1 1.1 1.1 1.1 1.1 1.1 1.1 1.1 1.1 1.1 </th <th></th> <th>solvents</th> <th></th> <th>hetamine</th> <th>1.4</th> <th>1.0</th> <th></th> <th></th> <th></th>		solvents		hetamine	1.4	1.0			
Residence area U.3	Total	4.5 (4.5)	2.8	2.6	1.4	1.2	1.1	1.5 (1.0)	6.0 (5.0)
Instrumental Instrumental Thokkaido 3.1 6.1 3.8 3.1 0.8 0.8 2.3 8.4 Thokaido 4.6 2.3 2.0 0.8 0.8 0.9 1.4 5.9 Hokuriku 5.2 2.6 1.9 1.3 0.6 0.6 0.6 5.8 Tosan 2.7 3.3 3.3 2.7 2.7 2.7 4.7 Tokai 6.4 3.4 2.4 1.8 1.5 1.8 7.6 Kinki 2.9 2.9 2.3 0.7 0.7 0.7 1.1 5.4 Chugoku 6.3 3.1 3.7 2.1 2.6 0.6 4.2 Som 3.1 1.7 2.2 0.9 0.4 0.9 3.9 Minami-Kyusyu 3.0 2.4 1.8 1.8 1.8 3.2 Sor 7 2.7 2.3 2.3 1.3 1.4 6.5 <td>Residence area</td> <td>(4.0)</td> <td>(2.1)</td> <td>(2.0)</td> <td>(1.4)</td> <td>(1.5)</td> <td>(1.2)</td> <td>(1.6)</td> <td>(5.9)</td>	Residence area	(4.0)	(2.1)	(2.0)	(1.4)	(1.5)	(1.2)	(1.6)	(5.9)
Instance b.1 b.1 b.3 b.1 b.3 b.4 b.3 b.4 b.5 b.3 b.4 b.4 b.4 b.5 b.4 b.5 b.4 b.5 b.4 b.5 b.4 b.5 b.4 b.5 b.4 b.4 <thb.4< th=""> b.4 <thb.4< th=""> <thb.4<< td=""><td>Hokkaido</td><td>9.1</td><td>61</td><td>3.8</td><td>9.1</td><td>0.8</td><td>0.8</td><td>93</td><td>8.4</td></thb.4<<></thb.4<></thb.4<>	Hokkaido	9.1	61	3.8	9.1	0.8	0.8	93	8.4
Kanto4.62.32.00.80.80.91.41.51.21.01.21.01.21.01.21.01.01.51.51.51.51.51.51.51.51.51.61.51.61.51.61.61.71.11.11.11.11.11.11.11.11.11.11.11.11.11.11.11.11.11.11.11.11.11.11.11.11.11.11.11.11.11.11.11.11.11.11.11.11.11.11.11.11.11.11.11.11.11.11.11.11.11.11.11.11.11.11.11.11.11.11.11.11.11.11.11.11.11.11.11.11.11.11.11.11.11.11.11.11.11.11.11.11.11.11.11.11.11.11.11.11.11.11.11.11.11.11.11.11.11.11.11.11.11.11.11.11.11.11.11.11.11.11.11.11.11.11.11.11.11.11.11.11.11.11.11.11.11.11.11.11.11.11.11.11.11.11.1 <th< td=""><td>Toboku</td><td>4.4</td><td>0.1 2.8</td><td>9.4</td><td>1.9</td><td>1.6</td><td>1.9</td><td>2.5</td><td>4.8</td></th<>	Toboku	4.4	0.1 2.8	9.4	1.9	1.6	1.9	2.5	4.8
Instant1.02.02.00.00.00.30.40.5Hokuriku5.22.61.91.30.60.60.65.8Tousan2.73.33.32.72.72.74.7Takai6.43.43.42.41.81.51.87.6Kinki2.92.92.30.70.70.71.15.4Chugoku6.33.13.72.12.62.63.17.9Shikoku9.12.35.72.31.11.11.11.1Hitter.Kyuayu3.11.72.20.90.40.90.93.9Minami-Kyusyu3.02.41.81.21.20.60.64.2Sex2.20.90.70.81.04.7Men5.73.83.01.81.61.52.17.5Women3.41.92.20.90.70.81.04.7Jos2.72.72.32.31.81.83.220s3.93.92.11.31.31.44.250s5.84.52.72.21.31.31.44.260s4.21.91.70.81.11.10.85.3Occupation3.34.02.82.42.02.410.9Full	Kanto	4.6	2.0	2.4	0.8	0.8	0.9	1.0	5.9
Instant 0.2 2.0 1.0 1.0 0.0 0.0 0.0 0.0 Tousan 2.7 2.7 2.7 2.7 2.7 4.7 Tokai 6.4 3.4 3.4 2.4 1.8 1.5 1.8 7.6 Kinki 2.9 2.9 2.3 0.7 0.7 1.1 5.4 Chugoku 6.3 3.1 3.7 2.1 2.6 2.6 3.1 7.9 Shikoku 9.1 2.3 5.7 2.3 1.1 1.1 1.1 1.1 Kitar-Kyusyu 3.0 2.4 1.8 1.2 1.2 0.6 0.6 4.2 Sox Men 3.4 1.9 2.2 0.9 0.7 0.8 1.0 4.7 Age group 10s 2.7 2.7 2.3 2.3 2.3 1.8 1.8 3.2 Jos 3.9 3.9 2.1 1.3 1.3 1.3 1.3 1.4 4.2 Os 3.7 1.9 2.3 1.4 </td <td>Hokuriku</td> <td>5.9</td> <td>2.0</td> <td>1.0</td> <td>1.3</td> <td>0.6</td> <td>0.6</td> <td>0.6</td> <td>5.8</td>	Hokuriku	5.9	2.0	1.0	1.3	0.6	0.6	0.6	5.8
Tokan 2.1 0.5 0.6 2.1 2.1 2.1 2.1 2.1 1.1 Tokan 2.9 2.9 2.3 0.7 0.7 0.7 1.1 5.4 Chugoku 6.3 3.1 3.7 2.1 2.6 2.6 3.1 1.7 Shikoku 9.1 2.3 5.7 2.3 1.1 1.1 1.1 1.1 Kita-Kyusyu 3.0 2.4 1.8 1.2 0.9 0.4 0.9 0.9 3.9 Mon 5.7 3.8 3.0 1.8 1.6 1.5 2.1 7.5 Women 3.4 1.9 2.2 0.9 0.7 0.8 1.0 4.7 Age group 10s 2.7 2.7 2.3 2.3 2.3 1.8 1.8 3.2 30s 5.8 4.5 2.7 2.2 1.3 1.3 2.4 9.0 40s 5.1 2.4 3.6 0.8 0.7 0.7 0.9 6.5 50s 3.7	Tousan	0.2 9.7	2.0	2.2	1.0 9.7	0.0 2 7	0.0 9.7	0.0 9.7	4.7
Kinki 2.9 2.9 2.3 0.7 0.7 0.7 1.0 1.0 1.0 Kinki 2.9 2.9 2.3 0.7 0.7 0.1 5.4 Shikoku 9.1 2.3 6.7 2.3 1.1 1.1 1.1 1.1 Kita Kyusyu 3.0 2.4 1.8 1.2 1.2 0.6 0.6 4.2 Sex Men 5.7 3.8 3.0 1.8 1.6 1.5 2.1 7.5 Women 3.4 1.9 2.2 0.9 0.7 0.8 1.0 4.7 Age group 10 2.7 2.7 2.3 2.3 1.3 1.3 2.4 6.5 30s 3.9 3.9 2.1 1.3 1.3 1.3 2.4 6.5 30s 3.7 1.9 2.3 1.4 1.3 1.3 1.4 4.2 60s 4.2 1.9 1.7 0.8 1.1 1.0 8.4 9.0 50s 3.7 1.9	Tokai	6.4	3.4	3.0 3.4	2.1	1.8	1.5	1.8	7.6
$\begin{array}{c c c c c c c c c c c c c c c c c c c $	Kinki	0.4 2.9	9.4 9.9	0.4 9.3	0.7	0.7	0.7	1.0	5.4
Consigned 0.5 0.1 0.1 0.1 1.3 Shikoku 9.1 2.3 5.7 2.3 1.1 1.1 1.1 1.1 Kitar-Kyusyu 3.0 2.4 1.8 1.2 0.9 0.4 0.9 0.9 3.9 Minami-Kyusyu 3.0 2.4 1.8 1.2 1.2 0.6 0.6 4.2 Sex Men 5.7 3.8 3.0 1.8 1.6 1.5 2.1 7.5 Women 3.4 1.9 2.2 0.9 0.7 0.8 1.0 4.7 Age group 10s 2.7 2.7 2.3 2.3 1.8 1.8 3.2 20s 3.9 3.9 2.1 1.3 1.3 1.3 2.4 6.5 30s 5.8 4.5 2.7 2.2 1.3 1.3 1.4 4.2 60s 4.2 1.9 1.7 0.8 1.1 1.0 8.5 3.0 Self employed business 8.9 7.3 4.0 2	Chugoku	63	2.0	2.0	0.7 9.1	2.6	2.6	1.1 9.1	7.9
Sinkoru 5.1 2.3 3.7 2.5 1.1 1.1 1.1 1.1 1.1 1.1 1.1 1.1 1.1 1.1 1.1 1.1 1.1 1.1 1.1 1.1 1.1 1.1 1.1 1.1 1.1 1.1 1.1 1.1 1.1 1.1 1.1 1.1 1.1 1.1 1.1 1.1 1.1 1.1 1.1 1.1 1.1 1.1 1.1 1.1 1.1 1.1 1.1 1.1 1.1 1.1 1.1 1.1 1.1 1.1 1.1 1.1 1.1 1.1 1.1 1.1 1.1 1.1 1.1 1.1 1.1 1.1 1.1 1.1 1.1 1.1 1.1 1.1 1.1 1.1 1.1 1.1 1.1 1.1 1.1 1.1 1.1 1.1 1.1 1.1 1.1 1.1 1.1 1.1 1.1 1.1 1.1 1.1 1.1 1.1 1.1 1.1 1.1 1.1 1.1 1.1 1.1 1.1 1.1 1.1 1.1	Shikoku	0.5	0.1	5.7	2.1	2.0	2.0	1.1	11.0
Ann Ryusyu3.11.12.20.50.40.50.53.9MinamirKyusyu3.02.41.81.21.20.60.64.2SexMen5.73.83.01.81.61.52.17.5Moren3.41.92.20.90.70.81.04.7Age group10s2.72.72.32.32.31.81.83.220s3.93.92.11.31.31.44.26.630s5.84.52.72.21.31.32.46.550s5.12.43.60.80.70.70.96.550s3.71.92.31.41.31.31.44.260s4.21.91.70.81.11.00.85.3OccupationSelf-employed business8.97.34.02.82.42.02.41.0Non-full-time employee5.02.52.31.31.00.91.76.3Non-full-time employee3.03.32.62.62.62.22.23.7Housewife (househusband)2.50.91.60.70.20.20.7 <th< td=""><td>Kito-Kuuouu</td><td>9.1 9.1</td><td>2.5</td><td>0.7 9.9</td><td>2.5</td><td>1.1</td><td>1.1</td><td>1.1</td><td>2.0</td></th<>	Kito-Kuuouu	9.1 9.1	2.5	0.7 9.9	2.5	1.1	1.1	1.1	2.0
Main ryusya 3.0 2.4 1.8 1.2 1.2 1.0 0.0 4.2 Sex Men 5.7 3.8 3.0 1.8 1.6 1.5 2.1 7.5 Women 3.4 1.9 2.2 0.9 0.7 0.8 1.0 4.7 Age group 10 2.7 2.7 2.3 2.3 1.8 1.8 3.2 20s 3.9 3.9 2.1 1.3 1.3 1.3 2.4 6.5 30s 5.8 4.5 2.7 2.2 1.3 1.3 2.4 9.0 40s 5.1 2.4 3.6 0.8 7 0.7 9.9 6.5 50s 3.7 1.9 2.3 1.4 1.3 1.3 1.4 4.2 60s 4.2 1.9 1.7 0.8 1.1 1.1 0.8 5.3 Self employed business 8.9 7.3 4.0 2.8 2.4 2.0 2.4 10.9 Full-time employee 5.0 2.5	Minomi-Kuusuu	2.0	1.7	1.2	1.9	1.9	0.5	0.5	1.9
Men5.73.83.01.81.61.52.17.5Women3.41.92.20.90.70.81.04.7Age group </td <td>Sov</td> <td>5.0</td> <td>2.4</td> <td>1.0</td> <td>1.4</td> <td>1.4</td> <td>0.0</td> <td>0.0</td> <td>4.4</td>	Sov	5.0	2.4	1.0	1.4	1.4	0.0	0.0	4.4
Mem 5.7 5.8 5.0 1.8 1.6 1.3 2.1 1.3 Women 3.4 1.9 2.2 0.9 0.7 0.8 1.0 4.7 Age group 10s 2.7 2.7 2.3 2.3 2.3 1.8 1.8 3.2 20s 3.9 3.9 2.1 1.3 1.3 1.3 2.4 6.5 30s 5.8 4.5 2.7 2.2 1.3 1.3 2.4 9.0 40s 5.1 2.4 3.6 0.8 0.7 0.7 0.9 6.5 50s 3.7 1.9 2.3 1.4 1.3 1.3 1.4 4.2 60s 4.2 1.9 1.7 0.8 1.1 0.8 5.3 Occupation Self-employee 5.0 2.5 2.3 1.3 1.0 0.9 1.7 6.3 Non-full-time employee 3.3 0.3 2.	Mon	57	20	2.0	10	1.0	15	0.1	75
Wonen3.41.52.20.50.70.81.04.7Age group10s2.72.72.32.32.31.81.83.220s3.93.92.11.31.31.32.46.530s5.84.52.72.21.31.32.49.040s5.12.43.60.80.70.70.96.550s3.71.92.31.41.31.31.44.260s4.21.91.70.81.11.10.85.3OccupationSelf-employed business8.97.34.02.82.42.02.410.9Non-full-time employee5.02.52.31.31.00.91.76.3Non-full-time employee4.33.03.01.31.31.81.56.6Student3.03.32.62.62.62.22.73.9Unemployed3.42.22.80.60.60.66.66.6Other1.42.92.90.71.41.40.73.6No response/unknown25.00.025.00.00.00.025.0Junior college/university3.03.22.77.73.12.12.13.113.4Huse school6.1<	Womon	0.7 9.4	0.0 1.0	5.0 9.9	1.0	1.0	1.0	2.1	1.0
Are group10s2.72.72.32.31.81.81.83.220s3.93.92.11.31.31.32.49.040s5.12.43.60.80.70.96.550s3.71.92.31.41.31.31.44.260s4.21.91.70.81.11.10.85.3OccupationSelf-employed business8.97.34.02.82.42.02.410.9Full-time employee5.02.52.31.31.00.91.76.8Non-full-time employee4.33.03.01.31.31.81.56.6Student3.03.22.62.62.62.22.23.7Housewife (househusband)2.50.91.60.70.20.20.73.9Unemployed1.42.92.90.71.41.40.73.6No response/unknown25.00.025.00.00.00.025.0Junior high school10.37.27.73.12.12.13.113.4High school5.43.42.00.70.50.50.76.9Junior ingleg/university3.02.21.71.21.11.31.55.1Other0.00.00.00.0 <td>Age group</td> <td>0.4</td> <td>1.9</td> <td>2.2</td> <td>0.9</td> <td>0.7</td> <td>0.8</td> <td>1.0</td> <td>4.7</td>	Age group	0.4	1.9	2.2	0.9	0.7	0.8	1.0	4.7
10s 2.1 2.3 2.3 1.5 1.5 3.2 20s 3.9 3.9 2.1 1.3 1.3 1.3 1.3 2.4 6.5 30s 5.8 4.5 2.7 2.2 1.3 1.3 2.4 9.0 40s 5.1 2.4 3.6 0.8 0.7 0.7 0.9 6.5 50s 3.7 1.9 2.3 1.4 1.3 1.3 1.4 4.2 60s 4.2 1.9 1.7 0.8 1.1 1.1 0.8 5.3 Occupation 3.7 1.9 2.5 2.3 1.3 1.0 0.9 1.7 6.3 Non-full-time employee 5.0 2.5 2.3 1.3 1.3 1.8 1.5 6.6 Student 3.0 3.2 6.2 2.2 2.3 7.7 Housewife (househusband) 2.5 0.9 1.6 0.7 0.2 0.2 0.7 3.9 Unemployed 3.4 2.2 2.8 0.6 <td< td=""><td>Age group</td><td>97</td><td>97</td><td>0.0</td><td>99</td><td>0.9</td><td>10</td><td>10</td><td>2.9</td></td<>	Age group	97	97	0.0	9 9	0.9	10	10	2.9
20s 5.9 5.9 2.1 1.3 1.3 1.3 1.4 0.3 30s 5.8 4.5 2.7 2.2 1.3 1.3 2.4 0.0 40s 5.1 2.4 3.6 0.8 0.7 0.7 0.9 6.5 $50s$ 3.7 1.9 2.3 1.4 1.3 1.3 1.4 4.2 $60s$ 4.2 1.9 1.7 0.8 1.1 1.1 0.8 5.3 Occupation $Self$ employed business 8.9 7.3 4.0 2.8 2.4 2.0 2.4 10.9 Full-time employee 5.0 2.5 2.3 1.3 1.0 0.9 1.7 6.3 Non-full-time employee 4.3 3.0 3.0 1.3 1.3 1.8 1.5 6.6 Student 3.0 3.3 2.6 2.6 2.6 2.2 2.2 3.7 Housewife (househusband) 2.5 0.9 0.7 1.4 1.4 0.7 3.6 Other 1.4 2.9 2.9 0.7 1.4 1.4 0.7 3.6 No response/unknown 25.0 0.0 25.0 0.0 0.0 0.0 25.0 Junior high school 10.3 7.2 7.7 3.1 2.1 2.1 3.1 13.4 Junior college/university 3.0 2.2 1.7 1.2 1.1 1.3 1.7 5.0 Graduate school 6.1 </td <td>108</td> <td>2.7</td> <td>2.1</td> <td>2.0 0.1</td> <td>2.0 1.9</td> <td>2.3 1.9</td> <td>1.0</td> <td>1.8</td> <td><u>а.</u>2</td>	108	2.7	2.1	2.0 0.1	2.0 1.9	2.3 1.9	1.0	1.8	<u>а.</u> 2
3085.84.52.72.21.31.32.49.040s5.12.43.60.80.70.70.96.550s3.71.92.31.41.31.31.44.260s4.21.91.70.81.11.10.85.3Occupation $$$ $$$ $$$ $$$ $$$ $$$ $$$ $$$ $$$ $$$ $$$ $$$ $$$ $$$ $$$ $$$ $$$ $$$ $$$ $$$ $$$ $$$ $$$ $$$ $$$ $$$ $$$ $$$ $$$ $$$ $$$ $$$ $$$ $$$ $$$ $$$ $$$ $$$ $$$ $$$ $$$ $$$ $$$ $$$ $$$ $$$ $$$ $$$ $$$ $$$ $$$ $$$ $$$ $$$ $$$ $$$ $$$ $$$ $$$ $$$ $$$ $$$ $$$ $$$ $$$ $$$ $$$ $$$ $$$ $$$ $$$ $$$ $$$ $$$ $$$ $$$ $$$ $$$ $$$ $$$ $$$ $$$ $$$ $$$ $$$ $$$ $$$ $$$ $$$ $$$ $$$ $$$ $$$ $$$ $$$ $$$ $$$ $$$ $$$ $$$ $$$ $$$ $$$ $$$ $$$ $$$ $$$ $$$ $$$ $$$ $$$ $$$ $$$ $$$ $$$ $$$ $$$ $$$ $$$ $$$ $$$ $$$ $$$ $$$ $$$ $$$ $$$ $$$ $$$ <td>208</td> <td>3.9 F 0</td> <td>5.9 4 5</td> <td>2.1</td> <td>1.0</td> <td>1.0</td> <td>1.0</td> <td>2.4</td> <td>6.0</td>	208	3.9 F 0	5.9 4 5	2.1	1.0	1.0	1.0	2.4	6.0
408 0.1 2.4 3.6 0.8 0.7 0.7 0.7 0.9 0.5 $50s$ 3.7 1.9 2.3 1.4 1.3 1.3 1.4 4.2 $60s$ 4.2 1.9 1.7 0.8 1.1 1.1 0.8 5.3 OccupationSelf-employed business 8.9 7.3 4.0 2.8 2.4 2.0 2.4 10.9 Full-time employee 5.0 2.5 2.3 1.3 1.0 0.9 1.7 6.3 Non-full-time employee 4.3 3.0 3.0 1.3 1.3 1.8 1.5 6.6 Student 3.0 3.3 2.6 2.6 2.2 2.7 7.7 Housewife (househushand) 2.5 0.9 1.6 0.7 0.2 0.2 0.7 Unemployed 3.4 2.2 2.8 0.6 0.6 0.6 6.6 Other 1.4 2.9 2.9 0.7 1.4 1.4 0.7 3.6 No response/unknown 25.0 0.2 0.7 1.4 1.4 0.7 3.6 No response/unknown 25.0 0.2 0.7 1.4 1.4 0.7 3.6 No cational school 10.3 7.2 7.7 3.1 2.1 2.1 3.1 3.0 3.2 2.6 1.1 1.0 0.8 1.3 5.8 Vocational school 5.4 3.4 2.0 0.7 <	308	0.8 F 1	4.0	2.7	2.2	1.3	1.3	2.4	9.0
b08 3.4 1.9 2.3 1.4 1.3 1.3 1.4 4.2 608 4.2 1.9 1.7 0.8 1.1 1.1 0.8 5.3 OccupationSelf-employed business 8.9 7.3 4.0 2.8 2.4 2.0 2.4 10.9 Full-time employee 5.0 2.5 2.3 1.3 1.0 0.9 1.7 6.3 Non-full-time employee 4.3 3.0 3.0 1.3 1.8 1.5 6.6 Student 3.0 3.3 2.6 2.6 2.2 2.2 3.7 Housewife (househusband) 2.5 0.9 1.6 0.7 0.2 0.2 0.7 3.9 Unemployed 3.4 2.2 2.8 0.6 0.6 0.6 0.6 5.6 Other 1.4 2.9 2.9 0.7 1.4 1.4 0.7 3.6 No response/unknown 25.0 0.0 25.0 0.0 0.0 0.0 0.0 0.0 Junior high school 10.3 7.2 7.7 3.1 2.1 2.1 3.1 13.4 High school 6.1 4.5 3.0 3.0 1.5 1.5 0.7 6.9 Junior college/university 3.0 2.2 1.7 1.2 1.1 1.3 1.7 5.0 Graduate school 6.1 4.5 3.0 3.0 1.5 1.5 9.1 Other 0	408	0.1 0.7	2.4	3.6 0.0	0.8	0.7	0.7	0.9	6.0
00s 4.2 1.9 1.7 0.8 1.1 1.1 0.8 5.3 Occupation Self-employed business 8.9 7.3 4.0 2.8 2.4 2.0 2.4 10.9 Full-time employee 5.0 2.5 2.3 1.3 1.0 0.9 1.7 6.3 Non-full-time employee 4.3 3.0 3.3 2.6 2.6 2.6 2.2 2.2 3.7 Housewife (househusband) 2.5 0.9 1.6 0.7 0.2 0.2 0.7 3.9 Unemployed 3.4 2.2 2.8 0.6 0.6 0.6 0.6 0.6 0.6 0.6 0.6 0.6 0.6 0.6 0.6 0.6 0.6 0.6 0.6 0.6 0.6 0.6 0.6 0.6 0.6 0.6 0.6 0.6 0.6 0.6 0.6 0.6 0.6 0.6 0.6 0.6 0.6 0.6 0.6 0.6	505	ə.7	1.9	2.0	1.4	1.5	1.5	1.4	4.2
Self employed business 8.9 7.3 4.0 2.8 2.4 2.0 2.4 10.9 Full-time employee 5.0 2.5 2.3 1.3 1.0 0.9 1.7 6.3 Non-full-time employee 4.3 3.0 3.0 1.3 1.3 1.8 1.5 6.6 Student 3.0 3.3 2.6 2.6 2.2 2.2 3.7 Housewife (househusband) 2.5 0.9 1.6 0.7 0.2 0.2 0.7 3.9 Unemployed 3.4 2.2 2.8 0.6 0.6 0.6 0.6 5.6 Other 1.4 2.9 2.9 0.7 1.4 1.4 0.7 3.6 No response/unknown 25.0 0.0 25.0 0.0 0.0 0.0 0.0 25.0 Junior high school 10.3 7.2 7.7 3.1 2.1 2.1 3.1 13.4 High school 4.6 2.2 2.6 1.1 1.0 0.8 1.3 5.8 J	Occurrentian	4.2	1.9	1.7	0.8	1.1	1.1	0.0	0.0
Set of hippiyed business5.97.34.02.82.42.02.410.9Full-time employee5.02.52.31.31.00.91.76.3Non-full-time employee4.33.03.01.31.31.81.56.6Student3.03.32.62.62.62.22.23.7Housewife (househusband)2.50.91.60.70.20.20.73.9Unemployed3.42.22.80.60.60.60.65.6Other1.42.92.90.71.41.40.73.6No response/unknown25.00.025.00.00.00.00.025.0Final academic backgroundJunior high school10.37.27.73.12.12.13.113.4Junior college/university3.02.21.71.21.11.31.75.0Graduate school6.14.53.03.01.51.59.1Other0.00.00.00.00.00.00.00.0In school3.03.32.62.62.22.23.7No response/unknown0.00.00.00.00.00.00.0In school3.03.32.62.62.22.23.7No response/unknown0.00.00.00.00.00.0 </td <td>Solf-complexed by siness</td> <td>8.0</td> <td>7 9</td> <td>4.0</td> <td>90</td> <td>9.4</td> <td>2.0</td> <td>9.4</td> <td>10.0</td>	Solf-complexed by siness	8.0	7 9	4.0	90	9.4	2.0	9.4	10.0
Non-full-time employee 5.0 2.3 2.3 1.3 1.0 0.9 1.7 6.3 Non-full-time employee 4.3 3.0 3.0 1.3 1.3 1.8 1.5 6.6 Student 3.0 3.3 2.6 2.6 2.2 2.2 2.7 3.9 Unewife (househusband) 2.5 0.9 1.6 0.7 0.2 0.2 0.7 3.9 Unemployed 3.4 2.2 2.8 0.6 0.6 0.6 0.6 5.6 Other 1.4 2.9 2.9 0.7 1.4 1.4 0.7 3.6 No response/unknown 25.0 0.0 25.0 0.0 0.0 0.0 25.0 Final academic backgroundJunior high school 10.3 7.2 7.7 3.1 2.1 2.1 3.1 13.4 High school 4.6 2.2 2.6 1.1 1.0 0.8 1.3 5.8 Vocational school 5.4 3.4 2.0 0.7 0.5 0.5 0.7 6.9 Junior college/university 3.0 2.2 1.7 1.2 1.1 1.3 1.7 5.0 Graduate school 6.1 4.5 3.0 3.0 1.5 1.5 1.5 9.1 Other 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 In school 3.0 3.3 2.6 2.6 2.2 2.2 3.7	Full-time employee	0.9 5.0	1.0 9.5	4.0	2.0 1.9	2.4	2.0	2.4	10.9
Non run run employee4.35.05.01.31.31.61.51.56.0Student3.03.32.62.62.22.23.7Housewife (househusband)2.50.91.60.70.20.20.73.9Unemployed3.42.22.80.60.60.60.65.6Other1.42.92.90.71.41.40.73.6No response/unknown25.00.025.00.00.00.025.0Final academic backgroundJunior high school10.37.27.73.12.12.13.113.4High school4.62.22.61.11.00.81.35.8Vocational school5.43.42.00.70.50.50.76.9Junior college/university3.02.21.71.21.11.31.75.0Graduate school6.14.53.03.01.51.51.59.1Other0.00.00.00.00.00.00.00.0In school3.03.32.62.62.22.23.7No response/unknown0.00.00.00.00.00.0In school3.03.32.62.62.22.23.7No response/unknown0.00.00.00.00.00.0In school	Non-full-time employee	0.0 4.2	2.0	2.0	1.0	1.0	1.9	1.7	0.0
Student5.05.32.62.62.62.22.25.7Housewife (househusband)2.50.91.60.70.20.20.73.9Unemployed3.42.22.80.60.60.60.65.6Other1.42.92.90.71.41.40.73.6No response/unknown25.00.025.00.00.00.025.0Final academic backgroundJunior high school10.37.27.73.12.12.13.113.4High school4.62.22.61.11.00.81.35.8Vocational school5.43.42.00.70.50.50.76.9Junior college/university3.02.21.71.21.11.31.75.0Graduate school6.14.53.03.01.51.59.1Other0.00.00.00.00.00.00.0In school3.03.32.62.62.22.23.7No response/unknown0.00.00.00.00.00.00.0Time spent on the Internet1.21.31.11.11.86.91 to <2 hours	Student	4.0	0.U 9.9	5.0 9.6	1.0	1.5	1.0	1.0	0.0
Housewire (nousenusband)2.50.91.60.70.20.20.73.9Unemployed 3.4 2.2 2.8 0.6 0.6 0.6 0.6 5.6 Other 1.4 2.9 2.9 0.7 1.4 1.4 0.7 3.6 No response/unknown 25.0 0.0 25.0 0.0 0.0 0.0 0.0 0.0 Final academic backgroundJunior high school 10.3 7.2 7.7 3.1 2.1 2.1 3.1 13.4 High school 4.6 2.2 2.6 1.1 1.0 0.8 1.3 5.8 Vocational school 5.4 3.4 2.0 0.7 0.5 0.5 0.7 6.9 Junior college/university 3.0 2.2 1.7 1.2 1.1 1.3 1.7 5.0 Graduate school 6.1 4.5 3.0 3.0 1.5 1.5 9.1 Other 0.0 0.0 0.0 0.0 0.0 0.0 0.0 In school 3.0 3.3 2.6 2.6 2.2 2.2 3.7 No response/unknown 0.0 0.0 0.0 0.0 0.0 0.0 0.0 Time spent on the Internet 1.2 2.8 1.6 1.6 1.5 1.9 6.0 1 to <2 hours	Haussenife (hausshucherd)	5.U	0.0	2.0	2.0	2.0	2.2	2.2	ə.7 2 0
Other 5.4 2.2 2.8 0.6 0.6 0.6 0.6 0.6 0.6 0.6 0.6 0.6 0.6 0.6 0.6 0.6 0.6 0.6 0.6 0.6 0.6 0.6 0.6 0.6 0.6 0.6 0.6 0.6 0.6 0.6 0.6 0.6 0.6 0.6 0.6 0.6 0.6 0.6 0.6 0.6 0.6 0.6 0.6 0.6 0.6 0.6 0.6 0.6 0.6 0.6 0.6 0.6 0.6 0.6 0.6 0.6 0.6 0.6 0.6 0.6 0.6 0.6 0.6 0.6 0.6 0.6 0.6 0.6 0.6 0.6 0.6 0.6 0.6 0.6 0.6 0.6 0.6 0.6 0.6 0.6 0.6 0.6 0.6 0.6 0.6 0.6 0.6 0.6 0.6 0.6 0.6 0.6 0.6 0.6 0.6 0.6 0.6 0.6 0.6 0.6 0.6 0.6 0.6 0.6 0.6 0.6 0.6 0.6 0.6 0.6 0.6 0.6 0.6 0.6 0.6 0.6 0.6 0.6 0.6 0.6 0.6 0.6 0.6 0.6 0.6 0.6 0.6 0.6 0.6 0.6 0.6 0.6 0.6 0.6 0.6 0.6 0.6 0.6 0.6 0.6 0.6 0.6 0.6 0.6 <th< td=""><td>Linemployed</td><td>2.0</td><td>0.9</td><td>1.0</td><td>0.7</td><td>0.2</td><td>0.2</td><td>0.7</td><td>5.9</td></th<>	Linemployed	2.0	0.9	1.0	0.7	0.2	0.2	0.7	5.9
Noter1.42.92.90.71.41.40.75.6No response/unknown25.00.025.00.00.00.00.025.0Final academic backgroundJunior high school10.37.27.73.12.12.13.113.4High school4.62.22.61.11.00.81.35.8Vocational school5.43.42.00.70.50.50.76.9Junior college/university3.02.21.71.21.11.31.75.0Graduate school6.14.53.03.01.51.51.59.1Other0.00.00.00.00.00.00.00.0In school3.03.32.62.62.22.23.7No response/unknown0.00.00.00.00.00.00.0Time spent on the Internet112.52.81.61.61.51.96.01 to <2 hours	Other	0.4 1.4	2.2	2.0	0.6	0.0	0.0	0.0	0.0 9.6
No response/unknown25.0 0.0 25.0 0.0 0.0 0.0 0.0 25.0 Final academic backgroundJunior high school 10.3 7.2 7.7 3.1 2.1 2.1 3.1 13.4 High school 4.6 2.2 2.6 1.1 1.0 0.8 1.3 5.8 Vocational school 5.4 3.4 2.0 0.7 0.5 0.5 0.7 6.9 Junior college/university 3.0 2.2 1.7 1.2 1.1 1.3 1.7 5.0 Graduate school 6.1 4.5 3.0 3.0 1.5 1.5 1.5 9.1 Other 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 In school 3.0 3.3 2.6 2.6 2.2 2.2 3.7 No response/unknown 0.0 0.0 0.0 0.0 0.0 0.0 0.0 Time spent on the Internet 4.4 1.9 3.3 0.9 1.2 1.2 0.9 5.6 <1 hour	Ne regreen ge (un known	1.4	2.9	2.9	0.7	1.4	1.4	0.7	0.0 95 0
Junior high school10.37.27.73.12.12.13.113.4High school4.62.22.61.11.00.81.35.8Vocational school5.43.42.00.70.50.50.76.9Junior college/university3.02.21.71.21.11.31.75.0Graduate school6.14.53.03.01.51.51.59.1Other0.00.00.00.00.00.00.00.0In school3.03.32.62.62.22.23.7No response/unknown0.00.00.00.00.00.00.0Time spent on the InternetVoresponse/unknown4.41.93.30.91.21.20.95.6<1 hour	Final academic background	20.0	0.0	20.0	0.0	0.0	0.0	0.0	20.0
Junior high school10.31.21.13.12.12.13.113.4High school4.62.22.61.11.00.81.35.8Vocational school5.43.42.00.70.50.50.76.9Junior college/university3.02.21.71.21.11.31.75.0Graduate school6.14.53.03.01.51.51.59.1Other0.00.00.00.00.00.00.00.0In school3.03.32.62.62.62.22.23.7No response/unknown0.00.00.00.00.00.00.00.0Time spent on the Internet7.12.52.81.61.61.51.96.01 to <2 hours	Junior high school	10.2	79	77	9.1	91	9.1	9.1	19.4
High school4.02.22.01.11.00.01.35.8Vocational school5.43.42.00.70.50.50.76.9Junior college/university3.02.21.71.21.11.31.75.0Graduate school6.14.53.03.01.51.51.59.1Other0.00.00.00.00.00.00.00.0In school3.03.32.62.62.22.23.7No response/unknown0.00.00.00.00.00.00.0Time spent on the Internet73.30.91.21.20.95.6<1 hour	High school	10.5	1.4	1.1 9.6	1.1	2.1 1.0	2.1	1.2	5.9
Vocational school 5.4 5.4 5.4 2.0 6.7 6.5 6.5 6.7 6.5 Junior college/university 3.0 2.2 1.7 1.2 1.1 1.3 1.7 5.0 Graduate school 6.1 4.5 3.0 3.0 1.5 1.5 1.5 9.1 Other 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 In school 3.0 3.3 2.6 2.6 2.2 2.2 3.7 No response/unknown 0.0 0.0 0.0 0.0 0.0 0.0 0.0 Time spent on the Internet 1.4 1.9 3.3 0.9 1.2 1.2 0.9 5.6 <1 hour	Vocational school	4.0 5.4	2.2	2.0	1.1	0.5	0.5	1.5	6.0
Sufficiency 3.0 2.2 1.7 1.2 1.1 1.5 1.7 3.0 Graduate school 6.1 4.5 3.0 3.0 1.5 1.5 1.5 9.1 Other 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 In school 3.0 3.3 2.6 2.6 2.6 2.2 2.2 3.7 No response/unknown 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 Time spent on the InternetNone 4.4 1.9 3.3 0.9 1.2 1.2 0.9 5.6 <1 hour	Junior collogo/university	2.0	0.4	2.0	1.9	0.5	1.2	1.7	5.0
Other 0.1 4.3 3.0 3.0 1.3 1.5 1.5 1.5 5.1 Other 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 In school 3.0 3.3 2.6 2.6 2.2 2.2 2.7 3.7 No response/unknown 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 Time spent on the InternetNone 4.4 1.9 3.3 0.9 1.2 1.2 0.9 5.6 <1 hour	Graduate school	6.1	4.5	2.0	2.0	1.1	1.5	1.7	0.1
Other 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 <td< td=""><td>Other</td><td>0.1</td><td>4.0</td><td>0.0</td><td>0.0</td><td>1.5</td><td>1.0</td><td>1.5</td><td>9.1 0.0</td></td<>	Other	0.1	4.0	0.0	0.0	1.5	1.0	1.5	9.1 0.0
In school 5.0 5.0 5.3 2.6 2.6 2.6 2.2 2.2 5.7 No response/unknown 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 Time spent on the Internet 4.4 1.9 3.3 0.9 1.2 1.2 0.9 5.6 <1 hour	In school	2.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
No response/ulknown 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 <th< td=""><td>No response/unknown</td><td>0.0</td><td>0.0</td><td>2.0</td><td>2.0</td><td>2.0</td><td>2.2</td><td>2.2</td><td>0.0</td></th<>	No response/unknown	0.0	0.0	2.0	2.0	2.0	2.2	2.2	0.0
None 4.4 1.9 3.3 0.9 1.2 1.2 0.9 5.6 <1 hour	Time grant on the Internet	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
None 4.4 1.5 5.3 0.9 1.2 1.2 0.9 5.6 <1 hour	None	4.4	1.0	2.2	0.0	1.9	19	0.0	5.6
<1 hour 4.1 2.5 2.6 1.6 1.5 1.5 1.5 0.6 1 to <2 hours 4.3 1.8 1.8 0.6 0.6 0.5 0.6 5.2 2 to <3 hours 4.7 3.5 2.2 1.3 1.1 1.1 1.8 6.9 3 to <5 hours 4.1 3.4 2.8 2.5 1.9 1.9 2.5 5.3 ≥ 5 hours 5.7 4.5 2.8 1.7 0.7 0.9 1.9 7.6 Na regregene/unknown		4.4	1.5	0.0 9.0	1.6	1.2	1.4	1.0	6.0
$1 \text{ to } \sim 2 \text{ hours}$ 4.5 1.6 1.6 0.6 0.6 0.5 0.6 5.2 $2 \text{ to } < 3 \text{ hours}$ 4.7 3.5 2.2 1.3 1.1 1.1 1.8 6.9 $3 \text{ to } < 5 \text{ hours}$ 4.1 3.4 2.8 2.5 1.9 1.9 2.5 5.3 $\geq 5 \text{ hours}$ 5.7 4.5 2.8 1.7 0.7 0.9 1.9 7.6 No mercence/unknown 0.0 0.0 0.0 0.0 0.0 0.0 0.0	1 to < 2 hours	4.1	4.0 1 0	4.0 1 Q	1.0	1.0	1.0	1.9 0.6	0.0 E 9
2.60 < 5 hours 4.7 5.5 2.2 1.5 1.1 1.1 1.6 6.9 $3 \text{ to } < 5 \text{ hours}$ 4.1 3.4 2.8 2.5 1.9 1.9 2.5 5.3 $\geq 5 \text{ hours}$ 5.7 4.5 2.8 1.7 0.7 0.9 1.9 7.6 No regression of the metric state	2 to < 2 hours	4.0 17	1.0 9 5	1.0	1.9	1.0	0.0	1.0	0.4 6.0
$ \begin{array}{cccccccccccccccccccccccccccccccccccc$	2 to <5 hours	·±.1	9.0 9.4	2.2 9.8	1.0 9 5	1.1	1.1	1.0 9.5	5.2
= 0 10010 0.1 4.0 2.0 1.1 0.1 0.3 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0	>5 hours	-1.1 K 7	45	2.0	2.0	1.5	0.0	2.0 1 0	0.0 7 G
NO RESOLUTE NOW/D UU	No response/unknown	0.0	1.0 0.0	0.0	1.7	0.0	0.0	0.0	0.0

Rate of having a close drug abuser: The proportion of respondents knowing anybody who uses or has used illegal drugs around them.

10/	<u>۱</u>
1 7	Ŋ.

		Analgesics	5	1	ranquilize	rs		Hypnotic	es
	Past-year	Past 30-	Chronic	Past-year	Past 30-	Chronic	Past-year	Past 30-	Chronic use
	use	day use	use	use	day use	use	use	day use	
Total	63.0	26.7	2.5	6.0	4.3	3.1	6.2	4.4	2.9
	(62.9)	(26.9)	(2.3)	(5.6)	(4.2)	(3.0)	(6.1)	(4.3)	(2.8)
Residence area									
Hokkaido	73.3	30.5	1.5	8.4	7.6	4.6	9.9	6.9	3.8
Tohoku	60.4	19.2	2.8	6.0	5.2	2.8	5.2	5.2	2.8
Kanto	63.2	27.5	2.7	7.2	5.5	4.0	7.4	5.3	3.4
Hokuriku	62.3	24.7	3.9	3.2	1.9	1.3	4.5	2.6	0.6
Tousan	58.7	24.0	2.7	5.3	2.7	1.3	6.0	4.0	3.3
Tokai	66.2	29.9	1.5	4.0	3.4	2.1	4.0	2.7	1.8
Kinki	58.1	26.2	2.3	6.1	3.6	2.9	6.1	4.5	3.4
Chugoku	58.6	24.6	2.1	4.7	2.6	2.1	5.2	3.1	2.1
Shikoku	71.6	29.5	4.5	8.0	4.5	5.7	6.8	3.4	3.4
Kita-Kyusyu	64.6	27.1	2.6	3.9	2.6	2.2	5.2	3.9	2.6
Minami-Kyusyu	66.7	29.1	1.8	7.3	4.8	3.6	6.1	3.6	3.0
Sex									
Men	53.0	15.4	2.0	4.6	3.5	2.8	5.0	3.7	2.4
	(53.1)	(15.3)	(1.9)	(4.2)	(3.3)	(2.7)	(5.2)	(3.6)	(2.3)
Women	72.0	36.9	3.0	7.2	5.0	3.4	7.2	5.0	3.4
	(71.9)	(37.5)	(2.7)	(6.9)	(5.0)	(3.2)	(7.0)	(4.9)	(3.2)
Age group									
10s	57.2	24.8	0.0	3.2	1.8	1.4	1.8	0.5	0.0
20s	62.6	28.0	1.8	5.8	3.4	2.1	3.7	2.4	1.3
30s	70.3	32.7	1.6	5.1	3.6	2.7	4.5	3.4	2.7
40s	66.4	28.6	2.7	6.7	4.3	3.5	7.1	4.8	2.9
50s	63.0	25.3	3.5	6.2	4.9	3.5	7.6	5.5	3.3
60s	51.8	18.2	3.6	7.2	6.1	4.0	8.7	6.8	5.1
Occupation									
Self-employed business	56.9	16.9	2.0	4.8	3.6	2.8	2.8	2.4	2.0
Full-time employee	63.5	25.4	2.3	4.6	2.8	2.0	5.2	3.5	2.0
Non-full-time employee	67.8	29.4	3.3	5.1	3.8	3.0	4.6	3.0	2.0
Student	56.1	26.2	0.0	2.6	1.5	0.7	1.5	0.4	0.0
Housewife (househusband)	71.6	38.1	3.4	7.6	6.0	3.4	8.9	6.0	3.7
Unemployed	48.0	20.1	2.8	19.6	15.6	12.3	17.3	13.4	11.2
Other	60.9	22.5	5.1	8.7	7.2	5.8	12.3	11.6	8.0
No response/unknown	50.0	25.0	0.0	25.0	25.0	25.0	25.0	25.0	25.0
Final academic background									
Junior high school	56.2	21.6	6.2	9.8	8.2	6.2	9.3	7.2	5.7
High school	63.8	27.1	2.8	6.1	4.4	3.4	7.1	4.6	3.0
Vocational school	70.4	31.0	3.4	6.9	4.2	3.2	7.4	5.9	4.4
Junior college/university	63.3	25.6	1.8	5.6	4.1	2.7	5.2	4.0	2.3
Graduate school	53.0	24.2	0.0	6.1	4.5	4.5	7.6	6.1	4.5
Other	50.0	25.0	6.3	12.5	12.5	0.0	6.3	6.3	0.0
In school	56.1	26.2	0.0	2.6	1.5	0.7	1.5	0.4	0.0
No response/unknown	25.0	25.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Time spent on the Internet									
None	49.7	17.2	3.3	7.7	6.3	5.1	8.2	7.0	5.1
<1 hour	61.2	24.9	2.8	6.6	5.2	3.6	6.7	4.9	3.3
1 to <2 hours	65.9	27.0	1.7	5.4	3.4	2.8	6.2	4.5	2.2
2 to <3 hours	69.6	33.0	3.1	5.3	3.3	2.9	5.1	3.3	2.4
3 to <5 hours	68.4	29.1	2.5	5.0	3.8	1.6	4.7	3.1	1.9
≥5 hours	65.2	30.7	1.9	5.4	3.3	2.1	5.2	2.8	2.4
No response/unknown	31.3	18.8	0.0	6.3	63	0.0	12.5	0.0	0.0

Rate of having a close drug abuser: The proportion of respondents knowing anybody who uses or has used illegal drugs around them.

Chronic use: The proportion of respondents who have used any analgesic, tranquilizer, or hypnotic ≥three times a week.

Table 6. I	Prevalence of	f Alcohol	and/or '	Tobacco	Use ((n =	3076)
------------	---------------	-----------	----------	---------	-------	------	-------

	Alcohol and/or tobacco use							
		Alcohol use			Tobacco use			
	Lifetime	Past-year	Past 30-	Lifetime	Past-year	Past 30-day		
	prevalence	prevalence	day	prevalence	prevalence	prevalence		
			prevalence					
Total	93.4	79.8	67.0	59.8	26.9	24.3		
	(93.8)	(80.2)	(67.0)	(59.8)	(26.2)	(23.2)		
Residence area								
Hokkaido	96.9	84.7	67.9	77.9	36.6	33.6		
Tohoku	92.0	77.2	65.2	59.2	29.6	28.4		
Kanto	92.8	81.3	69.7	60.7	26.4	23.7		
Hokuriku	96.1	86.4	68.8	66.9	29.2	26.6		
Tousan	94.0	80.0	64.0	55.3	22.0	21.3		
Tokai	95.4	78.0	67.4	57.3	27.1	23.5		
Kinki	93.9	76.7	63.6	55.7	24.4	21.7		
Chugoku	89.5	77.0	61.3	56.5	26.7	23.6		
Shikoku	98.9	79.5	61.4	67.0	31.8	29.5		
Kita-Kyusyu	91.3	79.9	68.1	59.0	24.5	22.7		
Minami-Kyusyu	91.5	79.4	70.9	55.2	27.3	22.4		
Sex								
Men	93.7	84.4	75.0	76.2	40.9	37.9		
	(94.2)	(84.6)	(74.9)	(75.0)	(40.2)	(36.8)		
Women	93.0	75.6	59.7	44.8	14.1	11.8		
	(93.4)	(76.1)	(59.7)	(45.8)	(13.3)	(10.6)		
Age group								
10s	36.0	25.2	14.9	6.8	4.5	2.7		
20s	97.1	90.3	76.7	42.9	26.7	23.0		
-00 30s	98.6	83.9	70.0	68.7	20.1 32 7	29.1		
40s	98.8	85.9	71.9	67.6	30.9	28.4		
50%	97.7	81.7	70.4	67.9	28.8	26.5		
605	96.2	79.5	67.4	63.2	20.0 21.6	19.9		
Occupation	50.2	15.0	07.4	05.2	21.0	10.0		
Solf-omployed husiness	97.6	80.1	79.4	79.0	28.3	36.3		
Full-time employee	97.0	80.7	78.1	69.1	33.8	30.8		
Non-full-time employee	97.7	82.5	66.2	58.6	93.4	20.8		
Student	50.2	41.3	31.0	8.9	4.4	1.8		
Hausswife (househushend)	05.0	41.0	59.5	0.J	4.4	1.0		
Unomployed	99.9 09.9	67.6	50.2	40.0	22.4	10.8		
Other	94.0	70.0	09.2 01.0	67.4	20.0	25.0		
Ne we we we have been a source of the second	94.9	79.0 75.0	61.6 85 0	57.4	29.0	24.6		
Fight and and the shares of the second	100.0	75.0	25.0	50.0	50.0	50.0		
Final academic background	00.0	75.9	<u> </u>	77.0	F 9.0	F1 F		
Junior nign school	92.3 07.0	70.0 07.1	60.8 71.0	11.8	00.0 00.5	01.0 20.4		
nign school	97.6	04.1	71.6	67.3	00.1	30.4		
	98.0	83.0	67.7	65.5	26.1	23.9		
Junior college/university	98.5	84.3	71.8	59.6	21.4	18.8		
Graduate school	100.0	89.4	81.8	48.5	9.1	7.6		
Other	87.5	81.3	68.8	62.5	12.5	12.5		
In school	50.2	41.3	31.0	8.9	4.4	1.8		
No response/unknown	75.0	62.5	37.5	37.5	12.5	12.5		
Time spent on the Internet		<u> </u>			22 C	C 1 2		
None	91.8	68.8	55.5	57.1	33.1	31.2		
<1 hour	97.0	84.3	71.4	64.5	24.0	21.6		
1 to <2 hours	93.8	81.7	72.0	61.8	26.2	21.9		
2 to <3 hours	91.4	78.7	66.5	57.6	27.5	25.5		
3 to <5 hours	90.3	81.9	62.5	54.1	25.0	23.4		
≥5 hours	92.0	80.1	67.6	57.4	27.9	25.1		
No response/unknown	93.8	56.3	43.8	50.0	25.0	25.0		

(%)

Table 7.	Basic	demographics	by	Residence	Area	(n =	3076)
----------	-------	--------------	----	-----------	------	------	-------

					-	Residen	ce area					
	Hokk	aido	Toho	oku	Kar	nto	Hoku	riku	Tous	san	Tok	ai
	n =	131	n = 2	250	n = 9	948	n =	154	n =	150	n = :	328
	n	(%)	n	(%)	n	(%)	n	(%)	n	(%)	n	(%)
Sex												
Men	65	(49.6)	114	(45.6)	466	(49.2)	83	(53.9)	71	(47.3)	157	(47.9)
Women	66	(50.4)	136	(54.4)	482	(50.8)	71	(46.1)	79	(52.7)	171	(52.1)
Age group												
10s	9	(6.9)	16	(6.4)	82	(8.6)	11	(7.1)	7	(4.7)	15	(4.6)
20s	16	(12.2)	41	(16.4)	129	(13.6)	14	(9.1)	14	(9.3)	44	(13.4)
30s	29	(22.1)	30	(12.0)	158	(16.7)	28	(18.2)	27	(18.0)	81	(24.7)
40s	28	(21.4)	49	(19.6)	255	(26.9)	42	(27.3)	36	(24.0)	69	(21.0)
50s	28	(21.4)	55	(22.0)	191	(20.1)	36	(23.4)	39	(26.0)	83	(25.3)
60s	21	(16.0)	59	(23.6)	133	(14.0)	23	(14.9)	27	(18.0)	36	(11.0)
Mean age (year)	43.36		44.85		42.27		44.21		45.60		42.69	
Occupation												
Self-employed business	6	(4.6)	30	(12.0)	67	(7.1)	8	(5.2)	16	(10.7)	29	(8.8)
Full-time employee	61	(46.6)	106	(42.4)	429	(45.3)	91	(59.1)	77	(51.3)	159	(48.5)
Non-full-time employee	13	(9.9)	34	(13.6)	125	(13.2)	20	(13.0)	22	(14.7)	34	(10.4)
Student	11	(8.4)	17	(6.8)	96	(10.1)	13	(8.4)	8	(5.3)	25	(7.6)
Housewife (househusband)	28	(21.4)	24	(9.6)	130	(13.7)	10	(6.5)	21	(14.0)	54	(16.5)
Unemployed	7	(5.3)	25	(10.0)	55	(5.8)	8	(5.2)	1	(.7)	15	(4.6)
Other	5	(3.8)	14	(5.6)	46	(4.9)	4	(2.6)	5	(3.3)	12	(3.7)
No response/unknown	0	(.0)	0	(.0)	0	(.0)	0	(.0)	0	(.0)	0	(.0)
Final academic background												
Junior high school	13	(9.9)	23	(9.2)	52	(5.5)	12	(7.8)	4	(2.7)	19	(5.8)
High school	43	(32.8)	129	(51.6)	309	(32.6)	69	(44.8)	56	(37.3)	143	(43.6)
Vocational school	24	(18.3)	26	(10.4)	132	(13.9)	25	(16.2)	26	(17.3)	31	(9.5)
Junior college/university	38	(29.0)	46	(18.4)	311	(32.8)	35	(22.7)	54	(36.0)	102	(31.1)
Graduate school	1	(.8)	4	(1.6)	40	(4.2)	0	(.0)	1	(.7)	5	(1.5)
Other	1	(.8)	4	(1.6)	7	(.7)	0	(.0)	0	(.0)	2	(.6)
In school	11	(8.4)	17	(6.8)	96	(10.1)	13	(8.4)	8	(5.3)	25	(7.6)
No response/unknown	0	(.0)	1	(.4)	1	(.1)	0	(.0)	1	(.7)	1	(.3)
Cellular phone												
Smartphone	82	(62.6)	148	(59.2)	679	(71.6)	98	(63.6)	97	(64.7)	232	(70.7)
Conventional cellular phone	44	(33.6)	91	(36.4)	259	(27.3)	54	(35.1)	52	(34.7)	95	(29.0)
PHS	0	(.0)	2	(.8)	14	(1.5)	1	(.6)	0	(.0)	3	(.9)
Other	0	(.0)	2	(.8)	5	(.5)	0	(.0)	2	(1.3)	1	(.3)
None	3	(2.3)	12	(4.8)	24	(2.5)	5	(3.2)	3	(2.0)	6	(1.8)
No response/unknown	2	(1.5)	1	(.4)	2	(.2)	0	(.0)	0	(.0)	2	(.6)
Time spent on the Internet												
None	17	(13.0)	42	(16.8)	96	(10.1)	26	(16.9)	29		37	(11.3)
<1 hour	35	(26.7)	70	(28.0)	222	(23.4)	36	(23.4)	53	(35.3)	90	(27.4)
1 to < 2 hours	27	(20.6)	42	(16.8)	213	(22.5)	40	(26.0)	22	(14.7)	67	(20.4)
2 to <3 hours	22	(16.8)	31	(12.4)	146	(15.4)	22	(14.3)	20	(13.3)	44	(13.4)
3 to <5 hours	13	(9.9)	35	(14.0)	109	(11.5)	15	(9.7)	10	(6.7)	37	(11.3)
≥5 hours	15	(11.5)	29	(11.6)	159	(16.8)	14	(9.1)	15	(10.0)	52	(15.9)
No response/unknown	2	(1.5)	1	(.4)	3	(.3)	1	(.6)	1	(.7)	1	(.3)

						Re	sidence a	area					
	Kir	ıki	Chug	oku	Shik	oku	Kita-K	yusyu	Minami- Total				
	n = .	442	n = 1	191	n =	88	n = 2	229	n = 165		n = 3	8076	P-value
	n	(%)	n	(%)	n	(%)	n	(%)	n	(%)	n	(%)	
Sex													0.714
Men	194	(43.9)	91	(47.6)	43	(48.9)	103	(45.0)	79	(47.9)	1,466	(47.7)	
Women	248	(56.1)	100	(52.4)	45	(51.1)	126	(55.0)	86	(52.1)	1,610	(52.3)	
Age group													0.003
10s	29	(6.6)	18	(9.4)	4	(4.5)	16	(7.0)	15	(9.1)	222	(7.2)	
20s	51	(11.5)	18	(9.4)	11	(12.5)	27	(11.8)	17	(10.3)	382	(12.4)	
30s	72	(16.3)	27	(14.1)	18	(20.5)	51	(22.3)	32	(19.4)	553	(18.0)	
40s	109	(24.7)	54	(28.3)	24	(27.3)	54	(23.6)	31	(18.8)	751	(24.4)	
50s	108	(24.4)	41	(21.5)	20	(22.7)	44	(19.2)	50	(30.3)	695	(22.6)	
60s	73	(16.5)	33	(17.3)	11	(12.5)	37	(16.2)	20	(12.1)	473	(15.4)	
Mean age (year)	44.14		44.08		43.05		42.68		42.87		43.30		0.089
Occupation													< 0.001
Self-employed business	39	(8.8)	13	(6.8)	5	(5.7)	25	(10.9)	10	(6.1)	248	(8.1)	
Full-time employee	157	(35.5)	98	(51.3)	51	(58.0)	102	(44.5)	75	(45.5)	1,406	(45.7)	
Non-full-time employee	65	(14.7)	25	(13.1)	8	(9.1)	28	(12.2)	20	(12.1)	394	(12.8)	
Student	39	(8.8)	21	(11.0)	4	(4.5)	21	(9.2)	16	(9.7)	271	(8.8)	
Housewife (househusband)	88	(19.9)	20	(10.5)	12	(13.6)	25	(10.9)	24	(14.5)	436	(14.2)	
Unemployed	29	(6.6)	7	(3.7)	5	(5.7)	12	(5.2)	15	(9.1)	179	(5.8)	
Other	23	(5.2)	7	(3.7)	3	(3.4)	14	(6.1)	5	(3.0)	138	(4.5)	
No response/unknown	2	(.5)	0	(.0)	0	(.0)	2	(.9)	0	(.0)	4	(.1)	
Final academic background													< 0.001
Junior high school	37	(8.4)	5	(2.6)	8	(9.1)	14	(6.1)	7	(4.2)	194	(6.3)	
High school	162	(36.7)	77	(40.3)	35	(39.8)	83	(36.2)	80	(48.5)	1,186	(38.6)	
Vocational school	58	(13.1)	32	(16.8)	11	(12.5)	23	(10.0)	18	(10.9)	406	(13.2)	
Junior college/university	140	(31.7)	54	(28.3)	27	(30.7)	81	(35.4)	41	(24.8)	929	(30.2)	
Graduate school	4	(.9)	2	(1.0)	3	(3.4)	4	(1.7)	2	(1.2)	66	(2.1)	
Other	1	(.2)	0	(.0)	0	(.0)	0	(.0)	1	(.6)	16	(.5)	
In school	39	(8.8)	21	(11.0)	4	(4.5)	21	(9.2)	16	(9.7)	271	(8.8)	
No response/unknown	1	(.2)	0	(.0)	0	(.0)	3	(1.3)	0	(.0)	8	(.3)	
Cellular phone													
Smartphone	303	(68.6)	128	(67.0)	62	(70.5)	155	(67.7)	111	(67.3)	2,095	(68.1)	0.065
Conventional cellular phone	137	(31.0)	63	(33.0)	23	(26.1)	66	(28.8)	52	(31.5)	936	(30.4)	0.220
PHS	2	(.5)	2	(1.0)	2	(2.3)	2	(.9)	4	(2.4)	32	(1.0)	0.372
Other	4	(.9)	0	(.0)	1	(1.1)	5	(2.2)	2	(1.2)	22	(.7)	0.247
None	15	(3.4)	4	(2.1)	1	(1.1)	6	(2.6)	3	(1.8)	82	(2.7)	0.546
No response/unknown	1	(.2)	1	(.5)	1	(1.1)	2	(.9)	0	(.0)	12	(.4)	0.405
Time spent on the Internet													0.009
None	75	(17.0)	23	(12.0)	10	(11.4)	39	(17.0)	35		429	(13.9)	
<1 hour	104	(23.5)	53	(27.7)	19	(21.6)	63	(27.5)	43	(26.1)	788	(25.6)	
1 to <2 hours	90	(20.4)	41	(21.5)	21	(23.9)	52	(22.7)	34	(20.6)	649	(21.1)	
2 to <3 hours	74	(16.7)	28	(14.7)	19	(21.6)	24	(10.5)	21	(12.7)	451	(14.7)	
3 to <5 hours	44	(10.0)	15	(7.9)	9	(10.2)	22	(9.6)	11	(6.7)	320	(10.4)	
≥5 hours	53	(12.0)	30	(15.7)	9	(10.2)	27	(11.8)	20	(12.1)	423	(13.8)	
No response/unknown	2	(.5)	1	(.5)	1	(1.1)	2	(.9)	1	(.6)	16	(.5)	

				Sex			
	Me	en	Won	nen	Tot	al	
	n = 1	466	n = 1	610	n = 3	8076	P-value
	n	(%)	n	(%)	n	(%)	
Residence area							0.714
Hokkaido	65	(4.4)	66	(4.1)	131	(4.3)	
Tohoku	114	(7.8)	136	(8.4)	250	(8.1)	
Kanto	466	(31.8)	482	(29.9)	948	(30.8)	
Hokuriku	83	(5.7)	71	(4.4)	154	(5.0)	
Tousan	71	(4.8)	79	(4.9)	150	(4.9)	
Tokai	157	(10.7)	171	(10.6)	328	(10.7)	
Kinki	194	(13.2)	248	(15.4)	442	(14.4)	
Chugoku	91	(6.2)	100	(6.2)	191	(6.2)	
Shikoku	43	(2.9)	45	(2.8)	88	(2.9)	
Kita-Kyusyu	103	(7.0)	126	(7.8)	229	(7.4)	
Minami-Kyusyu	79	(5.4)	86	(5.3)	165	(5.4)	
Age group							0.697
10s	111	(7.6)	111	(6.9)	222	(7.2)	
20s	169	(11.5)	213	(13.2)	382	(12.4)	
30s	271	(18.5)	282	(17.5)	553	(18.0)	
40s	356	(24.3)	395	(24.5)	751	(24.4)	
50s	328	(22.4)	367	(22.8)	695	(22.6)	
60s	231	(15.8)	242	(15.0)	473	(15.4)	
Mean age (year)	43.45		43.16		43.30		0.558
Occupation							< 0.001
Self-employed business	179	(12.2)	69	(4.3)	248	(8.1)	
Full-time employee	913	(62.3)	493	(30.6)	1,406	(45.7)	
Non-full-time employee	91	(6.2)	303	(18.8)	394	(12.8)	
Student	132	(9.0)	139	(8.6)	271	(8.8)	
Housewife (househusband)	1	(.1)	435	(27.0)	436	(14.2)	
Unemployed	94	(6.4)	85	(5.3)	179	(5.8)	
Other	56	(3.8)	82	(5.1)	138	(4.5)	
No response/unknown	0	(.0)	4	(.2)	4	(.1)	
Final academic background							< 0.001
Junior high school	116	(7.9)	78	(4.8)	194	(6.3)	
High school	567	(38.7)	619	(38.4)	1,186	(38.6)	
Vocational school	137	(9.3)	269	(16.7)	406	(13.2)	
Junior college/university	450	(30.7)	479	(29.8)	929	(30.2)	
Graduate school	51	(3.5)	15	(.9)	66	(2.1)	
Other	10	(.7)	6	(.4)	16	(.5)	
In school	132	(9.0)	139	(8.6)	271	(8.8)	
No response/unknown	3	(.2)	5	(.3)	8	(.3)	
Cellular phone							
Smartphone	984	(67.1)	1,111	(69.0)	2,095	(68.1)	0.466
Conventional cellular phone	475	(32.4)	461	(28.6)	936	(30.4)	0.072
PHS	20	(1.4)	12	(.7)	32	(1.0)	0.221
Other	11	(.8)	11	(.7)	22	(.7)	0.895
None	40	(2.7)	42	(2.6)	82	(2.7)	0.898
No response/unknown	5	(.3)	7	(.4)	12	(.4)	0.677
Time spent on the Internet							0.040
None	178	(12.1)	251	(15.6)	429	(13.9)	
<1 hour	372	(25.4)	416	(25.8)	788	(25.6)	
1 to <2 hours	332	(22.6)	317	(19.7)	649	(21.1)	
2 to <3 hours	232	(15.8)	219	(13.6)	451	(14.7)	
3 to <5 hours	145	(9.9)	175	(10.9)	320	(10.4)	
≥5 hours	200	(13.6)	223	(13.9)	423	(13.8)	
No response/unknown	-00	(5)	9	(6)	16	(5)	

Table 8. Basic demographics by Sex (n = 3076)

								Age gr	oup						
	1	0s	2	0s	3	0s	4	0s	5	0s	6	0s	To	otal	
	n =	222	n =	382	n =	553	n =	751	n =	695	n =	473	n =	3076	P-value
	n	(%)	n	(%)	n	(%)	n	(%)	n	(%)	n	(%)	n	(%)	
Residence area															0.003
Hokkaido	9	(4.1)	16	(4.2)	29	(5.2)	28	(3.7)	28	(4.0)	21	(4.4)	131	(4.3)	
Tohoku	16	(7.2)	41	(10.7)	30	(5.4)	49	(6.5)	55	(7.9)	59	(12.5)	250	(8.1)	
Kanto	82	(36.9)	129	(33.8)	158	(28.6)	255	(34.0)	191	(27.5)	133	(28.1)	948	(30.8)	
Hokuriku	11	(5.0)	14	(3.7)	28	(5.1)	42	(5.6)	36	(5.2)	23	(4.9)	154	(5.0)	
Tousan	7	(3.2)	14	(3.7)	27	(4.9)	36	(4.8)	39	(5.6)	27	(5.7)	150	(4.9)	
Tokai	15	(6.8)	44	(11.5)	81	(14.6)	69	(9.2)	83	(11.9)	36	(7.6)	328	(10.7)	
Kinki	29	(13.1)	51	(13.4)	72	(13.0)	109	(14.5)	108	(15.5)	73	(15.4)	442	(14.4)	
Chugoku	18	(8.1)	18	(4.7)	27	(4.9)	54	(7.2)	41	(5.9)	33	(7.0)	191	(6.2)	
Shikoku	4	(1.8)	11	(2.9)	18	(3.3)	24	(3.2)	20	(2.9)	11	(2.3)	88	(2.9)	
Kita-Kyusyu	16	(7.2)	27	(7.1)	51	(9.2)	54	(7.2)	44	(6.3)	37	(7.8)	229	(7.4)	
Minami-Kyusyu	15	(6.8)	17	(4.5)	32	(5.8)	31	(4.1)	50	(7.2)	20	(4.2)	165	(5.4)	
Sex															0.697
Men	111	(50.0)	169	(44.2)	271	(49.0)	356	(47.4)	328	(47.2)	231	(48.8)	1,466	(47.7)	
Women	111	(50.0)	213	(55.8)	282	(51.0)	395	(52.6)	367	(52.8)	242	(51.2)	1,610	(52.3)	
Occupation															< 0.001
Self-employed business	1	(.5)	8	(2.1)	23	(4.2)	58	(7.7)	98	(14.1)	60	(12.7)	248	(8.1)	
Full-time employee	6	(2.7)	206	(53.9)	329	(59.5)	422	(56.2)	315	(45.3)	128	(27.1)	1,406	(45.7)	
Non-full-time employee	5	(2.3)	49	(12.8)	60	(10.8)	114	(15.2)	105	(15.1)	61	(12.9)	394	(12.8)	
Student	207	(93.2)	62	(16.2)	1	(.2)	1	(.1)	0	(.0)	0	(.0)	271	(8.8)	
Housewife (househusband)	0	(.0)	21	(5.5)	94	(17.0)	99	(13.2)	105	(15.1)	117	(24.7)	436	(14.2)	
Unemployed	2	(.9)	24	(6.3)	20	(3.6)	28	(3.7)	31	(4.5)	74	(15.6)	179	(5.8)	
Other	1	(.5)	12	(3.1)	24	(4.3)	29	(3.9)	39	(5.6)	33	(7.0)	138	(4.5)	
No response/unknown	0	(.0)	0	(.0)	2	(.4)	0	(.0)	2	(.3)	0	(.0)	4	(.1)	
Final academic background															< 0.001
Junior high school	4	(1.8)	19	(5.0)	26	(4.7)	47	(6.3)	34	(4.9)	64	(13.5)	194	(6.3)	
High school	11	(5.0)	111	(29.1)	188	(34.0)	293	(39.0)	336	(48.3)	247	(52.2)	1,186	(38.6)	
Vocational school	0	(.0)	61	(16.0)	95	(17.2)	116	(15.4)	89	(12.8)	45	(9.5)	406	(13.2)	
Junior college/university	0	(.0)	119	(31.2)	214	(38.7)	269	(35.8)	223	(32.1)	104	(22.0)	929	(30.2)	
Graduate school	0	(.0)	5	(1.3)	24	(4.3)	19	(2.5)	9	(1.3)	9	(1.9)	66	(2.1)	
Other	0	(.0)	4	(1.0)	2	(.4)	5	(.7)	2	(.3)	3	(.6)	16	(.5)	
In school	207	(93.2)	62	(16.2)	1	(.2)	1	(.1)	0	(.0)	0	(.0)	271	(8.8)	
No response/unknown	0	(.0)	1	(.3)	3	(.5)	1	(.1)	2	(.3)	1	(.2)	8	(.3)	
Cellular phone															
Smartphone	200	(90.1)	371	(97.1)	484	(87.5)	553	(73.6)	363	(52.2)	124	(26.2)	2,095	(68.1)	< 0.001
Conventional cellular phone	11	(5.0)	18	(4.7)	81	(14.6)	204	(27.2)	312	(44.9)	310	(65.5)	936	(30.4)	< 0.001
PHS	0	(.0)	2	(.5)	5	(.9)	13	(1.7)	8	(1.2)	4	(.8)	32	(1.0)	0.161
Other	1	(.5)	3	(.8)	5	(.9)	3	(.4)	4		6	(1.3)	22	(.7)	0.361
None	10	(4.5)	0	(.0)	5	(.9)	12	(1.6)	20	(2.9)	35	(7.4)	82	(2.7)	< 0.001
No response/unknown	0	(.0)	0	(.0)	3	(.5)	1	(.1)	4	(.6)	4	(.8)	12	(.4)	0.212
Time spent on the Internet															< 0.001
None	5	(2.3)	9	(2.4)	17	(3.1)	52	(6.9)	145	(20.9)	201	(42.5)	429	(13.9)	
<1 hour	16	(7.2)	40	(10.5)	127	(23.0)	223	(29.7)	237	(34.1)	145	(30.7)	788	(25.6)	
1 to <2 hours	44	(19.8)	76	(19.9)	135	(24.4)	194	(25.8)	139	(20.0)	61	(12.9)	649	(21.1)	
2 to <3 hours	56	(25.2)	81	(21.2)	102	(18.4)	110	(14.6)	78	(11.2)	24	(5.1)	451	(14.7)	
3 to <5 hours	49	(22.1)	81	(21.2)	70	(12.7)	77	(10.3)	30	(4.3)	13	(2.7)	320	(10.4)	
≥5 hours	51	(23.0)	95	(24.9)	100	(18.1)	92	(12.3)	61	(8.8)	24	(5.1)	423	(13.8)	
No response/unknown	1	(.5)	0	(.0)	2	(.4)	3	(.4)	5	(.7)	5	(1.1)	16	(.5)	

Table 10.	Basic demogra	phics by	Occupation	(n = 3076)
-----------	---------------	----------	------------	------------

		Occupation								
	Self-em	ployed	Full-1	time	Non-fu	ll-time	Stuc	dent	House	ewife
	n = 2	248	n = 1	406	n = 394		n = 271		n = -	436
	n	(%)	n	(%)	n	(%)	n	(%)	n	(%)
Residence area										
Hokkaido	6	(2.4)	61	(4.3)	13	(3.3)	11	(4.1)	28	(6.4)
Tohoku	30	(12.1)	106	(7.5)	34	(8.6)	17	(6.3)	24	(5.5)
Kanto	67	(27.0)	429	(30.5)	125	(31.7)	96	(35.4)	130	(29.8)
Hokuriku	8	(3.2)	91	(6.5)	20	(5.1)	13	(4.8)	10	(2.3)
Tousan	16	(6.5)	77	(5.5)	22	(5.6)	8	(3.0)	21	(4.8)
Tokai	29	(11.7)	159	(11.3)	34	(8.6)	25	(9.2)	54	(12.4)
Kinki	39	(15.7)	157	(11.2)	65	(16.5)	39	(14.4)	88	(20.2)
Chugoku	13	(5.2)	98	(7.0)	25	(6.3)	21	(7.7)	20	(4.6)
Shikoku	5	(2.0)	51	(3.6)	8	(2.0)	4	(1.5)	12	(2.8)
Kita-Kyusyu	25	(10.1)	102	(7.3)	28	(7.1)	21	(7.7)	25	(5.7)
Minami-Kyusyu	10	(4.0)	75	(5.3)	20	(5.1)	16	(5.9)	24	(5.5)
Sex										
Men	179	(72.2)	913	(64.9)	91	(23.1)	132	(48.7)	1	(.2)
Women	69	(27.8)	493	(35.1)	303	(76.9)	139	(51.3)	435	(99.8)
Age group										
10s	1	(.4)	6	(.4)	5	(1.3)	207	(76.4)	0	(.0)
20s	8	(3.2)	206	(14.7)	49	(12.4)	62	(22.9)	21	(4.8)
30s	23	(9.3)	329	(23.4)	60	(15.2)	1	(.4)	94	(21.6)
40s	58	(23.4)	422	(30.0)	114	(28.9)	1	(.4)	99	(22.7)
50s	98	(39.5)	315	(22.4)	105	(26.6)	0	(.0)	105	(24.1)
60s	60	(24.2)	128	(9.1)	61	(15.5)	0	(.0)	117	(26.8)
Mean age (year)	51.19		43.10		45.71		18.16		48.83	
Final academic background										
Junior high school	26	(10.5)	71	(5.0)	24	(6.1)	0	(.0)	31	(7.1)
High school	102	(41.1)	547	(38.9)	185	(47.0)	0	(.0)	201	(46.1)
Vocational school	39	(15.7)	210	(14.9)	53	(13.5)	0	(.0)	58	(13.3)
Junior college/university	74	(29.8)	523	(37.2)	125	(31.7)	0	(.0)	141	(32.3)
Graduate school	5	(2.0)	47	(3.3)	5	(1.3)	0	(.0)	2	(.5)
Other	1	(.4)	7	(.5)	1	(.3)	0	(.0)	2	(.5)
In school	0	(.0)	0	(.0)	0	(.0)	271	(100.0)	0	(.0)
No response/unknown	1	(.4)	1	(.1)	1	(.3)	0	(.0)	1	(.2)
Cellular phone										
Smartphone	131	(52.8)	1,040	(74.0)	258	(65.5)	250	(92.3)	257	(58.9)
Conventional cellular phone	113	(45.6)	392	(27.9)	137	(34.8)	12	(4.4)	157	(36.0)
PHS	7	(2.8)	17	(1.2)	1	(.3)	0	(.0)	4	(.9)
Other	0	(.0)	8	(.6)	0	(.0)	0	(.0)	4	(.9)
None	8	(3.2)	9	(.6)	6	(1.5)	10	(3.7)	19	
No response/unknown	1	(.4)	4	(.3)	2	(.5)	0	(.0)	3	(.7)
Time spent on the Internet										
None	46	(18.5)	131	(9.3)	64	(16.2)	5	(1.8)	97	(22.2)
<1 hour	68	(27.4)	395	(28.1)	95	(24.1)	24	(8.9)	130	(29.8)
1 to <2 hours	49	(19.8)	341	(24.3)	82	(20.8)	48	(17.7)	79	(18.1)
2 to <3 hours	29	(11.7)	221	(15.7)	52	(13.2)	67	(24.7)	48	(11.0)
3 to <5 hours	24	(9.7)	125	(8.9)	46	(11.7)	62	(22.9)	34	(7.8)
≥5 hours	29	(11.7)	186	(13.2)	53	(13.5)	65	(24.0)	46	(10.6)
No response/unknown	3	(1.2)	7	(.5)	2	(.5)	0	(.0)	2	(.5)

				(Occupati	on			
	Unem	oloyed	Oth	ner	Unkn	own	Tot	al	
	n =	179	n =	138	n =	4	n = 3	076	P-value
	n	(%)	n	(%)	n	(%)	n	(%)	
Residence area									< 0.001
Hokkaido	7	(3.9)	5	(3.6)	0	(.0)	131	(4.3)	
Tohoku	25	(14.0)	14	(10.1)	0	(.0)	250	(8.1)	
Kanto	55	(30.7)	46	(33.3)	0	(.0)	948	(30.8)	
Hokuriku	8	(4.5)	4	(2.9)	0	(.0)	154	(5.0)	
Tousan	1	(.6)	5	(3.6)	0	(.0)	150	(4.9)	
Tokai	15	(8.4)	12	(8.7)	0	(.0)	328	(10.7)	
Kinki	29	(16.2)	23	(16.7)	2	(50.0)	442	(14.4)	
Chugoku	7	(3.9)	7	(5.1)	0	(.0)	191	(6.2)	
Shikoku	5	(2.8)	3	(2.2)	0	(.0)	88	(2.9)	
Kita-Kyusyu	12	(6.7)	14	(10.1)	2	(50.0)	229	(7.4)	
Minami-Kyusyu	15	(8.4)	5	(3.6)	0	(.0)	165	(5.4)	
Sex									< 0.001
Men	94	(52.5)	56	(40.6)	0	(.0)	1,466	(47.7)	
Women	85	(47.5)	82	(59.4)	4	(100.0)	1,610	(52.3)	
Age group									< 0.001
10s	2	(1.1)	1	(.7)	0	(.0)	222	(7.2)	
20s	24	(13.4)	12	(8.7)	0	(.0)	382	(12.4)	
30s	20	(11.2)	24	(17.4)	2	(50.0)	553	(18.0)	
40s	28	(15.6)	29	(21.0)	0	(.0)	751	(24.4)	
50s	31	(17.3)	39	(28.3)	2	(50.0)	695	(22.6)	
60s	74	(41.3)	33	(23.9)	0	(.0)	473	(15.4)	
Mean age (year)	49.38		48.12		44.75		43.30		< 0.001
Final academic background									< 0.001
Junior high school	26	(14.5)	16	(11.6)	0	(.0)	194	(6.3)	
High school	90	(50.3)	61	(44.2)	0	(.0)	1,186	(38.6)	
Vocational school	21	(11.7)	23	(16.7)	2	(50.0)	406	(13.2)	
Junior college/university	36	(20.1)	30	(21.7)	0	(.0)	929	(30.2)	
Graduate school	3	(1.7)	4	(2.9)	0	(.0)	66	(2.1)	
Other	2	(1.1)	3	(2.2)	0	(.0)	16	(.5)	
In school	0	(.0)	0	(.0)	0	(.0)	271	(8.8)	
No response/unknown	1	(.6)	1	(.7)	2	(50.0)	8	(.3)	
Cellular phone									
Smartphone	79	(44.1)	77	(55.8)	3	(75.0)	2,095	(68.1)	< 0.001
Conventional cellular phone	77	(43.0)	48	(34.8)	0	(.0)	936	(30.4)	< 0.001
PHS	2	(1.1)	1	(.7)	0	(.0)	32	(1.0)	< 0.001
Other	3	(1.7)	7	(5.1)	0	(.0)	22	(.7)	< 0.001
None	23	(12.8)	7	(5.1)	0	(.0)	82	(2.7)	< 0.001
No response/unknown	0	(.0)	1	(.7)	1	(25.0)	12	(.4)	< 0.001
Time spent on the Internet									< 0.001
None	50	(27.9)	35	(25.4)	1	(25.0)	429	(13.9)	
<1 hour	39	(21.8)	36	(26.1)	1	(25.0)	788	(25.6)	
1 to <2 hours	28	(15.6)	22	(15.9)	0	(.0)	649	(21.1)	
2 to <3 hours	19	(10.6)	14	(10.1)	1	(25.0)	451	(14.7)	
3 to <5 hours	18	(10.1)	11	(8.0)	0	(.0)	320	(10.4)	
≥5 hours	25	(14.0)	19	(13.8)	0	(.0)	423	(13.8)	
No response/unknown	0	(.0)	1	(.7)	1	(25.0)	16	(.5)	

Table 11. Basic demographics by Drug Use Experience (n = 3076)

_				Drug u	se experie	nce			
_	Lifetir	ne	No lifet	time	Unkno	wn	Tota	1	
	experience		experie	ence					
	n = 7	8	n = 29	(%)	n = 5	8	n = 30)76 (%)	P-value
Residence area	11	(70)	11	(70)	11	(70)	11	(70)	0.798
Hokkaido	6	(7,7)	120	(4.1)	5	(86)	131	(4.3)	0.150
Toboku	4	(5.1)	239	(8.1)	7	(12.1)	250	(4.0)	
Kanto	-4 95	(32.1)	909	(30.9)	14	(12.1) (94.1)	948	(30.8)	
Hokuriku	20	(3.8)	149	(50.5)	9	(3.4)	154	(50.0)	
Tousan	9	(2.6)	140	(0.1)	4	(6.9)	154	(3.0)	
Tokai	10	(12.0)	219	(10.6)	4 6	(0.3)	398	(4.0)	
Kinki	10	(12.0) (16.7)	420	(10.0)	0	(10.5)	149	(10.7)	
Chugoku	10 6	(10.7)	420	(6.1)	5	(10.0)	101	(14.4)	
Shikoku	1	(1.1)	86	(0.1)	1	(0.0)	131	(0.2)	
Kito-Kun ann	1	(1.0)	00	(2.9)	1	(1.7)	00 990	(2.9)	
Min om i-Kungang	ວ =	(0.0)	150	(7.0)	ວ ດ	(0.2)	105	(7.4)	
Minami ⁻ Kyusyu	0	(0.4)	199	(0.4)	2	(5.4)	100	(0.4)	<0.001
Sex	F 0	$(\nabla A A)$	1974	$(AC \overline{Z})$	9.4	(50.0)	1400		<0.001
Wen	86 80	(74.4)	1574	(46.7)	34	(38.6)	1466	(47.7)	
women	20	(25.6)	1966	(53.3)	24	(41.4)	1610	(52.3)	0.101
Age group	0	(0)	210	$(\overline{n}, 4)$	0	(= 0)	222	(5.0)	0.101
10s	0	(.0)	219	(7.4)	3	(5.2)	222	(7.2)	
20s	8	(10.3)	368	(12.5)	6	(10.3)	382	(12.4)	
30s	15	(19.2)	530	(18.0)	8	(13.8)	553	(18.0)	
40s	23	(29.5)	718	(24.4)	10	(17.2)	751	(24.4)	
50s	23	(29.5)	655	(22.3)	17	(29.3)	695	(22.6)	
60s	9	(11.5)	450	(15.3)	14	(24.1)	473	(15.4)	
Mean age (year)	45.51		43.16		47.05		43.30		0.041
Occupation				()					0.014
Self-employed business	14	(17.9)	227	(7.7)	7	(12.1)	248	(8.1)	
Full-time employee	36	(46.2)	1345	(45.7)	25	(43.1)	1406	(45.7)	
Non-full-time employee	14	(17.9)	375	(12.8)	5	(8.6)	394	(12.8)	
Student	0	(.0)	268	(9.1)	3	(5.2)	271	(8.8)	
Housewife (househusband)	5	(6.4)	422	(14.4)	9	(15.5)	436	(14.2)	
Unemployed	6	(7.7)	169	(5.7)	4	(6.9)	179	(5.8)	
Other	3	(3.8)	130	(4.4)	5	(8.6)	138	(4.5)	
No response/unknown	0	(.0)	4	(.1)	0	(.0)	4	(.1)	
Final academic background									< 0.001
Junior high school	23	(29.5)	162	(5.5)	9	(15.5)	194	(6.3)	
High school	34	(43.6)	1128	(38.4)	24	(41.4)	1186	(38.6)	
Vocational school	9	(11.5)	393	(13.4)	4	(6.9)	406	(13.2)	
Junior college/university	10	(12.8)	904	(30.7)	15	(25.9)	929	(30.2)	
Graduate school	1	(1.3)	64	(2.2)	1	(1.7)	66	(2.1)	
Other	1	(1.3)	13	(.4)	2	(3.4)	16	(.5)	
In school \Box	0	(.0)	268	(9.1)	3	(5.2)	271	(8.8)	
No response/unknown	0	(.0)	8	(.3)	0	(.0)	8	(.3)	
Cellular phone									
Smartphone	56	(71.8)	2011	(68.4)	28	(48.3)	2095	(68.1)	< 0.001
Conventional cellular phone	21	(26.9)	892	(30.3)	23	(39.7)	936	(30.4)	< 0.001
PHS	2	(2.6)	27	(.9)	3	(5.2)	32	(1.0)	< 0.001
Other	1	(1.3)	19	(.6)	2	(3.4)	22	(.7)	< 0.001
None	2	(2.6)	77	(2.6)	3	(5.2)	82	(2.7)	< 0.001
No response/unknown	0	(.0)	9	(.3)	3	(5.2)	12	(.4)	< 0.001
Time spent on the Internet									0.010
None	7	(9.0)	403	(13.7)	19	(32.8)	429	(13.9)	
<1 hour	25	(32.1)	751	(25.5)	12	(20.7)	788	(25.6)	
1 to <2 hours	17	(21.8)	622	(21.2)	10	(17.2)	649	(21.1)	
2 to <3 hours	10	(12.8)	434	(14.8)	7	(12.1)	451	(14.7)	
3 to <5 hours	5	(6.4)	313	(10.6)	2	(3.4)	320	(10.4)	
≥5 hours	14	(17.9)	402	(13.7)	7	(12.1)	423	(13.8)	
No response/unknown	0	(.0)	15	(.5)	1	(1.7)	16	(.5)	

						Residenc	ce area					
	Hokk	aido	Toho	oku	Kar	nto	Hoku	riku	Tous	san	Tok	ai
	n=1	31	n=2	50	n=9	48	n=1	54	n=1	50	n=3	28
	n -	(%)		(%)	n	(%)	n	(%)	n	(%)	n	(%)
	11	(70)	11	(70)	11	(70)	11	(70)	11	(70)	11	(70)
Lifetime alcohol use	105	(00.0)		(a a a)		(a a a)		(001)		(α, α, α)		
Yes	127	(96.9)	230	(92.0)	880	(92.8)	148	(96.1)	141	(94.0)	313	(95.4)
Age at first alcohol use								(0.0)				(, , ,)
Never	4	(3.1)	20	(8.0)	65	(6.9)	6	(3.9)	9	(6.0)	15	(4.6)
≤ 9 years old	8	(6.1)	7	(2.8)	46	(4.9)	4	(2.6)	8	(5.3)	9	(2.7)
10–11 years old	3	(2.3)	2	(.8)	17	(1.8)	4	(2.6)	4	(2.7)	7	(2.1)
12–13 years old	6	(4.6)	2	(.8)	26	(2.7)	4	(2.6)	4	(2.7)	11	(3.4)
14–15 years old	16	(12.2)	10	(4.0)	46	(4.9)	12	(7.8)	7	(4.7)	24	(7.3)
16–17 years old	23	(17.6)	33	(13.2)	138	(14.6)	19	(12.3)	13	(8.7)	40	(12.2)
18–19 years old	40	(30.5)	79	(31.6)	316	(33.3)	55	(35.7)	44	(29.3)	95	(29.0)
≥ 20 years old	30	(22.9)	96	(38.4)	289	(30.5)	49	(31.8)	61	(40.7)	123	(37.5)
Age unknown	1	(.8)	1	(.4)	2	(.2)	1	(.6)	0	(.0)	4	(1.2)
Age at the start of chronic	alcoholu	ise										
Never	4	(3.1)	19	(7.6)	66	(7.0)	6	(3.9)	8	(5.3)	15	(4.6)
≤9 years old	0	(.0)	0	(.0)	0	(.0)	0	(.0)	0	(.0)	0	(.0)
10–11 years old	0	(.0)	0	(.0)	0	(.0)	0	(.0)	0	(.0)	0	(.0)
12–13 years old	1	(.8)	0	(.0)	0	(.0)	0	(.0)	0	(.0)	0	(.0)
14–15 years old	1	(.8)	1	(.4)	2	(.2)	1	(.6)	0	(.0)	4	(1.2)
16–17 years old	5	(3.8)	7	(2.8)	26	(2.7)	3	(1.9)	1	(.7)	6	(1.8)
18–19 years old	26	(19.8)	47	(18.8)	156	(16.5)	28	(18.2)	24	(16.0)	64	(19.5)
≥ 20 years old	83	(63.4)	163	(65.2)	622	(65.6)	103	(66.9)	104	(69.3)	204	(62.2)
Age unknown	11	(8.4)	12	(4.8)	74	(7.8)	13	(8.4)	12	(8.0)	35	(10.7)
Past-year alcohol use												
Yes	111	(84.7)	193	(77.2)	771	(81.3)	133	(86.4)	120	(80.0)	256	(78.0)
Number of days of alcohol	use with	in the pa	ist 30 da	ays								
0 day	41	(31.3)	87	(34.8)	286	(30.2)	48	(31.2)	53	(35.3)	107	(32.6)
1–2 days	20	(15.3)	49	(19.6)	164	(17.3)	26	(16.9)	25	(16.7)	65	(19.8)
3–5 days	17	(13.0)	22	(8.8)	130	(13.7)	9	(5.8)	15	(10.0)	35	(10.7)
6–9 days	15	(11.5)	6	(2.4)	73	(7.7)	10	(6.5)	12	(8.0)	23	(7.0)
10–19 days	12	(9.2)	19	(7.6)	88	(9.3)	10	(6.5)	12	(8.0)	23	(7.0)
20–29 days	17	(13.0)	32	(12.8)	104	(11.0)	24	(15.6)	19	(12.7)	38	(11.6)
Every day	8	(6.1)	35	(14.0)	102	(10.8)	27	(17.5)	13	(8.7)	37	(11.3)
Frequency unknown	0	(.0)	0	(.0)	0	(.0)	0	(.0)	0	(.0)	0	(.0)
Lifetime tobacco use												
Yes	102	(77.9)	148	(59.2)	575	(60.7)	103	(66.9)	83	(55.3)	188	(57.3)
Age at first tobacco use												
Never	26	(19.8)	99	(39.6)	364	(38.4)	51	(33.1)	64	(42.7)	136	(41.5)
≤9 years old	1	(.8)	1	(.4)	9	(.9)	0	(.0)	2	(1.3)	0	(.0)
10–11 years old	0	(.0)	5	(2.0)	4	(.4)	0	(.0)	2	(1.3)	4	(1.2)
12–13 years old	4	(3.1)	5	(2.0)	19	(2.0)	5	(3.2)	1	(.7)	8	(2.4)
14–15 years old	13	(9.9)	12	(4.8)	54	(5.7)	7	(4.5)	7	(4.7)	23	(7.0)
16–17 years old	16	(12.2)	29	(11.6)	114	(12.0)	22	(14.3)	11	(7.3)	36	(11.0)
18–19 years old	31	(23.7)	47	(18.8)	162	(17.1)	23	(14.9)	31	(20.7)	52	(15.9)
≥20 years old	37	(28.2)	49	(19.6)	209	(22.0)	44	(28.6)	28	(18.7)	65	(19.8)
Age unknown	0	(.0)	0	(.0)	4	(.4)	2	(1.3)	1	(.7)	0	(.0)
Age at the start of chronic	tobacco	use										
Never	26	(19.8)	98	(39.2)	364	(38.4)	50	(32.5)	64	(42.7)	137	(41.8)
≤9 years old	0	(.0)	0	(.0)	1	(.1)	0	(.0)	0	(.0)	0	(.0)
10–11 years old	0	(.0)	1	(.4)	1	(.1)	0	(.0)	0	(.0)	0	(.0)
12–13 years old	Ő	(.0)	0	(0)	3	(3)	0	(0)	Ő	(.0)	2	(.6)
14–15 years old	4	(3.1)	6	(2, 4)	19	(2.0)	4	(2, 6)	3	(2.0)	4	(1.2)
16–17 years old	4	(3.1)	14	(5.6)	57	$(\underline{6}, 0)$	11	(2.0)	4	(2.7)	21	(6.4)
18–19 years old	24	(18.3)	36	(14.4)	127	(13.4)	23	(14.9)	24	(16.0)	43	(13.1)
>20 years old	44	(33.6)	64	(14.4) (25.6)	2/9	(10.4) (26.3)	45	(14.0) (29.2)	23	(10.0)	81	(10.1)
Age unknown	26	(10.8)	97	(20.0)	118	(20.0)	20	(13.0)	19	(12.0)	37	(24.7)
Past-year tobacco use	20	(10.0)	21	(10.0)	110	(12.4)	20	(10.0)	10	(12.1)	51	(11.0)
Ves	18	(36.6)	74	(29.6)	250	(26.4)	45	(29.2)	22	(22.0)	89	(97.1)
Number of days of tobacco	use with	$\frac{100.0}{100}$	ast 30 d	(20.0) avs	200	(20.4)	40	(20.2)	00	(22.0)	00	(21.1)
0 day	QC	(65 c)	177	(70.9)	717	(75.6)	119	(79.4)	110	(77 9)	940	(75.0)
1_2 dave	00	(0.6)	T ()	(10.0)	111	(10.0)	113	(10.4)	110	(11.3)	249	(10.9)
1-2 days 3-5 days	1	(.8)	0 0	(2.0)	о г	()	1	(.0)	1	(.0)	2	(.0)
0-0 days 6-9 days	1	(.8)	2	(.8)	5 1	(.5)	1	(.6)	1	(.7)	1	(.3)
10 10 days	1	(.8)	1	(.4)	1	(.1)	0	(.0)	0	(1.0)	1	(.3)
10-19 uays	2	(1.5)	0	(.0)	8	(.8)	3	(1.9)	2	(1.3)	2	(.6)
20–29 days	3	(2.3)	2	(.8)	9	(.9)	2	(1.3)	2	(1.3)	3	(.9)
Every day	36	(27.5)	61	(24.4)	197	(20.8)	35	(22.7)	27	(18.0)	68	(20.7)
riequency unknown	0	0.07	0	0.0	0	0.07	0	0.07	0	0.07	0	

Respondents with "no response/unknown" are not included. For age at the start of chronic alcohol use, respondents not having reached the stage of chronic alcohol use are included in "age unknown." For age at the start of chronic tobacco use, respondents not having reached the stage of chronic tobacco use are included in "age unknown."

Table 12. Alcohol and/or Tobacco Use by Residence area(n=3076) continued

	Residence area												
	Kin	ıki	Chug	oku	Shike	oku	Kita-K	yusyu	Mina	ımi-	Tot	al	
	n=4	42	n=1	91	n=8	38	n=2	29	n=1	65	n=30	076	p-value
	n	(%)	n	(%)	n	(%)	 n	(%)	n	(%)	n	(%)	P
Lifetime cleakel was	11	(70)	11	(70)	11	(70)	11	(70)	11	(70)	11	(70)	
Ver		(00.0)	1 - 1		07	(0,0,0)	200	(01, 0)		(01)	a a z a	(00.1)	0.032
Age at first alcohol use	415	(93.9)	171	(89.5)	87	(98.9)	209	(91.3)	151	(91.5)	2,872	(93.4)	0.001
Novor	97	(0, 1)	10	(0, 4)	1	(1 1)	10	(0.9)	14	(0 E)	100	(C 4)	0.001
<9 years old	21	(6.1) (5.4)	10	(9.4) (3.1)	1	(1.1) (1.1)	19	(0.3)	14	(0.0)	190	(0.4)	
10_11 years old	24 10	(0.4)	1	(5.1)	1 9	(1,1) (2,4)	10	(7.0)	4	(2.4) (1.9)	100 61	(4.3)	
12–13 years old	10	(2.3)	1 7	(3.7)	ວ 1	(0.4)	0	(3.0)	2 5	(1.2)	00	(2.0)	
14–15 years old	20	(3.4)	11	(5.1)	8	(1.1) (0.1)	8	(3.5)	11	(6.7)	173	(2.3)	
16–17 years old	44	(4.0)	25	(13.0)	19	(14.8)	22	(9.6)	10	(6.1)	380	(12.0)	
18–19 years old	128	(10.0)	48	(15.1) (25.1)	23	(14.0) (26.1)	71	(31.0)	10 52	(31.5)	951	(12.4)	
≥ 20 years old	170	(38.5)	73	(38.2)	37	(42.0)	75	(32.8)	67	(40.6)	1 070	(34.8)	
Age unknown	4	(9)	.0	(00.2)	1	(1 1)	.0	(0)	0	(0)	1,010	(5)	
Age at the start of chronic alco	holus	e (.0)	0	(.0)	1	(1.1)	0	(.0)	0	(.0)	11	(.0)	0.050
Never	26	(5.9)	19	(9.9)	1	$(1 \ 1)$	19	(8.3)	14	(85)	197	(6.4)	0.000
≤9 vears old	20	(0.0)	0	(0.0)	0	(1.1)	0	(0.0)	0	(0.0)	0	(0.1)	
10–11 years old	2	(.5)	Ő	(.0)	0	(.0)	0	(.0)	1	(.6)	3	(.1)	
12–13 years old	1	(.2)	0	(.0)	1	(1.1)	Ő	(.0)	0	(.0)	3	(.1)	
14–15 years old	0	(.0)	2	(1.0)	0	(.0)	3	(1.3)	1	(.6)	15	(.5)	
16–17 years old	7	(1.6)	2	(1.0)	2	(2.3)	1	(.4)	4	(2.4)	64	(2.1)	
18–19 years old	68	(15.4)	20	(10.5)	18	(20.5)	45	(19.7)	23	(13.9)	519	(16.9)	
≥ 20 years old	289	(65.4)	124	(64.9)	56	(63.6)	139	(60.7)	110	(66.7)	1,997	(64.9)	
Age unknown	48	(10.9)	23	(12.0)	10	(11.4)	21	(9.2)	12	(7.3)	271	(8.8)	
Past-year alcohol use													0.072
Yes	339	(76.7)	147	(77.0)	70	(79.5)	183	(79.9)	131	(79.4)	2,454	(79.8)	
Number of days of alcohol use	within	the past	t 30 day	s									0.171
0 day	160	(36.2)	73	(38.2)	34	(38.6)	71	(31.0)	48	(29.1)	1,008	(32.8)	
1–2 days	73	(16.5)	27	(14.1)	11	(12.5)	34	(14.8)	32	(19.4)	526	(17.1)	
3–5 days	52	(11.8)	26	(13.6)	9	(10.2)	33	(14.4)	17	(10.3)	365	(11.9)	
6–9 days	37	(8.4)	7	(3.7)	4	(4.5)	15	(6.6)	10	(6.1)	212	(6.9)	
10–19 days	33	(7.5)	11	(5.8)	7	(8.0)	21	(9.2)	20	(12.1)	256	(8.3)	
20–29 days	43	(9.7)	26	(13.6)	10	(11.4)	27	(11.8)	18	(10.9)	358	(11.6)	
Every day	43	(9.7)	20	(10.5)	13	(14.8)	26	(11.4)	20	(12.1)	344	(11.2)	
Frequency unknown	0	(.0)	0	(.0)	0	(.0)	0	(.0)	0	(.0)	0	(.0)	
Lifetime tobacco use													0.002
Yes	246	(55.7)	108	(56.5)	59	(67.0)	135	(59.0)	91	(55.2)	1,838	(59.8)	
Age at first tobacco use													0.136
Never	190	(43.0)	81	(42.4)	28	(31.8)	91	(39.7)	74	(44.8)	1,204	(39.1)	
≤9 years old	5	(1.1)	2	(1.0)	0	(.0)	3	(1.3)	0	(.0)	23	(.7)	
10–11 years old	7	(1.6)	0	(.0)	1	(1.1)	1	(.4)	1	(.6)	25	(.8)	
12–13 years old	12	(2.7)	4	(2.1)	1	(1.1)	3	(1.3)	3	(1.8)	65	(2.1)	
14-15 years old	26	(5.9)	6	(3.1)	11	(12.5)	14	(6.1)	9	(5.5)	182	(5.9)	
16-17 years old	47	(10.6)	23	(12.0)	10	(11.4)	24	(10.5)	16	(9.7)	348	(11.3)	
10-19 years old	62	(14.0)	34	(17.8)	20	(22.7)	33	(14.4)	26	(15.8)	521	(16.9)	
Ago unknown	80	(19.2)	38 1	(19.9)	16	(18.2)	96 1	(24.5)	36	(21.8)	663	(21.6)	
Age at the start of chronic tob	2 2000-118	(.0)	1	(.3)	0	(.0)	1	(.4)	0	(.0)	11	(.4)	0.444
Never	100	(43.0)	81	(19.4)	28	(31.8)	01	(30.7)	73	(112)	1 202	(30.1)	0.444
<9 years old	130	(43.0)	01	(42.4)	20	(01.0)	1	(33.1)	10	(44.2)	1,202	(33.1)	
10–11 years old	0	(.0)	0	(.0)	1	(1, 1)	0	(.4)	0	(.0)	3	(1)	
12–13 years old	3	(.0)	0	(.0)	0	(1.1)	1	(.0)	2	(1.2)	11	(.1)	
14–15 years old	10	(2,3)	4	(2.1)	4	(4.5)	4	(1.7)	4	(2.4)	66	(2.1)	
16–17 years old	20	(4.5)	14	(7.3)	7	(8.0)	14	(6.1)	10	(2.1) (6.1)	176	(5.7)	
18–19 years old	63	(14.3)	29	(15.2)	19	(21.6)	31	(13.5)	22	(13.3)	441	(14.3)	
≥20 years old	103	(23.3)	45	(23.6)	19	(21.6)	59	(25.8)	38	(23.0)	780	(25.4)	
Age unknown	47	(10.6)	16	(8.4)	9	(10.2)	25	(10.9)	15	(9.1)	359	(11.7)	
Past-year tobacco use													0.653
Yes	108	(24.4)	51	(26.7)	28	(31.8)	56	(24.5)	45	(27.3)	827	(26.9)	
Number of days of tobacco use	within	n the pas	t 30 day	'S									0.635
0 day	345	(78.1)	144	(75.4)	62	(70.5)	174	(76.0)	127	(77.0)	2,310	(75.1)	
1–2 days	3	(.7)	2	(1.0)	0	(.0)	2	(.9)	0	(.0)	20	(.7)	
3–5 days	1	(.2)	1	(.5)	0	(.0)	1	(.4)	1	(.6)	15	(.5)	
6–9 days	0	(.0)	0	(.0)	1	(1.1)	1	(.4)	0	(.0)	6	(.2)	
10–19 days	2	(.5)	1	(.5)	1	(1.1)	0	(.0)	2	(1.2)	23	(.7)	
20–29 days	9	(2.0)	0	(.0)	0	(.0)	6	(2.6)	4	(2.4)	40	(1.3)	
Every day	81	(18.3)	41	(21.5)	24	(27.3)	42	(18.3)	30	(18.2)	642	(20.9)	
Frequency unknown	0	(.0)	0	(.0)	0	(.0)	0	(.0)	0	(.0)	0	(.0)	

Respondents with "no response/unknown" are not included. For age at the start of chronic alcohol use, respondents not having reached the stage of chronic alcohol use are included in "age unknown." For age at the start of chronic tobacco use, respondents not having reached the stage of chronic tobacco use are included in "age unknown."

Table 13.	Alcohol and/or	Tobacco	Use by	Sex ((n = 3076)
-----------	----------------	---------	--------	-------	------------

				Sex					
	Ma		Won	lon	Tet	-ol			
	IVIE	100	won	1011 010	100	al 070	D 1		
	n = 1	.466	n = 1	.610	n = 3	076	P-value		
	n	(%)	n	(%)	n	(%)			
Lifetime alcohol use							0.448		
Yes	1,374	(93.7)	1,498	(93.0)	2,872	(93.4)			
Age at first alcohol use							< 0.001		
Never	90	(6.1)	108	(6.7)	198	(6.4)			
<0 years ald	67	(4.6)	66	(4, 1)	199	(4.9)			
	07	(4.0)	00	(4.1)	100	(4.0)			
10–11 years old	35	(2.4)	26	(1.6)	61	(2.0)			
12–13 years old	57	(3.9)	33	(2.0)	90	(2.9)			
14–15 years old	107	(7.3)	66	(4.1)	173	(5.6)			
16–17 years old	242	(16.5)	138	(8.6)	380	(12.4)			
18–19 years old	507	(34.6)	444	(27.6)	951	(30.9)			
≥ 20 years old	252	(94.1)	717	(44.5)	1 070	(94.9)			
	555	(24.1)	111	(44.0)	1,070	(04.0)			
Age unknown	6	(.4)	0	(.3)	14	()	0.004		
Age at the start of chronic alcohol use				<i>,</i> ,			< 0.001		
Never	89	(6.1)	108	(6.7)	197	(6.4)			
≤9 years old	0	(.0)	0	(.0)	0	(.0)			
10–11 years old	0	(.0)	3	(.2)	3	(.1)			
12–13 years old	3	(2)	0	(0)	3	(1)			
14 15 years old	11	(0)	4	(.0)	15	(.1)			
	11	(0.0)	4	(.2)	10	(0.1)			
16–17 years old	41	(2.8)	23	(1.4)	64	(2.1)			
18–19 years old	325	(22.2)	194	(12.0)	519	(16.9)			
≥ 20 years old	888	(60.6)	1,109	(68.9)	1,997	(64.9)			
Age unknown	106	(7.2)	165	(10.2)	271	(8.8)			
Past-year alcohol use		(((010)	< 0.001		
Vog	1 997	(911)	1 917	(75.c)	9 454	(70.8)	\$0.001		
Number of down of alashal use within the past 20	1,201	(04.4)	1,417	(75.0)	2,404	(19.0)	.0.001		
Number of days of alcohol use within the past so	Juays			<i>,</i> ,			< 0.001		
0 day	363	(24.8)	645	(40.1)	1,008	(32.8)			
1–2 days	201	(13.7)	325	(20.2)	526	(17.1)			
3–5 days	159	(10.8)	206	(12.8)	365	(11.9)			
6–9 days	105	(7.2)	107	(6.6)	212	(6.9)			
10 10 dove	149	(0.8)	1107	(0.0)	950	(0.0)			
10-15 days	140	(9.0)	110	(7.0)	200	(0.0)			
20–29 days	234	(16.0)	124	(7.7)	358	(11.6)			
Every day	258	(17.6)	86	(5.3)	344	(11.2)			
Frequency unknown	0	(.0)	0	(.0)	0	(.0)			
Lifetime tobacco use							< 0.001		
Yes	1 1 1 7	(76.2)	721	(44.8)	1 838	(59.8)			
Age at first tobacco use	1,111	((11:0)	1,000	(00.0)	<0.001		
Novor	949	(99.4)	001	(E2 E)	1.904	(20.1)	<0.001		
	343	(25.4)	001	(05.0)	1,204	(59.1)			
29 years old	13	(.9)	10	(.6)	23	(.7)			
10–11 years old	19	(1.3)	6	(.4)	25	(.8)			
12–13 years old	45	(3.1)	20	(1.2)	65	(2.1)			
14–15 years old	134	(9.1)	48	(3.0)	182	(5.9)			
16–17 vears old	242	(165)	106	(6.6)	348	(11.3)			
18-19 years old	334	(22.8)	187	(11.6)	521	(16.9)			
200 magne ald	004	(22.0)	107	(11.0)	021	(10.3)			
220 years old	325	(22.2)	338	(21.0)	663	(21.6)			
Age unknown	5	(.3)	6	(.4)	11	(.4)			
Age at the start of chronic tobacco use							< 0.001		
Never	344	(23.5)	858	(53.3)	1,202	(39.1)			
≤9 years old	0	(.0)	2	(.1)	2	(.1)			
10–11 years old	3	(2)	0	(0)	3	(1)			
12-13 years old	7	(.5)	4	(.0)	11	(.1)			
14 15 years old		(.0)	4	(.2)	11	(0.1)			
14-15 years old	58	(4.0)	8	(.5)	66	(2.1)			
16–17 years old	120	(8.2)	56	(3.5)	176	(5.7)			
18–19 years old	326	(22.2)	115	(7.1)	441	(14.3)			
≥20 years old	456	(31.1)	324	(20.1)	780	(25.4)			
Age unknown	147	(10.0)	212	(13.2)	359	(11.7)			
Past-vear tobacco use	1.11	(10.0)	-14	(10.4)	000	(11.1)	<0.001		
Vec	000	(10,0)	207	(1 4 1)	007	(20, 0)	<0.001		
	600	(40.9)	227	(14.1)	827	(26.9)			
Number of days of tobacco use within the past 3	u days						< 0.001		
0 day	904	(61.7)	1,406	(87.3)	2,310	(75.1)			
1–2 days	11	(.8)	9	(.6)	20	(.7)			
3–5 days	13	(9)	2	(1)	15	(5)			
6–9 davs	10	(3)		(1)	6	(9)			
10 10 days	-4 1 <i>1</i> 7	(1.0)	4	(.1)	0	(.4)			
10-19 days	17	(1.2)	6	(.4)	23	(.7)			
20–29 days	31	(2.1)	9	(.6)	40	(1.3)			
Every day	480	(32.7)	162	(10.1)	642	(20.9)			
Frequency unknown	Ω	(0)	Ο	(0)	Ο	(0)			

Respondents with "no response/unknown" are not included. For age at the start of chronic alcohol use, respondents not having reached the stage of chronic alcohol use are included in "age unknown." For age at the start of chronic tobacco use, respondents not having reached the stage of chronic tobacco use are included in "age unknown."
Table 14. Alcohol and/or	Tobacco U	Use by Age	group(n=3076)
--------------------------	-----------	------------	---------------

								Age gro	oup						
-	1	0s	2	0s	3	0s	4	0s	5	0s	6	0s	Tot	al	
	n=	222	n=	382	n=	553	n=	751	n=	695	n=	473	n=30	076	p-value
	n	(%)	n	(%)	n	(%)	n	(%)	n	(%)	n	(%)	n	(%)	P
Lifetime alcohol use		(, 0)		(70)		() 0)		(70)		(, ,		(, 0)		(, 0)	<0.001
Yes	80	(36.0)	371	(97.1)	545	(98.6)	742	(98.8)	679	(977)	455	(96.2)	2.872	(93.4)	<0.001
Age at first alcohol use	00	(00.0)	011	(01.1)	010	(00.0)	112	(00.0)	010	(01.1)	100	(00.2)	2,012	(00.1)	< 0.001
Never	142	(64.0)	10	(2.6)	8	(1.4)	8	(1.1)	14	(2.0)	16	(3.4)	198	(6.4)	
≤9 years old	11	(5.0)	19	(5.0)	25	(4.5)	30	(4.0)	32	(4.6)	16	(3.4)	133	(4.3)	
10–11 years old	8	(3.6)	5	(1.3)	9	(1.6)	15	(2.0)	21	(3.0)	3	(.6)	61	(2.0)	
12–13 years old	12	(5.4)	10	(2.6)	20	(3.6)	25	(3.3)	18	(2.6)	5	(1.1)	90	(2.9)	
14–15 years old	12	(5.4)	25	(6.5)	53	(9.6)	44	(5.9)	29	(4.2)	10	(2.1)	173	(5.6)	
16–17 years old	14	(6.3)	36	(9.4)	79	(14.3)	113	(15.0)	90	(12.9)	48	(10.1)	380	(12.4)	
18–19 years old	20	(9.0)	102	(26.7)	167	(30.2)	249	(33.2)	254	(36.5)	159	(33.6)	951	(30.9)	
≥ 20 years old	0	(.0)	173	(45.3)	190	(34.4)	265	(35.3)	231	(33.2)	211	(44.6)	1,070	(34.8)	
Age unknown	3 alcoho	(1.4)	1	(.3)	2	(.4)	1	(.1)	4	(.6)	3	(.6)	14	(.5)	<0.001
Never	1/1	(63.5)	11	(20)	Q	(1 4)	7	(0)	15	(2, 2)	15	(2, 9)	107	(6.4)	<0.001
<9 years old	141	(03.3)	0	(2.3)	0	(1.4)	0	(.3)	10	(2.2)	10	(0.2)	157	(0.4)	
10–11 years old	1	(.0)	0	(.0)	1	(2)	0	(.0)	1	(1)	0	(.0)	3	(1)	
12–13 years old	0	(.0)	1	(.3)	2	(.4)	0	(.0)	0	(.0)	Ő	(.0)	3	(.1)	
14–15 years old	2	(.9)	3	(.8)	2	(.4)	3	(.4)	2	(.3)	3	(.6)	15	(.5)	
16–17 years old	8	(3.6)	11	(2.9)	21	(3.8)	15	(2.0)	4	(.6)	5	(1.1)	64	(2.1)	
18–19 years old	27	(12.2)	66	(17.3)	93	(16.8)	131	(17.4)	142	(20.4)	60	(12.7)	519	(16.9)	
≥ 20 years old	1	(.5)	280	(73.3)	388	(70.2)	552	(73.5)	455	(65.5)	321	(67.9)	1,997	(64.9)	
Age unknown	41	(18.5)	10	(2.6)	38	(6.9)	41	(5.5)	75	(10.8)	66	(14.0)	271	(8.8)	
Past-year alcohol use								<i>,</i> ,		<i>,</i> ,					< 0.001
Yes	56	(25.2)	345	(90.3)	464	(83.9)	645	(85.9)	568	(81.7)	376	(79.5)	2,454	(79.8)	
Number of days of alcohol	use w	itnin the	e past	30 days	1.05	(22, 2)	010	(22.0)	000	(20.0)	1 50		1 000	(00.0)	< 0.001
0 day	188	(84.7)	115	(23.3)	165	(29.8)	210	(28.0)	206	(29.6)	150	(31.7)	1,008	(32.8)	
1-2 days	16	(7.2)	115	(30.1)	113	(20.4)	126	(16.8)	92 74	(13.2)	64 20	(13.5)	526 265	(17.1)	
6-9 days	0	(3.0) (1.8)	10	(20.4) (12.6)	70 52	(13.2) (9.4)	95 51	(6.8)	14 36	(10.0) (5.2)	59 91	(0.2)	000 919	(11.9) (6.9)	
10–19 days	3	(1.0)	28	(12.0) (7.3)	51	(9.4)	66	(0.0)	71	(10.2)	37	(4.4)	212	(0.3)	
20–29 days	2	(.9)	16	(4.2)	57	(10.3)	111	(14.8)	107	(15.4)	65	(13.7)	358	(11.6)	
Every day	0	(.0)	8	(2.1)	41	(7.4)	93	(12.4)	109	(15.7)	93	(19.7)	344	(11.2)	
Frequency unknown	0	(.0)	0	(.0)	0	(.0)	0	(.0)	0	(.0)	0	(.0)	0	(.0)	
Lifetime tobacco use															< 0.001
Yes	15	(6.8)	164	(42.9)	380	(68.7)	508	(67.6)	472	(67.9)	299	(63.2)	1,838	(59.8)	
Age at first tobacco use															< 0.001
Never	205	(92.3)	217	(56.8)	171	(30.9)	233	(31.0)	217	(31.2)	161	(34.0)	1,204	(39.1)	
≤9 years old	0	(.0)	1	(.3)	3	(.5)	11	(1.5)	7	(1.0)	1	(.2)	23	(.7)	
10–11 years old	0	(.0)	3	(.8)	7	(1.3)	6	(.8)	8	(1.2)	1	(.2)	25	(.8)	
12-13 years old		(.5)	-7	(1.8)	20	(3.6)	22	(2.9)	13	(1.9)	10	(.4)	65	(2.1)	
16-17 years old	6 9	(2.1) (1.4)	22	(0.8)	49	(8.9)	07 02	(7.6)	30 109	(0.2)	12	(2.5)	182	(0.9)	
18–19 years old	3 3	(1.4) (1.4)	20 40	(0.8)	79 79	(14.3) (14.1)	95 119	(12.4) (15.7)	105	(14.6) (22.7)	44 117	(9.5)	540 591	(11.3) (16.0)	
≥20 years old	0	(1.4)	40 63	(10.5)	141	(14.1) (25.5)	198	(10.1) (26.4)	139	(20.0)	199	(24.7) (25.8)	663	(10.3) (21.6)	
Age unknown	2	(9)	2	(10.5)	3	(20.0)	3	(4)	100	(1)	0	(0)	11	(4)	
Age at the start of chronic	tobaco	co use	-	(10)	0	(10)	0	(11)	-	(11)	0	(10)		(, 1)	< 0.001
Never	205	(92.3)	217	(56.8)	169	(30.6)	234	(31.2)	217	(31.2)	160	(33.8)	1,202	(39.1)	
≤9 years old	0	(.0)	1	(.3)	0	(.0)	1	(.1)	0	(.0)	0	(.0)	2	(.1)	
10–11 years old	0	(.0)	1	(.3)	0	(.0)	2	(.3)	0	(.0)	0	(.0)	3	(.1)	
12–13 years old	0	(.0)	0	(.0)	4	(.7)	5	(.7)	2	(.3)	0	(.0)	11	(.4)	
14–15 years old	2	(.9)	12	(3.1)	22	(4.0)	22	(2.9)	4	(.6)	4	(.8)	66	(2.1)	
16–17 years old	3	(1.4)	10	(2.6)	54	(9.8)	59	(7.9)	37	(5.3)	13	(2.7)	176	(5.7)	
18–19 years old	2	(.9)	35	(9.2)	82	(14.8)	86	(11.5)	156	(22.4)	80	(16.9)	441	(14.3)	
≥20 years old	0	(.0)	71	(18.6)	143	(25.9)	229	(30.5)	180	(25.9)	157	(33.2)	780	(25.4)	
Age unknown Past-year tobacco uso	8	(3.6)	34	(8.9)	75	(13.6)	104	(13.8)	93	(13.4)	45	(9.5)	359	(11.7)	<0.001
Vog	10	(A E)	109	(96 7)	101	(22.7)	999	(30.0)	900	(99 0)	109	(91 c)	007	(96 0)	<0.001
Number of days of tobacco	use w	(4.0) vithin th	e past	(20.1) 30 davs	191	(02.1)	497	(30.9)	200	(20.8)	102	(21.0)	041	(20.9)	<0.001
0 day	213	(95.9)	2.92	(76.4)	390	(70.5)	534	$(71\ 1)$	509	(73.9)	379	(78.6)	2 310	(75.1)	~0.001
1-2 days	0	(0)	8	(2.1)	6	$(1 \ 1)$	2	(3)	1	(1)	3	(6)	2,010	(7)	
3–5 days	1	(.5)	1	(.3)	4	(.7)	5	(.7)	4	(.6)	0	(.0)	15	(.5)	
6–9 days	0	(.0)	3	(.8)	0	(.0)	2	(.3)	0	(.0)	1	(.2)	6	(.2)	
10–19 days	1	(.5)	5	(1.3)	5	(.9)	4	(.5)	4	(.6)	4	(.8)	23	(.7)	
20–29 days	1	(.5)	4	(1.0)	10	(1.8)	9	(1.2)	10	(1.4)	6	(1.3)	40	(1.3)	
Every day	3	(1.4)	67	(17.5)	136	(24.6)	191	(25.4)	165	(23.7)	80	(16.9)	642	(20.9)	
Frequency unknown	0	(.0)	0	(.0)	0	(.0)	0	(.0)	0	(.0)	0	(.0)	0	(.0)	

"10s" refers to those aged 15 to 19, and "60s" refers to those aged 60 to 64.

Respondents with "no response/unknown" are not included. For age at the start of chronic alcohol use, respondents not having reached the stage of chronic alcohol use are included in "age unknown." For age at the start of chronic tobacco use, respondents not having reached the stage of chronic tobacco use are included in "age unknown."

Table 15. Alcohol and/or Tobacco Use by Occupation(n=3076)

					Occup	ation				
	Self-em	ployed	Full-	time	Non-fu	ll-time	Stud	lent	House	wife
	n=2	248	n=1-	406	n=3	94	n=2	271	n=4	36
	n	(%)	n	(%)	n	(%)	n	(%)	n	(%)
Lifetime alcohol use										
Yes	242	(97.6)	1,391	(98.9)	385	(97.7)	136	(50.2)	418	(95.9)
Age at first alcohol use						<i>(</i>)		<i>,</i> ,		
Never	5	(2.0)	14	(1.0)	8	(2.0)	135	(49.8)	16	(3.7)
$\leq 9 \text{ years old}$	9	(3.6)	66	(4.7)	19	(4.8)	14	(5.2)	11	(2.5)
10-11 years old	9	(3.6)	25	(1.8)	7	(1.8)	10	(2.6)	6	(1.4)
12–13 years old	8	(3.2)	48	(3.4)	7	(1.8)	13	(4.8)	10	(2.3)
16 17 years old	18	(7.3)	93	(6.6)	18	(4.6)	13	(4.8)	19	(4.4)
18-19 years old	46	(18.0) (22.7)	209	(14.9)	30 199	(8.9)	19	(7.0)	42	(9.6)
≥ 20 years old	70	(32.1) (28.2)	411	(33.3)	161	(30.0)	30 91	(13.3)	208	(27.1) (47.7)
Age unknown	10	(20.2)	400	(33.3)	101	(40.9)	2	(11.4) (11)	208	(41.1)
Age at the start of chronic	e alcohol	use	0	(.4)	0	(.0)	0	(1.1)	-r	(.0)
Never	5	(2,0)	14	(1 0)	8	(2,0)	134	(49.4)	17	(3.9)
≤9 vears old	0	$(\underline{2},0)$	0	(0)	0	$(\underline{2},0)$	0	(10.1)	0	(0.0)
10–11 years old	1	(.4)	0	(.0)	0	(.0)	1	(.4)	0	(.0)
12–13 years old	1	(.4)	2	(.1)	0	(.0)	0	(.0)	0	(.0)
14–15 years old	3	(1.2)	7	(.5)	0	(.0)	2	(.7)	1	(.2)
16–17 years old	3	(1.2)	31	(2.2)	5	(1.3)	6	(2.2)	9	(2.1)
18–19 years old	57	(23.0)	298	(21.2)	50	(12.7)	29	(10.7)	47	(10.8)
≥ 20 years old	160	(64.5)	968	(68.8)	293	(74.4)	58	(21.4)	307	(70.4)
Age unknown	17	(6.9)	85	(6.0)	37	(9.4)	40	(14.8)	54	(12.4)
Past-year alcohol use										
Yes	221	(89.1)	1,261	(89.7)	325	(82.5)	112	(41.3)	302	(69.3)
Number of days of alcoho	l use with	nin the p	ast 30 d	ays						
0 day	50	(20.2)	307	(21.8)	133	(33.8)	186	(68.6)	205	(47.0)
1–2 days	32	(12.9)	260	(18.5)	72	(18.3)	40	(14.8)	68	(15.6)
3–5 days	23	(9.3)	175	(12.4)	54	(13.7)	22	(8.1)	50	(11.5)
6–9 days	14	(5.6)	110	(7.8)	27	(6.9)	14	(5.2)	32	(7.3)
10–19 days	24	(9.7)	139	(9.9)	38	(9.6)	3	(1.1)	28	(6.4)
20–29 days	42	(16.9)	223	(15.9)	36	(9.1)	4	(1.5)	27	(6.2)
Every day	62	(25.0)	191	(13.6)	34	(8.6)	1	(.4)	24	(5.5)
Frequency unknown	0	(.0)	0	(.0)	0	(.0)	0	(.0)	0	(.0)
Voc	100	$(\overline{a} 0, 0)$	071	(00, 1)	001	$(\mathbf{r} \circ c)$	0.4	(0,0)	200	(10,0)
Δq_{0} at first tobacco use	196	(79.0)	971	(69.1)	231	(58.6)	24	(8.9)	203	(46.6)
Novor	10	(10, 4)	499	(20, 0)	150	(40.1)	945	(00, 4)	997	(59.1)
<9 years old	40	(19.4)	422	(30.0)	100	(40.1)	240	(90.4)	227	(32.1)
10–11 years old	4 5	(1.0)	12	(1.3)	9	(.0)	0	(.4)	1	(.2)
12–13 years old	5	(2.0)	39	(2.8)	4	(1.0)	1	(.0)	7	(1.6)
14–15 years old	22	(8.9)	107	(2.0)	17	(4.3)	5	(1.4)	13	(3.0)
16–17 years old	48	(19.3)	199	(14.2)	36	(9.1)	2	(1.0)	24	(5.5)
18–19 vears old	51	(20.6)	273	(19.4)	78	(19.8)	5	(1.8)	62	(14.2)
≥20 years old	58	(23.4)	320	(22.8)	90	(22.8)	8	(3.0)	94	(21.6)
Age unknown	1	(.4)	5	(.4)	1	(.3)	2	(.7)	1	(.2)
Age at the start of chronic	e tobacco	use								
Never	48	(19.4)	422	(30.0)	158	(40.1)	245	(90.4)	226	(51.8)
≤9 years old	0	(.0)	1	(.1)	1	(.3)	0	(.0)	0	(.0)
10–11 years old	1	(.4)	2	(.1)	0	(.0)	0	(.0)	0	(.0)
12–13 years old	4	(1.6)	4	(.3)	0	(.0)	0	(.0)	0	(.0)
14–15 years old	6	(2.4)	44	(3.1)	3	(.8)	2	(.7)	4	(.9)
16–17 years old	21	(8.5)	108	(7.7)	13	(3.3)	1	(.4)	15	(3.4)
18–19 years old	59	(23.8)	240	(17.1)	58	(14.7)	2	(.7)	41	(9.4)
≥20 years old	70	(28.2)	402	(28.6)	102	(25.9)	4	(1.5)	86	(19.7)
Age unknown	35	(14.1)	170	(12.1)	54	(13.7)	15	(5.5)	57	(13.1)
Past-year tobacco use		<i>,</i> ,		<i>,</i> , ,						
Yes	95	(38.3)	475	(33.8)	92	(23.4)	12	(4.4)	53	(12.2)
number of days of tobacco	o use wit	nin the p	oast 30 d	ays				(c = z)		(00 -)
U day	154	(62.1)	964	(68.6)	310	(78.7)	263	(97.0)	388	(89.0)
1-2 days	4	(1.6)	8	(.6)	3	(.8)	1	(.4)	0	(.0)
3–5 days	1	(.4)	13	(.9)	0	(.0)	0	(.0)	1	(.2)
0-9 days	0	(.0)	2	(.1)	0	(.0)	1	(.4)	1	(.2)
10-19 uays 20-29 days	1	(.4)	10	(1)	C C	(1.3)	1	(.0)	1	(.2)
20–20 uays Every dev	9 70	(2.0) (91.0)	20	(1.4)	0	(1.0)	1	(.4)	1 49	(0,0)
Frequency unknown	19	(01.9)	000	(21.0)	00	(11.3)	4	(.)	40	(0)

Respondents with "no response/unknown" are not included. For age at the start of chronic alcohol use, respondents not having reached the stage of chronic alcohol use are included in "age unknown." For age at the start of chronic tobacco use, respondents not having reached the stage of chronic tobacco use are included in "age unknown."

Table 15. Alcohol and/or Tobacco Use by Occupation (n=3076) continued

				0	ccupati	on			
	Unem	ployed	Oth	ner	Unkr	nown	Tot	al	
	n=1	79	n=1	.38	n=	-4	n=3	076	p-value
	n	(%)	n	(%)	n	(%)	n	(%)	
Lifetime alcohol use		<i>,</i> , ,		<i>,</i> , ,				<i>,</i> , ,	< 0.001
Yes	165	(92.2)	131	(94.9)	4	(100.0)	2,872	(93.4)	
Age at first alcohol use		()	_	()		(-)			< 0.001
Never	13	(7.3)	7	(5.1)	0	(.0)	198	(6.4)	
≤ 9 years old	6	(3.4)	8	(5.8)	0	(.0)	133	(4.3)	
10–11 years old	2	(1.1)	5	(3.6)	0	(.0)	61	(2.0)	
12–13 years old	2	(1.1)	2	(1.4)	0	(.0)	90	(2.9)	
14–15 years old	5	(2.8)	1	(5.1)	0	(.0)	173	(5.6)	
16-17 years old	17	(9.5)	12	(8.7)	0	(.0)	380	(12.4)	
18–19 years old	53	(29.6)	47	(34.1)	1	(25.0)	951	(30.9)	
2 20 years old	19	(44.1)	50	(36.2)	3	(75.0)	1,070	(34.8)	
Age at the start of chronic alcohol use	1	(.6)	0	(.0)	0	(.0)	14	(.5)	<0.001
Novor	19	(c, 7)	7	(5,1)	0	(0)	107	(c, A)	<0.001
<0 years old	12	(0.1)	<i>'</i>	(0.1)	0	(.0)	197	(0.4)	
10 11 years old	1	(.0)	0	(.0)	0	(.0)	0	(.0)	
12-13 years old	1	(.0)	0	(.0)	0	(.0)	0 9	(.1)	
14-15 years old	1	(.0)	1	(.0)	0	(.0)	ม 15	(.1)	
16-17 years old	1	(0.0)	1	(.1)	0	(.0)	10 64	(.0)	
18-19 years old	4	(2.2)	16	(4.0)	0	(.0)	510	(2.1)	
≥ 20 years old	114	(12.3) (62.7)	10	(11.0) (67.4)	4	(100, 0)	1 007	(10.9)	
Age unknown	114 93	(03.7) (12.8)	95 15	(07.4)	4	(100.0)	1,997	(04.9)	
Past-year alcohol use	20	(12.0)	10	(10.3)	0	(.0)	211	(0.0)	<0.001
Yes	191	(67.6)	109	(79.0)	3	(75.0)	2 454	(79.8)	<0.001
Number of days of alcohol use within the	e past 30	davs	105	(13.0)	0	(15.0)	2,404	(13.0)	<0.001
0 day	72	(40.2)	53	(38.4)	9	(50.0)	1 008	(32.8)	<0.001
1-2 days	14	(40.2) (15.1)	26	(18.8)	1	(30.0)	526	(32.0) (17.1)	
3-5 days	21	(10.1) (11.7)	20	(10.0)	1	(20.0)	365	(11,1)	
6-9 days	21	(11.7) (4.5)	20	(14.0) (5.1)	0	(.0)	919	(11.3)	
10-19 days	14	(4.0)	10	(0.1) (7.2)	0	(.0)	212	(0.3)	
20–29 days	14	(1.0) (9.5)	10	(7.2) (6.5)	0	(.0)	258	(0.0)	
Every day	10	(10.6)	19	(0.0)	0	(.0)	344	(11.0)	
Frequency unknown	10	(10.0)	10	(0.4)	0	(.0)	0	(11.2)	
Lifetime tobacco use	0	(.0)	0	(.0)	0	(.0)	0	(.0)	< 0.001
Yes	118	(65.9)	93	(67.4)	2	(50.0)	1 838	(59.8)	-0.001
Age at first tobacco use	110	(00.0)	00	(0111)	-	(00.0)	1,000	(0010)	<0.001
Never	59	(33.0)	43	(31.2)	2	(50.0)	1.204	(39.1)	
≤9 years old	1	(.6)	1	(.7)	0	(.0)	23	(.7)	
10–11 years old	1	(.6)	0	(.0)	0	(.0)	25	(.8)	
12–13 years old	3	(1.7)	4	(2.9)	0	(.0)	65	(2.1)	
14–15 years old	13	(7.3)	5	(3.6)	0	(.0)	182	(5.9)	
16–17 years old	23	(12.8)	15	(10.9)	1	(25.0)	348	(11.3)	
18–19 years old	28	(15.6)	24	(17.4)	0	(.0)	521	(16.9)	
≥20 years old	49	(27.4)	43	(31.2)	1	(25.0)	663	(21.6)	
Age unknown	0	(.0)	1	(.7)	0	(.0)	11	(.4)	
Age at the start of chronic tobacco use									< 0.001
Never	58	(32.4)	43	(31.2)	2	(50.0)	1,202	(39.1)	
≤9 years old	0	(.0)	0	(.0)	0	(.0)	2	(.1)	
10–11 years old	0	(.0)	0	(.0)	0	(.0)	3	(.1)	
12–13 years old	1	(.6)	2	(1.4)	0	(.0)	11	(.4)	
14–15 years old	3	(1.7)	4	(2.9)	0	(.0)	66	(2.1)	
16–17 years old	14	(7.8)	4	(2.9)	0	(.0)	176	(5.7)	
18–19 years old	23	(12.8)	18	(13.0)	0	(.0)	441	(14.3)	
≥20 years old	61	(34.1)	53	(38.4)	2	(50.0)	780	(25.4)	
Age unknown	16	(8.9)	12	(8.7)	0	(.0)	359	(11.7)	
Past-year tobacco use									< 0.001
Yes	58	(32.4)	40	(29.0)	2	(50.0)	827	(26.9)	
Number of days of tobacco use within th	e past 30	days							< 0.001
0 day	125	(69.8)	104	(75.4)	2	(50.0)	2,310	(75.1)	
1-2 days	2	(1.1)	2	(1.4)	0	(.0)	20	(.7)	
3–5 days	0	(.0)	0	(.0)	0	(.0)	15	(.5)	
6–9 days	1	(.6)	1	(.7)	0	(.0)	6	(.2)	
10–19 days	4	(2.2)	2	(1.4)	0	(.0)	23	(.7)	
20–29 days	3	(1.7)	4	(2.9)	0	(.0)	40	(1.3)	
Every day	43	(24.0)	25	(18.1)	2	(50.0)	642	(20.9)	
Frequency unknown	0	(0)	0	(0)	0	(0)	0	(0)	

Respondents with "no response/unknown" are not included. For age at the start of chronic alcohol use,

respondents not having reached the stage of chronic alcohol use are included in "age unknown." For age at the start of chronic tobacco use, respondents not having reached the stage of chronic tobacco use are included in "age unknown."

_				Drug ı	use expe	rience			
	Lifet	time	No life	etime	Unkn	own	Tot	al	
	n=	78	n=29	940	n={	58	n=30	076	p-value
	n	(%)	n	(%)	n	(%)	n	(%)	
Lifetime alcohol use									0.050
Yes	78	(100.0)	2741	(93.2)	53	(91.4)	2872	(93.4)	0.000
Age at first alcohol use									< 0.001
Never	0	(.0)	194	(6.6)	4	(6.9)	198	(6.4)	
≤9 years old	8	(10.3)	125	(4.3)	0	(.0)	133	(4.3)	
10–11 years old	4	(5.1)	56	(1.9)	1	(1.7)	61	(2.0)	
12–13 years old	10	(12.8)	79	(2.7)	1	(1.7)	90	(2.9)	
14–15 years old	16	(20.5)	153	(5.2)	4	(6.9)	173	(5.6)	
16-17 years old	20	(25.6)	352	(12.0)	8	(13.8)	380	(12.4)	
≥ 20 years old	15	(19.2)	917 1046	(31.2)	19	(32.8)	991 1070	(30.9)	
Age unknown	4	(0.1) (1.3)	1040	(35.0)	20	(34.0)	1070	(34.6)	
Age at the start of chronic	alcohol	use	10	(.4)	0	(.0)	14	(.0)	< 0.001
Never	0	(.0)	193	(6.6)	4	(6.9)	197	(6.4)	-0.001
≤9 years old	0	(.0)	0	(.0)	0	(.0)	0	(.0)	
10–11 years old	0	(.0)	3	(.1)	0	(.0)	3	(.1)	
12–13 years old	2	(2.6)	1	(0.03)	0	(.0)	3	(.1)	
14–15 years old	4	(5.1)	10	(.3)	1	(1.7)	15	(.5)	
16–17 years old	10	(12.8)	54	(1.8)	0	(.0)	64	(2.1)	
18–19 years old	29	(37.2)	478	(16.3)	12	(20.7)	519	(16.9)	
≥ 20 years old	31	(39.7)	1933	(65.7)	33	(56.9)	1997	(64.9)	
Age unknown	2	(2.6)	262	(8.9)	7	(12.1)	271	(8.8)	
Past-year alcohol use	-	(02, 0)	00.11	(=0, 0)			0.4 .	$(\overline{} \circ \circ)$	0.001
Yes Number of days of alcohol	'72	(92.3) hin tho r	2341 post 30 d	(79.6)	41	(70.7)	2454	(79.8)	0.001
0 dow	15 use with	(10.9)	079	(99-1)	91	(26.2)	1009	(22.8)	0.001
1_2 days	10	(19.2) (7.7)	974 513	(33.1)	21 7	(30.2) (19.1)	526	(32.0) (17.1)	
3–5 days	11	(1.1)	350	(17.4) (11.0)	1	(12.1) (6.9)	365	(17.1) (11.0)	
6–9 days	5	(6.4)	205	(11.0)	4 2	(0.3)	212	(11.0) (6.9)	
10–19 days	7	(9.0)	243	(8.3)	6	(10.3)	256	(8.3)	
20–29 days	18	(23.1)	331	(11.3)	9	(15.5)	358	(11.6)	
Every day	16	(20.5)	320	(10.9)	8	(13.8)	344	(11.2)	
Frequency unknown	0	(.0)	0	(.0)	0	(.0)	0	(.0)	
Lifetime tobacco use									< 0.001
Yes	77	(98.7)	1725	(58.7)	36	(62.1)	1838	(59.8)	
Age at first tobacco use				<i>,</i> ,					< 0.001
Never	1	(1.3)	1182	(40.2)	21	(36.2)	1204	(39.1)	
≤ 9 years old	4	(5.1)	19	(.6)	0	(.0)	23	(.7)	
10-11 years old	6	(7.7)	18	(.6)	1	(1.7)	25	(.8)	
14 15 years old	10	(12.8)	55 157	(1.9)	0	(.0)	65 199	(2.1)	
16–17 years old	21 94	(20.9)	218	(0.0)	4	(0.9)	348	(0.9)	
18–19 years old	24 7	(30.8)	504	(10.0) (17.1)	10	(10.3) (17.2)	540 591	(11.0) (16.0)	
≥ 20 years old	5	(6.4)	643	(17.1) (21.9)	15	(17.2) (25.9)	663	(10.3)	
Age unknown	0	(0.4)	11	(.4)	0	(.0)	11	(.4)	
Age at the start of chronic	tobacco	use		(11)	0	()		(11)	< 0.001
Never	1	(1.3)	1180	(40.1)	21	(36.2)	1202	(39.1)	
≤9 years old	1	(1.3)	1	(0.03)	0	(.0)	2	(.1)	
10–11 years old	2	(2.6)	1	(0.03)	0	(.0)	3	(.1)	
12–13 years old	8	(10.3)	3	(.1)	0	(.0)	11	(.4)	
14–15 years old	13	(16.7)	52	(1.8)	1	(1.7)	66	(2.1)	
16–17 years old	24	(30.8)	151	(5.1)	1	(1.7)	176	(5.7)	
18–19 years old	18	(23.1)	411	(14.0)	12	(20.7)	441	(14.3)	
≥20 years old	9	(11.5)	755	(25.7)	16	(27.6)	780	(25.4)	
Age unknown Past-year tobacco yea	2	(2.6)	351	(11.9)	6	(10.3)	359	(11.7)	Z0 001
Voc	10	$(\mathbf{F} \mathbf{O}, \mathbf{O})$		(05 5)	0.4	(11 1)	007	(\mathbf{n},\mathbf{n})	< 0.001
Number of days of tobacco	46 1180 wit	(09.0) thin the r	757 1911 nast	(20.7) lavs	24	(41.4)	827	(26.9)	<0.001
0 day	200 WIL	(43 G)	2930	(76.9)	27	(63.8)	2310	(75.1)	~0.001
1-2 days	1	(1.3)	2209 18	(6)	1	(17)	2010	(70.1)	
3-5 days	1	(1.3)	13	(4)	1	(1.7)	15	(5)	
6–9 days	0	(.0)	6	(.2)	0	(.0)	6	(.2)	
10–19 days	2	(2.6)	21	(.7)	Õ	(.0)	23	(.7)	
20–29 days	1	(1.3)	37	(1.3)	2	(3.4)	40	(1.3)	
Every day	39	(50.0)	587	(20.0)	16	(27.6)	642	(20.9)	
Frequency unknown	0	(0)	Ω	(0)	0	(0)	Ο	(0)	

Respondents with "no response/unknown" are not included. For age at the start of chronic alcohol use, respondents not having reached the stage of chronic alcohol use are included in "age unknown." For age at the start of chronic tobacco use, respondents not having reached the stage of chronic tobacco use are included in "age unknown."

Table 17. Medications use by Residence area (n=3076)

						Residence	ce area					
-	Hokk	aido	Toho	oku	Kar	Kanto Hokur			curiku Tousan			cai
	n=1	31	n=2	50	n=9	948	n=1	54	n=150		n=3	28
	n	(%)	n	(%)	n	(%)	n	(%)	n	(%)	n	(%)
Household medicines												
None	14	(10.7)	34	(13.6)	107	(11.3)	11	(7.1)	19	(12.7)	35	(10.7)
Cold medicines	101	(77.1)	179	(71.6)	672	(70.9)	122	(79.2)	111	(74.0)	229	(69.8)
Antipyretic analgesics	73	(55.7)	127	(50.8)	529	(55.8)	85	(55.2)	79	(52.7)	192	(58.5)
Drugs for rhinitis (allergy drugs)	39	(29.8)	79	(31.6)	313	(33.0)	44	(28.6)	53	(35.3)	106	(32.3)
Motion sickness drugs	22	(16.8)	35	(14.0)	155	(16.4)	27	(17.5)	17	(11.3)	48	(14.6)
Gastrointestinal medicines	77	(58.8)	143	(57.2)	533	(56.2)	102	(66.2)	84	(56.0)	185	(56.4)
Laxatives	25	(19.1)	41	(16.4)	134	(14.1)	27	(17.5)	25	(16.7)	51	(15.5)
Cough medicines	27	(20.6)	55	(22.0)	196	(20.7)	35	(22.7)	30	(20.0)	78	(23.8)
Chinese herbal medicines	18	(13.7)	35	(14.0)	139	(14.7)	26	(16.9)	28	(18.7)	55	(16.8)
Vitamin supplements	25	(19.1)	40	(16.0)	191	(20.1)	25	(16.2)	25	(16.7)	57	(17.4)
Other supplements	29	(22.1)	60	(24.0)	234	(24.7)	37	(24.0)	27	(18.0)	82	(25.0)
Other	3	(2.3)	9	(3.6)	25	(2.6)	10	(6.5)	5	(3.3)	6	(1.8)
No response/unknown	2	(1.5)	2	(.8)	6	(.6)	0	(.0)	0	(.0)	2	(.6)
Medicinal drugs used within the past	year											
None	4	(3.1)	26	(10.4)	69	(7.3)	10	(6.5)	13	(8.7)	23	(7.0)
Cold medicines	92	(70.2)	165	(66.0)	635	(67.0)	100	(64.9)	97	(64.7)	208	(63.4)
Antipyretic analgesics	96	(73.3)	151	(60.4)	599	(63.2)	96	(62.3)	88	(58.7)	217	(66.2)
Drugs for rhinitis (allergy drugs)	32	(24.4)	72	(28.8)	315	(33.2)	42	(27.3)	42	(28.0)	100	(30.5)
Motion sickness drugs	10	(7.6)	14	(5.6)	66	(7.0)	13	(8.4)	7	(4.7)	19	(5.8)
Gastrointestinal medicines	56	(42.7)	93	(37.2)	369	(38.9)	57	(37.0)	51	(34.0)	113	(34.5)
Laxatives	23	(17.6)	29	(11.6)	80	(8.4)	20	(13.0)	17	(11.3)	37	(11.3)
Cough medicines	26	(19.8)	48	(19.2)	204	(21.5)	23	(14.9)	23	(15.3)	57	(17.4)
Chinese herbal medicines	23	(17.6)	26	(10.4)	150	(15.8)	17	(11.0)	30	(20.0)	41	(12.5)
Vitamin supplements	24	(18.3)	31	(12.4)	176	(18.6)	20	(13.0)	24	(16.0)	49	(14.9)
Other supplements	24	(18.3)	55	(22.0)	222	(23.4)	33	(21.4)	32	(21.3)	68	(20.7)
Other	12	(9.2)	24	(9.6)	73	(7.7)	14	(9.1)	8	(5.3)	25	(7.6)
No response/unknown	2	(1.5)	1	(.4)	3	(.3)	0	(.0)	0	(.0)	1	(.3)

Table 17. Medications useby Residence area(n=3076) continued

	Residence area												
-	Kir	ıki	Chug	goku	Shik	oku	Kita-K	yusyu	Minami-		Total		
	n=4	42	n=1	.91	n=8	88	n=2	29	n=165		n=3076		p-value
	n	(%)	n	(%)	n	(%)	n	(%)	n	(%)	n	(%)	
Household medicines													
None	66	(14.9)	21	(11.0)	9	(10.2)	38	(16.6)	27	(16.4)	381	(12.4)	0.250
Cold medicines	318	(71.9)	146	(76.4)	61	(69.3)	151	(65.9)	102	(61.8)	2192	(71.3)	0.066
Antipyretic analgesics	234	(52.9)	109	(57.1)	52	(59.1)	125	(54.6)	96	(58.2)	1701	(55.3)	0.808
Drugs for rhinitis (allergy drugs)	149	(33.7)	55	(28.8)	28	(31.8)	57	(24.9)	49	(29.7)	972	(31.6)	0.634
Motion sickness drugs	86	(19.5)	30	(15.7)	16	(18.2)	28	(12.2)	16	(9.7)	480	(15.6)	0.262
Gastrointestinal medicines	231	(52.3)	107	(56.0)	40	(45.5)	123	(53.7)	86	(52.1)	1711	(55.6)	0.267
Laxatives	85	(19.2)	43	(22.5)	13	(14.8)	29	(12.7)	22	(13.3)	495	(16.1)	0.237
Cough medicines	91	(20.6)	54	(28.3)	20	(22.7)	46	(20.1)	27	(16.4)	659	(21.4)	0.559
Chinese herbal medicines	77	(17.4)	30	(15.7)	15	(17.0)	35	(15.3)	21	(12.7)	479	(15.6)	0.872
Vitamin supplements	87	(19.7)	32	(16.8)	12	(13.6)	34	(14.8)	26	(15.8)	554	(18.0)	0.672
Other supplements	100	(22.6)	45	(23.6)	21	(23.9)	53	(23.1)	34	(20.6)	722	(23.5)	0.877
Other	13	(2.9)	4	(2.1)	1	(1.1)	10	(4.4)	2	(1.2)	88	(2.9)	0.329
No response/unknown	1	(.2)	2	(1.0)	0	(.0)	1	(.4)	0	(.0)	16	(.5)	0.635
Medicinal drugs used within the past y	vear												
None	40	(9.0)	21	(11.0)	5	(5.7)	19	(8.3)	16	(9.7)	246	(8.0)	0.147
Cold medicines	270	(61.1)	113	(59.2)	55	(62.5)	150	(65.5)	105	(63.6)	1990	(64.7)	0.215
Antipyretic analgesics	257	(58.1)	112	(58.6)	63	(71.6)	148	(64.6)	110	(66.7)	1937	(63.0)	0.019
Drugs for rhinitis (allergy drugs)	127	(28.7)	44	(23.0)	22	(25.0)	56	(24.5)	47	(28.5)	899	(29.2)	0.062
Motion sickness drugs	33	(7.5)	17	(8.9)	7	(8.0)	14	(6.1)	17	(10.3)	217	(7.1)	0.332
Gastrointestinal medicines	161	(36.4)	68	(35.6)	32	(36.4)	79	(34.5)	63	(38.2)	1142	(37.1)	0.420
Laxatives	57	(12.9)	24	(12.6)	8	(9.1)	14	(6.1)	18	(10.9)	327	(10.6)	0.016
Cough medicines	73	(16.5)	32	(16.8)	13	(14.8)	50	(21.8)	30	(18.2)	579	(18.8)	0.143
Chinese herbal medicines	68	(15.4)	29	(15.2)	13	(14.8)	41	(17.9)	24	(14.5)	462	(15.0)	0.113
Vitamin supplements	77	(17.4)	25	(13.1)	13	(14.8)	36	(15.7)	33	(20.0)	508	(16.5)	0.156
Other supplements	94	(21.3)	40	(20.9)	19	(21.6)	45	(19.7)	40	(24.2)	672	(21.8)	0.565
Other	49	(11.1)	18	(9.4)	8	(9.1)	23	(10.0)	8	(4.8)	262	(8.5)	0.178
No response/unknown	0	(.0)	2	(1.0)	1	(1.1)	0	(.0)	0	(.0)	10	(.3)	0.153

For household medicines and drugs used within the past year, vitamin supplements are not included in "other supplements," and

"gastrointestinal medicines" include antiflatulents and antidiarrheics.

Table 18. Medications use by Sex (n = 3076)

				Sex			
	Me	en	Won	nen	Tot	al	
	n = 1	466	n = 1	610	n = 3	076	P-value
	n	(%)	n	(%)	n	(%)	
Household medicines							
None	212	(14.5)	169	(10.5)	381	(12.4)	0.002
Cold medicines	1031	(70.3)	1161	(72.1)	2192	(71.3)	0.309
Antipyretic analgesics	681	(46.5)	1020	(63.4)	1701	(55.3)	< 0.001
Drugs for rhinitis (allergy drugs)	446	(30.4)	526	(32.7)	972	(31.6)	0.216
Motion sickness drugs	196	(13.4)	284	(17.6)	480	(15.6)	0.003
Gastrointestinal medicines	824	(56.2)	887	(55.1)	1711	(55.6)	0.379
Laxatives	165	(11.3)	330	(20.5)	495	(16.1)	< 0.001
Cough medicines	303	(20.7)	356	(22.1)	659	(21.4)	0.319
Chinese herbal medicines	214	(14.6)	265	(16.5)	479	(15.6)	0.188
Vitamin supplements	247	(16.8)	307	(19.1)	554	(18.0)	0.145
Other supplements	306	(20.9)	416	(25.8)	722	(23.5)	0.003
Other	38	(2.6)	50	(3.1)	88	(2.9)	0.346
No response/unknown	10	(.7)	6	(.4)	16	(.5)	0.233
Medicinal drugs used within the past year							
None	142	(9.7)	104	(6.5)	246	(8.0)	0.003
Cold medicines	923	(63.0)	1067	(66.3)	1990	(64.7)	0.129
Antipyretic analgesics	777	(53.0)	1160	(72.0)	1937	(63.0)	< 0.001
Drugs for rhinitis (allergy drugs)	379	(25.9)	520	(32.3)	899	(29.2)	< 0.001
Motion sickness drugs	75	(5.1)	142	(8.8)	217	(7.1)	< 0.001
Gastrointestinal medicines	537	(36.6)	605	(37.6)	1142	(37.1)	0.647
Laxatives	65	(4.4)	262	(16.3)	327	(10.6)	< 0.001
Cough medicines	228	(15.6)	351	(21.8)	579	(18.8)	< 0.001
Chinese herbal medicines	161	(11.0)	301	(18.7)	462	(15.0)	< 0.001
Vitamin supplements	202	(13.8)	306	(19.0)	508	(16.5)	< 0.001
Other supplements	270	(18.4)	402	(25.0)	672	(21.8)	< 0.001
Other	124	(8.5)	138	(8.6)	262	(8.5)	0.733
No response/unknown	6	(.4)	4	(.2)	10	(.3)	0.434

Table 19. Medications use by Age group(n=3076)

	Age group														
	1	0s	2	0s	3	0s	4	0s	5	0s 60		0s	To	tal	
	n=	222	n=	382	n=	553	n='	751	n=	695	n=473		n=3	076	p-value
	n	(%)	n	(%)	n	(%)	n	(%)	n	(%)	n	(%)	n	(%)	
Household medicines															
None	40	(18.0)	54	(14.1)	61	(11.0)	80	(10.7)	81	(11.7)	65	(13.7)	381	(12.4)	0.008
Cold medicines	133	(59.9)	266	(69.6)	407	(73.6)	542	(72.2)	502	(72.2)	342	(72.3)	2192	(71.3)	0.004
Antipyretic analgesics	100	(45.0)	201	(52.6)	319	(57.7)	448	(59.7)	403	(58.0)	230	(48.6)	1701	(55.3)	< 0.001
Drugs for rhinitis (allergy drugs)	73	(32.9)	116	(30.4)	174	(31.5)	263	(35.0)	223	(32.1)	123	(26.0)	972	(31.6)	0.012
Motion sickness drugs	70	(31.5)	56	(14.7)	78	(14.1)	148	(19.7)	91	(13.1)	37	(7.8)	480	(15.6)	< 0.001
Gastrointestinal medicines	94	(42.3)	176	(46.1)	278	(50.3)	432	(57.5)	436	(62.7)	295	(62.4)	1711	(55.6)	< 0.001
Laxatives	45	(20.3)	55	(14.4)	68	(12.3)	109	(14.5)	134	(19.3)	84	(17.8)	495	(16.1)	0.001
Cough medicines	51	(23.0)	65	(17.0)	108	(19.5)	150	(20.0)	172	(24.7)	113	(23.9)	659	(21.4)	0.006
Chinese herbal medicines	25	(11.3)	47	(12.3)	93	(16.8)	127	(16.9)	120	(17.3)	67	(14.2)	479	(15.6)	0.020
Vitamin supplements	30	(13.5)	56	(14.7)	107	(19.3)	139	(18.5)	137	(19.7)	85	(18.0)	554	(18.0)	0.038
Other supplements	36	(16.2)	62	(16.2)	125	(22.6)	174	(23.2)	192	(27.6)	133	(28.1)	722	(23.5)	< 0.001
Other	3	(1.4)	3	(.8)	10	(1.8)	24	(3.2)	30	(4.3)	18	(3.8)	88	(2.9)	0.001
No response/unknown	4	(1.8)	3	(.8)	2	(.4)	2	(.3)	1	(.1)	4	(.8)	16	(.5)	0.040
Medicinal drugs used within the past year															
None	30	(13.5)	40	(10.5)	41	(7.4)	44	(5.9)	47	(6.8)	44	(9.3)	246	(8.0)	0.003
Cold medicines	134	(60.4)	260	(68.1)	394	(71.2)	504	(67.1)	425	(61.2)	273	(57.7)	1990	(64.7)	< 0.001
Antipyretic analgesics	127	(57.2)	239	(62.6)	389	(70.3)	499	(66.4)	438	(63.0)	245	(51.8)	1937	(63.0)	< 0.001
Drugs for rhinitis (allergy drugs)	81	(36.5)	115	(30.1)	168	(30.4)	234	(31.2)	201	(28.9)	100	(21.1)	899	(29.2)	0.002
Motion sickness drugs	42	(18.9)	32	(8.4)	31	(5.6)	54	(7.2)	39	(5.6)	19	(4.0)	217	(7.1)	< 0.001
Gastrointestinal medicines	54	(24.3)	121	(31.7)	188	(34.0)	291	(38.7)	289	(41.6)	199	(42.1)	1142	(37.1)	< 0.001
Laxatives	17	(7.7)	44	(11.5)	41	(7.4)	75	(10.0)	87	(12.5)	63	(13.3)	327	(10.6)	0.016
Cough medicines	46	(20.7)	76	(19.9)	110	(19.9)	141	(18.8)	112	(16.1)	94	(19.9)	579	(18.8)	0.324
Chinese herbal medicines	21	(9.5)	58	(15.2)	99	(17.9)	118	(15.7)	104	(15.0)	62	(13.1)	462	(15.0)	0.071
Vitamin supplements	23	(10.4)	61	(16.0)	98	(17.7)	130	(17.3)	121	(17.4)	75	(15.9)	508	(16.5)	0.158
Other supplements	23	(10.4)	57	(14.9)	117	(21.2)	171	(22.8)	184	(26.5)	120	(25.4)	672	(21.8)	< 0.001
Other	3	(1.4)	12	(3.1)	29	(5.2)	69	(9.2)	86	(12.4)	63	(13.3)	262	(8.5)	< 0.001
No response/unknown	0	(.0)	0	(.0)	1	(.2)	2	(.3)	3	(.4)	4	(.8)	10	(.3)	0.252

"10s" refers to those aged 15 to 19, and "60s" refers to those aged 60 to 64.

For household medicines and drugs used within the past year, vitamin supplements are not included in "other supplements," and "gastrointestinal medicines" include antiflatulents and antidiarrheics.

-42 -

Table 20. Medications use by Occupation(n=3076)

					Occup	ation						
	Self-em	ployed	Full-	time	Non-fu	ll-time	Stud	ent	Housewife			
	n=2	48	n=1-	406	n=3	94	n=2	71	n=4	36		
	n	(%)	n	(%)	n	(%)	n	(%)	n	(%)		
Household medicines												
None	38	(15.3)	159	(11.3)	36	(9.1)	47	(17.3)	46	(10.6)		
Cold medicines	169	(68.1)	1,021	(72.6)	298	(75.6)	169	(62.4)	325	(74.5)		
Antipyretic analgesics	125	(50.4)	767	(54.6)	258	(65.5)	125	(46.1)	274	(62.8)		
Drugs for rhinitis (allergy drugs)	73	(29.4)	457	(32.5)	137	(34.8)	90	(33.2)	135	(31.0)		
Motion sickness drugs	32	(12.9)	193	(13.7)	80	(20.3)	79	(29.2)	72	(16.5)		
Gastrointestinal medicines	152	(61.3)	791	(56.3)	230	(58.4)	119	(43.9)	255	(58.5)		
Laxatives	45	(18.1)	179	(12.7)	84	(21.3)	53	(19.6)	85	(19.5)		
Cough medicines	58	(23.4)	280	(19.9)	97	(24.6)	60	(22.1)	100	(22.9)		
Chinese herbal medicines	50	(20.2)	213	(15.1)	65	(16.5)	31	(11.4)	79	(18.1)		
Vitamin supplements	45	(18.1)	263	(18.7)	71	(18.0)	41	(15.1)	76	(17.4)		
Other supplements	64	(25.8)	314	(22.3)	101	(25.6)	42	(15.5)	131	(30.0)		
Other	10	(4.0)	31	(2.2)	13	(3.3)	3	(1.1)	24	(5.5)		
No response/unknown	0	(.0)	7	(.5)	1	(.3)	4	(1.5)	2	(.5)		
Medicinal drugs used within the past year												
None	28	(11.3)	87	(6.2)	27	(6.9)	38	(14.0)	31	(7.1)		
Cold medicines	142	(57.3)	958	(68.1)	259	(65.7)	171	(63.1)	286	(65.6)		
Antipyretic analgesics	141	(56.9)	893	(63.5)	267	(67.8)	152	(56.1)	312	(71.6)		
Drugs for rhinitis (allergy drugs)	58	(23.4)	419	(29.8)	132	(33.5)	101	(37.3)	127	(29.1)		
Motion sickness drugs	15	(6.0)	82	(5.8)	29	(7.4)	48	(17.7)	35	(8.0)		
Gastrointestinal medicines	102	(41.1)	528	(37.6)	160	(40.6)	71	(26.2)	166	(38.1)		
Laxatives	22	(8.9)	110	(7.8)	56	(14.2)	21	(7.7)	75	(17.2)		
Cough medicines	44	(17.7)	250	(17.8)	78	(19.8)	54	(19.9)	101	(23.2)		
Chinese herbal medicines	38	(15.3)	197	(14.0)	65	(16.5)	29	(10.7)	89	(20.4)		
Vitamin supplements	35	(14.1)	238	(16.9)	64	(16.2)	35	(12.9)	81	(18.6)		
Other supplements	60	(24.2)	307	(21.8)	95	(24.1)	27	(10.0)	115	(26.4)		
Other	22	(8.9)	108	(7.7)	32	(8.1)	5	(1.8)	53	(12.2)		
No response/unknown	1	(.4)	5	(.4)	1	(.3)	0	(.0)	1	(.2)		

	Occupation										
	Unem	oloyed	Oth	ier	Unkn	own	Total				
	n=1	79	n=1	.38	n=	4	n=3076		p-value		
	n	(%)	n	(%)	n	(%)	n	(%)			
Household medicines											
None	34	(19.0)	21	(15.2)	0	(.0)	381	(12.4)	0.003		
Cold medicines	110	(61.5)	97	(70.3)	3	(75.0)	2,192	(71.3)	0.002		
Antipyretic analgesics	75	(41.9)	74	(53.6)	3	(75.0)	1,701	(55.3)	< 0.001		
Drugs for rhinitis (allergy drugs)	44	(24.6)	36	(26.1)	0	(.0)	972	(31.6)	0.134		
Motion sickness drugs	11	(6.1)	13	(9.4)	0	(.0)	480	(15.6)	< 0.001		
Gastrointestinal medicines	87	(48.6)	75	(54.3)	2	(50.0)	1,711	(55.6)	0.005		
Laxatives	23	(12.8)	24	(17.4)	2	(50.0)	495	(16.1)	< 0.001		
Cough medicines	32	(17.9)	32	(23.2)	0	(.0)	659	(21.4)	0.274		
Chinese herbal medicines	24	(13.4)	16	(11.6)	1	(25.0)	479	(15.6)	0.104		
Vitamin supplements	27	(15.1)	30	(21.7)	1	(25.0)	554	(18.0)	0.536		
Other supplements	31	(17.3)	37	(26.8)	2	(50.0)	722	(23.5)	0.001		
Other	3	(1.7)	4	(2.9)	0	(.0)	88	(2.9)	0.018		
No response/unknown	2	(1.1)	0	(.0)	0	(.0)	16	(.5)	0.279		
Medicinal drugs used within the past year											
None	25	(14.0)	10	(7.2)	0	(.0)	246	(8.0)	< 0.001		
Cold medicines	82	(45.8)	91	(65.9)	1	(25.0)	1,990	(64.7)	< 0.001		
Antipyretic analgesics	86	(48.0)	84	(60.9)	2	(50.0)	1,937	(63.0)	< 0.001		
Drugs for rhinitis (allergy drugs)	29	(16.2)	32	(23.2)	1	(25.0)	899	(29.2)	0.001		
Motion sickness drugs	2	(1.1)	6	(4.3)	0	(.0)	217	(7.1)	< 0.001		
Gastrointestinal medicines	61	(34.1)	53	(38.4)	1	(25.0)	1,142	(37.1)	0.043		
Laxatives	19	(10.6)	23	(16.7)	1	(25.0)	327	(10.6)	< 0.001		
Cough medicines	21	(11.7)	31	(22.5)	0	(.0)	579	(18.8)	0.138		
Chinese herbal medicines	23	(12.8)	20	(14.5)	1	(25.0)	462	(15.0)	0.084		
Vitamin supplements	21	(11.7)	33	(23.9)	1	(25.0)	508	(16.5)	0.177		
Other supplements	27	(15.1)	39	(28.3)	2	(50.0)	672	(21.8)	< 0.001		
Other	29	(16.2)	13	(9.4)	0	(.0)	262	(8.5)	< 0.001		
No response/unknown	2	(1.1)	0	(.0)	0	(.0)	10	(.3)	0.649		

Table 20. Medications use by Occupation (n=3076) continued

Table 21. Me	dications use	by D	rug use	experience	(n=3076)
--------------	---------------	------	---------	------------	----------

_	Drug use experience								
	Lifet	ime	No life	etime	Unkn	own	Tot	al	
	n=	78	n=29	940	n=58		n=3076		p-value
	n	(%)	n	(%)	n	(%)	n	(%)	
Household medicines									
None	8	(10.3)	358	(12.2)	15	(25.9)	381	(12.4)	0.024
Cold medicines	52	(66.7)	2,108	(71.7)	32	(55.2)	2,192	(71.3)	0.043
Antipyretic analgesics	49	(62.8)	1,633	(55.5)	19	(32.8)	1,701	(55.3)	0.004
Drugs for rhinitis (allergy drugs)	24	(30.8)	936	(31.8)	12	(20.7)	972	(31.6)	0.334
Motion sickness drugs	9	(11.5)	467	(15.9)	4	(6.9)	480	(15.6)	0.224
Gastrointestinal medicines	43	(55.1)	1,637	(55.7)	31	(53.4)	1,711	(55.6)	0.856
Laxatives	13	(16.7)	476	(16.2)	6	(10.3)	495	(16.1)	0.610
Cough medicines	22	(28.2)	628	(21.4)	9	(15.5)	659	(21.4)	0.322
Chinese herbal medicines	10	(12.8)	462	(15.7)	7	(12.1)	479	(15.6)	0.698
Vitamin supplements	16	(20.5)	535	(18.2)	3	(5.2)	554	(18.0)	0.085
Other supplements	18	(23.1)	697	(23.7)	7	(12.1)	722	(23.5)	0.234
Other	3	(3.8)	83	(2.8)	2	(3.4)	88	(2.9)	0.817
No response/unknown	1	(1.3)	15	(.5)	0	(.0)	16	(.5)	0.553
Medicinal drugs used within the past year									
None	4	(5.1)	232	(7.9)	10	(17.2)	246	(8.0)	< 0.001
Cold medicines	50	(64.1)	1,908	(64.9)	32	(55.2)	1,990	(64.7)	0.005
Antipyretic analgesics	53	(67.9)	1,854	(63.1)	30	(51.7)	1,937	(63.0)	0.002
Drugs for rhinitis (allergy drugs)	18	(23.1)	872	(29.7)	9	(15.5)	899	(29.2)	0.001
Motion sickness drugs	6	(7.7)	208	(7.1)	3	(5.2)	217	(7.1)	0.012
Gastrointestinal medicines	23	(29.5)	1,109	(37.7)	10	(17.2)	1,142	(37.1)	< 0.001
Laxatives	7	(9.0)	315	(10.7)	5	(8.6)	327	(10.6)	0.012
Cough medicines	18	(23.1)	549	(18.7)	12	(20.7)	579	(18.8)	0.008
Chinese herbal medicines	8	(10.3)	447	(15.2)	7	(12.1)	462	(15.0)	0.007
Vitamin supplements	15	(19.2)	488	(16.6)	5	(8.6)	508	(16.5)	0.003
Other supplements	22	(28.2)	644	(21.9)	6	(10.3)	672	(21.8)	0.001
Other	6	(7.7)	250	(8.5)	6	(10.3)	262	(8.5)	0.012
No response/unknown	2	(2.6)	8	(.3)	0	(.0)	10	(.3)	0.002

Table 22. A	nalgesic 1	Use by	Residence	area(n=3076)
-------------	------------	--------	-----------	--------------

_						Residenc	e area					
_	Hokl	kaido	Toh	oku	Kar	nto	Hoku	uriku	Tou	san	Tol	xai
	n=	131	n=2	250	n=9	948	n=	154	n=1	150	n=3	28
	n	(%)	n	(%)	n	(%)	n	(%)	n	(%)	n	(%)
Past-year analgesic use												
No	34	(26.0)	99	(39.6)	346	(36.5)	58	(37.7)	62	(41.3)	111	(33.8)
Yes	96	(73.3)	151	(60.4)	599	(63.2)	96	(62.3)	88	(58.7)	217	(66.2)
Frequency of the past-year and	algesic u	use										
None	34	(26.0)	99	(39.6)	346	(36.5)	58	(37.7)	62	(41.3)	111	(33.8)
≦5 times a year	52	(39.7)	90	(36.0)	330	(34.8)	49	(31.8)	49	(32.7)	115	(35.1)
Approx. 6–11 times a year	7	(5.3)	15	(6.0)	76	(8.0)	11	(7.1)	9	(6.0)	27	(8.2)
Approx. 12–24 times a year	17	(13.0)	18	(7.2)	75	(7.9)	11	(7.1)	15	(10.0)	42	(12.8)
Approx. 25–51 times a year	13	(9.9)	8	(3.2)	47	(5.0)	9	(5.8)	8	(5.3)	16	(4.9)
Approx. 1–2 times a week	3	(2.3)	3	(1.2)	22	(2.3)	5	(3.2)	1	(.7)	5	(1.5)
Approx. 3–6 times a week	0	(.0)	3	(1.2)	7	(.7)	2	(1.3)	2	(1.3)	2	(.6)
Almost every day	2	(1.5)	4	(1.6)	19	(2.0)	4	(2.6)	2	(1.3)	3	(.9)
Frequency unknown	2	(1.5)	10	(4.0)	23	(2.4)	5	(3.2)	2	(1.3)	7	(2.1)
Chronic analgesic use												
No	126	(96.2)	233	(93.2)	896	(94.5)	143	(92.9)	144	(96.0)	316	(96.3)
Yes	2	(1.5)	7	(2.8)	26	(2.7)	6	(3.9)	4	(2.7)	5	(1.5)
Source of analgesics												
Never obtained	27	(20.6)	84	(33.6)	294	(31.0)	49	(31.8)	55	(36.7)	91	(27.7)
Household medicines	15	(11.5)	35	(14.0)	134	(14.1)	23	(14.9)	22	(14.7)	43	(13.1)
Family	10	(7.6)	8	(3.2)	39	(4.1)	4	(2.6)	5	(3.3)	15	(4.6)
Clinics/hospitals	43	(32.8)	57	(22.8)	228	(24.1)	35	(22.7)	35	(23.3)	95	(29.0)
Pharmacies/drugstores	58	(44.3)	81	(32.4)	388	(40.9)	60	(39.0)	57	(38.0)	145	(44.2)
Friends/acquaintances	0	(.0)	2	(.8)	12	(1.3)	1	(.6)	0	(.0)	1	(.3)
Romantic partners	0	(.0)	0	(.0)	1	(.1)	0	(.0)	0	(.0)	0	(.0)
Internet	1	(.8)	1	(.4)	2	(.2)	1	(.6)	0	(.0)	0	(.0)
Other	0	(.0)	0	(.0)	4	(.4)	0	(.0)	0	(.0)	0	(.0)
Source unknown	3	(2.3)	8	(3.2)	13	(1.4)	3	(1.9)	2	(1.3)	5	(1.5)
Reason for analgesic use												
None	34	(26.0)	99	(39.6)	346	(36.5)	58	(37.7)	62	(41.3)	111	(33.8)
Headache	59	(45.0)	76	(30.4)	377	(39.8)	54	(35.1)	60	(40.0)	137	(41.8)
Toothache	16	(12.2)	40	(16.0)	94	(9.9)	19	(12.3)	9	(6.0)	32	(9.8)
Low back pain	10	(7.6)	17	(6.8)	70	(7.4)	10	(6.5)	11	(7.3)	25	(7.6)
Menstrual pain	14	(10.7)	32	(12.8)	125	(13.2)	15	(9.7)	14	(9.3)	37	(11.3)
Stomachache	6	(4.6)	5	(2.0)	31	(3.3)	5	(3.2)	2	(1.3)	11	(3.4)
Stiff shoulder	4	(3.1)	7	(2.8)	46	(4.9)	5	(3.2)	6	(4.0)	18	(5.5)
Recreation (pleasure)	0	(.0)	0	(.0)	0	(.0)	0	(.0)	0	(.0)	0	(.0)
Other	14	(10.7)	22	(8.8)	101	(10.7)	17	(11.0)	19	(12.7)	32	(9.8)
Reason for use unknown	4	(3.1)	8	(3.2)	20	(2.1)	5	(3.2)	2		6	(1.8)
Past 30-day analgesic use												
No	90	(68.7)	202	(80.8)	682	(71.9)	114	(74.0)	113	(75.3)	230	(70.1)
Yes	40	(30.5)	48	(19.2)	261	(27.5)	38	(24.7)	36	(24.0)	98	(29.9)
Type of analgesics used												
Nonopioid analgesics	29	(100.0)	39	(100.0)	225	(97.4)	35	(100.0)	30	(100.0)	85	(97.7)
Opioid analgesics	0	(.0)	0	(.0)	0	(.0)	0	(.0)	0	(.0)	0	(.0)
Co-analgesics	0	(.0)	1	(2.6)	5	(2.2)	1	(2.9)	0	(.0)	2	(2.3)
Other	0	(.0)	1	(2.6)	6	(2.6)	0	(.0)	0	(.0)	3	(3.4)

Table 22. Analgesic	Use by	Residence	area(n=3076)	continued
---------------------	--------	-----------	--------------	-----------

_	R					esidence area							
_	Ki	nki	Chu	Igoku	Shi	koku	Kita-l	Kyusyu	Min	ami-	Tot	al	
	n=	442	n=	191	n	=88	n=	229	n=	165	n=30	076	p-value
	n	(%)	n	(%)	n	(%)	n	(%)	n	(%)	n	(%)	
Past-year analgesic use													0.097
No	185	(41.9)	78	(40.8)	25	(28.4)	81	(35.4)	55	(33.3)	1,134	(36.9)	
Yes	257	(58.1)	112	(58.6)	63	(71.6)	148	(64.6)	110	(66.7)	1,937	(63.0)	
Frequency of the past-year and	algesic	use											0.707
None	185	(41.9)	78	(40.8)	25	(28.4)	81	(35.4)	55	(33.3)	1,134	(36.9)	
≦5 times a year	140	(31.7)	62	(32.5)	32	(36.4)	82	(35.8)	63	(38.2)	1,064	(34.6)	
Approx. 6–11 times a year	31	(7.0)	15	(7.9)	$\overline{7}$	(8.0)	18	(7.9)	16	(9.7)	232	(7.5)	
Approx. 12–24 times a year	37	(8.4)	19	(9.9)	8	(9.1)	18	(7.9)	13	(7.9)	273	(8.9)	
Approx. 25–51 times a year	21	(4.8)	9	(4.7)	10	(11.4)	14	(6.1)	8	(4.8)	163	(5.3)	
Approx. 1–2 times a week	6	(1.4)	1	(.5)	1	(1.1)	7	(3.1)	4	(2.4)	58	(1.9)	
Approx. 3–6 times a week	3	(.7)	2	(1.0)	2	(2.3)	1	(.4)	1	(.6)	25	(.8)	
Almost every day	7	(1.6)	2	(1.0)	2	(2.3)	5	(2.2)	2	(1.2)	52	(1.7)	
Frequency unknown	12	(2.7)	2	(1.0)	1	(1.1)	3	(1.3)	3	(1.8)	70	(2.3)	
Chronic analgesic use													0.893
No	420	(95.0)	184	(96.3)	83	(94.3)	220	(96.1)	159	(96.4)	2,924	(95.1)	
Yes	10	(2.3)	4	(2.1)	4	(4.5)	6	(2.6)	3	(1.8)	77	(2.5)	
Source of analgesics													
Never obtained	156	(35.3)	67	(35.1)	21	(23.9)	73	(31.9)	48	(29.1)	965	(31.4)	0.078
Household medicines	52	(11.8)	21	(11.0)	11	(12.5)	26	(11.4)	15	(9.1)	397	(12.9)	0.637
Family	20	(4.5)	9	(4.7)	3	(3.4)	6	(2.6)	12	(7.3)	131	(4.3)	0.329
Clinics/hospitals	94	(21.3)	59	(30.9)	37	(42.0)	65	(28.4)	44	(26.7)	792	(25.7)	0.004
Pharmacies/drugstores	171	(38.7)	53	(27.7)	30	(34.1)	95	(41.5)	70	(42.4)	1,208	(39.3)	0.031
Friends/acquaintances	4	(.9)	1	(.5)	1	(1.1)	1	(.4)	4	(2.4)	27	(.9)	0.362
Romantic partners	1	(.2)	0	(.0)	0	(.0)	0	(.0)	0	(.0)	2	(.1)	0.840
Internet	0	(.0)	1	(.5)	0	(.0)	0	(.0)	0	(.0)	6	(.2)	0.526
Other	0	(.0)	1	(.5)	0	(.0)	1	(.4)	1	(.6)	7	(.2)	0.584
Source unknown	8	(1.8)	2	(1.0)	0	(.0)	2	(.9)	1	(.6)	47	(1.5)	0.532
Reason for analgesic use													
None	185	(41.9)	78	(40.8)	25	(28.4)	81	(35.4)	55	(33.3)	1,134	(36.9)	0.097
Headache	157	(35.5)	78	(40.8)	46	(52.3)	92	(40.2)	79	(47.9)	1,215	(39.5)	0.018
Toothache	30	(6.8)	12	(6.3)	9	(10.2)	26	(11.4)	18	(10.9)	305	(9.9)	0.045
Low back pain	20	(4.5)	8	(4.2)	9	(10.2)	14	(6.1)	13	(7.9)	207	(6.7)	0.607
Menstrual pain	43	(9.7)	9	(4.7)	5	(5.7)	28	(12.2)	13	(7.9)	335	(10.9)	0.108
Stomachache	19	(4.3)	5	(2.6)	1	(1.1)	7	(3.1)	6	(3.6)	98	(3.2)	0.730
Stiff shoulder	11	(2.5)	6	(3.1)	8	(9.1)	9	(3.9)	5	(3.0)	125	(4.1)	0.287
Recreation (pleasure)	0	(.0)	0	(.0)	0	(.0)	0	(.0)	0	(.0)	0	(.0)	0.554
Other	39	(8.8)	19	(9.9)	8	(9.1)	31	(13.5)	10	(6.1)	312	(10.1)	0.605
Reason for use unknown	12	(2.7)	4	(2.1)	1	(1.1)	3	(1.3)	4		69	(2.2)	0.895
Past 30-day analgesic use													0.206
No	323	(73.1)	141	(73.8)	62	(70.5)	167	(72.9)	117	(70.9)	2,241	(72.9)	
Yes	116	(26.2)	47	(24.6)	26	(29.5)	62	(27.1)	48	(29.1)	820	(26.7)	
Type of analgesics used													
Nonopioid analgesics	99	(97.1)	41	(100.0)	20	(95.2)	57	(100.0)	40	(93.0)	700	(97.9)	0.331
Opioid analgesics	3	(2.9)	0	(.0)	1	(4.8)	0	(.0)	0	(.0)	4	(.6)	0.025
Co-analgesics	1	(1.0)	1	(2.4)	0	(.0)	1	(1.8)	0	(.0)	12	(1.7)	0.962
Other	5	(4.9)	0	(.0)	1	(4.8)	1	(1.8)	3	(7.0)	20	(2.8)	0.419

	Sex						
	Me	en	Won	nen	Tot	al	
	n = 1	466	n = 1	610	n = 3	8076	P-value
	n	(%)	n	(%)	n	(%)	
Past-year analgesic use							< 0.001
No	685	(46.7)	449	(27.9)	1,134	(36.9)	
Yes	777	(53.0)	1,160	(72.0)	1,937	(63.0)	
Frequency of the past-year analy	gesic use	<u>,</u>					< 0.001
None	685	(46.7)	449	(27.9)	1,134	(36.9)	
≦5 times a year	520	(35.5)	544	(33.8)	1,064	(34.6)	
Approx. 6–11 times a year	89	(6.1)	143	(8.9)	232	(7.5)	
Approx. 12–24 times a year	54	(3.7)	219	(13.6)	273	(8.9)	
Approx. 25–51 times a year	34	(2.3)	129	(8.0)	163	(5.3)	
Approx. 1–2 times a week	16	(1.1)	42	(2.6)	58	(1.9)	
Approx. 3–6 times a week	9	(.6)	16	(1.0)	25	(.8)	
Almost every day	20	(1.4)	32	(2.0)	52	(1.7)	
Frequency unknown	35	(2.4)	35	(2.2)	70	(2.3)	
Chronic analgesic use							0.159
No	1,398	(95.4)	1,526	(94.8)	2,924	(95.1)	
Yes	29	(2.0)	48	(3.0)	77	(2.5)	
Source of analgesics							
Never obtained	597	(40.7)	368	(22.9)	965	(31.4)	< 0.001
Household medicines	168	(11.5)	229	(14.2)	397	(12.9)	0.002
Family	63	(4.3)	68	(4.2)	131	(4.3)	0.018
Clinics/hospitals	300	(20.5)	492	(30.6)	792	(25.7)	< 0.001
Pharmacies/drugstores	457	(31.2)	751	(46.6)	1,208	(39.3)	< 0.001
Friends/acquaintances	7	(.5)	20	(1.2)	27	(.9)	0.001
Romantic partners	1	(.1)	1	(.1)	2	(.1)	0.018
Internet	2	(.1)	4	(.2)	6	(.2)	0.014
Other	2	(.1)	5	(.3)	7	(.2)	0.011
Source unknown	25	(1.7)	22	(1.4)	47	(1.5)	0.444
Reason for analgesic use							
None	685	(46.7)	449	(27.9)	1,134	(36.9)	< 0.001
Headache	433	(29.5)	782	(48.6)	1,215	(39.5)	< 0.001
Toothache	160	(10.9)	145	(9.0)	305	(9.9)	0.071
Low back pain	98	(6.7)	109	(6.8)	207	(6.7)	0.349
Menstrual pain	0	(.0)	335	(20.8)	335	(10.9)	< 0.001
Stomachache	38	(2.6)	60	(3.7)	98	(3.2)	0.072
Stiff shoulder	30	(2.0)	95	(5.9)	125	(4.1)	< 0.001
Recreation (pleasure)	0	(.0)	0	(.0)	0	(.0)	0.147
Other	132	(9.0)	180	(11.2)	312	(10.1)	0.050
Reason for use unknown	41	(2.8)	28	(1.7)	69	(2.2)	0.048
Past 30-day analgesic use							< 0.001
No	1,230	(83.9)	1,011	(62.8)	2,241	(72.9)	
Yes	226	(15.4)	594	(36.9)	820	(26.7)	
Type of analgesics used							
Nonopioid analgesics	178	(97.3)	522	(98.1)	700	(97.9)	< 0.001
Opioid analgesics	1	(.5)	3	(.6)	4	(.6)	0.364
Co-analgesics	6	(3.3)	6	(1.1)	12	(1.7)	0.871
Other	4	(2, 2)	16	(3.0)	20	(2.8)	0.013

Table 23. Analgesic Use by Sex (n = 3076)

Table 24. Analgesic	Use by Ag	e group(n=3076)
---------------------	-----------	-----------------

_							1	Age grou	ıp						
	1	l0s	2	20s	3	0s	4	Os	5	0s	6	0s	Total		
	n=	222	n=	382	n=	553	n=	751	n=	695	n=	473	n=30	076	p-value
	n	(%)	n	(%)	n	(%)	n	(%)	n	(%)	n	(%)	n	(%)	
Past-year analgesic use															< 0.001
No	95	(42.8)	143	(37.4)	164	(29.7)	250	(33.3)	257	(37.0)	225	(47.6)	1,134	(36.9)	
Yes	127	(57.2)	239	(62.6)	389	(70.3)	499	(66.4)	438	(63.0)	245	(51.8)	1,937	(63.0)	
Frequency of the past-year anal	lgesic ı	ıse													< 0.001
None	95	(42.8)	143	(37.4)	164	(29.7)	250	(33.3)	257	(37.0)	225	(47.6)	1,134	(36.9)	
≦5 times a year	63	(28.4)	119	(31.2)	192	(34.7)	273	(36.4)	250	(36.0)	167	(35.3)	1,064	(34.6)	
Approx. 6–11 times a year	14	(6.3)	32	(8.4)	41	(7.4)	67	(8.9)	60	(8.6)	18	(3.8)	232	(7.5)	
Approx. 12–24 times a year	34	(15.3)	44	(11.5)	72	(13.0)	68	(9.1)	41	(5.9)	14	(3.0)	273	(8.9)	
Approx. 25–51 times a year	9	(4.1)	26	(6.8)	44	(8.0)	40	(5.3)	30	(4.3)	14	(3.0)	163	(5.3)	
Approx. 1–2 times a week	1	(.5)	2	(.5)	19	(3.4)	17	(2.3)	15	(2.2)	4	(.8)	58	(1.9)	
Approx. 3–6 times a week	0	(.0)	4	(1.0)	3	(.5)	6	(.8)	10	(1.4)	2	(.4)	25	(.8)	
Almost every day	0	(.0)	3	(.8)	6	(1.1)	14	(1.9)	14	(2.0)	15	(3.2)	52	(1.7)	
Frequency unknown	6	(2.7)	9	(2.4)	12	(2.2)	14	(1.9)	18	(2.6)	11	(2.3)	70	(2.3)	
Chronic analgesic use															0.159
No	216	(97.3)	366	(95.8)	532	(96.2)	715	(95.2)	653	(94.0)	442	(93.4)	2,924	(95.1)	
Yes	0	(.0)	7	(1.8)	9	(1.6)	20	(2.7)	24	(3.5)	17	(3.6)	77	(2.5)	
Source of analgesics															
Never obtained	87	(39.2)	126	(33.0)	143	(25.9)	203	(27.0)	211	(30.4)	195	(41.2)	965	(31.4)	< 0.001
Household medicines	27	(12.2)	51	(13.4)	73	(13.2)	96	(12.8)	100	(14.4)	50	(10.6)	397	(12.9)	0.459
Family	37	(16.7)	40	(10.5)	23	(4.2)	14	(1.9)	11	(1.6)	6	(1.3)	131	(4.3)	< 0.001
Clinics/hospitals	36	(16.2)	93	(24.3)	150	(27.1)	200	(26.6)	192	(27.6)	121	(25.6)	792	(25.7)	0.033
Pharmacies/drugstores	54	(24.3)	154	(40.3)	269	(48.6)	328	(43.7)	259	(37.3)	144	(30.4)	1,208	(39.3)	< 0.001
Friends/acquaintances	1	(.5)	9	(2.4)	8	(1.4)	4	(.5)	4	(.6)	1	(.2)	27	(.9)	0.013
Romantic partners	0	(.0)	1	(.3)	0	(.0)	1	(.1)	0	(.0)	0	(.0)	2	(.1)	0.420
Internet	0	(.0)	0	(.0)	1	(.2)	3	(.4)	1	(.1)	1	(.2)	6	(.2)	0.524
Other	0	(.0)	0	(.0)	3	(.5)	4	(.5)	0	(.0)	0	(.0)	7	(.2)	0.109
Source unknown	5	(2.3)	7	(1.8)	8	(1.4)	12	(1.6)	10	(1.4)	5	(1.1)	47	(1.5)	0.877
Reason for analgesic use															
None	95	(42.8)	143	(37.4)	164	(29.7)	250	(33.3)	257	(37.0)	225	(47.6)	1134	(36.9)	< 0.001
Headache	73	(32.9)	144	(37.7)	265	(47.9)	334	(44.5)	276	(39.7)	123	(26.0)	1215	(39.5)	< 0.001
Toothache	14	(6.3)	33	(8.6)	49	(8.9)	83	(11.1)	78	(11.2)	48	(10.1)	305	(9.9)	0.071
Low back pain	11	(5.0)	11	(2.9)	33	(6.0)	57	(7.6)	51	(7.3)	44	(9.3)	207	(6.7)	0.002
Menstrual pain	52	(23.4)	99	(25.9)	92	(16.6)	81	(10.8)	11	(1.6)	0	(.0)	335	(10.9)	< 0.001
Stomachache	5	(2.3)	14	(3.7)	18	(3.3)	22	(2.9)	24	(3.5)	15	(3.2)	98	(3.2)	0.340
Stiff shoulder	4	(1.8)	8	(2.1)	32	(5.8)	36	(4.8)	29	(4.2)	16	(3.4)	125	(4.1)	0.013
Recreation (pleasure)	0	(.0)	0	(.0)	0	(.0)	0	(.0)	0	(.0)	0	(.0)	0	(.0)	0.075
Other	13	(5.9)	25	(6.5)	59	(10.7)	73	(9.7)	86	(12.4)	56	(11.8)	312	(10.1)	0.004
Reason for use unknown	8	(3.6)	11	(2.9)	11	(2.0)	17	(2.3)	11		11	(2.3)	69	(2.2)	0.529
Past 30-day analgesic use															< 0.001
No	167	(75.2)	275	(72.0)	369	(66.7)	534	(71.1)	517	(74.4)	379	(80.1)	2,241	(72.9)	
Yes	55	(24.8)	107	(28.0)	181	(32.7)	215	(28.6)	176	(25.3)	86	(18.2)	820	(26.7)	
Type of analgesics used															
Nonopioid analgesics	47	(100.0)	97	(100.0)	164	(99.4)	181	(97.8)	145	(94.8)	66	(97.1)	700	(97.9)	< 0.001
Opioid analgesics	0	(.0)	0	(.0)	0	(.0)	1	(.5)	3	(2.0)	0	(.0)	4	(.6)	0.221
Co-analgesics	0	(.0)	0	(.0)	2	(1.2)	3	(1.6)	1	(.7)	6	(8.8)	12	(1.7)	0.025
Other	0	(.0)	0	(.0)	4	(2.4)	4	(2.2)	10	(6.5)	2	(2.9)	20	(2.8)	0.047

``10s" refers to those aged 15 to 19, and ``60s" refers to those aged 60 to 64.

Table 25. A	nalgesic	Use b	y Occup	pation (n:	=3076)
-------------	----------	-------	---------	------------	--------

	Occupation										
	Self-em	ployed	Full-	time	Non-fu	ll-time	Stuc	lent	Housewife		
	n=2	48	n=1-	406	n=3	894	n=2	271	n=4	36	
	n	(%)	n	(%)	n	(%)	n	(%)	n	(%)	
Past-year analgesic use											
No	105	(42.3)	511	(36.3)	127	(32.2)	119	(43.9)	124	(28.4)	
Yes	141	(56.9)	893	(63.5)	267	(67.8)	152	(56.1)	312	(71.6)	
Frequency of the past-year ar	nalgesic u	ıse									
None	105	(42.3)	511	(36.3)	127	(32.2)	119	(43.9)	124	(28.4)	
≦5 times a year	91	(36.7)	517	(36.8)	144	(36.5)	71	(26.2)	150	(34.4)	
Approx. 6–11 times a year	15	(6.0)	114	(8.1)	29	(7.4)	17	(6.3)	37	(8.5)	
Approx. 12–24 times a year	10	(4.0)	112	(8.0)	36	(9.1)	40	(14.8)	52	(11.9)	
Approx. 25–51 times a year	. 7	(2.8)	63	(4.5)	26	(6.6)	16	(5.9)	41	(9.4)	
Approx. 1–2 times a week	4	(1.6)	22	(1.6)	12	(3.0)	1	(.4)	11	(2.5)	
Approx. 3–6 times a week	1	(.4)	10	(.7)	6	(1.5)	0	(.0)	5	(1.1)	
Almost every day	4	(1.6)	22	(1.6)	7	(1.8)	0	(.0)	10	(2.3)	
Frequency unknown	9	(3.6)	33	(2.3)	7	(1.8)	7	(2.6)	6	(1.4)	
Chronic analgesic use											
No	232	(93.5)	1,339	(95.2)	374	(94.9)	264	(97.4)	415	(95.2)	
Yes	5	(2.0)	32	(2.3)	13	(3.3)	0	(.0)	15	(3.4)	
No response/unknown	11	(4.4)	35	(2.5)	7	(1.8)	7	(2.6)	6	(1.4)	
Source of analgesics											
Never obtained	88	(35.5)	436	(31.0)	98	(24.9)	109	(40.2)	104	(23.9)	
Household medicines	31	(12.5)	190	(13.5)	64	(16.2)	29	(10.7)	57	(13.1)	
Family	9	(3.6)	54	(3.8)	11	(2.8)	40	(14.8)	8	(1.8)	
Clinics/hospitals	67	(27.0)	355	(25.2)	109	(27.7)	45	(16.6)	140	(32.1)	
Pharmacies/drugstores	74	(29.8)	560	(39.8)	180	(45.7)	71	(26.2)	211	(48.4)	
Friends/acquaintances	2	(.8)	12	(.9)	3	(.8)	1	(.4)	2	(.5)	
Romantic partners	0	(.0)	2	(.1)	0	(.0)	0	(.0)	0	(.0)	
Internet	1	(.4)	2	(.1)	1	(.3)	0	(.0)	2	(.5)	
Other	0	(.0)	5	(.4)	0	(.0)	2	(.7)	0	(.0)	
Source unknown	5	(2.0)	22	(1.6)	7	(1.8)	6	(2.2)	5	(1.1)	
Reason for analgesic use											
None	105	(42.3)	511	(36.3)	127	(32.2)	119	(43.9)	124	(28.4)	
Headache	76	(30.6)	535	(38.1)	185	(47.0)	83	(30.6)	226	(51.8)	
Toothache	32	(12.9)	158	(11.2)	39	(9.9)	15	(5.5)	33	(7.6)	
Low back pain	22	(8.9)	101	(7.2)	17	(4.3)	13	(4.8)	32	(7.3)	
Menstrual pain	6	(2.4)	126	(9.0)	61	(15.5)	68	(25.1)	52	(11.9)	
Stomachache	11	(4.4)	43	(3.1)	18	(4.6)	6	(2.2)	11	(2.5)	
Stiff shoulder	11	(4.4)	57	(4.1)	13	(3.3)	4	(1.5)	28	(6.4)	
Recreation (pleasure)	0	(.0)	0	(.0)	0	(.0)	0	(.0)	0	(.0)	
Other	26	(10.5)	143	(10.2)	35	(8.9)	17	(6.3)	60	(13.8)	
Reason for use unknown	7	(2.8)	35	(2.5)	6	(1.5)	8	(3.0)	5		
Past 30-day analgesic use											
No	203	(81.9)	1,044	(74.3)	275	(69.8)	200	(73.8)	268	(61.5)	
Yes	42	(16.9)	357	(25.4)	116	(29.4)	71	(26.2)	166	(38.1)	
No response/unknown	- 3	(1.2)	5	(.4)	3	(.8)	0	(.0)	2	(.5)	
Type of analgesics used	2				-				-		
Nonopioid analgesics	27	(90.0)	316	(99.4)	97	(97.0)	60	(100.0)	144	(98.0)	
Opioid analgesics	- 1	(3.3)	2	(.6)	0	(.0)	0	(.0)	1	(.7)	
Co-analgesics	- 1	(3.3)	4	(1.3)	1	(1.0)	0	(.0)	- 4	(2.7)	
Other	2	(6.7)	5	(1.6)	3	(3.0)	0	(.0)	6	(4.1)	

	Occupation								
-	Unemp	ployed	Otl	ner	Unkı	nown	Tot	al	
	n=1	79	n=	138	n	=4	n=30	076	p-value
	n	(%)	n	(%)	n	(%)	n	(%)	
Past-year analgesic use									< 0.001
No	92	(51.4)	54	(39.1)	2	(50.0)	1,134	(36.9)	
Yes	86	(48.0)	84	(60.9)	2	(50.0)	1,937	(63.0)	
Frequency of the past-year an	algesic	use							< 0.001
None	92	(51.4)	54	(39.1)	2	(50.0)	1,134	(36.9)	
≦5 times a year	47	(26.3)	43	(31.2)	1	(25.0)	1,064	(34.6)	
Approx. 6–11 times a year	9	(5.0)	11	(8.0)	0	(.0)	232	(7.5)	
Approx. 12–24 times a year	13	(7.3)	9	(6.5)	1	(25.0)	273	(8.9)	
Approx. 25–51 times a year	7	(3.9)	3	(2.2)	0	(.0)	163	(5.3)	
Approx. 1–2 times a week	2	(1.1)	6	(4.3)	0	(.0)	58	(1.9)	
Approx. 3–6 times a week	0	(.0)	3	(2.2)	0	(.0)	25	(.8)	
Almost every day	5	(2.8)	4	(2.9)	0	(.0)	52	(1.7)	
Frequency unknown	3	(1.7)	5	(3.6)	0	(.0)	70	(2.3)	
Chronic analgesic use									0.082
No	170	(95.0)	126	(91.3)	4	(100.0)	2,924	(95.1)	
Yes	5	(2.8)	7	(5.1)	0	(.0)	77	(2.5)	
No response/unknown	4	(2.2)	5	(3.6)	0	(.0)	75	(2.4)	
Source of analgesics									
Never obtained	83	(46.4)	45	(32.6)	2	(50.0)	965	(31.4)	< 0.001
Household medicines	14	(7.8)	12	(8.7)	0	(.0)	397	(12.9)	0.216
Family	3	(1.7)	6	(4.3)	0	(.0)	131	(4.3)	< 0.001
Clinics/hospitals	36	(20.1)	40	(29.0)	0	(.0)	792	(25.7)	0.003
Pharmacies/drugstores	58	(32.4)	52	(37.7)	2	(50.0)	1,208	(39.3)	< 0.001
Friends/acquaintances	3	(1.7)	4	(2.9)	0	(.0)	27	(.9)	0.375
Romantic partners	0	(.0)	0	(.0)	0	(.0)	2	(.1)	0.900
Internet	0	(.0)	0	(.0)	0	(.0)	6	(.2)	0.834
Other	0	(.0)	0	(.0)	0	(.0)	7	(.2)	0.549
Source unknown	0	(.0)	2	(1.4)	0	(.0)	47	(1.5)	0.699
Reason for analgesic use									
None	92	(51.4)	54	(39.1)	2	(50.0)	1,134	(36.9)	< 0.001
Headache	50	(27.9)	58	(42.0)	2	(50.0)	1,215	(39.5)	< 0.001
Toothache	14	(7.8)	14	(10.1)	0	(.0)	305	(9.9)	0.031
Low back pain	13	(7.3)	9	(6.5)	0	(.0)	207	(6.7)	0.188
Menstrual pain	12	(6.7)	10	(7.2)	0	(.0)	335	(10.9)	< 0.001
Stomachache	6	(3.4)	3	(2.2)	0	(.0)	98	(3.2)	0.313
Stiff shoulder	3	(1.7)	9	(6.5)	0	(.0)	125	(4.1)	0.022
Recreation (pleasure)	0	(.0)	0	(.0)	0	(.0)	0	(.0)	0.182
Other	13	(7.3)	18	(13.0)	0	(.0)	312	(10.1)	0.036
Reason for use unknown	4	(2.2)	4	(2.9)	0	(.0)	69	(2.2)	0.651
Past 30-day analgesic use									< 0.001
No	142	(79.3)	106	(76.8)	3	(75.0)	2,241	(72.9)	
Yes	36	(20.1)	31	(22.5)	1	(25.0)	820	(26.7)	
No response/unknown	1	(.6)	1	(.7)	0	(.0)	15	(.5)	
Type of analgesics used									
Nonopioid analgesics	28	(87.5)	28	(100.0)	0	(.0)	700	(97.9)	< 0.001
Opioid analgesics	0	(.0)	0	(.0)	0	(.0)	4	(.6)	0.880
Co-analgesics	2	(6.3)	0	(.0)	0	(.0)	12	(1.7)	0.354
Other	3	(9.4)	1	(3.6)	0	(.0)	20	(2.8)	0.170

Table 25. Analgesic Use by Occupation(n=3076)continued

				Drug u	ıse expe	rience			
	Lifet	ime	No life	etime	Unkn	own	Tot	al	
	n=	78	n=29	940	n=	58	n=30	076	p-value
	n	(%)	n	(%)	n	(%)	n	(%)	
Past-year analgesic use									0.373
No	25	(32.1)	1081	(36.8)	28	(48.3)	1134	(36.9)	
Yes	53	(67.9)	1854	(63.1)	30	(51.7)	1937	(63.0)	
Frequency of the past-year analge	esic use	e							0.587
None	25	(32.1)	1081	(36.8)	28	(48.3)	1134	(36.9)	
≤ 5 times a year	31	(39.7)	1018	(34.6)	15	(25.9)	1064	(34.6)	
Approx. 6–11 times a year	4	(5.1)	224	(7.6)	4	(6.9)	232	(7.5)	
Approx. 12–24 times a year	5	(6.4)	262	(8.9)	6	(10.3)	273	(8.9)	
Approx. 25–51 times a year	6	(7.7)	157	(5.3)	0	(.0)	163	(5.3)	
Approx. 1–2 times a week	2	(2.6)	56	(1.9)	0	(.0)	58	(1.9)	
Approx. 3–6 times a week	1	(1.3)	23	(.8)	1	(1.7)	25	(.8)	
Almost every day	3	(3.8)	47	(1.6)	2	(3.4)	52	(1.7)	
Frequency unknown	1	(1.3)	67	(2.3)	2	(3.4)	70	(2.3)	
No response/unknown	0	(.0)	5	(.2)	0	(.0)	5	(.2)	
Chronic analgesic use									0.314
No	73	(93.6)	2798	(95.2)	53	(91.4)	2924	(95.1)	
Yes	4	(5.1)	70	(2.4)	3	(5.2)	77	(2.5)	
Source of analgesics									
Never obtained	18	(23.1)	926	(31.5)	21	(36.2)	965	(31.4)	< 0.001
Household medicines	10	(12.8)	386	(13.1)	1	(1.7)	397	(12.9)	< 0.001
Family	2	(2.6)	125	(4.3)	4	(6.9)	131	(4.3)	< 0.001
Clinics/hospitals	31	(39.7)	751	(25.5)	10	(17.2)	792	(25.7)	< 0.001
Pharmacies/drugstores	30	(38.5)	1163	(39.6)	15	(25.9)	1208	(39.3)	< 0.001
Friends/acquaintances	3	(3.8)	24	(.8)	0	(.0)	27	(.9)	< 0.001
Romantic partners	0	(.0)	2	(.1)	0	(.0)	2	(.1)	< 0.001
Internet	0	(.0)	6	(.2)	0	(.0)	6	(.2)	< 0.001
Other	2	(2.6)	5	(.2)	0	(.0)	7	(.2)	< 0.001
Source unknown	0	(.0)	44	(1.5)	3	(5.2)	47	(1.5)	0.042
Reason for analgesic use									
None	25	(32.1)	1081	(36.8)	28	(48.3)	1134	(36.9)	0.373
Headache	30	(38.5)	1174	(39.9)	11	(19.0)	1215	(39.5)	0.029
Toothache	12	(15.4)	288	(9.8)	5	(8.6)	305	(9.9)	0.560
Low back pain	7	(9.0)	195	(6.6)	5	(8.6)	207	(6.7)	0.874
Menstrual pain	4	(5.1)	330	(11.2)	1	(1.7)	335	(10.9)	0.081
Stomachache	3	(3.8)	94	(3.2)	1	(1.7)	98	(3.2)	0.946
Stiff shoulder	3	(3.8)	121	(4.1)	1	(1.7)	125	(4.1)	0.897
Recreation (pleasure)	0	(.0)	0	(.0)	0	(.0)	0	(.0)	0.891
Other	13	(16.7)	293	(10.0)	6	(10.3)	312	(10.1)	0.412
Reason for use unknown	2	(2.6)	65	(2.2)	2	(3.4)	69	(2.2)	0.805
Past 30-day analgesic use									< 0.001
No	52	(66.7)	2149	(73.1)	40	(69.0)	2241	(72.9)	
Yes	25	(32.1)	780	(26.5)	15	(25.9)	820	(26.7)	
No response/unknown	1	(1.3)	11	(.4)	3	(5.2)	15	(.5)	
Type of analgesics used									
Nonopioid analgesics	19	(95.0)	674	(98.1)	7	(87.5)	700	(97.9)	0.140
Opioid analgesics	0	(.0)	4	(.6)	0	(.0)	4	(.6)	0.912
Co-analgesics	1	(5.0)	10	(1.5)	1	(12.5)	12	(1.7)	0.108
Other	0	(.0)	20	(2.9)	0	(.0)	20	(2.8)	0.628

Table 26. Analgesic Use by Drug use experience (n=3076)

Table 27.	Tranquilizer	Use b	y Residence	area(n=3076	3)
-----------	--------------	-------	-------------	-------------	----

						Residenc	e area					
-	Hokk	aido	Toho	oku	Kar	nto	Hoku	riku	Tous	san	Tol	cai
	n=1	31	n=2	50	n=9	948	n=1	54	n=1	50	n=3	28
	n	(%)	n	(%)	n	(%)	n	(%)	n	(%)	n	(%)
Past-year tranquilizer use												
No	120	(91.6)	235	(94.0)	877	(92.5)	149	(96.8)	142	(94.7)	315	(96.0)
Yes	11	(8.4)	15	(6.0)	68	(7.2)	5	(3.2)	8	(5.3)	13	(4.0)
No response/unknown	0	(.0)	0	(.0)	3	(.3)	0	(.0)	0	(.0)	0	(.0)
Frequency of the past-year tran	nquilize	r use										
No	120	(91.6)	235	(94.0)	877	(92.5)	149	(96.8)	142	(94.7)	315	(96.0)
≤ 5 times a year	2	(1.5)	2	(.8)	9	(.9)	1	(.6)	3	(2.0)	3	(.9)
Approx. 6–11 times a year	0	(.0)	1	(.4)	7	(.7)	0	(.0)	1	(.7)	1	(.3)
Approx. 12–24 times a year	0	(.0)	2	(.8)	3	(.3)	1	(.6)	0	(.0)	0	(.0)
Approx. 25–51 times a year	1	(.8)	1	(.4)	4	(.4)	0	(.0)	1	(.7)	0	(.0)
Approx. 1–2 times a week	1	(.8)	0	(.0)	3	(.3)	1	(.6)	1	(.7)	2	(.6)
Approx. 3–6 times a week	0	(.0)	0	(.0)	1	(.1)	1	(.6)	0	(.0)	1	(.3)
Almost every day	6	(4.6)	7	(2.8)	37	(3.9)	1	(.6)	2	(1.3)	6	(1.8)
Frequency unknown	1	(.8)	2	(.8)	4	(.4)	0	(.0)	0	(.0)	0	(.0)
No response/unknown	0	(.0)	0	(.0)	3	(.3)	0	(.0)	0	(.0)	0	(.0)
Chronic tranquilizer use												
No	124	(94.7)	241	(96.4)	903	(95.3)	152	(98.7)	148	(98.7)	321	(97.9)
Yes	6	(4.6)	7	(2.8)	38	(4.0)	2	(1.3)	2	(1.3)	7	(2.1)
No response/unknown	1	(.8)	2	(.8)	7	(.7)	0	(.0)	0	(.0)	0	(.0)
Source of tranquilizers												
Never obtained	120	(91.6)	231	(92.4)	869	(91.7)	148	(96.1)	141	(94.0)	309	(94.2)
Household medicines	0	(.0)	0	(.0)	0	(.0)	0	(.0)	0	(.0)	0	(.0)
Family	1	(.8)	1	(.4)	1	(.1)	1	(.6)	0	(.0)	0	(.0)
Clinics/hospitals	7	(5.3)	9	(3.6)	47	(5.0)	3	(1.9)	7	(4.7)	13	(4.0)
Pharmacies/drugstores	3	(2.3)	3	(1.2)	25	(2.6)	1	(.6)	1	(.7)	2	(.6)
Friends/acquaintances	0	(.0)	1	(.4)	2	(.2)	0	(.0)	0	(.0)	0	(.0)
Romantic partners	0	(.0)	0	(.0)	0	(.0)	0	(.0)	0	(.0)	0	(.0)
Internet	0	(.0)	0	(.0)	0	(.0)	0	(.0)	0	(.0)	0	(.0)
Other	0	(.0)	0	(.0)	1	(.1)	0	(.0)	0	(.0)	0	(.0)
Source unknown	0	(.0)	2	(.8)	0	(.0)	0	(.0)	1	(.7)	0	(.0)
No response/unknown	0	(.0)	4	(1.6)	9	(.9)	1	(.6)	1	(.7)	5	(1.5)
Reason for tranquilizer use												
None	120	(91.6)	235	(94.0)	877	(92.5)	149	(96.8)	142	(94.7)	315	(96.0)
To improve insomnia	3	(2.3)	5	(2.0)	27	(2.8)	1	(.6)	2	(1.3)	5	(1.5)
To eliminate anxiety	6	(4.6)	9	(3.6)	40	(4.2)	4	(2.6)	3	(2.0)	6	(1.8)
To reduce stress	2	(1.5)	2	(.8)	15	(1.6)	1	(.6)	2	(1.3)	5	(1.5)
To treat hypertension	1	(.8)	1	(.4)	3	(.3)	0	(.0)	0	(.0)	0	(.0)
Recreation (pleasure)	0	(.0)	1	(.4)	0	(.0)	0	(.0)	0	(.0)	0	(.0)
Other	3	(2.3)	4	(1.6)	16	(1.7)	0	(.0)	2	(1.3)	1	(.3)
Reason for use unknown	0	(.0)	0	(.0)	0	(.0)	0	(.0)	1	(.7)	0	(.0)
No response/unknown	0	(.0)	0	(.0)	3	(.3)	0	(.0)	0	(.0)	0	(.0)
Past 30-day tranquilizer use												
No	121	(92.4)	235	(94.0)	887	(93.6)	151	(98.1)	145	(96.7)	315	(96.0)
Yes	10	(7.6)	13	(5.2)	52	(5.5)	3	(1.9)	4	(2.7)	11	(3.4)
No response/unknown	0	(.0)	2	(.8)	9	(.9)	0	(.0)	1	(.7)	2	(.6)

Table 27. Tranquilizer	Use by Residence	area(n=3076)continued
------------------------	------------------	-----------------------

_	Residence area												
_	Kir	ıki	Chug	oku	Shik	oku	Kita-K	yusyu	Mina	ımi-	Tot	al	
	n=4	42	n=1	.91	n=	88	n=2	29	n=1	65	n=30	076	p-value
	n	(%)	n	(%)	n	(%)	n	(%)	n	(%)	n	(%)	
Past-year tranquilizer use													0.564
No	415	(93.9)	182	(95.3)	81	(92.0)	219	(95.6)	153	(92.7)	2888	(93.9)	
Yes	27	(6.1)	9	(4.7)	7	(8.0)	9	(3.9)	12	(7.3)	184	(6.0)	
No response/unknown	0	(.0)	0	(.0)	0	(.0)	1	(.4)	0	(.0)	4	(.1)	
Frequency of the past-year tran	quilize	r use											0.979
No	415	(93.9)	182	(95.3)	81	(92.0)	219	(95.6)	153	(92.7)	2888	(93.9)	
≤ 5 times a year	7	(1.6)	4	(2.1)	1	(1.1)	3	(1.3)	3	(1.8)	38	(1.2)	
Approx. 6–11 times a year	3	(.7)	0	(.0)	1	(1.1)	0	(.0)	1	(.6)	15	(.5)	
Approx. 12–24 times a year	1	(.2)	0	(.0)	0	(.0)	1	(.4)	0	(.0)	8	(.3)	
Approx. 25–51 times a year	1	(.2)	1	(.5)	0	(.0)	0	(.0)	1	(.6)	10	(.3)	
Approx. 1–2 times a week	1	(.2)	0	(.0)	0	(.0)	0	(.0)	1	(.6)	10	(.3)	
Approx. 3–6 times a week	2	(.5)	1	(.5)	0	(.0)	0	(.0)	1	(.6)	7	(.2)	
Almost every day	11	(2.5)	3	(1.6)	5	(5.7)	5	(2.2)	5	(3.0)	88	(2.9)	
Frequency unknown	1	(.2)	0	(.0)	0	(.0)	0	(.0)	0	(.0)	8	(.3)	
No response/unknown	0	(.0)	0	(.0)	0	(.0)	1	(.4)	0	(.0)	4	(.1)	
Chronic tranquilizer use													0.426
No	428	(96.8)	187	(97.9)	83	(94.3)	223	(97.4)	159	(96.4)	2969	(96.5)	
Yes	13	(2.9)	4	(2.1)	5	(5.7)	5	(2.2)	6	(3.6)	95	(3.1)	
No response/unknown	1	(.2)	0	(.0)	0	(.0)	1	(.4)	0	(.0)	12	(.4)	
Source of tranquilizers													
Never obtained	408	(92.3)	180	(94.2)	81	(92.0)	217	(94.8)	153	(92.7)	2857	(92.9)	0.524
Household medicines	0	(.0)	0	(.0)	0	(.0)	0	(.0)	0	(.0)	0	(.0)	0.679
Family	0	(.0)	0	(.0)	0	(.0)	1	(.4)	0	(.0)	5	(.2)	0.655
Clinics/hospitals	19	(4.3)	8	(4.2)	5	(5.7)	8	(3.5)	8	(4.8)	134	(4.4)	0.914
Pharmacies/drugstores	10	(2.3)	2	(1.0)	2	(2.3)	0	(.0)	1	(.6)	50	(1.6)	0.214
Friends/acquaintances	0	(.0)	0	(.0)	0	(.0)	0	(.0)	0	(.0)	3	(.1)	0.881
Romantic partners	0	(.0)	0	(.0)	0	(.0)	0	(.0)	0	(.0)	0	(.0)	0.679
Internet	0	(.0)	0	(.0)	0	(.0)	0	(.0)	0	(.0)	0	(.0)	0.679
Other	0	(.0)	0	(.0)	0	(.0)	0	(.0)	1	(.6)	2	(.1)	0.691
Source unknown	2	(.5)	0	(.0)	0	(.0)	0	(.0)	2	(1.2)	7	(.2)	0.062
No response/unknown	7	(1.6)	2	(1.0)	0	(.0)	3	(1.3)	0	(.0)	32	(1.0)	0.679
Reason for tranquilizer use				<i>,</i> , ,				<i>,</i> , ,				<i>,</i> , ,	
None	415	(93.9)	182	(95.3)	81	(92.0)	219	(95.6)	153	(92.7)	2888	(93.9)	0.564
To improve insomnia	8	(1.8)	4	(2.1)	4	(4.5)	7	(3.1)	3	(1.8)	69	(2.2)	0.785
To eliminate anxiety	11	(2.5)	5	(2.6)	3	(3.4)	3	(1.3)	8	(4.8)	98	(3.2)	0.538
To reduce stress	9	(2.0)	3	(1.6)	1	(1.1)	4	(1.7)	2	(1.2)	46	(1.5)	0.977
To treat hypertension	0	(.0)	0	(.0)	0	(.0)	0	(.0)	0	(.0)	5	(.2)	0.794
Recreation (pleasure)	0	(.0)	0	(.0)	0	(.0)	0	(.0)	0	(.0)	1	(0.03)	0.589
Other	4	(.9)	5	(2.6)	2	(2.3)	0	(.0)	2	(1.2)	39	(1.3)	0.419
Reason for use unknown	3	(.7)	0	(.0)	0	(.0)	0	(.0)	2	(1.2)	6	(.2)	0.026
No response/unknown	0	(.0)	0	(.0)	0	(.0)	1	(.4)	0	(.0)	4	(.1)	0.756
Past 30-day tranquilizer use	110	(0,1,0)	105	(0,0,0)		(05 5)	000	(00.1)	185	(05 e)	0010	(0, 1, 0)	0.264
INO	419	(94.8)	185	(96.9)	84	(95.5)	220	(96.1)	157	(95.2)	2919	(94.9)	
Yes	16	(3.6)	5	(2.6)	4	(4.5)	6	(2.6)	8	(4.8)	132	(4.3)	
No response/unknown	7	(1.6)	1	(.5)	0	(.0)	3	(1.3)	0	(.0)	25	(.8)	

_	Sex						
	Me	en	Won	nen	Tot	al	
	n = 1	466	n = 1	610	n = 3	076	P-value
	n	(%)	n	(%)	n	(%)	
Past-year tranquilizer use							0.007
No	1397	(95.3)	1491	(92.6)	2888	(93.9)	
Yes	68	(4.6)	116	(7.2)	184	(6.0)	
No response/unknown	1	(.1)	3	(.2)	4	(.1)	
Frequency of the past-year tranquilizer use							0.009
No	1397	(95.3)	1491	(92.6)	2888	(93.9)	
≤ 5 times a year	8	(.5)	30	(1.9)	38	(1.2)	
Approx. 6–11 times a year	5	(.3)	10	(.6)	15	(.5)	
Approx. 12–24 times a year	1	(.1)	7	(.4)	8	(.3)	
Approx. 25–51 times a year	3	(.2)	7	(.4)	10	(.3)	
Approx. 1–2 times a week	4	(.3)	6	(.4)	10	(.3)	
Approx. 3–6 times a week	3	(.2)	4	(.2)	7	(.2)	
Almost every day	38	(2.6)	50	(3.1)	88	(2.9)	
Frequency unknown	6	(.4)	2	(.1)	8	(.3)	
No response/unknown	1	(.1)	3	(.2)	4	(.1)	
Chronic tranquilizer use							0.514
No	1418	(96.7)	1551	(96.3)	2969	(96.5)	
Yes	41	(2.8)	54	(3.4)	95	(3.1)	
No response/unknown	7	(.5)	5	(.3)	12	(.4)	
Source of tranquilizers							
Never obtained	1386	(94.5)	1471	(91.4)	2857	(92.9)	0.003
Household medicines	0	(.0)	0	(.0)	0	(.0)	0.130
Family	2	(.1)	3	(.2)	5	(.2)	0.300
Clinics/hospitals	39	(2.7)	95	(5.9)	134	(4.4)	< 0.001
Pharmacies/drugstores	25	(1.7)	25	(1.6)	50	(1.6)	0.303
Friends/acquaintances	2	(.1)	1	(.1)	3	(.1)	0.257
Romantic partners	0	(.0)	0	(.0)	0	(.0)	0.130
Internet	0	(.0)	0	(.0)	0	(.0)	0.130
Other	0	(.0)	2	(.1)	2	(.1)	0.127
Source unknown	4	(.3)	3	(.2)	7	(.2)	0.615
No response/unknown	11	(.8)	21	(1.3)	32	(1.0)	0.130
Reason for tranquilizer use							
None	1397	(95.3)	1491	(92.6)	2888	(93.9)	0.007
To improve insomnia	23	(1.6)	46	(2.9)	69	(2.2)	0.036
To eliminate anxiety	29	(2.0)	69	(4.3)	98	(3.2)	0.001
To reduce stress	14	(1.0)	32	(2.0)	46	(1.5)	0.041
To treat hypertension	3	(.2)	2	(.1)	5	(.2)	0.569
Recreation (pleasure)	1	(.1)	0	(.0)	1	(0.03)	0.383
Other	19	(1.3)	20	(1.2)	39	(1.3)	0.657
Reason for use unknown	3	(.2)	3	(.2)	6	(.2)	0.909
No response/unknown	1	(.1)	3	(.2)	4	(.1)	0.364
Past 30-day tranquilizer use							0.041
No	1406	(95.9)	1513	(94.0)	2919	(94.9)	
Yes	52	(3.5)	80	(5.0)	132	(4.3)	
No response/unknown	8	(.5)	17	(1.1)	25	(.8)	

Table 29. Tranquilizer Use by Age group(n=3076)

	Age group														
-	1	0s	2	0s	3	0s	4	0s	5	0s	6	0s	To	tal	
	n=	222	n=	382	n=	553	n=	751	n=	695	n=	473	n=3	076	p-value
	n	(%)	n	(%)	n	(%)	n	(%)	n	(%)	n	(%)	n	(%)	
Past-year tranquilizer use															0.002
No	215	(96.8)	360	(94.2)	525	(94.9)	701	(93.3)	652	(93.8)	435	(92.0)	2888	(93.9)	
Yes	7	(3.2)	22	(5.8)	28	(5.1)	50	(6.7)	43	(6.2)	34	(7.2)	184	(6.0)	
No response/unknown	0	(.0)	0	(.0)	0	(.0)	0	(.0)	0	(.0)	4	(.8)	4	(.1)	
Frequency of the past-year tr	anqui	lizer use													0.097
No	215	(96.8)	360	(94.2)	525	(94.9)	701	(93.3)	652	(93.8)	435	(92.0)	2888	(93.9)	
≤ 5 times a year	1	(.5)	6	(1.6)	7	(1.3)	9	(1.2)	10	(1.4)	5	(1.1)	38	(1.2)	
Approx. 6–11 times a year	1	(.5)	3	(.8)	2	(.4)	3	(.4)	2	(.3)	4	(.8)	15	(.5)	
Approx. 12–24 times a yea	0	(.0)	1	(.3)	0	(.0)	5	(.7)	1	(.1)	1	(.2)	8	(.3)	
Approx. 25–51 times a yea	0	(.0)	1	(.3)	2	(.4)	4	(.5)	1	(.1)	2	(.4)	10	(.3)	
Approx. 1–2 times a week	0	(.0)	1	(.3)	2	(.4)	1	(.1)	4	(.6)	2	(.4)	10	(.3)	
Approx. 3–6 times a week	0	(.0)	2	(.5)	1	(.2)	3	(.4)	1	(.1)	0	(.0)	7	(.2)	
Almost every day	3	(1.4)	6	(1.6)	14	(2.5)	23	(3.1)	23	(3.3)	19	(4.0)	88	(2.9)	
Frequency unknown	2	(.9)	2	(.5)	0	(.0)	2	(.3)	1	(.1)	1	(.2)	8	(.3)	
No response/unknown	0	(.0)	0	(.0)	0	(.0)	0	(.0)	0	(.0)	4	(.8)	4	(.1)	
Chronic tranquilizer use															0.088
No	217	(97.7)	372	(97.4)	538	(97.3)	723	(96.3)	670	(96.4)	449	(94.9)	2969	(96.5)	
Yes	3	(1.4)	8	(2.1)	15	(2.7)	26	(3.5)	24	(3.5)	19	(4.0)	95	(3.1)	
No response/unknown	2	(.9)	2	(.5)	0	(.0)	2	(.3)	1	(.1)	5	(1.1)	12	(.4)	
Source of tranquilizers															
Never obtained	214	(96.4)	356	(93.2)	521	(94.2)	696	(92.7)	645	(92.8)	425	(89.9)	2857	(92.9)	0.010
Household medicines	0	(.0)	0	(.0)	0	(.0)	0	(.0)	0	(.0)	0	(.0)	0	(.0)	0.006
Family	1	(.5)	2	(.5)	1	(.2)	0	(.0)	1	(.1)	0	(.0)	5	(.2)	0.012
Clinics/hospitals	3	(1.4)	13	(3.4)	18	(3.3)	40	(5.3)	33	(4.7)	27	(5.7)	134	(4.4)	0.002
Pharmacies/drugstores	2	(.9)	4	(1.0)	9	(1.6)	15	(2.0)	10	(1.4)	10	(2.1)	50	(1.6)	0.034
Friends/acquaintances	0	(.0)	0	(.0)	0	(.0)	2	(.3)	0	(.0)	1	(.2)	3	(.1)	0.021
Romantic partners	0	(.0)	0	(.0)	0	(.0)	0	(.0)	0	(.0)	0	(.0)	0	(.0)	0.006
Internet	0	(.0)	0	(.0)	0	(.0)	0	(.0)	0	(.0)	0	(.0)	0	(.0)	0.006
Other	0	(.0)	2	(.5)	0	(.0)	0	(.0)	0	(.0)	0	(.0)	2	(.1)	0.001
Source unknown	1	(.5)	2	(.5)	0	(.0)	1	(.1)	2	(.3)	1	(.2)	7	(.2)	0.603
No response/unknown	1	(.5)	4	(1.0)	4	(.7)	5	(.7)	5	(.7)	13	(2.7)	32	(1.0)	0.006
Reason for tranquilizer use															
None	215	(96.8)	360	(94.2)	525	(94.9)	701	(93.3)	652	(93.8)	435	(92.0)	2888	(93.9)	0.002
To improve insomnia	0	(.0)	5	(1.3)	11	(2.0)	20	(2.7)	21	(3.0)	12	(2.5)	69	(2.2)	< 0.001
To eliminate anxiety	4	(1.8)	15	(3.9)	14	(2.5)	29	(3.9)	20	(2.9)	16	(3.4)	98	(3.2)	0.003
To reduce stress	1	(.5)	6	(1.6)	5	(.9)	12	(1.6)	10	(1.4)	12	(2.5)	46	(1.5)	0.001
To treat hypertension	0	(.0)	1	(.3)	0	(.0)	1	(.1)	1	(.1)	2	(.4)	5	(.2)	0.004
Recreation (pleasure)	0	(.0)	1	(.3)	0	(.0)	0	(.0)	0	(.0)	0	(.0)	1	(0.03)	0.001
Other	2	(.9)	5	(1.3)	6	(1.1)	12	(1.6)	6	(.9)	8	(1.7)	39	(1.3)	0.006
Reason for use unknown	1	(.5)	1	(.3)	1	(.2)	2	(.3)	1	(.1)	0	(.0)	6	(.2)	0.842
No response/unknown	0	(.0)	0	(.0)	0	(.0)	0	(.0)	0	(.0)	4	(.8)	4	(.1)	0.001
Past 30-day tranquilizer use															0.014
No	217	(97.7)	368	(96.3)	529	(95.7)	715	(95.2)	656	(94.4)	434	(91.8)	2919	(94.9)	
Yes	4	(1.8)	13	(3.4)	20	(3.6)	32	(4.3)	34	(4.9)	29	(6.1)	132	(4.3)	
No response/unknown	1	(.5)	1	(.3)	4	(.7)	4	(.5)	5	(.7)	10	(2.1)	25	(.8)	

"10s" refers to those aged 15 to 19, and "60s" refers to those aged 60 to 64.

For the source of tranquilizers, "pharmacies/drugstores" include external prescription.

					Occup	ation				
	Self-em	ployed	Full-	time	Non-fu	ll-time	Stud	lent	House	ewife
	n=2	248	n=1-	406	n=3	94	n=2	271	n=4	36
	n	(%)	n	(%)	n	(%)	n	(%)	n	(%)
Past-year tranquilizer use										
No	235	(94.8)	1342	(95.4)	373	(94.7)	264	(97.4)	402	(92.2)
Yes	12	(4.8)	64	(4.6)	20	(5.1)	7	(2.6)	33	(7.6)
No response/unknown	1	(.4)	0	(.0)	1	(.3)	0	(.0)	1	(.2)
Frequency of the past-year tran	nquilizer ı	ıse								
No	235	(94.8)	1342	(95.4)	373	(94.7)	264	(97.4)	402	(92.2)
≤ 5 times a year	1	(.4)	16	(1.1)	5	(1.3)	1	(.4)	11	(2.5)
Approx. 6–11 times a year	2	(.8)	4	(.3)	2	(.5)	1	(.4)	4	(.9)
Approx. 12–24 times a year	1	(.4)	2	(.1)	0	(.0)	1	(.4)	1	(.2)
Approx. 25–51 times a year	0	(.0)	4	(.3)	1	(.3)	0	(.0)	2	(.5)
Approx. 1–2 times a week	1	(.4)	5	(.4)	0	(.0)	0	(.0)	0	(.0)
Approx. 3–6 times a week	0	(.0)	4	(.3)	1	(.3)	0	(.0)	0	(.0)
Almost every day	7	(2.8)	24	(1.7)	11	(2.8)	2	(.7)	15	(3.4)
Frequency unknown	0	(.0)	5	(.4)	0	(.0)	2	(.7)	0	(.0)
No response/unknown	1	(.4)	0	(.0)	1	(.3)	0	(.0)	1	(.2)
Chronic tranquilizer use										
No	240	(96.8)	1373	(97.7)	381	(96.7)	267	(98.5)	420	(96.3)
Yes	7	(2.8)	28	(2.0)	12	(3.0)	2	(.7)	15	(3.4)
No response/unknown	1	(.4)	5	(.4)	1	(.3)	2	(.7)	1	(.2)
Source of tranquilizers										
Never obtained	232	(93.5)	1330	(94.6)	370	(93.9)	263	(97.0)	395	(90.6)
Household medicines	0	(.0)	0	(.0)	0	(.0)	0	(.0)	0	(.0)
Family	0	(.0)	3	(.2)	0	(.0)	2	(.7)	0	(.0)
Clinics/hospitals	6	(2.4)	45	(3.2)	16	(4.1)	2	(.7)	30	(6.9)
Pharmacies/drugstores	5	(2.0)	19	(1.4)	3	(.8)	2	(.7)	6	(1.4)
Friends/acquaintances	1	(.4)	1	(.1)	0	(.0)	0	(.0)	0	(.0)
Romantic partners	0	(.0)	0	(.0)	0	(.0)	0	(.0)	0	(.0)
Internet	0	(.0)	0	(.0)	0	(.0)	0	(.0)	0	(.0)
Other	0	(.0)	1	(.1)	1	(.3)	0	(.0)	0	(.0)
Source unknown	1	(.4)	2	(.1)	0	(.0)	1	(.4)	2	(.5)
No response/unknown	4	(1.6)	11	(.8)	4	(1.0)	1	(.4)	7	(1.6)
Reason for tranquilizer use										
None	235	(94.8)	1342	(95.4)	373	(94.7)	264	(97.4)	402	(92.2)
To improve insomnia	1	(.4)	27	(1.9)	6	(1.5)	0	(.0)	11	(2.5)
To eliminate anxiety	2	(.8)	34	(2.4)	12	(3.0)	4	(1.5)	18	(4.1)
To reduce stress	5	(2.0)	18	(1.3)	1	(.3)	0	(.0)	9	(2.1)
To treat hypertension	0	(.0)	2	(.1)	2	(.5)	0	(.0)	0	(.0)
Recreation (pleasure)	0	(.0)	1	(.1)	0	(.0)	0	(.0)	0	(.0)
Other	6	(2.4)	14	(1.0)	5	(1.3)	2	(.7)	3	(.7)
Reason for use unknown	0	(.0)	2	(.1)	0	(.0)	1	(.4)	1	(.2)
No response/unknown	1	(.4)	0	(.0)	1	(.3)	0	(.0)	1	(.2)
Past 30-day tranquilizer use										
No	236	(95.2)	1358	(96.6)	377	(95.7)	266	(98.2)	405	(92.9)
Yes	9	(3.6)	39	(2.8)	15	(3.8)	4	(1.5)	26	(6.0)
No response/unknown	3	(1.2)	9	(.6)	2	(.5)	1	(.4)	5	(1.1)

Table 30. Tranquilizer Use by Occupation (n=3076)

For the source of tranquilizers, "pharmacies/drugstores" include external prescription.

				00	ccupatio	n			
	Unem	ployed	Oth	er	Unkn	own	Tot	al	
	n=1	79	n=1	38	n=	4	n=3	076	p-value
	n	(%)	n	(%)	n	(%)	n	(%)	
Past-year tranquilizer use									< 0.001
No	143	(79.9)	126	(91.3)	3	(75.0)	2888	(93.9)	
Yes	35	(19.6)	12	(8.7)	1	(25.0)	184	(6.0)	
No response/unknown	1	(.6)	0	(.0)	0	(.0)	4	(.1)	
Frequency of the past-year trang	uilizer use								< 0.001
No	143	(79.9)	126	(91.3)	3	(75.0)	2888	(93.9)	
≤ 5 times a year	3	(1.7)	1	(.7)	0	(.0)	38	(1.2)	
Approx. 6–11 times a year	1	(.6)	1	(.7)	0	(.0)	15	(.5)	
Approx. 12–24 times a year	2	(1.1)	1	(.7)	0	(.0)	8	(.3)	
Approx. 25–51 times a year	2	(1.1)	1	(.7)	0	(.0)	10	(.3)	
Approx. 1–2 times a week	4	(2.2)	0	(.0)	0	(.0)	10	(.3)	
Approx. 3–6 times a week	1	(.6)	0	(.0)	1	(25.0)	7	(.2)	
Almost every day	21	(11.7)	8	(5.8)	0	(.0)	88	(2.9)	
Frequency unknown	1	(.6)	0	(.0)	0	(.0)	8	(.3)	
No response/unknown	1	(.6)	0	(.0)	0	(.0)	4	(.1)	
Chronic tranquilizer use									< 0.001
No	155	(86.6)	130	(94.2)	3	(75.0)	2969	(96.5)	
Yes	22	(12.3)	8	(5.8)	1	(25.0)	95	(3.1)	
No response/unknown	2	(1.1)	0	(.0)	0	(.0)	12	(.4)	
Source of tranquilizers									
Never obtained	141	(78.8)	123	(89.1)	3	(75.0)	2857	(92.9)	< 0.001
Household medicines	0	(.0)	0	(.0)	0	(.0)	0	(.0)	0.634
Family	0	(.0)	0	(.0)	0	(.0)	5	(.2)	0.511
Clinics/hospitals	25	(14.0)	9	(6.5)	1	(25.0)	134	(4.4)	< 0.001
Pharmacies/drugstores	10	(5.6)	4	(2.9)	1	(25.0)	50	(1.6)	< 0.001
Friends/acquaintances	1	(.6)	0	(.0)	0	(.0)	3	(.1)	0.540
Romantic partners	0	(.0)	0	(.0)	0	(.0)	0	(.0)	0.634
Internet	0	(.0)	0	(.0)	0	(.0)	0	(.0)	0.634
Other	0	(.0)	0	(.0)	0	(.0)	2	(.1)	0.879
Source unknown	1	(.6)	0	(.0)	0	(.0)	7	(.2)	0.764
No response/unknown	3	(1.7)	2	(1.4)	0	(.0)	32	(1.0)	0.634
Reason for tranquilizer use									
None	143	(79.9)	126	(91.3)	3	(75.0)	2888	(93.9)	< 0.001
To improve insomnia	18	(10.1)	5	(3.6)	1	(25.0)	69	(2.2)	< 0.001
To eliminate anxiety	20	(11.2)	8	(5.8)	0	(.0)	98	(3.2)	< 0.001
To reduce stress	10	(5.6)	3	(2.2)	0	(.0)	46	(1.5)	< 0.001
To treat hypertension	1	(.6)	0	(.0)	0	(.0)	5	(.2)	0.482
Recreation (pleasure)	0	(.0)	0	(.0)	0	(.0)	1	(0.03)	0.873
Other	8	(4.5)	1	(.7)	0	(.0)	39	(1.3)	0.017
Reason for use unknown	2	(1.1)	0	(.0)	0	(.0)	6	(.2)	0.188
No response/unknown	1	(.6)	0	(.0)	0	(.0)	4	(.1)	0.416
Past 30-day tranquilizer use									< 0.001
No	147	(82.1)	127	(92.0)	3	(75.0)	2919	(94.9)	
Yes	28	(15.6)	10	(7.2)	1	(25.0)	132	(4.3)	
No response/unknown	4	(2.2)	1	(.7)	0	(.0)	25	(.8)	

Table 30. Tranquilizer Use by Occupation(n=3076)continued

	Drug use experience								
-	Lifet	ime	No life	etime	Unkn	own	Tot	al	
	n=	78	n=2	940	n=	58	n=30	076	p-value
	n	(%)	n	(%)	n	(%)	n	(%)	
Past-year tranquilizer use									0.869
No	72	(92.3)	2760	(93.9)	56	(96.6)	2888	(93.9)	
Yes	6	(7.7)	176	(6.0)	2	(3.4)	184	(6.0)	
No response/unknown	0	(.0)	4	(.1)	0	(.0)	4	(.1)	
Frequency of the past-year tranqu	lizer us	е							0.785
No	72	(92.3)	2760	(93.9)	56	(96.6)	2888	(93.9)	
≤ 5 times a year	0	(.0)	37	(1.3)	1	(1.7)	38	(1.2)	
Approx. 6–11 times a year	2	(2.6)	13	(.4)	0	(.0)	15	(.5)	
Approx. 12–24 times a year	0	(.0)	8	(.3)	0	(.0)	8	(.3)	
Approx. 25–51 times a year	0	(.0)	10	(.3)	0	(.0)	10	(.3)	
Approx. 1–2 times a week	1	(1.3)	9	(.3)	0	(.0)	10	(.3)	
Approx. 3–6 times a week	0	(.0)	7	(.2)	0	(.0)	7	(.2)	
Almost every day	3	(3.8)	84	(2.9)	1	(1.7)	88	(2.9)	
Frequency unknown	0	(.0)	8	(.3)	0	(.0)	8	(.3)	
No response/unknown	0	(.0)	4	(.1)	0	(.0)	4	(.1)	
Chronic tranquilizer use									0.899
No	75	(96.2)	2837	(96.5)	57	(98.3)	2969	(96.5)	
Yes	3	(3.8)	91	(3.1)	1	(1.7)	95	(3.1)	
No response/unknown	0	(.0)	12	(.4)	0	(.0)	12	(.4)	
Source of tranquilizers									
Never obtained	72	(92.3)	2732	(92.9)	53	(91.4)	2857	(92.9)	0.022
Household medicines	0	(.0)	0	(.0)	0	(.0)	0	(.0)	0.005
Family	0	(.0)	5	(.2)	0	(.0)	5	(.2)	0.030
Clinics/hospitals	3	(3.8)	130	(4.4)	1	(1.7)	134	(4.4)	0.022
Pharmacies/drugstores	2	(2.6)	48	(1.6)	0	(.0)	50	(1.6)	0.019
Friends/acquaintances	1	(1.3)	2	(.1)	0	(.0)	3	(.1)	< 0.001
Romantic partners	0	(.0)	0	(.0)	0	(.0)	0	(.0)	0.005
Internet	0	(.0)	0	(.0)	0	(.0)	0	(.0)	0.005
Other	1	(1.3)	1	(0.03)	0	(.0)	2	(.1)	< 0.001
Source unknown	0	(.0)	6	(.2)	1	(1.7)	7	(.2)	0.051
No response/unknown	0	(.0)	29	(1.0)	3	(5.2)	32	(1.0)	0.005
Reason for tranquilizer use									
None	72	(92.3)	2760	(93.9)	56	(96.6)	2888	(93.9)	0.869
To improve insomnia	2	(2.6)	67	(2.3)	0	(.0)	69	(2.2)	0.814
To eliminate anxiety	5	(6.4)	92	(3.1)	1	(1.7)	98	(3.2)	0.518
To reduce stress	1	(1.3)	44	(1.5)	1	(1.7)	46	(1.5)	0.994
To treat hypertension	1	(1.3)	4	(.1)	0	(.0)	5	(.2)	0.169
Recreation (pleasure)	0	(.0)	1	(0.03)	0	(.0)	1	(0.03)	0.994
Other	1	(1.3)	38	(1.3)	0	(.0)	39	(1.3)	0.918
Reason for use unknown	0	(.0)	5	(.2)	1	(1.7)	6	(.2)	0.027
No response/unknown	0	(.0)	4	(.1)	0	(.0)	4	(.1)	0.912
Past 30-day tranquilizer use									0.156
No	74	(94.9)	2790	(94.9)	55	(94.8)	2919	(94.9)	
Yes	4	(5.1)	127	(4.3)	1	(1.7)	132	(4.3)	
No response/unknown	0	(.0)	23	(.8)	2	(3.4)	25	(.8)	

Table 31. Tranquilizer Use by Drug use experience (n=3076)

For the source of tranquilizers, "pharmacies/drugstores" include external prescription.

Table 32. Hypnotic Use by Residence area(n=3076)

						Residenc	e area					
	Hokk	aido	Toho	oku	Kanto		Hokuriku		Tousan		Tokai	
	n=1	.31	n=2	50	n=9	948	n=1	54	n=1	50	n=3	328
	n	(%)	n	(%)	n	(%)	n	(%)	n	(%)	n	(%)
Past-year hypnotic use												
No	118	(90.1)	237	(94.8)	873	(92.1)	147	(95.5)	141	(94.0)	314	(95.7)
Yes	13	(9.9)	13	(5.2)	70	(7.4)	7	(4.5)	9	(6.0)	13	(4.0)
No response/unknown	0	(.0)	0	(.0)	5	(.5)	0	(.0)	0	(.0)	1	(.3)
Frequency of the past-year hypno	tic use											
No	118	(90.1)	237	(94.8)	873	(92.1)	147	(95.5)	141	(94.0)	314	(95.7)
≦5 times a year	5	(3.8)	0	(.0)	23	(2.4)	3	(1.9)	2	(1.3)	5	(1.5)
Approx. 6–11 times a year	0	(.0)	1	(.4)	4	(.4)	1	(.6)	0	(.0)	0	(.0)
Approx. 12–24 times a year	1	(.8)	2	(.8)	3	(.3)	1	(.6)	1	(.7)	0	(.0)
Approx. 25–51 times a year	1	(.8)	0	(.0)	4	(.4)	1	(.6)	1	(.7)	0	(.0)
Approx. 1–2 times a week	1	(.8)	2	(.8)	3	(.3)	0	(.0)	0	(.0)	1	(.3)
Approx. 3–6 times a week	0	(.0)	2	(.8)	5	(.5)	1	(.6)	2	(1.3)	0	(.0)
Almost every day	5	(3.8)	5	(2.0)	27	(2.8)	0	(.0)	3	(2.0)	6	(1.8)
Frequency unknown	0	(.0)	1	(.4)	1	(.1)	0	(.0)	0	(.0)	1	(.3)
No response/unknown	0	(.0)	0	(.0)	5	(.5)	0	(.0)	0	(.0)	1	(.3)
Chronic hypnotic use												
No	126	(96.2)	242	(96.8)	910	(96.0)	153	(99.4)	145	(96.7)	320	(97.6)
Yes	5	(3.8)	7	(2.8)	32	(3.4)	1	(.6)	5	(3.3)	6	(1.8)
No response/unknown	0	(.0)	1	(.4)	6	(.6)	0	(.0)	0	(.0)	2	(.6)
Source of hypnotics												
Never obtained	118	(90.1)	235	(94.0)	868	(91.6)	145	(94.2)	140	(93.3)	311	(94.8)
Household medicines	0	(.0)	0	(.0)	1	(.1)	0	(.0)	0	(.0)	0	(.0)
Family	0	(.0)	0	(.0)	1	(.1)	0	(.0)	0	(.0)	0	(.0)
Clinics/hospitals	10	(7.6)	9	(3.6)	49	(5.2)	4	(2.6)	7	(4.7)	14	(4.3)
Pharmacies/drugstores	3	(2.3)	4	(1.6)	22	(2.3)	3	(1.9)	1	(.7)	1	(.3)
Friends/acquaintances	0	(.0)	0	(.0)	1	(.1)	0	(.0)	1	(.7)	0	(.0)
Romantic partners	0	(.0)	0	(.0)	0	(.0)	0	(.0)	0	(.0)	0	(.0)
Internet	0	(.0)	0	(.0)	1	(.1)	1	(.6)	0	(.0)	0	(.0)
Other	0	(.0)	0	(.0)	0	(.0)	0	(.0)	0	(.0)	0	(.0)
Source unknown	0	(.0)	0	(.0)	2	(.2)	0	(.0)	0	(.0)	0	(.0)
No response/unknown	0	(.0)	2	(.8)	10	(1.1)	1	(.6)	1	(.7)	3	(.9)
Reason for hypnotic use												
None	118	(90.1)	237	(94.8)	873	(92.1)	147	(95.5)	141	(94.0)	314	(95.7)
To improve insomnia	11	(8.4)	13	(5.2)	55	(5.8)	7	(4.5)	8	(5.3)	10	(3.0)
To eliminate anxiety	1	(.8)	0	(.0)	11	(1.2)	0	(.0)	2	(1.3)	1	(.3)
To reduce stress	0	(.0)	0	(.0)	5	(.5)	1	(.6)	1	(.7)	0	(.0)
To treat hypertension	0	(.0)	0	(.0)	0	(.0)	0	(.0)	1	(.7)	1	(.3)
Recreation (pleasure)	0	(.0)	0	(.0)	1	(.1)	0	(.0)	0	(.0)	0	(.0)
Other	3	(2.3)	0	(.0)	7	(.7)	0	(.0)	1	(.7)	3	(.9)
Reason for use unknown	0	(.0)	0	(.0)	2	(.2)	0	(.0)	0	(.0)	0	(.0)
No response/unknown	0	(.0)	0	(.0)	5	(.5)	0	(.0)	0	(.0)	1	(.3)
Past 30-day hypnotic use												
No	122	(93.1)	237	(94.8)	890	(93.9)	149	(96.8)	143	(95.3)	316	(96.3)
Yes	9	(6.9)	13	(5.2)	50	(5.3)	4	(2.6)	6	(4.0)	9	(2.7)
No response/unknown	0	(.0)	0	(.0)	8	(.8)	1	(.6)	1	(.7)	3	(.9)

For the source of hypnotics, "pharmacies/drugstores" include external prescription.

The number of hypnotics used (average) and the type of hypnotics used are based on the past 30-day use.

Table 32.	Hypnotic	Use	by	Residence are	a(n=3076)	continued
-----------	----------	-----	----	---------------	-----------	-----------

_						Res	sidence a	irea					
	Kir	nki	Chug	goku	Shik	oku	Kita-K	yusyu	Mina	umi-	Tot	al	
	n=4	42	n=1	.91	n=8	88	n=2	29	n=1	65	n=30	076	p-value
	n	(%)	n	(%)	n	(%)	n	(%)	n	(%)	n	(%)	
Past-year hypnotic use													0.581
No	415	(93.9)	181	(94.8)	82	(93.2)	216	(94.3)	155	(93.9)	2879	(93.6)	
Yes	27	(6.1)	10	(5.2)	6	(6.8)	12	(5.2)	10	(6.1)	190	(6.2)	
No response/unknown	0	(.0)	0	(.0)	0	(.0)	1	(.4)	0	(.0)	7	(.2)	
Frequency of the past-year hyp	notic us	зе											0.942
No	415	(93.9)	181	(94.8)	82	(93.2)	216	(94.3)	155	(93.9)	2879	(93.6)	
≤ 5 times a year	6	(1.4)	3	(1.6)	3	(3.4)	4	(1.7)	3	(1.8)	57	(1.9)	
Approx. 6–11 times a year	1	(.2)	0	(.0)	0	(.0)	1	(.4)	0	(.0)	8	(.3)	
Approx. 12–24 times a year	2	(.5)	0	(.0)	0	(.0)	1	(.4)	0	(.0)	11	(.4)	
Approx. 25–51 times a year	1	(.2)	3	(1.6)	0	(.0)	0	(.0)	0	(.0)	11	(.4)	
Approx. 1–2 times a week	1	(.2)	0	(.0)	0	(.0)	0	(.0)	1	(.6)	9	(.3)	
Approx. 3–6 times a week	5	(1.1)	1	(.5)	0	(.0)	1	(.4)	1	(.6)	18	(.6)	
Almost every day	10	(2.3)	3	(1.6)	3	(3.4)	5	(2.2)	4	(2.4)	71	(2.3)	
Frequency unknown	1	(.2)	0	(.0)	0	(.0)	0	(.0)	1	(.6)	5	(.2)	
No response/unknown	0	(.0)	0	(.0)	0	(.0)	1	(.4)	0	(.0)	7	(.2)	
Chronic hypnotic use													0.931
No	426	(96.4)	187	(97.9)	85	(96.6)	222	(96.9)	159	(96.4)	2975	(96.7)	
Yes	15	(3.4)	4	(2.1)	3	(3.4)	6	(2.6)	5	(3.0)	89	(2.9)	
No response/unknown	1	(.2)	0	(.0)	0	(.0)	1	(.4)	1	(.6)	12	(.4)	
Source of hypnotics													
Never obtained	408	(92.3)	179	(93.7)	82	(93.2)	213	(93.0)	155	(93.9)	2854	(92.8)	0.787
Household medicines	0	(.0)	0	(.0)	0	(.0)	0	(.0)	1	(.6)	2	(.1)	0.777
Family	4	(.9)	0	(.0)	0	(.0)	0	(.0)	0	(.0)	5	(.2)	0.242
Clinics/hospitals	17	(3.8)	7	(3.7)	5	(5.7)	8	(3.5)	9	(5.5)	139	(4.5)	0.850
Pharmacies/drugstores	10	(2.3)	4	(2.1)	2	(2.3)	3	(1.3)	0	(.0)	53	(1.7)	0.620
Friends/acquaintances	0	(.0)	0	(.0)	0	(.0)	0	(.0)	0	(.0)	2	(.1)	0.721
Romantic partners	0	(.0)	0	(.0)	0	(.0)	0	(.0)	0	(.0)	0	(.0)	0.811
Internet	1	(.2)	0	(.0)	0	(.0)	0	(.0)	0	(.0)	3	(.1)	0.872
Other	1	(.2)	0	(.0)	0	(.0)	0	(.0)	0	(.0)	1	(0.03)	0.915
Source unknown	0	(.0)	0	(.0)	0	(.0)	1	(.4)	0	(.0)	3	(.1)	0.831
No response/unknown	5	(1.1)	2	(1.0)	0	(.0)	4	(1.7)	0	(.0)	28	(.9)	0.811
Reason for hypnotic use													
None	415	(93.9)	181	(94.8)	82	(93.2)	216	(94.3)	155	(93.9)	2879	(93.6)	0.581
To improve insomnia	22	(5.0)	10	(5.2)	5	(5.7)	9	(3.9)	8	(4.8)	158	(5.1)	0.751
To eliminate anxiety	6	(1.4)	1	(.5)	0	(.0)	2	(.9)	4	(2.4)	28	(.9)	0.445
To reduce stress	1	(.2)	1	(.5)	0	(.0)	1	(.4)	2	(1.2)	12	(.4)	0.760
To treat hypertension	0	(.0)	0	(.0)	0	(.0)	0	(.0)	0	(.0)	2	(.1)	0.408
Recreation (pleasure)	0	(.0)	0	(.0)	0	(.0)	0	(.0)	0	(.0)	1	(0.03)	0.966
Other	2	(.5)	0	(.0)	2	(2.3)	2	(.9)	1	(.6)	21	(.7)	0.395
Reason for use unknown	1	(.2)	0	(.0)	0	(.0)	0	(.0)	0	(.0)	3	(.1)	0.962
No response/unknown	0	(.0)	0	(.0)	0	(.0)	1	(.4)	0	(.0)	7	(.2)	0.642
Past 30-day hypnotic use													0.719
No	417	(94.3)	184	(96.3)	85	(96.6)	217	(94.8)	159	(96.4)	2919	(94.9)	
Yes	20	(4.5)	6	(3.1)	3	(3.4)	9	(3.9)	6	(3.6)	135	(4.4)	
No response/unknown	5	(1.1)	1	(.5)	0	(.0)	3	(1.3)	0	(.0)	22	(.7)	

The number of hypnotics used (average) and the type of hypnotics used are based on the past 30-day use.

				Sex			
	Me	n	Wom	en	Tota	al	
	n = 14	466	n = 16	310	n = 30	076	P-value
	n	(%)	n	(%)	n	(%)	
Past-year hypnotic use							0.022
No	1387	(94.6)	1492	(92.7)	2879	(93.6)	
Yes	74	(5.0)	116	(7.2)	190	(6.2)	
No response/unknown	5	(.3)	2	(.1)	7	(.2)	
Frequency of the past-year hypn	otic use						0.431
No	1387	(94.6)	1492	(92.7)	2879	(93.6)	
≦5 times a year	20	(1.4)	37	(2.3)	57	(1.9)	
Approx. 6–11 times a year	4	(.3)	4	(.2)	8	(.3)	
Approx. 12–24 times a year	5	(.3)	6	(.4)	11	(.4)	
Approx. 25–51 times a year	4	(.3)	7	(.4)	11	(.4)	
Approx. 1–2 times a week	4	(.3)	5	(.3)	9	(.3)	
Approx. 3–6 times a week	6	(.4)	12	(.7)	18	(.6)	
Almost every day	29	(2.0)	42	(2.6)	71	(2.3)	
Frequency unknown	2	(.1)	3	(.2)	5	(.2)	
No response/unknown	5	(.3)	2	(.1)	7	(.2)	
Chronic hypnotic use							0.215
No	1424	(97.1)	1551	(96.3)	2975	(96.7)	
Yes	35	(2.4)	54	(3.4)	89	(2.9)	
No response/unknown	7	(.5)	5	(.3)	12	(.4)	
Source of hypnotics							
Never obtained	1381	(94.2)	1473	(91.5)	2854	(92.8)	0.014
Household medicines	0	(.0)	2	(.1)	2	(.1)	0.178
Family	2	(.1)	3	(.2)	5	(.2)	0.419
Clinics/hospitals	44	(3.0)	95	(5.9)	139	(4.5)	< 0.001
Pharmacies/drugstores	30	(2.0)	23	(1.4)	53	(1.7)	0.192
Friends/acquaintances	1	(.1)	1	(.1)	2	(.1)	0.445
Romantic partners	0	(.0)	0	(.0)	0	(.0)	0.204
Internet	1	(.1)	2	(.1)	3	(.1)	0.393
Other	0	(.0)	1	(.1)	1	(0.03)	0.282
Source unknown	0	(.0)	3	(.2)	3	(.1)	0.098
No response/unknown	10	(.7)	18	(1.1)	28	(.9)	0.204
Reason for hypnotic use							
None	1387	(94.6)	1492	(92.7)	2879	(93.6)	0.022
To improve insomnia	62	(4.2)	96	(6.0)	158	(5.1)	0.044
To eliminate anxiety	10	(.7)	18	(1.1)	28	(.9)	0.203
To reduce stress	7	(.5)	5	(.3)	12	(.4)	0.342
To treat hypertension	0	(.0)	2	(.1)	2	(.1)	0.182
Recreation (pleasure)	1	(.1)	0	(.0)	1	(0.03)	0.261
Other	6	(.4)	15	(.9)	21	(.7)	0.097
Reason for use unknown	0	(.0)	3	(.2)	3	(.1)	0.098
No response/unknown	5	(.3)	2	(.1)	7	(.2)	0.207
Past 30-day hypnotic use							0.104
No	1404	(95.8)	1515	(94.1)	2919	(94.9)	
Yes	54	(3.7)	81	(5.0)	135	(4.4)	
No response/unknown	8	(.5)	14	(.9)	22	(.7)	

The number of hypnotics used (average) and the type of hypnotics used are based on the past 30day use.

	Age group														
	1	0s	2	0s	3	0s	4	0s	5	0s	6	0s	Tot	tal	
	n=	=222	n=	382	n=	553	n=	751	n=	695	n=	473	n=3	076	p-value
	n	(%)	n	(%)	n	(%)	n	(%)	n	(%)	n	(%)	n	(%)	
Past-year hypnotic use															0.002
No	218	(98.2)	368	(96.3)	527	(95.3)	696	(92.7)	641	(92.2)	429	(90.7)	2879	(93.6)	
Yes	4	(1.8)	14	(3.7)	25	(4.5)	53	(7.1)	53	(7.6)	41	(8.7)	190	(6.2)	
No response/unknown	0	(.0)	0	(.0)	1	(.2)	2	(.3)	1	(.1)	3	(.6)	7	(.2)	
Frequency of the past-year hypn	otic us	se													0.013
No	218	(98.2)	368	(96.3)	527	(95.3)	696	(92.7)	641	(92.2)	429	(90.7)	2879	(93.6)	
≤ 5 times a year	3	(1.4)	5	(1.3)	7	(1.3)	16	(2.1)	17	(2.4)	9	(1.9)	57	(1.9)	
Approx. 6–11 times a year	0	(.0)	0	(.0)	0	(.0)	2	(.3)	3	(.4)	3	(.6)	8	(.3)	
Approx. 12–24 times a year	1	(.5)	2	(.5)	1	(.2)	6	(.8)	0	(.0)	1	(.2)	11	(.4)	
Approx. 25–51 times a year	0	(.0)	1	(.3)	0	(.0)	5	(.7)	2	(.3)	3	(.6)	11	(.4)	
Approx. 1–2 times a week	0	(.0)	1	(.3)	1	(.2)	2	(.3)	4	(.6)	1	(.2)	9	(.3)	
Approx. 3–6 times a week	0	(.0)	2	(.5)	1	(.2)	3	(.4)	4	(.6)	8	(1.7)	18	(.6)	
Almost every day	0	(.0)	3	(.8)	14	(2.5)	19	(2.5)	19	(2.7)	16	(3.4)	71	(2.3)	
Frequency unknown	0	(.0)	0	(.0)	1	(.2)	0	(.0)	4	(.6)	0	(.0)	5	(.2)	
No response/unknown	0	(.0)	0	(.0)	1	(.2)	2	(.3)	1	(.1)	3	(.6)	7	(.2)	
Chronic hypnotic use															0.007
No	222	(100.0)	377	(98.7)	536	(96.9)	727	(96.8)	667	(96.0)	446	(94.3)	2975	(96.7)	
Yes	0	(.0)	5	(1.3)	15	(2.7)	22	(2.9)	23	(3.3)	24	(5.1)	89	(2.9)	
No response/unknown	0	(.0)	0	(.0)	2	(.4)	2	(.3)	5	(.7)	3	(.6)	12	(.4)	
Source of hypnotics															
Never obtained	216	(97.3)	366	(95.8)	523	(94.6)	692	(92.1)	637	(91.7)	420	(88.8)	2854	(92.8)	< 0.001
Household medicines	1	(.5)	0	(.0)	1	(.2)	0	(.0)	0	(.0)	0	(.0)	2	(.1)	0.025
Family	0	(.0)	1	(.3)	0	(.0)	2	(.3)	1	(.1)	1	(.2)	5	(.2)	0.135
Clinics/hospitals	4	(1.8)	11	(2.9)	17	(3.1)	32	(4.3)	40	(5.8)	35	(7.4)	139	(4.5)	< 0.001
Pharmacies/drugstores	0	(.0)	4	(1.0)	6	(1.1)	21	(2.8)	16	(2.3)	6	(1.3)	53	(1.7)	0.004
Friends/acquaintances	0	(.0)	0	(.0)	0	(.0)	1	(.1)	1	(.1)	0	(.0)	2	(.1)	0.129
Romantic partners	0	(.0)	0	(.0)	0	(.0)	0	(.0)	0	(.0)	0	(.0)	0	(.0)	0.025
Internet	0	(.0)	0	(.0)	1	(.2)	2	(.3)	0	(.0)	0	(.0)	3	(.1)	0.071
Other	0	(.0)	0	(.0)	0	(.0)	0	(.0)	1	(.1)	0	(.0)	1	(0.03)	0.092
Source unknown	0	(.0)	0	(.0)	1	(.2)	1	(.1)	0	(.0)	1	(.2)	3	(.1)	0.793
No response/unknown	1	(.5)	2	(.5)	4	(.7)	6	(.8)	4	(.6)	11	(2.3)	28	(.9)	0.025
Reason for hypnotic use															
None	218	(98.2)	368	(96.3)	527	(95.3)	696	(92.7)	641	(92.2)	429	(90.7)	2879	(93.6)	0.002
To improve insomnia	3	(1.4)	10	(2.6)	16	(2.9)	45	(6.0)	46	(6.6)	38	(8.0)	158	(5.1)	< 0.001
To eliminate anxiety	2	(.9)	2	(.5)	2	(.4)	10	(1.3)	6	(.9)	6	(1.3)	28	(.9)	0.457
To reduce stress	0	(.0)	2	(.5)	4	(.7)	2	(.3)	1	(.1)	3	(.6)	12	(.4)	0.451
To treat hypertension	0	(.0)	0	(.0)	0	(.0)	0	(.0)	1	(.1)	1	(.2)	2	(.1)	0.569
Recreation (pleasure)	0	(.0)	0	(.0)	0	(.0)	1	(.1)	0	(.0)	0	(.0)	1	(0.03)	0.606
Other	0	(.0)	1	(.3)	7	(1.3)	4	(.5)	5	(.7)	4	(.8)	21	(.7)	0.365
Reason for use unknown	0	(.0)	1	(.3)	1	(.2)	1	(.1)	0	(.0)	0	(.0)	3	(.1)	0.714
No response/unknown	0	(.0)	0	(.0)	1	(.2)	2	(.3)	1	(.1)	3	(.6)	7	(.2)	0.399
Past 30-day hypnotic use															< 0.001
No	220	(99.1)	372	(97.4)	532	(96.2)	711	(94.7)	652	(93.8)	432	(91.3)	2919	(94.9)	
Yes	1	(.5)	9	(2.4)	19	(3.4)	36	(4.8)	38	(5.5)	32	(6.8)	135	(4.4)	
No response/unknown	1	(.5)	1	(.3)	2	(.4)	4	(.5)	5	(.7)	9	(1.9)	22	(.7)	

"10s" refers to those aged 15 to 19, and "60s" refers to those aged 60 to 64.

For the source of hypnotics, "pharmacies/drugstores" include external prescription.

The number of hypnotics used (average) and the type of hypnotics used are based on the past 30-day use.

					Occupation					
	Self-em	ployed	Full-	time	Non-fu	ll-time	Stu	dent	House	ewife
	n=2	48	n=1-	406	n=3	894	n=	271	n=4	36
	n	(%)	n	(%)	n	(%)	n	(%)	n	(%)
Past-year hypnotic use										
No	240	(96.8)	1329	(94.5)	375	(95.2)	267	(98.5)	397	(91.1)
Yes	7	(2.8)	73	(5.2)	18	(4.6)	4	(1.5)	39	(8.9)
No response/unknown	1	(.4)	4	(.3)	1	(.3)	0	(.0)	0	(.0)
Frequency of the past-year hypn	otic use									
No	240	(96.8)	1,329	(94.5)	375	(95.2)	267	(98.5)	397	(91.1)
≦5 times a year	1	(.4)	22	(1.6)	6	(1.5)	3	(1.1)	15	(3.4)
Approx. 6–11 times a year	0	(.0)	5	(.4)	1	(.3)	0	(.0)	2	(.5)
Approx. 12–24 times a year	0	(.0)	5	(.4)	3	(.8)	1	(.4)	1	(.2)
Approx. 25–51 times a year	0	(.0)	8	(.6)	0	(.0)	0	(.0)	1	(.2)
Approx. 1–2 times a week	1	(.4)	3	(.2)	0	(.0)	0	(.0)	2	(.5)
Approx. 3–6 times a week	2	(.8)	6	(.4)	0	(.0)	0	(.0)	3	(.7)
Almost every day	3	(1.2)	22	(1.6)	8	(2.0)	0	(.0)	13	(3.0)
Frequency unknown	0	(.0)	2	(.1)	0	(.0)	0	(.0)	2	(.5)
No response/unknown	1	(.4)	4	(.3)	1	(.3)	0	(.0)	0	(.0)
Chronic hypnotic use										
No	242	(97.6)	1372	(97.6)	385	(97.7)	271	(100.0)	418	(95.9)
Yes	5	(2.0)	28	(2.0)	8	(2.0)	0	(.0)	16	(3.7)
No response/unknown	1	(.4)	6	(.4)	1	(.3)	0	(.0)	2	(.5)
Source of hypnotics										
Never obtained	237	(95.6)	1320	(93.9)	372	(94.4)	266	(98.2)	391	(89.7)
Household medicines	0	(.0)	0	(.0)	1	(.3)	1	(.4)	0	(.0)
Family	0	(.0)	1	(.1)	1	(.3)	0	(.0)	1	(.2)
Clinics/hospitals	6	(2.4)	49	(3.5)	14	(3.6)	3	(1.1)	32	(7.3)
Pharmacies/drugstores	2	(.8)	28	(2.0)	3	(.8)	0	(.0)	5	(1.1)
Friends/acquaintances	0	(.0)	0	(.0)	0	(.0)	0	(.0)	1	(.2)
Romantic partners	0	(.0)	0	(.0)	0	(.0)	0	(.0)	0	(.0)
Internet	0	(.0)	1	(.1)	0	(.0)	0	(.0)	2	(.5)
Other	0	(.0)	0	(.0)	0	(.0)	0	(.0)	1	(.2)
Source unknown	0	(.0)	0	(.0)	1	(.3)	0	(.0)	2	(.5)
No response/unknown	4	(1.6)	13	(.9)	3	(.8)	1	(.4)	3	(.7)
Reason for hypnotic use										
None	240	(96.8)	1329	(94.5)	375	(95.2)	267	(98.5)	397	(91.1)
To improve insomnia	6	(2.4)	63	(4.5)	15	(3.8)	2	(.7)	29	(6.7)
To eliminate anxiety	1	(.4)	8	(.6)	2	(.5)	1	(.4)	8	(1.8)
To reduce stress	0	(.0)	6	(.4)	1	(.3)	0	(.0)	2	(.5)
To treat hypertension	0	(.0)	0	(.0)	0	(.0)	0	(.0)	2	(.5)
Recreation (pleasure)	0	(.0)	0	(.0)	0	(.0)	0	(.0)	0	(.0)
Other	1	(.4)	6	(.4)	2	(.5)	1	(.4)	8	(1.8)
Reason for use unknown	0	(.0)	1	(.1)	1	(.3)	0	(.0)	1	(.2)
No response/unknown	1	(.4)	4	(.3)	1	(.3)	0	(.0)	0	(.0)
Past 30-day hypnotic use										
No	238	(96.0)	1348	(95.9)	381	(96.7)	269	(99.3)	407	(93.3)
Yes	6	(2.4)	49	(3.5)	12	(3.0)	1	(.4)	26	(6.0)
No response/unknown	4	(1.6)	9	(6)	1	(3)	1	(4)	3	(7)

Table 35. Hypnotic Use by Occupation (n=3076)

For the source of hypnotics, "pharmacies/drugstores" include external prescription.

The number of hypnotics used (average) and the type of hypnotics used are based on the past 30-day use.

				00	cupatio	n				
	Unem	ployed	Oth	ner	Unkn	own	Tot	Total		
	n=1	79	n=1	.38	n=	4	n=3	076	p-value	
	n	(%)	n	(%)	n	(%)	n	(%)		
Past-year hypnotic use									< 0.001	
No	147	(82.1)	121	(87.7)	3	(75.0)	2879	(93.6)		
Yes	31	(17.3)	17	(12.3)	1	(25.0)	190	(6.2)		
No response/unknown	1	(.6)	0	(.0)	0	(.0)	7	(.2)		
Frequency of the past-year hype	notic use								< 0.001	
No	147	(82.1)	121	(87.7)	3	(75.0)	2879	(93.6)		
≦5 times a year	7	(3.9)	3	(2.2)	0	(.0)	57	(1.9)		
Approx. 6–11 times a year	0	(.0)	0	(.0)	0	(.0)	8	(.3)		
Approx. 12–24 times a year	1	(.6)	0	(.0)	0	(.0)	11	(.4)		
Approx. 25–51 times a year	1	(.6)	1	(.7)	0	(.0)	11	(.4)		
Approx. 1–2 times a week	2	(1.1)	1	(.7)	0	(.0)	9	(.3)		
Approx. 3–6 times a week	3	(1.7)	3	(2.2)	1	(25.0)	18	(.6)		
Almost every day	17	(9.5)	8	(5.8)	0	(.0)	71	(2.3)		
Frequency unknown	0	(.0)	1	(.7)	0	(.0)	5	(.2)		
No response/unknown	1	(.6)	0	(.0)	0	(.0)	7	(.2)		
Chronic hypnotic use									< 0.001	
No	158	(88.3)	126	(91.3)	3	(75.0)	2975	(96.7)		
Yes	20	(11.2)	11	(8.0)	1	(25.0)	89	(2.9)		
No response/unknown	1	(.6)	1	(.7)	0	(.0)	12	(.4)		
Source of hypnotics										
Never obtained	146	(81.6)	119	(86.2)	3	(75.0)	2854	(92.8)	< 0.001	
Household medicines	0	(.0)	0	(.0)	0	(.0)	2	(.1)	0.708	
Family	1	(.6)	1	(.7)	0	(.0)	5	(.2)	0.800	
Clinics/hospitals	21	(11.7)	13	(9.4)	1	(25.0)	139	(4.5)	< 0.001	
Pharmacies/drugstores	9	(5.0)	5	(3.6)	1	(25.0)	53	(1.7)	< 0.001	
Friends/acquaintances	1	(.6)	0	(.0)	0	(.0)	2	(.1)	0.505	
Romantic partners	0	(.0)	0	(.0)	0	(.0)	0	(.0)	0.872	
Internet	0	(.0)	0	(.0)	0	(.0)	3	(.1)	0.742	
Other	0	(.0)	0	(.0)	0	(.0)	1	(0.03)	0.818	
Source unknown	0	(.0)	0	(.0)	0	(.0)	3	(.1)	0.251	
No response/unknown	2	(1.1)	2	(1.4)	0	(.0)	28	(.9)	0.872	
Reason for hypnotic use										
None	147	(82.1)	121	(87.7)	3	(75.0)	2879	(93.6)	< 0.001	
To improve insomnia	29	(16.2)	14	(10.1)	0	(.0)	158	(5.1)	< 0.001	
To eliminate anxiety	4	(2.2)	3	(2.2)	1	(25.0)	28	(.9)	< 0.001	
To reduce stress	2	(1.1)	1	(.7)	0	(.0)	12	(.4)	0.860	
To treat hypertension	0	(.0)	0	(.0)	0	(.0)	2	(.1)	0.348	
Recreation (pleasure)	1	(.6)	0	(.0)	0	(.0)	1	(0.03)	0.145	
Other	2	(1.1)	1	(.7)	0	(.0)	21	(.7)	0.405	
Reason for use unknown	0	(.0)	0	(.0)	0	(.0)	3	(.1)	0.912	
No response/unknown	1	(.6)	0	(.0)	0	(.0)	7	(.2)	0.851	
Past 30-day hypnotic use									< 0.001	
No	152	(84.9)	121	(87.7)	3	(75.0)	2919	(94.9)		
Yes	24	(13.4)	16	(11.6)	1	(25.0)	135	(4.4)		
No response/unknown	3	(1 7)	1	(7)	0	(0)	22	(7)		

Table 35. Hypnotic Use by Occupation (n=3076) continued

The number of hypnotics used (average) and the type of hypnotics used are based on the past 30-day use.

				Drug use experience					
=	Lifet	ime	No life	etime	Unkn	lown	Tot	al	
	n=	78	n=29	940	n=	58	n=30	076	p-value
	n	(%)	n	(%)	n	(%)	n	(%)	
Past-year hypnotic use									0.081
No	70	(89.7)	2755	(93.7)	54	(93.1)	2879	(93.6)	
Yes	8	(10.3)	179	(6.1)	3	(5.2)	190	(6.2)	
No response/unknown	0	(.0)	6	(.2)	1	(1.7)	7	(.2)	
Frequency of the past-year hypnot	tic use								0.012
No	70	(89.7)	2755	(93.7)	54	(93.1)	2879	(93.6)	
≦5 times a year	2	(2.6)	54	(1.8)	1	(1.7)	57	(1.9)	
Approx. 6–11 times a year	0	(.0)	7	(.2)	1	(1.7)	8	(.3)	
Approx. 12–24 times a year	0	(.0)	10	(.3)	1	(1.7)	11	(.4)	
Approx. 25–51 times a year	1	(1.3)	10	(.3)	0	(.0)	11	(.4)	
Approx. 1–2 times a week	2	(2.6)	7	(.2)	0	(.0)	9	(.3)	
Approx. 3–6 times a week	0	(.0)	18	(.6)	0	(.0)	18	(.6)	
Almost every day	3	(3.8)	68	(2.3)	0	(.0)	71	(2.3)	
Frequency unknown	0	(.0)	5	(.2)	0	(.0)	5	(.2)	
No response/unknown	0	(.0)	6	(.2)	1	(1.7)	7	(.2)	
Chronic hypnotic use									0.296
No	75	(96.2)	2843	(96.7)	57	(98.3)	2975	(96.7)	
Yes	3	(3.8)	86	(2.9)	0	(.0)	89	(2.9)	
No response/unknown	0	(.0)	11	(.4)	1	(1.7)	12	(.4)	
Source of hypnotics									
Never obtained	70	(89.7)	2733	(93.0)	51	(87.9)	2854	(92.8)	< 0.001
Household medicines	0	(.0)	2	(.1)	0	(.0)	2	(.1)	< 0.001
Family	1	(1.3)	4	(.1)	0	(.0)	5	(.2)	< 0.001
Clinics/hospitals	3	(3.8)	134	(4.6)	2	(3.4)	139	(4.5)	< 0.001
Pharmacies/drugstores	5	(6.4)	47	(1.6)	1	(1.7)	53	(1.7)	< 0.001
Friends/acquaintances	1	(1.3)	1	(0.03)	0	(.0)	2	(.1)	< 0.001
Romantic partners	0	(.0)	0	(.0)	0	(.0)	0	(.0)	< 0.001
Internet	0	(.0)	3	(.1)	0	(.0)	3	(.1)	< 0.001
Other	0	(.0)	1	(0.03)	0	(.0)	1	(0.03)	< 0.001
Source unknown	0	(.0)	3	(.1)	0	(.0)	3	(.1)	0.933
No response/unknown	0	(.0)	24	(.8)	4	(6.9)	28	(.9)	< 0.001
Reason for hypnotic use									
None	70	(89.7)	2755	(93.7)	54	(93.1)	2879	(93.6)	0.081
To improve insomnia	6	(7.7)	150	(5.1)	2	(3.4)	158	(5.1)	0.120
To eliminate anxiety	0	(.0)	28	(1.0)	0	(.0)	28	(.9)	0.123
To reduce stress	0	(.0)	11	(.4)	1	(1.7)	12	(.4)	0.062
To treat hypertension	0	(.0)	2	(.1)	0	(.0)	2	(.1)	0.195
Recreation (pleasure)	1	(1.3)	0	(.0)	0	(.0)	1	(0.03)	< 0.001
Other	0	(.0)	21	(.7)	0	(.0)	21	(.7)	0.139
Reason for use unknown	1	(1.3)	2	(.1)	0	(.0)	3	(.1)	0.003
No response/unknown	0	(.0)	6	(.2)	1	(1.7)	7	(.2)	0.051
Past 30-day hypnotic use									< 0.001
No	71	(91.0)	2796	(95.1)	52	(89.7)	2919	(94.9)	
Yes	7	(9.0)	126	(4.3)	2	(3.4)	135	(4.4)	
No response/unknown	0	(.0)	18	(.6)	4	(6.9)	22	(.7)	

Table 36. Hypnotic Use by Drug use experience (n=3076)

The number of hypnotics used (average) and the type of hypnotics used are based on the past 30-day use.

Table 37. Knowledge of	n and/or Awareness	s of Drug Abuse	by Residence	area(n=3076)
------------------------	--------------------	-----------------	--------------	--------------

]	Residen	ce are	a				
	Hok	kaido	Toł	noku	Ka	into	Hok	uriku	Τοι	ısan	То	kai
	n=	131	n=	250	n=	948	n=	154	n=	150	n=	328
	n	(%)	n	(%)	n	(%)	n	(%)	n	(%)	n	(%)
[Knowledge] Drug dependence												
Know	128	(97.7)	245	(98.0)	933	(98.4)	150	(97.4)	146	(97.3)	320	(97.6)
Do not know	3	(2.3)	5	(2.0)	15	(1.6)	4	(2.6)	4	(2.7)	8	(2.4)
[Knowledge] Hallucination												
Know	125	(95.4)	243	(97.2)	917	(96.7)	148	(96.1)	144	(96.0)	313	(95.4)
Do not know	6	(4.6)	6	(2.4)	31	(3.3)	6	(3.9)	6	(4.0)	14	(4.3)
[Knowledge] Delusion												
Know	120	(91.6)	239	(95.6)	888	(93.7)	141	(91.6)	134	(89.3)	302	(92.1)
Do not know	10	(7.6)	10	(4.0)	60	(6.3)	12	(7.8)	16	(10.7)	25	(7.6)
[Knowledge] Flashback												
Know	100	(76.3)	202	(80.8)	746	(78.7)	127	(82.5)	121	(80.7)	259	(79.0)
Do not know	31	(23.7)	46	(18.4)	198	(20.9)	27	(17.5)	29	(19.3)	69	(21.0)
[Knowledge] Cannabis-induced hal	lucina	tions/de	lusion									
Know	100	(76.3)	195	(78.0)	739	(78.0)	121	(78.6)	118	(78.7)	254	(77.4)
Do not know	31	(23.7)	53	(21.2)	208	(21.9)	33	(21.4)	32	(21.3)	74	(22.6)
[Knowledge] Cannabis-induced am	otivat	ional syı	ndrom	e								
Know	73	(55.7)	157	(62.8)	582	(61.4)	85	(55.2)	86	(57.3)	202	(61.6)
Do not know	58	(44.3)	92	(36.8)	365	(38.5)	69	(44.8)	63	(42.0)	126	(38.4)
View on cannabis use												
Under no situation should it be u	used, r	egardle	ss of w	hether	legally	v prohibi	ited or	not				
	108	(82.4)	202	(80.8)	771	(81.3)	134	(87.0)	123	(82.0)	270	(82.3)
It should not be used because it :	is lega	lly proh	ibited									
	15	(11.5)	36	(14.4)	135	(14.2)	14	(9.1)	21	(14.0)	35	(10.7)
A little use should be allowed alt	hough	legally	prohik	oited								
	0	(.0)	0	(.0)	4	(.4)	0	(.0)	0	(.0)	2	(.6)
It is an individual freedom and s	hould	not be le	egally	prohibit	ed							
	1	(.8)	3	(1.2)	12	(1.3)	2	(1.3)	0	(.0)	5	(1.5)
Do not know/cannot decide												
	7	(5.3)	8	(3.2)	24	(2.5)	4	(2.6)	5	(3.3)	16	(4.9)
[Knowledge] Methamphetamine-in	duced	l halluci	nation	s/delusio	on							
Know	117	(89.3)	224	(89.6)	859	(90.6)	140	(90.9)	139	(92.7)	299	(91.2)
Do not know	14	(10.7)	25	(10.0)	86	(9.1)	14	(9.1)	10	(6.7)	29	(8.8)
View on methamphetamine use												
Under no situation should it be u	used, r	regardle	ss of w	hether	legally	v prohibi	ited or	not				
	114	(87.0)	222	(88.8)	852	(89.9)	142	(92.2)	138	(92.0)	294	(89.6)
It should not be used because it :	is lega	lly proh	ibited									
	11	(8.4)	18	(7.2)	68	(7.2)	8	(5.2)	10	(6.7)	20	(6.1)
A little use should be allowed alt	hough	legally	prohik	oited								
	0	(.0)	0	(.0)	1	(.1)	0	(.0)	0	(.0)	0	(.0)
It is an individual freedom and s	hould	not be le	egally	prohibit	ed							
	0	(.0)	2	(.8)	10	(1.1)	1	(.6)	0	(.0)	4	(1.2)
Do not know/cannot decide												
	5	(3.8)	8	(3.2)	16	(1.7)	2	(1.3)	2	(1.3)	9	(2.7)
"No response/unknown" are not in	cluded	l.										

Table 37. Knowledge or	n and/or Awareness o	of Drug Abuse)	by Residence area	(n=3076) continued
------------------------	----------------------	-----------------	-------------------	--------------------

	Residence area												
	Ki	inki	Chu	goku	Shi	koku	Kita-I	Xyusyu	Min	ami-	To	tal	
	n=	442	n=	191	n	=88	n=	229	n=	165	n=3	076	p-value
	n	(%)	n	(%)	n	(%)	n	(%)	n	(%)	n	(%)	
[Knowledge] Drug dependence													0.879
Know	429	(97.1)	189	(99.0)	87	(98.9)	223	(97.4)	161	(97.6)	3011	(97.9)	
Do not know	13	(2.9)	2	(1.0)	1	(1.1)	6	(2.6)	4	(2.4)	65	(2.1)	
[Knowledge] Hallucination													0.870
Know	418	(94.6)	184	(96.3)	84	(95.5)	220	(96.1)	156	(94.5)	2952	(96.0)	
Do not know	23	(5.2)	7	(3.7)	4	(4.5)	9	(3.9)	8	(4.8)	120	(3.9)	
[Knowledge] Delusion													0.240
Know	395	(89.4)	175	(91.6)	79	(89.8)	212	(92.6)	155	(93.9)	2840	(92.3)	
Do not know	44	(10.0)	15	(7.9)	9	(10.2)	17	(7.4)	10	(6.1)	228	(7.4)	
[Knowledge] Flashback													0.803
Know	334	(75.6)	147	(77.0)	68	(77.3)	181	(79.0)	129	(78.2)	2414	(78.5)	
Do not know	107	(24.2)	44	(23.0)	20	(22.7)	48	(21.0)	36	(21.8)	655	(21.3)	
[Knowledge] Cannabis-induced ha	llucina	tions/de	lusion	L									0.816
Know	343	(77.6)	147	(77.0)	67	(76.1)	186	(81.2)	130	(78.8)	2400	(78.0)	
Do not know	98	(22.2)	44	(23.0)	20	(22.7)	42	(18.3)	35	(21.2)	670	(21.8)	
[Knowledge] Cannabis-induced am	otivat	ional syr	ndrom	е									0.419
Know	256	(57.9)	117	(61.3)	57	(64.8)	144	(62.9)	112	(67.9)	1871	(60.8)	
Do not know	184	(41.6)	74	(38.7)	31	(35.2)	83	(36.2)	53	(32.1)	1198	(38.9)	
View on cannabis use													0.624
Under no situation should it be u	used, r	egardles	ss of w	hether	legal	ly prohi	bited o	or not					
	361	(81.7)	168	(88.0)	75	(85.2)	191	(83.4)	141	(85.5)	2544	(82.7)	
It should not be used because it	is lega	lly prohi	ibited										
	56	(12.7)	12	(6.3)	11	(12.5)	26	(11.4)	13	(7.9)	374	(12.2)	
A little use should be allowed alt	hough	n legally	prohil	oited									
	2	(.5)	0	(.0)	0	(.0)	0	(.0)	0	(.0)	8	(.3)	
It is an individual freedom and s	hould	not be le	egally	prohibit	ed								
	3	(.7)	3	(1.6)	2	(2.3)	4	(1.7)	3	(1.8)	38	(1.2)	
Do not know/cannot decide													
	17	(3.8)	8	(4.2)	0	(.0)	8	(3.5)	7	(4.2)	104	(3.4)	
[Knowledge] Methamphetamine-ir	nduced	l hallucii	nation	s/delusio	on								0.763
Know	384	(86.9)	171	(89.5)	78	(88.6)	206	(90.0)	147	(89.1)	2764	(89.9)	
Do not know	55	(12.4)	19	(9.9)	10	(11.4)	23	(10.0)	16	(9.7)	301	(9.8)	
View on methamphetamine use													0.744
Under no situation should it be	used, r	regardles	ss of w	hether	legal	ly prohi	bited o	or not					
	395	(89.4)	176	(92.1)	79	(89.8)	203	(88.6)	150	(90.9)	2765	(89.9)	
It should not be used because it	is lega	lly prohi	ibited										
	32	(7.2)	11	(5.8)	7	(8.0)	15	(6.6)	5	(3.0)	205	(6.7)	
A little use should be allowed alt	hough	ı legally	prohil	oited		()				()			
	1	(.2)	0	(.0)	0	(.0)	0	(.0)	0	(.0)	2	(.1)	
It is an individual freedom and s	- hould	not be le	egallv	prohibit	ed	()	-	(/	-	(,	-	/	
· · · · · · · · · · · · · · · · · · ·	0	(.0)	0	(.0)	2	(2.3)	2	(.9)	1	(.6)	22	(.7)	
Do not know/cannot decide	Ŭ	()	Ŭ	()	-	(0)	-	()	-	()		/	
	12	(2.7)	4	(2.1)	0	(.0)	8	(3.5)	7	(4.2)	73	(2.4)	
"NT		/	-	/	~	()	~	/		/		/	

"No response/unknown" are not included.

Table 38.	Knowledge on	and/or	Awareness of	f Drug	Abuse	by Sex	(n =	3076)
-----------	--------------	--------	--------------	--------	-------	--------	------	-------

-	3.6		117	Sex	m , 1		
	Men		Wome	n	Total		
	n = 146	56 (a/)	n = 16	10	n = 30'	(6	P-value
[V. amladaa] D	n	(%)	n	(%)	n	(%)	0.101
[Knowledge] Drug dependence	1 (00		1 500		0011		0.131
Know	1429	(97.5)	1582	(98.3)	3011	(97.9)	
Do not know	37	(2.5)	28	(1.7)	65	(2.1)	
[Knowledge] Hallucination	1 (0 0		1				0.984
Know	1406	(95.9)	1546	(96.0)	2952	(96.0)	
Do not know	58	(4.0)	62	(3.9)	120	(3.9)	
[Knowledge] Delusion							0.302
Know	1343	(91.6)	1497	(93.0)	2840	(92.3)	
Do not know	118	(8.0)	110	(6.8)	228	(7.4)	
[Knowledge] Flashback							0.504
Know	1138	(77.6)	1276	(79.3)	2414	(78.5)	
Do not know	324	(22.1)	331	(20.6)	655	(21.3)	
[Knowledge] Cannabis-induced ha	llucinations/d	elusion					0.021
Know	1112	(75.9)	1288	(80.0)	2400	(78.0)	
Do not know	351	(23.9)	319	(19.8)	670	(21.8)	
[Knowledge] Cannabis-induced an	notivational sy	ndrome					0.533
Know	886	(60.4)	985	(61.2)	1871	(60.8)	
Do not know	578	(39.4)	620	(38.5)	1198	(38.9)	
View on cannabis use							< 0.001
Under no situation should it be	used, regardle	ess of wheth	er legally p	rohibited or	not		
	1109	(75.6)	1435	(89.1)	2544	(82.7)	
It should not be used because it	is legally prob	nibited					
	246	(16.8)	128	(8.0)	374	(12.2)	
A little use should be allowed al	though legally	v prohibited					
	6	(.4)	2	(.1)	8	(.3)	
It is an individual freedom and s	should not be	legally prohi	ibited				
	32	(2.2)	6	(.4)	38	(1.2)	
Do not know/cannot decide							
	71	(4.8)	33	(2.0)	104	(3.4)	
[Knowledge] Methamphetamine-in	nduced halluc	inations/del	usion		-	/	0.032
Know	1296	(88.4)	1468	(91.2)	2764	(89.9)	
Do not know	163	(11.1)	138	(8.6)	301	(9.8)	
View on methamphetamine use	100	(1111)	100	(0.0)	001	(0.0)	<0.001
Under no situation should it be	used, regardle	ess of wheth	er legallv n	rohibited or	not		2.001
	1256	(85.7)	1509	(93.7)	2765	(89.9)	
It should not be used because it	is legally prof	nibited	1000	(30.1)	1.00	(00.0)	
1. Should not be used because it	143	(9.8)	62	(3.9)	205	(67)	
A little use should be allowed al	though legall	v prohibited	02	(0.0)	200	(0.1)	
23 mue use snould be allowed al	nough legally	(1)	1	(1)	9	(1)	
It is an individual freedom and	t hould not ho	(.1)	1 ibitod	(.1)	4	(.1)	
it is an mulviqual freedom and s		(1 1)	onnea	(4)	00	(7)	
	16	(1.1)	6	(.4)	22	(.7)	
Do not know/cannot decide			~ .	(-		
	49	(3.3)	24	(1.5)	73	(2.4)	

Table 39. Knowledge on and/or Awareness of Drug Abuse by Age group(n=3076)

	Age group														
	10s 20s		30s		40s		5	50s		60s		Total			
	n=222		n=382		n=553		n=751		n=695		n=473		n=3076		p-value
	n	(%)	n	(%)	n	(%)	n	(%)	n	(%)	n	(%)	n	(%)	
[Knowledge] Drug dependence															0.191
Know	218	(98.2)	378	(99.0)	543	(98.2)	738	(98.3)	677	(97.4)	457	(96.6)	3011	(97.9)	
Do not know	4	(1.8)	4	(1.0)	10	(1.8)	13	(1.7)	18	(2.6)	16	(3.4)	65	(2.1)	
[Knowledge] Hallucination															0.082
Know	217	(97.7)	373	(97.6)	532	(96.2)	725	(96.5)	663	(95.4)	442	(93.4)	2952	(96.0)	
Do not know	5	(2.3)	8	(2.1)	20	(3.6)	25	(3.3)	31	(4.5)	31	(6.6)	120	(3.9)	
[Knowledge] Delusion															0.511
Know	204	(91.9)	361	(94.5)	506	(91.5)	698	(92.9)	643	(92.5)	428	(90.5)	2840	(92.3)	
Do not know	18	(8.1)	19	(5.0)	45	(8.1)	52	(6.9)	51	(7.3)	43	(9.1)	228	(7.4)	
[Knowledge] Flashback															0.082
Know	182	(82.0)	320	(83.8)	441	(79.7)	570	(75.9)	534	(76.8)	367	(77.6)	2414	(78.5)	
Do not know	40	(18.0)	61	(16.0)	112	(20.3)	180	(24.0)	158	(22.7)	104	(22.0)	655	(21.3)	
[Knowledge] Cannabis-induced h	nalluci	nations/	delusi	on											0.036
Know	186	(83.8)	316	(82.7)	420	(75.9)	582	(77.5)	535	(77.0)	361	(76.3)	2400	(78.0)	
Do not know	36	(16.2)	64	(16.8)	133	(24.1)	168	(22.4)	157	(22.6)	112	(23.7)	670	(21.8)	
[Knowledge] Cannabis-induced a	motiv	ational	svndro	ome											< 0.001
Know	163	(73.4)	255	(66.8)	300	(54.2)	432	(57.5)	431	(62.0)	290	(61.3)	1871	(60.8)	
Do not know	59	(26.6)	125	(32.7)	253	(45.8)	317	(42.2)	262	(37.7)	182	(38.5)	1198	(38.9)	
View on cannabis use		,				,		,				,		,	< 0.001
Under no situation should it b	e used	. regard	less o	f wheth	er leg	ally prol	hibited	l or not							
	178	(80.2)	311	(81.4)	423	(76.5)	611	(81.4)	601	(86.5)	420	(88.8)	2544	(82.7)	
It should not be used because	it is le	gally pro	hibite	ed		(1010)		(,		(0000)		(0000)		(0=11)	
	31	(14.0)	47	(12.3)	91	(16.5)	100	(13.3)	66	(9.5)	39	(8.2)	374	(12.2)	
A little use should be allowed	althou	gh legal	lv pro	hibited	01	(10.0)	100	(10.0)	00	(0.0)	00	(0.2)	0.1	(1=.=/	
Ti note ale bioara se anowed	0	(0)	19 pro 4	(1.0)	1	(2)	1	(1)	1	(1)	1	(2)	8	(3)	
It is an individual freedom and	lshou	ld not be	۔ اورما د	ly prohi	ihitad	()	Ŧ	(.1)	1	(.1)	1	()	0	(.0)	
it is an individual freedom and	2 SHOU	(1 4)	s ic gai	(9.1)	a a	(1.6)	11	(1.5)	4	(6)	g	(6)	38	(1.9)	
Do not know/cannot decide	5	(1.4)	0	(2.1)	5	(1.0)	11	(1.0)	4	(.0)	0	(.0)	50	(1.2)	
Do not know/cannot decide	10	(4.5)	11	(2.9)	20	(5.2)	97	(3.6)	91	(3.0)	6	$(1 \ 3)$	104	(3.4)	
[Knowlodge] Methemphotemine	-indua	(4.5)	11 ainati	(2.9)	20	(0.2)	21	(5.0)	21	(5.0)	0	(1.5)	104	(0.4)	0.053
Know	909	(01 0)	961	(04.5)	1010	(00, 1)	675	(80.0)	619	(99.1)	41 <i>C</i>	(97.0)	9764	(80.0)	0.000
Denothrow	10	(91.0)	201	(94.0)	490	(90.1)	075	(0, 0)	012	(00.1)	410	(07.9)	2704	(0.9.9)	
Do not know	18	(8.1)	20	(0.2)	94	(9.8)	12	(9.6)	01	(11.7)	96	(11.8)	501	(9.8)	<0.001
View on methamphetamine use	d		1	£ h - + h	o en 10 en		h:1.:	1							<0.001
Under no situation should it b	e used	(04.7)		(on o)	er leg		nibited	(00.0)	0.40	(02,0)	490	(00, 0)	0705	(00.0)	
	188	(84.7)	340	(89.0)	470	(85.0)	683	(90.9)	646	(92.9)	438	(92.6)	2765	(89.9)	
It should not be used because	it is le	gally pro	onibite	ed (5 - 1)	-	(101)	10	(0,1)	0.0	(1, 0)			00 F	(a, \overline{a})	
	19	(8.6)	27	(7.1)	56	(10.1)	46	(6.1)	30	(4.3)	27	(5.7)	205	(6.7)	
A little use should be allowed a	althou	gh legal	ly pro	hibited	_		_	(-)						(-)	
$ \begin{array}{cccccccccccccccccccccccccccccccccccc$															
It is an individual indexidual indexidual not be legally prohibited $(1,0)$ $(1,0)$ $(1,1)$ $(2,1)$ $(3,1)$ $(3,1)$ $(3,1)$ $(3,1)$ $(3,1)$ $(3,1)$ $(3,1)$ $(3,1)$ $(3,1)$ $(3,1)$ $(3,1)$ $(3,1)$ $(3,1)$ $(3,1)$ $(3,1)$ $(3,1)$ $(3,1)$ $(3,1)$ $(3,1)$ $(3,1)$ $(3,1)$ $(3,1)$ $(3,1)$ $(3,1)$ $(3,1)$ $(3,1)$ $(3,1)$ $(3,1)$ $(3,1)$ $(3,1)$ $(3,1)$ $(3,1)$ $(3,1)$ $(3,1)$ $(3,1)$ $(3,1)$ $(3,1)$ $(3,1)$ $(3,1)$ $(3,1)$ $(3,1)$ $(3,1)$ $(3,1)$ $(3,1)$ $(3,1)$ $(3,1)$ $(3,1)$ $(3,1)$ $(3,1)$ $(3,1)$ $(3,1)$ $(3,1)$ $(3,1)$ $(3,1)$ $(3,1)$ $(3,1)$ $(3,1)$ $(3,1)$ $(3,1)$ $(3,1)$ $(3,1)$ $(3,1)$ $(3,1)$ $(3,1)$ $(3,1)$ $(3,1)$ $(3,1)$ $(3,1)$ $(3,1)$ $(3,1)$ $(3,1)$ $(3,1)$ $(3,1)$ $(3,1)$ $(3,1)$ $(3,1)$ $(3,1)$ $(3,1)$ $(3,1)$ $(3,1)$ $(3,1)$ $(3,1)$ $(3,1)$ $(3,1)$ $(3,1)$ $(3,1)$ $(3,1)$ $(3,1)$ $(3,1)$ $(3,1)$ $(3,1)$ $(3,1)$ $(3,1)$ $(3,1)$ $(3,1)$ $(3,1)$ $(3,1)$ $(3,1)$ $(3,1)$ $(3,1)$ $(3,1)$ $(3,1)$ $(3,1)$ $(3,1)$ $(3,1)$ $(3,1)$ $(3,1)$ $(3,1)$ $(3,1)$ $(3,1)$ $(3,1)$ $(3,1)$ $(3,1)$ $(3,1)$ $(3,1)$ $(3,1)$ $(3,1)$ $(3,1)$ $(3,1)$ $(3,1)$ $(3,1)$ $(3,1)$ $(3,1)$ $(3,1)$ $(3,1)$ $(3,1)$ $(3,1)$ $(3,1)$ $(3,1)$ $(3,1)$ $(3,1)$ $(3,1)$ $(3,1)$ $(3,1)$ $(3,1)$ $(3,1)$ $(3,1)$ $(3,1)$ $(3,1)$ $(3,1)$ $(3,1)$ $(3,1)$ $(3,1)$ $(3,1)$ $(3,1)$ $(3,1)$ $(3,1)$ $(3,1)$ $(3,1)$ $(3,1)$ $(3,1)$ $(3,1)$ $(3,1)$ $(3,1)$ $(3,1)$ $(3,1)$ $(3,1)$ $(3,1)$ $(3,1)$ $(3,1)$ $(3,1)$ $(3,1)$ $(3,1)$ $(3,1)$ $(3,1)$ $(3,1)$ $(3,1)$ $(3,1)$ $(3,1)$ $(3,1)$ $(3,1)$ $(3,1)$ $(3,1)$ $(3,1)$ $(3,1)$ $(3,1)$ $(3,1)$ $(3,1)$ $(3,1)$ $(3,1)$ $(3,1)$ $(3,1)$ $(3,1)$ $(3,1)$ $(3,1)$ $(3,1)$ $(3,1)$ $(3,1)$ $(3,1)$ $(3,1)$ $(3,1)$ $(3,1)$ $(3,1)$ $(3,1)$ $(3,1)$ $(3,1)$ $(3,1)$ $(3,1)$ $(3,1)$ $(3,1)$ $(3,1)$ $(3,1)$ $(3,1)$ $(3,1)$ $(3,1)$ $(3,1)$ $(3,1)$ $(3,1)$ $(3,1)$ $(3,1)$ $(3,1)$ $(3,1)$ $(3,1)$ $(3,1)$ $(3,1)$ $(3,1)$ $(3,1)$ $(3,1)$ $(3,1)$ $(3,1)$ $(3,1)$ $(3,1)$ $(3,1)$ $(3,1)$ $(3,1)$ $(3,1)$ $(3,1)$ $(3,1)$ $(3,1)$ $(3,1)$ $(3,1)$ $(3,1)$ $(3,1)$ $(3,1)$ $(3,1)$ $(3,1)$ $(3,1)$ $(3,1)$ $(3,1)$ $(3,1)$ $(3,1)$ $(3,1)$ $(3,1)$															
	4	(1.8)	5	(1.3)	6	(1.1)	6	(.8)	0	(.0)	1	(.2)	22	(.7)	
Do not know/cannot decide		(a)	_			()		()			_	(-)		10 1	
	11	(5.0)	9	(2.4)	20	(3.6)	13	(1.7)	17	(2.4)	3	(.6)	73	(2.4)	

``10s" refers to those aged 15 to 19, and ``60s" refers to those aged 60 to 64.

"No response/unknown" are not included.
					Occup	ation								
	Self-em	ployed	Full-t	time	Non-fu	ll-time	Stud	lent	House	ewife				
	n=2	248	n=14	406	n=3	94	n=2	71	n=4	36				
	n	(%)	n	(%)	n	(%)	n	(%)	n	(%)				
[Knowledge] Drug dependence														
Know	242	(97.6)	1388	(98.7)	385	(97.7)	267	(98.5)	426	(97.7)				
Do not know	6	(2.4)	18	(1.3)	9	(2.3)	4	(1.5)	10	(2.3)				
[Knowledge] Hallucination														
Know	235	(94.8)	1368	(97.3)	378	(95.9)	265	(97.8)	412	(94.5)				
Do not know	13	(5.2)	35	(2.5)	15	(3.8)	6	(2.2)	24	(5.5)				
[Knowledge] Delusion														
Know	231	(93.1)	1311	(93.2)	370	(93.9)	250	(92.3)	400	(91.7)				
Do not know	16	(6.5)	90	(6.4)	23	(5.8)	21	(7.7)	36	(8.3)				
[Knowledge] Flashback														
Know	187	(75.4)	1117	(79.4)	317	(80.5)	225	(83.0)	331	(75.9)				
Do not know	60	(24.2)	287	(20.4)	75	(19.0)	46	(17.0)	104	(23.9)				
[Knowledge] Cannabis-induced h	allucinati	ions/delu	sion											
Know	187	(75.4)	1102	(78.4)	317	(80.5)	227	(83.8)	341	(78.2)				
Do not know	61	(24.6)	302	(21.5)	75	(19.0)	44	(16.2)	94	(21.6)				
[Knowledge] Cannabis-induced a	motivatio	nal sync	lrome											
Know	146	(58.9)	864	(61.5)	240	(60.9)	200	(73.8)	238	(54.6)				
Do not know	102	(41.1)	541	(38.5)	150	(38.1)	71	(26.2)	197	(45.2)				
View on cannabis use		,		(,		()		(,						
Under no situation should it be	e used. re	gardless	of whet	ther leg	allv proh	ibited or	not							
	196	(79.0)	1130	(80.4)	339	(86.0)	220	(81.2)	407	(93.3)				
It should not be used because i	t is legall	v prohib	ited											
	34	(13.7)	201	(14.3)	40	(10.2)	37	(13.7)	24	(5.5)				
A little use should be allowed a	lthough	legally p	ohibited	d		(/		(/		(0.0)				
	g 0	(0)	4	(3)	2	(5)	0	(0)	0	(0)				
It is an individual freedom and	should n	ot be leg	ally prol	hibited	-	(10)	Ũ	(10)	0	(10)				
	4	(1.6)	20	(1.4)	3	(8)	4	(1 5)	0	(0)				
Do not know/cannot decide	1	(1.0)	20	(1.1)	0	(.0)		(1.0)	0	(.0)				
Do not know/cannot dechae	13	(5.2)	51	(36)	7	(1.8)	10	(3.7)	3	(7)				
[Knowledge] Methamphetamine-	induced l	(0.2)	tions/de	Jusion	'	(1.0)	10	(0.1)	5	(.1)				
Know	915	(86.7)	1983	(91.3)	356	(90.4)	949	(91.9)	389	(89.2)				
Do not know	210	(12.5)	1200	(31.0)	34	(86)	240	(31.3)	46	(10.6)				
View on mothemphotemine use	51	(12.0)	122	(0.1)	04	(0.0)	20	(1.4)	40	(10.0)				
Under no situation should it be	used re	aardlass	ofwhot	hor log	ally prob	ibitod or	not							
Onder no situation should it be	290 e useu, re	(99.7)	1951		264	(02.4)	1101 999	(86.0)	499	(06.8)				
It should not be used because i	220	v prohib	1201	(05.0)	504	(32.4)	200	(00.0)	422	(30.0)				
It should not be used because I		(0 1)	110	(7.8)	10	$(1 \circ)$	99	(9 E)	10	(9.9)				
A little use should be allowed a	20 Ithough I	(0.1)	110 ahihita	1	19	(4.0)	20	(0.0)	10	(2.0)				
A little use should be allowed a		(o)	onnoneo	ر (1)	0	(0)	0	(0)	0	(0)				
It is an individual freedom and	ohould n	(.0)		(.1)	0	(.0)	0	(.0)	0	(.0)				
n is an muividual freedom and	snoula n	ot be leg	any pro		0	(0)	4	(1 =)	0	(0)				
Do not know/conrat deside	1	(.4)	9	(.6)	ð	(.8)	4	(1.0)	0	(.0)				
Do not know/cannot decide	C	(9.4)	01	(<u>0</u> 0)	C	(1 E)	11	(4 1)	n	(7)				
	6	(2.4)	31	(2.2)	6	(1.0)	11	(4.1)	3	(.7)				

Table 40. Knowledge on and/or Awareness of Drug Abuse by Occupation (n=3076)

"No response/unknown" are not included.

Table 40. Knowledge on and/or	Awareness of Drug Abuse by	v Occupation (n=3076) continued	
rable for fine age off and of	in aronood or brag moade of	, occupation (in solis, continued	

				00	ccupatio	on			
	Unem	oloyed	Oth	er	Unkr	nown	Tot	al	
	n=1	79	n=1	38	n=	=4	n=30	076	p-value
	n	(%)	n	(%)	n	(%)	n	(%)	
[Knowledge] Drug dependence									< 0.001
Know	171	(95.5)	128	(92.8)	4	(100.0)	3011	(97.9)	
Do not know	8	(4.5)	10	(7.2)	0	(.0)	65	(2.1)	
[Knowledge] Hallucination									0.002
Know	164	(91.6)	126	(91.3)	4	(100.0)	2952	(96.0)	
Do not know	15	(8.4)	12	(8.7)	0	(.0)	120	(3.9)	
[Knowledge] Delusion									0.038
Know	156	(87.2)	118	(85.5)	4	(100.0)	2840	(92.3)	
Do not know	23	(12.8)	19	(13.8)	0	(.0)	228	(7.4)	
[Knowledge] Flashback									0.319
Know	131	(73.2)	103	(74.6)	3	(75.0)	2414	(78.5)	
Do not know	47	(26.3)	35	(25.4)	1	(25.0)	655	(21.3)	
[Knowledge] Cannabis-induced	hallucina	tions/delu	asion						0.049
Know	123	(68.7)	100	(72.5)	3	(75.0)	2400	(78.0)	
Do not know	55	(30.7)	38	(27.5)	1	(25.0)	670	(21.8)	
[Knowledge] Cannabis-induced	amotivati	ional syn	drome						< 0.001
Know	97	(54.2)	83	(60.1)	3	(75.0)	1871	(60.8)	
Do not know	82	(45.8)	54	(39.1)	1	(25.0)	1198	(38.9)	
View on cannabis use									< 0.001
Under no situation should it l	oe used, r	egardless	s of whe	ether leg	ally pro	hibited o	or not		
	137	(76.5)	112	(81.2)	3	(75.0)	2544	(82.7)	
It should not be used because	it is lega	lly prohib	oited						
	26	(14.5)	12	(8.7)	0	(.0)	374	(12.2)	
A little use should be allowed	although	legally p	rohibite	ed					
	1	(.6)	1	(.7)	0	(.0)	8	(.3)	
It is an individual freedom an	d should	not be leg	gally pro	ohibited					
	4	(2.2)	3	(2.2)	0	(.0)	38	(1.2)	
Do not know/cannot decide									
	10	(5.6)	9	(6.5)	1	(25.0)	104	(3.4)	
[Knowledge] Methamphetamine	e-induced	hallucina	ations/d	lelusion					0.009
Know	151	(84.4)	117	(84.8)	4	(100.0)	2764	(89.9)	
Do not know	28	(15.6)	20	(14.5)	0	(.0)	301	(9.8)	
View on methamphetamine use									0.001
Under no situation should it l	oe used, r	egardless	s of whe	ether leg	ally pro	hibited o	or not		
	151	(84.4)	121	(87.7)	3	(75.0)	2765	(89.9)	
It should not be used because	it is lega	lly prohib	oited						
	15	(8.4)	8	(5.8)	0	(.0)	205	(6.7)	
A little use should be allowed	although	legally p	rohibite	ed					
	0	(.0)	0	(.0)	0	(.0)	2	(.1)	
It is an individual freedom an	d should	not be les	gally pro	ohibited					
	3	(1.7)	2	(1.4)	0	(.0)	22	(.7)	
Do not know/cannot decide									
	8	(4 5)	7	(5.1)	1	(25.0)	73	(2.4)	

Table 41. Knowledge on and/or Awareness o	f Drug Abuse by	Drug use experience (n=3076
-------------------------------------------	-----------------	-----------------------------

					Drug u	ise exper	ience			
$ \begin{array}{ $		Lifet	ime	No life	etime	Unkno	own	Tot	al	
$\begin{array}{ c c c c c c } & n = 78 & n = 2940 & n = 58 & n = 3976 & p value \\ \hline n & (%) & n &$		experi	ience	exper	ience					
$\begin{array}{ c c c c c c c c c c c c c c c c c c c$		n='	78	n=29	940	n=5	8	n=30	076	p-value
IR.nowledge] Drug dependence <		n	(%)	n	(%)	n	(%)	n	(%)	
Know 74 (94.9) 2884 (98.1) 53 (91.4) 3011 (97.9) Do not know 4 (5.1) 56 (1.0) 5 (8.6) 66 (7.0) Knowledge] Hallucination 73 (93.6) 2828 (96.2) 51 (87.9) 2952 (96.0) Do not know 73 (92.3) 2723 (92.6) 45 (7.6) 2840 (92.3) Do not know 6 (7.7) 210 (7.1) 12 20.7) 288 (7.4) Know 68 (87.2) 2305 (7.8.4) 11 (70.7) 2400 (7.0) Know 68 (87.2) 2304 (7.8.4) 11 (70.7) 2400 (7.0) Monw 23 (29.5) 631 (21.5) 631 (21.6) 7.6 2400 (7.0) 10.0 10.0 10.0 10.0 10.0 10.0 10.0 10.0 10.0 10.0 10.0	[Knowledge] Drug dependence									< 0.001
De not know 4 (5.1) 56 (1.9) 5 (8.6) 65 (2.1) [Knowledge] Hallucination	Know	74	(94.9)	2884	(98.1)	53	(91.4)	3011	(97.9)	
[Knowledge] Hallucination 0.01 6.0 93.6 26.2 61 87.9 295.2 96.01 [Knowledge] Delusion	Do not know	4	(5.1)	56	(1.9)	5	(8.6)	65	(2.1)	
Know73(93.6)2828(96.2)51(87.9)2952(96.0)Do not know5(6.4)109(3.7)6(10.3)120(3.9)[Knowledge] Delusion2723(92.6)45(77.6)2840(92.3)Do not know6(7.7)210(7.1)12(20.7)228(7.4)Do not know6(8(87.2)2305(7.8.4)41(70.7)2414(78.5)Do not know10(12.8)629(21.4)16(27.6)650(21.8)[Knowledge] Cannabis-induced hallucinations/delusion(78.4)41(70.7)2400(78.0)Do not know55(70.5)2304(78.4)41(70.7)2400(78.0)[Knowledge] Cannabis-induced amtivational syndrome(78.1)2414(78.0)(78.0)Do not know23(29.5)631(21.5)16(27.6)670(21.8)[Knowledge] Cannabis-induced amtivational syndrome(78.1)18.9)(38.9)23(39.7)198(38.9)Under no situation should it be used, regardless of whether legally prohibited(74.1)2544(82.7)I tashudh not be used because it is legally prohibited(74.1)2544(82.7)I tashudh not be used allowed allowugh legally prohibited </td <td>[Knowledge] Hallucination</td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td>0.001</td>	[Knowledge] Hallucination									0.001
Do not know5(6.4)109(3.7)6(10.3)120(3.9)[Knowledge] Delusion	Know	73	(93.6)	2828	(96.2)	51	(87.9)	2952	(96.0)	
[Knowledge] Delusion<	Do not know	5	(6.4)	109	(3.7)	6	(10.3)	120	(3.9)	
Know 72 (92.3) 2723 (92.6) 45 (77.6) 2840 (92.3) Do not know 6 (7.7) 210 (7.1) 12 (20.7) 228 (7.4) [Knowledge] Flashback	[Knowledge] Delusion									< 0.001
$ \begin{array}{ $	Know	72	(92.3)	2723	(92.6)	45	(77.6)	2840	(92.3)	
[Knowledge] Flashback 0.028 Know 68 (87.2) 2305 (78.4) 41 (70.7) 24.14 (78.5) Do not know 10 (12.8) 629 (21.4) 16 (27.6) 55 (21.3) [Knowledge] Cannabis-induced hallucinations/etusion 55 (70.5) 2204 (78.4) 41 (70.7) 2400 (78.0) Do not know 23 (29.5) 631 (21.5) 16 (27.6) 6700 (21.8) [Knowledge] Cannabis-induced amotivational symtrom 0.023 (38.9) 23 (39.7) 1180 (80.8) Do not know 32 (41.0) 1143 (38.9) 23 (39.7) 1180 (80.8) Under no situation should it be used, regardless of whether legally prohibited - -	Do not know	6	(7.7)	210	(7.1)	12	(20.7)	228	(7.4)	
Know68(87.2)2305(78.4)41(70.7)2414(78.5)Do not know10(12.8)629(21.4)16(27.6)655(21.3)Know55(70.5)2304(78.4)41(70.7)2400(78.0)Do not know23(29.5)631(21.6)16(27.6)607(21.8)[Knowledge] Cannabis-induced amotivationationationationationationationation	[Knowledge] Flashback									0.028
Do not know10(12.8)629(21.4)16(27.6)655(21.3)[Knowledge] Cannabis-induced hallucinations/de/use0.023(70.5)2304(78.4)41(70.7)2400(78.0)Know23(29.5)631(21.5)16(27.6)630(78.1)(78.7)2400(78.0)[Knowledge] Cannabis-induced amotivational syndrom23(59.0)1791(60.9)34(58.6)1871(60.8)Do not know32(41.0)1143(38.9)23(39.7)1198(38.9)O not know32(41.0)1143(38.9)23(37.4)12.44(82.7)Under no situation should it be used, regardless of whether legally problem17.1(74.1)25.44(82.7)(8.6)18.7(12.2)It should not be used because it is legally19.124.58(83.6)43(74.1)25.44(82.7)It is an individual freedom and should not be legally problem3(3.8)5(.2)0(.0)8(.3)It is an individual freedom and should not be legally problem2(2.6)94(3.2)8(13.8)104(3.4)It know68(87.2)260(90.1)46(79.3)276(8.9)(.10)It is an individual freedom and should not be used, regardless of whether legally problem5(.6.7)5(8.10)276(8.9)It is now68(87.2)260(90.1)	Know	68	(87.2)	2305	(78.4)	41	(70.7)	2414	(78.5)	
[Knowledge] Cannabis-induced hallucinations/delines0.0230.0010.0010.0010.0010.0010.0010.0010.0010.0010.0010.0010.0010.0010.0010.0010.0010.0010.0010.0010.0010.0010.0010.0010.0010.0010.0010.0010.0010.0010.0010.0010.0010.0010.0010.0010.0010.0010.0010.0010.0010.0010.0010.0010.0010.0010.0010.0010.0010.0010.0010.0010.0010.0010.0010.0010.0010.0010.0010.0010.0010.0010.0010.0010.0010.0010.0010.0010.0010.0010.0010.0010.0010.0010.0010.0010.0010.0010.0010.0010.0010.0010.0010.0010.0010.0010.0010.0010.0010.0010.0010.0010.0010.0010.0010.0010.0010.0010.0010.0010.0010.0010.0010.0010.0010.0010.0010.0010.0010.0010.0010.0010.0010.0010.0010.0010.0010.0010.0010.0010.0010.0010.0010.0010.0010.0010.0010.0010.0010.0010.0010.0010.0010.0010.0010.0010.0010.0010.0010.0010.001	Do not know	10	(12.8)	629	(21.4)	16	(27.6)	655	(21.3)	
Know55(70.5)2304(78.4)41(70.7)2400(78.0)Do not know23(29.5)631(21.5)16(27.6)670(21.8)[Knowledge]Cannabis-induced amotivational symtroms5(60.9)34(58.6)1871(60.9)Do not know32(41.0)1714(38.9)23(39.7)1198(38.9)Do not know32(41.0)1714(38.9)33(74.1)2544(82.7)Under no situation should it be used, regardless of whether legally prohibited or not43(55.1)2458(83.6)43(74.1)2544(82.7)It should not be used because it is legally prohibited21(26.9)34(11.8)5(8.6)374(12.9)It is an individual freedom and should not be used here used lecause it be used.71.1028(1.0)1(1.7)38(1.2)It is an individual freedom and should not be used.9(11.5)28(1.0)1(1.7)38(1.2)It is an individual freedom and should not be used.2(2.6)94(3.2)8(13.8)104(3.4)[Know68(87.2)2650(90.1)46(79.3)2764(89.9)Do not know/cannot decide1(2.8)280(9.5)11(1.0)301(9.9)[Know leagle]111.3192(6.5)5(8.6)205(6.7)Do not know	[Knowledge] Cannabis-induced h	nallucina	tions/de	lusion						0.023
Do not know 23 (29.5) 631 (21.5) 16 (27.6) 670 (21.8) [Knowledge] Cannabis-induced amotivational symbols 0 1791 (60.9) 34 (58.6) 1871 (60.8) Mow 32 (41.0) 1143 (38.9) 23 (39.7) 1198 (38.9) View on cannabis use	Know	55	(70.5)	2304	(78.4)	41	(70.7)	2400	(78.0)	
$ \begin{bmatrix} \text{Know} & 46 & 59.0 & 1791 & 60.9 & 34 & 58.6 & 1871 & 60.8 \\ \text{Know} & 32 & (41.0) & 1143 & (38.9) & 23 & (39.7) & 1198 & (38.9) \\ \text{On on know} & 32 & (41.0) & 1143 & (38.9) & 23 & (39.7) & 1198 & (38.9) \\ \text{View on cannabis use} & & & & & & & & & & & & & & & & & & &$	Do not know	23	(29.5)	631	(21.5)	16	(27.6)	670	(21.8)	
$ \begin{array}{ c c c c c c c c c c c c c c c c c c c$	[Knowledge] Cannabis-induced a	amotivat	ional syı	ndrome						0.188
Do not know32(41.0)1143(38.9)23(39.7)1198(38.9)View on cannabis use	Know	46	(59.0)	1791	(60.9)	34	(58.6)	1871	(60.8)	
View on cannabis use < < < < < < < < < < < < < < < < < < <	Do not know	32	(41.0)	1143	(38.9)	23	(39.7)	1198	(38.9)	
Under no situation should it be used, regardless of whether legally prohibited or not $\begin{array}{c c c c c c c c c c c c c c c c c c c $	View on cannabis use									< 0.001
$ \begin{array}{c c c c c c c c c c c c c c c c c c c $	Under no situation should it b	e used, 1	regardle	ss of wh	ether leg	gally proh	ibited or	r not		
It should not be used because it is legally prohibited (12.2) A little use should be allowed although legally prohibited (12.2) A little use should be allowed although legally prohibited (12.2) A little use should freedom and should not be legally prohibited (12.2) It is an individual freedom and should not be legally prohibited (12.2) Do not know/cannot decide 2 (2.6) 94 (3.2) 8 (1.3) 104 (3.4) [Knowledge] Methamphetamine-induced hallucinations/delusion Know 68 (87.2) 2650 (90.1) 46 (79.3) 2764 (89.9) Do not know 10 (12.8) 280 (9.5) 11 (19.0) 301 (9.8) View on methamphetamine use Under no situation should it be used, regardless of whether legally prohibited or not 60 (76.9) 2658 (90.4) 47 (81.0) 2765 (89.9) It should not be used because it is legally prohibited 8 (10.3) 192 (6.5) 5 (8.6) 205 (6.7) A little use should be allowed although legally prohibited 15 should not be used although legally prohibited 8 (10.3) 192 (6.5) 5 (8.6) 205 (6.7) A little use should be allowed although legally prohibited 16 (0) 2 (1.1) 0 (0.0) 2 (1.1) 17 ti sa an individual freedom and should not be legally prohibited 8 (10.3) 14 (5.0) 0 (0.0) 22 (7.1) 17 to not know/cannot decide 2 (2.6) 65 (2.2) 6 (10.3) 73 (2.4)		43	(55.1)	2458	(83.6)	43	(74.1)	2544	(82.7)	
$\begin{array}{c c c c c c c c c c c c c c c c c c c $	It should not be used because	it is lega	lly prohi	ibited						
A little use should be allowed although legally prohibited 3 (3.8) 5 $(.2)$ 0 $(.0)$ 8 $(.3)$ It is an individual freedom and should not be legally prohibited 9 (1.5) 28 (1.0) 1 (1.7) 38 (1.2) Do not know/cannot decide 2 (2.6) 94 (3.2) 8 (1.8) 104 (3.4) [Knowledge] Methamphetamine-induced hallucinations/deluxion 1 (1.7) 38 (1.2) 0.039 Manow 68 (87.2) 2650 (90.1) 46 (79.3) 2764 (89.9) Do not know 10 (12.8) 280 (9.5) 11 (19.0) 301 (9.8) View on methamphetamine use (76.9) 2658 (90.4) 47 (81.0) 2765 (89.9) It should not be used because it is legally prohibited -60 (76.9) 2658 (90.4) 47 (81.0) 2765 (89.9) (89.9) It should not be used because it is legally prohibited -66.5 (2.6) 5		21	(26.9)	348	(11.8)	5	(8.6)	374	(12.2)	
3(3.8)5(.2)0(.0)8(.3)It is an individual freedom and should rot be legally prohibited9(11.5)28(1.0)1(1.7)38(1.2)Do not know/cannot decide2(2.6)94(3.2)8(13.8)104(3.4)[Knowledge] Methamphetamine-induced hallucinations/deluxations/deluxations/deluxations/deluxations/deluxations/deluxations/deluxations/deluxations/deluxations/deluxations/deluxations/deluxations/deluxations/deluxations/deluxations/deluxations/deluxations/deluxations/deluxations/deluxation8(87.2)2650(90.1)46(79.3)2764(89.9)Do not know10(12.8)280(9.5)11(19.0)301(9.8)View on methamphetamine useColspan="4">Colspan="4">Colspan="4">Colspan="4">Colspan="4">Colspan="4">Colspan="4">Colspan="4">Colspan="4">Colspan="4">Colspan="4">Colspan="4">Colspan="4">Colspan="4">Colspan="4">Colspan="4">Colspan="4">Colspan="4">Colspan="4">Colspan="4">Colspan="4">Colspan="4">Colspan="4">Colspan="4">Colspan="4">Colspan="4">Colspan="4">Colspan="4">Colspan="4">Colspan="4">Colspan="4">Colspan="4">Colspan="4">Colspan="4">Colspan="4">Colspan="4">Colspan="4">Colspan="4">Colspan="4">Colspan="4">Colspan="4">Colspan="4">Colspan="4">Colspan="4">Colspan="4">Colspan="4">Colspan="4">Colspan="4">Colspan="4">Colspan="4">Colspan="4">Colspan="4">Colspan="4">Colspan="4">Colspan="4">Colspan="4">Colspan="4">Colspan="4">Colspan="4">Colspan="4">Colspan="4">Colspan="4">Colspan="4">Colspan="4">Colspan="4">Colspan="4">Colspan="4">Colspan="4">Colspan="4">Colspan="4">Colspan="4">Colspan="4">Colspan="4">Colspan="4">Colspan="4">Colspan="4">Colspan="4">Colspan="4">Colspan="	A little use should be allowed	although	n legally	prohibit	ed					
It is an individual freedom and should not be legally prohibited $\begin{array}{c c c c c c c c c c c c c c c c c c c $		3	(3.8)	5	(.2)	0	(.0)	8	(.3)	
$\begin{array}{c c c c c c c c } 9 & (11.5) & 28 & (1.0) & 1 & (1.7) & 38 & (1.2) \\ \hline \begin{tabular}{ c c c c c c } Do not know/cannot decide & 2 & (2.6) & 94 & (3.2) & 8 & (13.8) & 104 & (3.4) \\ \hline \begin{tabular}{ c c c c c } 2 & (2.6) & 94 & (3.2) & 8 & (13.8) & 104 & (3.4) \\ \hline \begin{tabular}{ c c c c c } I & I & I & I & I & I & I & I & I & I $	It is an individual freedom and	l should	not be le	egally pr	ohibited					
Do not know/cannot decide 2 (2.6) 94 (3.2) 8 (13.8) 104 (3.4) [Knowledge] Methamphetamine interest transmitter 101 (12.8) 2650 (90.1) 46 (79.3) 2764 (89.9) Mow 68 (87.2) 2650 (90.1) 46 (79.3) 2764 (89.9) Do not know 10 (12.8) 280 (9.5) 11 (19.0) 301 (9.8) View on methamphetamine use 10^{-1} 2658 (90.4) 47 (81.0) 2765 (89.9) Inder no situation should it be used. 10^{-1} 2658 (90.4) 47 (81.0) 2765 (89.9) It should not be used because it is legally prohibited 103 192 (6.5) 5 (8.6) 205 (6.7) A little use should be allowed although by the legally prohibited 103 103 14 $(.5)$ 0 $(.0)$ 22 $(.7)$ It is an individual freedom and should 103 14 $(.5)$		9	(11.5)	28	(1.0)	1	(1.7)	38	(1.2)	
$ \begin{array}{c c c c c c c c c c c c c c c c c c c $	Do not know/cannot decide									
		2	(2.6)	94	(3.2)	8	(13.8)	104	(3.4)	
Know68(87.2)2650(90.1)46(79.3)2764(89.9)Do not know10(12.8)280(9.5)11(19.0)301(9.8)View on methamphetamine use (76.9) 2658(90.4)47(81.0)2765(89.9)Under no situation should it be used, regardless of whether legally prohibited or not (76.9) 2658(90.4)47(81.0)2765(89.9)It should not be used because it is legally prohibited 8 (10.3)192(6.5)5(8.6)205(6.7)A little use should be allowed although legally prohibited $(.0)$ 2 $(.1)$ 0 $(.0)$ 2 $(.1)$ It is an individual freedom and should not be legally prohibited 8 (10.3) 14 $(.5)$ 0 $(.0)$ 22 $(.7)$ Do not know/cannot decide 2 (2.6) 65 (2.2) 6 (10.3) 73 (2.4)	[Knowledge] Methamphetamine	-induced	l hallucii	nations/o	delusion					0.039
$ \begin{array}{cccccccccccccccccccccccccccccccccccc$	Know	68	(87.2)	2650	(90.1)	46	(79.3)	2764	(89.9)	
View on methamphetamine use<0.001Under no situation should it be used, regardless of whether legally prohibited or vot60 (76.9) 2658 (90.4) 47 (81.0) 2765 (89.9) It should not be used because it is legally prohibited8 (10.3) 192 (6.5) 5 (8.6) 205 (6.7) A little use should be allowed although legally prohibited0 $(.0)$ 2 $(.1)$ 0 $(.0)$ 2 $(.1)$ It is an individual freedom and should not be legally prohibited8 (10.3) 14 $(.5)$ 0 $(.0)$ 22 $(.7)$ Do not know/cannot decide2 (2.6) 65 (2.2) 6 (10.3) 73 (2.4)	Do not know	10	(12.8)	280	(9.5)	11	(19.0)	301	(9.8)	
Under no situation should it be used, regardless of whether legally prohibited or not $\begin{array}{cccccccccccccccccccccccccccccccccccc$	View on methamphetamine use									< 0.001
$\begin{array}{cccccccccccccccccccccccccccccccccccc$	Under no situation should it b	e used, 1	regardles	ss of wh	ether leg	gally proh	ibited or	r not		
It should not be used because it is legally prohibited $\begin{array}{cccccccccccccccccccccccccccccccccccc$		60	(76.9)	2658	(90.4)	47	(81.0)	2765	(89.9)	
$\begin{array}{cccccccccccccccccccccccccccccccccccc$	It should not be used because	it is lega	lly prohi	ibited						
A little use should be allowed although legally prohibited 0 (.0) 2 (.1) 0 (.0) 2 (.1) It is an individual freedom and should not be legally prohibited 8 (10.3) 14 (.5) 0 (.0) 22 (.7) Do not know/cannot decide 2 (2.6) 65 (2.2) 6 (10.3) 73 (2.4)		8	(10.3)	192	(6.5)	5	(8.6)	205	(6.7)	
$\begin{array}{cccccccccccccccccccccccccccccccccccc$	A little use should be allowed	although	n legally	prohibit	ed					
It is an individual freedom and should not be legally prohibited 8 (10.3) 14 (.5) 0 (.0) 22 (.7) Do not know/cannot decide 2 (2.6) 65 (2.2) 6 (10.3) 73 (2.4)		0	(.0)	2	(.1)	0	(.0)	2	(.1)	
$\begin{array}{cccccccccccccccccccccccccccccccccccc$	It is an individual freedom and	l should	not be le	egally pr	ohibited					
Do not know/cannot decide 2 (2.6) 65 (2.2) 6 (10.3) 73 (2.4)		8	(10.3)	14	(.5)	0	(.0)	22	(.7)	
2 (2.6) 65 (2.2) 6 (10.3) 73 (2.4)	Do not know/cannot decide									
		2	(2.6)	65	(2.2)	6	(10.3)	73	(2.4)	

"No response/unknown" are not included.

Table 42. NPS Use and Other Related	l Items by Residence area(n=3076
-------------------------------------	----------------------------------

						Residen	ce area	a				
	Hok	kaido	Toh	oku	Ka	nto	Hoky	uriku	Tou	Isan	To	kai
	n=	131	n=	250	n=	948	n=	154	n=	150	n=	328
	n	(%)	n	(%)	n	(%)	n	(%)	n	(%)	n	(%)
Harmful effects of NPSs												
Know	112	(85.5)	206	(82.4)	829	(87.4)	124	(80.5)	125	(83.3)	287	(87.5)
Do not know	19	(14.5)	42	(16.8)	117	(12.3)	30	(19.5)	24	(16.0)	39	(11.9)
No response/unknown	0	(.0)	2	(.8)	2	(.2)	0	(.0)	1	(.7)	2	(.6)
Japan's regulation for designa	ated sub	stances										
Know	73	(55.7)	149	(59.6)	548	(57.8)	81	(52.6)	90	(60.0)	193	(58.8)
Do not know	58	(44.3)	100	(40.0)	398	(42.0)	72	(46.8)	60	(40.0)	134	(40.9)
No response/unknown	0	(.0)	1	(.4)	2	(.2)	1	(.6)	0	(.0)	1	(.3)
The perceived number of NPS	Susers											
Increasing	70	(53.4)	145	(58.0)	561	(59.2)	79	(51.3)	91	(60.7)	188	(57.3)
Not changing	14	(10.7)	13	(5.2)	58	(6.1)	7	(4.5)	6	(4.0)	20	(6.1)
Decreasing	2	(1.5)	2	(.8)	9	(.9)	3	(1.9)	0	(.0)	9	(2.7)
Do not know	45	(34.4)	89	(35.6)	316	(33.3)	65	(42.2)	52	(34.7)	111	(33.8)
No response/unknown	0	(.0)	1	(.4)	4	(.4)	0	(.0)	1	(.7)	0	(.0)
Experience of NPS use (lifetin	ne)											
Never used	126	(96.2)	246	(98.4)	935	(98.6)	152	(98.7)	146	(97.3)	324	(98.8)
Have used	2	(1.5)	0	(.0)	2	(.2)	0	(.0)	0	(.0)	1	(.3)
No response/unknown	3	(2.3)	4	(1.6)	11	(1.2)	2	(1.3)	4	(2.7)	3	(.9)
Experience of NPS use (within	n the pa	st year)										
Never used	128	(97.7)	246	(98.4)	937	(98.8)	152	(98.7)	146	(97.3)	325	(99.1)
Have used	0	(.0)	0	(.0)	0	(.0)	0	(.0)	0	(.0)	0	(.0)
No response/unknown	3	(2.3)	4	(1.6)	11	(1.2)	2	(1.3)	4	(2.7)	3	(.9)
Type of NPSs used												
Never used	121	(92.4)	230	(92.0)	896	(94.5)	144	(93.5)	139	(92.7)	307	(93.6)
Herbal	2	(1.5)	0	(.0)	1	(.1)	0	(.0)	0	(.0)	0	(.0)
Liquid	2	(1.5)	0	(.0)	1	(.1)	0	(.0)	0	(.0)	1	(.3)
Powder	1	(.8)	0	(.0)	2	(.2)	0	(.0)	0	(.0)	1	(.3)
Other	0	(.0)	0	(.0)	0	(.0)	0	(.0)	0	(.0)	0	(.0)
Form unknown	0	(.0)	0	(.0)	0	(.0)	0	(.0)	0	(.0)	0	(.0)
No response/unknown	8	(6.1)	20	(8.0)	50	(5.3)	10	(6.5)	11	(7.3)	20	(6.1)
Hospital visit associated with 1	NPS use	•										
None												
	126	(96.2)	242	(96.8)	929	(98.0)	150	(97.4)	146	(97.3)	320	(97.6)
Have used an NPS but no h	nospital	visit asso	ociated	l with Nl	PS use							
	2	(1.5)	0	(.0)	2	(.2)	0	(.0)	0	(.0)	1	(.3)
Used an NPS and was take	n to hos	spital by	ambul	ance								
	0	(.0)	0	(.0)	0	(.0)	0	(.0)	0	(.0)	0	(.0)
Used an NPS and presente	d to a ps	ychiatri	c depa	rtment								
-	0	(.0)	0	(.0)	0	(.0)	0	(.0)	0	(.0)	0	(.0)
Used an NPS and presente	d to a de	epartme	nt of in	nternal n	nedicir	ne						
1	0	(.0)	0	(.0)	0	(.0)	0	(.0)	0	(.0)	0	(.0)
Used an NPS and presente	d to a tr	auma de	partm	ent		,		,		,		
	0	(.0)	0	(.0)	0	(.0)	0	(.0)	0	(.0)	0	(.0)
Used an NPS and presente	d to anv	other d	epartn	nent	Ŭ	()	0	()	0	()	Ŭ	()
e sou an 141 S and procente	0	(0)	0	(0)	0	(0)	0	(0)	0	(0)	0	(0)
Have used an NPS but hist	orv of h	ospital v	isit is 1	inknowi	า	(.0)	0		0	(.0)	0	(.0)
_14,0 4504 411 141 0 Dut 11100		(()	0	(0)	- 0	())	0	(0)	0	(0)	0	(0)
No response/unknown	5	(,	Ŭ	()	Ŭ	()	0	()	Ŭ	()	Ŭ	()
· · · · · · · · · · · · · · · · · · ·	3	(2.3)	8	(3.2)	17	(1.8)	4	(2.6)	4	(2.7)	7	(2.1)

For the type of NPSs used, all the responses of "form unknown" fell under the category of "No response/unknown," and no test was therefore performed.

Table 42. NPS Use and Other Related Items by Residence area(n=3076) continued

_						R	esiden	ce area					
	Ki	nki	Chu	goku	Shi	koku	Kita-K	Lyusyu	Min	ami-	Tot	al	
	n=	442	n=	191	n=	=88	n=	229	n=	165	n=30	076	p-value
	n	(%)	n	(%)	n	(%)	n	(%)	n	(%)	n	(%)	-
Harmful effects of NPSs													0.117
Know	377	(85.3)	171	(89.5)	72	(81.8)	200	(87.3)	136	(82.4)	2,639	(85.8)	
Do not know	62	(14.0)	20	(10.5)	16	(18.2)	29	(12.7)	26	(15.8)	424	(13.8)	
No response/unknown	3	(.7)	0	(.0)	0	(.0)	0	(.0)	3	(1.8)	13	(.4)	
Japan's regulation for designate	ed subs	tances											0.702
Know	229	(51.8)	109	(57.1)	44	(50.0)	139	(60.7)	94	(57.0)	1,749	(56.9)	
Do not know	210	(47.5)	82	(42.9)	43	(48.9)	89	(38.9)	70	(42.4)	1.316	(42.8)	
No response/unknown	3	(.7)	0	(.0)	1	(1.1)	1	(.4)	1	(.6)	11	(.4)	
The perceived number of NPS u	isers												0.357
Increasing	250	(56.6)	105	(55.0)	51	(58.0)	138	(60.3)	83	(50.3)	1.761	(57.2)	
Not changing	25	(5.7)	7	(3.7)	8	(9.1)	10	(4.4)	11	(6.7)	179	(5.8)	
Decreasing	4	(.9)	2	(1.0)	1	(1.1)	1	(.4)	0	(.0)		(1.1)	
Do not know	160	(36.2)	76	(39.8)	28	(31.8)	80	(34.9)	70	(42.4)	1 092	(35.5)	
No response/unknown	3	(7)	1	(5)	0	(0)	0	(0)	1	(6)	11	(4)	
Experience of NPS use (lifetime	e)	()	1	(.0)	0	(.0)	0	(.0)	1	(.0)	11	(, 1)	0.829
Never used	434	(98.2)	186	(97.4)	86	(97.7)	225	(98.3)	162	(98.2)	3.022	(98.2)	0.020
Have used	2	(5)	100	(5)	1	(11)	1	(4)	102	(6)	11	(4)	
No response/unknown	6	(1.4)	4	(2.1)	1	(1.1)	3	(1.3)	2	(1.2)	43	(14)	
Experience of NPS use (within	the pas	st vear)	1	(2.1)	1	(1.1)	0	(1.0)	-	(1.2)	10	(1.1)	0.932
Never used	436	(98.6)	187	(97.9)	87	(98.9)	226	(98.7)	163	(98.8)	3 033	(98.6)	0.001
Have used	001-	(00.0)	107	(01.0)	01	(00.0)	0	(00.1)	100	(00.0)	0,000	(00.0)	
No response/unknown	6	(1.0)	4	(2.1)	1	(1, 1)	3	(1.3)	2	(1.0)	43	(1.4)	
Type of NPSs used	0	(1.4)	-	(2.1)	1	(1.1)	5	(1.0)	4	(1.2)	40	(1.4)	
Never used	415	(03.0)	177	(92.7)	81	(92.0)	217	(94.8)	154	(93.3)	2 881	(93.7)	0.836
Herbal	910	(55.5)	1	(52.1)	1	(32.0)	217	(1)	104	(00.0)	2,001	(3)	0.000
Liquid	0	(.0)	0	(.0)	0	(1.1)	0	(.4)	0	(.0)	4	(.0)	0.402
Powder	0	(.0)	1	(.0)	0	(.0)	0	(.0)	1	(.0)	4	(.1)	0.135
Other	0	(.0)	0	(.0)	0	(.0)	0	(.0)	0	(.0)	0	(.2)	0.927
Formunknown	0	(.0)	0	(.0)	0	(.0)	0	(.0)	0	(.0)	0	(.0)	0.337
No response/unknown	25	(5.7)	12	(6.8)	G	(6.8)	11	(.0)	10	(6.1)	194	(6.0)	0.027
Hospital visit associated with NI	20 PS 1189	(0.1)	10	(0.0)	0	(0.0)	11	(4.0)	10	(0.1)	104	(0.0)	0.957
None													
ivone	497	$(0 \mathcal{C} \mathcal{C})$	194	(06.2)	95	$(0 \in \mathcal{C})$	991	(06.5)	150	(06.4)	2080	(07.9)	_
Have used an NPS but no ho	421 enital s	(30.0)	hatein	with NP	00 S 1196	(90.0)	221	(90.5)	109	(30.4)	2909	(31.2)	
Have used an NI S but no no	spital v	(E)	1	(5)	1	; (1 1)	1	(4)	1	(c)	11	(4)	
Used on NPS and was taken	to hos	(.0) aital by a	mbule	(.0)	1	(1.1)	1	(.4)	1	(.6)	11	(.4)	
Osed all WD alld was taken	0 105	(0)	0		0	(0)	0	(0)	0	(0)	0	(0)	_
Used an NPS and presented	to a new	(.0)	donar	(.0)	0	(.0)	0	(.0)	0	(.0)	0	(.0)	_
Osed an NIS and presented	to a ps		uepar		0	(0)	0	(0)	0	(0)	0	(0)	_
Used an NPS and presented	to a da	(.0)	t of in	(.0)	odiair	(.0)	0	(.0)	0	(.0)	0	(.0)	
Osed an NIS and presented			0		o	(0)	0	(0)	0	(0)	0	(0)	_
Used an NPS and presented	to o tre	(.0) umo dos	0 aantma	(.0)	0	(.0)	0	(.0)	0	(.0)	0	(.0)	_
Osed an NIS and presented	0 4 11 4			(0)	0	(0)	0	(0)	0	(0)	0	(0)	_
Used an NPS and presented	to any	(.0) othor do	nortm	(.0)	0	(.0)	0	(.0)	0	(.0)	0	(.0)	-
o seu an mi o anu presenteu	w any	(n)	partifi	(0)	0	()	0	()	0	(0)	0	()	
Have used an NDS but histor	U	(.U)	U ait is re	(.U)	0	(.0)	0	(.0)	U	(.0)	0	(.0)	-
mave used an INI 5 but Histor	y or no	opital VI	on 15 U	()	0	(0)	0	(0)	0	(0)	0	(0)	-
No response/unknown	0	(.0)	0	(.0)	U	(.0)	0	(.0)	0	(.0)	0	(.0)	-
10 response/unknown	13	(2.9)	6	(3 1)	2	(2.3)	7	(3 1)	5	(3.0)	76	(2.5)	-

For the type of NPSs used, all the responses of "form unknown" fell under the category of "No response/unknown," and no test was therefore performed.

				Sex			
	Men		Wome	n	Total	l	
	n = 146	36	n = 161	10	n = 30'	76	P-value
	n	(%)	n	(%)	n	(%)	
Harmful effects of NPSs							0.532
Know	1,261	(86.0)	1,378	(85.6)	2,639	(85.8)	
Do not know	197	(13.4)	227	(14.1)	424	(13.8)	
No response/unknown	8	(.5)	5	(.3)	13	(.4)	
Japan's regulation for designate	ed substances	5					< 0.001
Know	907	(61.9)	842	(52.3)	1,749	(56.9)	
Do not know	553	(37.7)	763	(47.4)	1,316	(42.8)	
No response/unknown	6	(.4)	5	(.3)	11	(.4)	
The perceived number of NPS	users						< 0.001
Increasing	782	(53.3)	979	(60.8)	1,761	(57.2)	
Not changing	103	(7.0)	76	(4.7)	179	(5.8)	
Decreasing	28	(1.9)	5	(.3)	33	(1.1)	
Do not know	549	(37.4)	543	(33.7)	1,092	(35.5)	
No response/unknown	4	(.3)	7	(.4)	11	(.4)	
Experience of NPS use (lifetime	e)						0.137
Never used	1,434	(97.8)	1,588	(98.6)	3,022	(98.2)	
Have used	8	(.5)	3	(.2)	11	(.4)	
No response/unknown	24	(1.6)	19	(1.2)	43	(1.4)	
Experience of NPS use (within	the past year)					0.281
Never used	1,442	(98.4)	1,591	(98.8)	3,033	(98.6)	
Have used	0	(.0)	0	(.0)	0	(.0)	
No response/unknown	24	(1.6)	19	(1.2)	43	(1.4)	
Type of NPSs used							
Never used	1.359	(92.7)	1.522	(94.5)	2,881	(93.7)	0.054
Herbal	5	(.3)	3	(.2)	8	(.3)	0.157
Liquid	3	(.2)	1	(.1)	4	(.1)	0.123
Powder	5	(.3)	1	(.1)	6	(.2)	0.047
Other	0	(.0)	0	(.0)	0	(.0)	0.085
Form unknown	0	(.0)	0	(.0)	0	(.0)	-
No response/unknown	99	(6.8)	85	(5,3)	184	(6.0)	0.085
Hospital visit associated with N	PS use	(0.0)	00	(0.0)	101	(0.0)	0.000
None	10 400						
TIONE	1 418	(96.7)	1 571	(97.6)	2 989	(97.2)	
Have used an NPS but no ho	nsnital visit as	sociated wit	h NPS use	(01.0)	2,000	(01.2)	
	8	(5)	3	(2)	11	(4)	-
Used an NPS and was taken	to hospital by	v amhulance	2	(.2)	11	(1)	
	0	(0)	0	(0)	0	(0)	
Used an NPS and presented	to a psychiatr	ric denartme	ent	(.0)	0	(.0)	
osed an Wib and presented		(0)	0	(0)	0	(0)	-
Used an NPS and presented	to a dopartm	(.0)	o nal modicinc	(.0)	0	(.0)	
Used an Wi b and presented				(0)	0	(0)	-
Used on NPS and presented	to o troumo d	(.0)	0	(.0)	0	(.0)	
oseu an mi o anu presenteu	n a trauma c	(n)	0	(0)	0	(0)	-
Used on NPS and presented	to any other	(.0)	0	(.0)	0	(.0)	
oseu an mi o anu presenteu	n any other	(n)	0	(0)	0	(0)	-
Have used on NDC but Lister	U www.of.hcomit-1	(.U)	U	(.0)	0	(.0)	-
mave used all INFO Dut HIStol	ry or nospital		0	(0)	0	(0)	-
No rosponso/unknown	U	(.0)	U	(.0)	0	(.0)	
THE TESPOILSE/UTIKITOWIT	40	(9.7)	36	(2.2)	76	(2.5)	-
	40	(4.1)	00	(4.4)	10	(4.0)	

Table 43. NPS Use and Other Related Items by Sex (n = 3076) $\,$

For the type of NPSs used, all the responses of "form unknown" fell under the category of "No

response/unknown," and no test was therefore performed.

Table 44	NPS Use	and Other	Related	Items by	Age	group(n=3076)
----------	---------	-----------	---------	----------	-----	---------------

	Age group														
_	1	0s	2	0s	3	0s	4	0s	5	0s	6	0s	Tot	al	
	n=	222	n=	382	n=	553	n=	751	n=	695	n=	473	n=30	076	p-value
	n	(%)	n	(%)	n	(%)	n	(%)	n	(%)	n	(%)	n	(%)	
Harmful effects of NPSs															0.898
Know	189	(85.1)	334	(87.4)	471	(85.2)	650	(86.6)	599	(86.2)	396	(83.7)	2,639	(85.8)	
Do not know	33	(14.9)	47	(12.3)	79	(14.3)	97	(12.9)	93	(13.4)	75	(15.9)	424	(13.8)	
No response/unknown	0	(.0)	1	(.3)	3	(.5)	4	(.5)	3	(.4)	2	(.4)	13	(.4)	
Japan's regulation for desi	gnated	l substai	nces												0.058
Know	109	(49.1)	203	(53.1)	301	(54.4)	427	(56.9)	413	(59.4)	296	(62.6)	1,749	(56.9)	
Do not know	112	(50.5)	178	(46.6)	250	(45.2)	322	(42.9)	279	(40.1)	175	(37.0)	1,316	(42.8)	
No response/unknown	1	(.5)	1	(.3)	2	(.4)	2	(.3)	3	(.4)	2	(.4)	11	(.4)	
The perceived number of N	NPS us	sers													< 0.001
Increasing	87	(39.2)	187	(49.0)	314	(56.8)	457	(60.9)	427	(61.4)	289	(61.1)	1,761	(57.2)	
Not changing	12	(5.4)	36	(9.4)	34	(6.1)	39	(5.2)	38	(5.5)	20	(4.2)	179	(5.8)	
Decreasing	4	(1.8)	5	(1.3)	6	(1.1)	10	(1.3)	5	(.7)	3	(.6)	33	(1.1)	
Do not know	119	(53.6)	154	(40.3)	195	(35.3)	243	(32.4)	221	(31.8)	160	(33.8)	1,092	(35.5)	
No response/unknown	0	(.0)	0	(.0)	4	(.7)	2	(.3)	4	(.6)	1	(.2)	11	(.4)	
Experience of NPS use (life	etime)														0.455
Never used	219	(98.6)	375	(98.2)	544	(98.4)	741	(98.7)	681	(98.0)	462	(97.7)	3,022	(98.2)	
Have used	0	(.0)	2	(.5)	4	(.7)	2	(.3)	3	(.4)	0	(.0)	11	(.4)	
No response/unknown	3	(1.4)	5	(1.3)	5	(.9)	8	(1.1)	11	(1.6)	11	(2.3)	43	(1.4)	
Experience of NPS use (wi	ithin tl	ne past v	ear)												0.449
Never used	219	(98.6)	377	(98.7)	548	(99.1)	743	(98.9)	684	(98.4)	462	(97.7)	3.033	(98.6)	
Have used	0	(.0)	0	(.0)	0	(.0)	0	(.0)	0	(.0)	0	(.0)	0	(.0)	
No response/unknown	3	(1.4)	5	(1.3)	5	(.9)	8	(1.1)	11	(1.6)	11	(2.3)	43	(1.4)	
Type of NPSs used		,		,				,		,		,		,	
Never used	211	(95.0)	362	(94.8)	509	(92.0)	700	(93.2)	654	(94.1)	445	(94.1)	2.881	(93.7)	0.535
Herbal	0	(.0)	2	(.5)	4	(.7)	1	(.1)	1	(.1)	0	(.0)	8	(.3)	0.281
Liquid	0	(.0)	0	(.0)	1	(.2)	2	(.3)	1	(.1)	0	(.0)	4	(.1)	0.780
Powder	0	(.0)	0	(.0)	2	(.4)	2	(.3)	2	(.3)	0	(.0)	6	(.2)	0.704
Other	0	(.0)	0	(.0)	0	(.0)	0	(.0)	0	(.0)	0	(.0)	0	(.0)	0.582
Form unknown	0	(.0)	0	(.0)	0	(.0)	0	(.0)	0	(.0)	0	(.0)	0	(.0)	
No response/unknown	11	(5.0)	18	(47)	40	(7.2)	49	(6.5)	38	(5.5)	28	(5.9)	184	(6.0)	0.582
Hospital visit associated wi	th NP	S use	10	(111)	10	()	10	(0.0)	00	(0.0)	-0	(0.0)	101	(0.0)	0.002
None		o ube													
Hone	216	(97.3)	378	(99.0)	529	(95.7)	735	(97.9)	672	(96 7)	459	(97.0)	2 989	(97.2)	-
Have used an NPS but i	no hos	nital visi	t assor	iated wi	th NP	S 1190	100	(01.0)	012	(00.1)	100	(01.0)	2,000	(01.2)	
Have used an IVI 5 but I	0	(0)	<i>v</i> assoc	(5)	A	(7)	9	(3)	3	(4)	0	(0)	11	(4)	-
Used an NPS and was to	akon t	o hosnit	ul hv a	(.0) mbulanc	T O	(.1)	2	(.0)	0	(1)	0	(.0)	11	()	
		()	11 Dy a. 0		0	(0)	0	(0)	0	(0)	0	(0)	0	(0)	-
Used on NPS and press	ntod to	(.0)	viotrio	(.0)	ont	(.0)	0	(.0)	0	(.0)	0	(.0)	0	(.0)	
Oseu all IVI D allu prese	0		0	(0)	0	(0)	0	(0)	0	(0)	0	(0)	0	(0)	_
Used on NDS and mean	ntod t	()	tmont	(.0)	un al ma	(.0)	0	(.0)	0	(.0)	0	(.0)	0	(.0)	
Used an NFS and prese	nteu u		o n		mai me		0	(0)	0	(0)	0	(0)	0	(0)	_
Used on NDC on damage		(.0)	0	(.0)	0	(.0)	0	(.0)	0	(.0)	0	(.0)	0	(.0)	
Used an NPS and prese	nted u	a traui	na dep	(o)	, 0	(0)	0	(0)	0	(0)	0	(0)	0	(0)	
Used on NDC on damage	U 	(.0)	0	(.0)	1	(.0)	0	(.0)	0	(.0)	0	(.0)	0	(.0)	
Used an NPS and prese	ntea ta		ier aej	partmen	ι Ω	(α)	0	()	0	()	0	()	0	(0)	
Horro mand on MDG 1 + 1	U	(.U)	U	(.0)	0	(.0)	U	(.0)	0	(.0)	0	(.0)	0	(.0)	-
nave used an NPS but I	nistory	or nosp	icai vis	(o)	nown	(α)	0	(α)	0	(α)	0	()	0	(0)	
No momente tradicio	0	(.0)	0	(.0)	0	(.0)	U	(.0)	0	(.0)	0	(.0)	0	(.0)	-
ivo response/unknown	0	(0.7)	0	(-)	00	(0, 0)	1.4	(1,0)	00	(0,0)	14	(0,0)	70	(0 F)	
	6	(2.7)	Z	(.5)	20	(3.6)	14	(1.9)	20	(2.9)	14	(3.0)	76	(2.5)	-

"10s" refers to those aged 15 to 19, and "60s" refers to those aged 60 to 64.

For the type of NPSs used, all the responses of "form unknown" fell under the category of "No response/unknown," and no test was therefore performed.

					Occup	ation								
	Self-em	ployed	Full-	time	Non-fu	ll-time	Stud	lent	House	ewife				
	n=2	248	n=1-	406	n=3	94	n=2	71	n=4	36				
	n	(%)	n	(%)	n	(%)	n	(%)	n	(%)				
Harmful effects of NPSs														
Know	216	(87.1)	1,228	(87.3)	333	(84.5)	239	(88.2)	373	(85.6)				
Do not know	32	(12.9)	171	(12.2)	59	(15.0)	32	(11.8)	61	(14.0)				
No response/unknown	0	(.0)	7	(.5)	2	(.5)	0	(.0)	2	(.5)				
Japan's regulation for design	nated sub	stances												
Know	165	(66.5)	822	(58.5)	217	(55.1)	127	(46.9)	244	(56.0)				
Do not know	83	(33.5)	579	(41.2)	174	(44.2)	142	(52.4)	192	(44.0)				
No response/unknown	0	(.0)	5	(.4)	3	(.8)	2	(.7)	0	(.0)				
The perceived number of N	PS users													
Increasing	151	(60.9)	795	(56.5)	242	(61.4)	111	(41.0)	280	(64.2)				
Not changing	15	(6.0)	90	(6.4)	19	(4.8)	21	(7.7)	16	(3.7)				
Decreasing	3	(1.2)	18	(1.3)	2	(.5)	5	(1.8)	2	(.5)				
Do not know	78	(31.5)	495	(35.2)	130	(33.0)	134	(49.4)	138	(31.7)				
No response/unknown	1	(.4)	8	(.6)	1	(.3)	0	(.0)	0	(.0)				
Experience of NPS use (life	time)													
Never used	243	(98.0)	1,381	(98.2)	390	(99.0)	269	(99.3)	426	(97.7)				
Have used	1	(.4)	7	(.5)	1	(.3)	0	(.0)	1	(.2)				
No response/unknown	4	(1.6)	18	(1.3)	3	(.8)	2	(.7)	9	(2.1)				
Experience of NPS use (with	hin the pa	st year)												
Never used	244	(98.4)	1,388	(98.7)	391	(99.2)	269	(99.3)	427	(97.9)				
Have used	0	(.0)	0	(.0)	0	(.0)	0	(.0)	0	(.0)				
No response/unknown	4	(1.6)	18	(1.3)	3	(.8)	2	(.7)	9	(2.1)				
Type of NPSs used														
Never used	226	(91.1)	1,320	(93.9)	371	(94.2)	258	(95.2)	408	(93.6)				
Herbal	0	(.0)	5	(.4)	1	(.3)	0	(.0)	1	(.2)				
Liquid	0	(.0)	4	(.3)	0	(.0)	0	(.0)	0	(.0)				
Powder	1	(.4)	5	(.4)	0	(.0)	0	(.0)	0	(.0)				
Other	0	(.0)	0	(.0)	0	(.0)	0	(.0)	0	(.0)				
Form unknown	0	(.0)	0	(.0)	0	(.0)	0	(.0)	0	(.0)				
No response/unknown	21	(8.5)	79	(5.6)	22	(5.6)	13	(4.8)	27	(6.2)				
Hospital visit associated with	n NPS use	:												
None														
	237	(95.6)	1.368	(97.3)	382	(97.0)	265	(97.8)	425	(97.5)				
Have used an NPS but no	hospital	visit asso	ociated v	vith NP	S use	(0.1.0)		(0.110)		(0)				
	1	(.4)	7	(.5)	1	(.3)	0	(.0)	1	(.2)				
Used an NPS and was tal	ren to hos	mital hv	amhulai	100	Ť	(.0)	0	(.0)	1	(
	0	(0)	0	(0)	0	(0)	0	(0)	0	(0)				
Used an NPS and present	ted to a ne	vchiatri	r denart	ment	0	(.0)	0	(.0)	0	(.0)				
e sou un 111 e una presen	0 נוסט נוסט גרביים 0	(0)	0	(0)	0	(0)	0	(0)	0	(0)				
Used an NPS and present	ted to a de	nartmei	nt of int	ernal m	edicine	(.0)	0	(.0)	0	(.0)				
Oseu an IVI o anu presen	0	(0)	0	(0)	0	(0)	0	(0)	0	(0)				
Used an NPS and present	ted to a tr	() ob emue	nartmei	(.0)	0	(.0)	0	(.0)	0	(.0)				
Oseu an IVI o anu presen	0	(())	0	(0)	0	(0)	0	(0)	0	(0)				
Used an NPS and present	tod to any	(.0)	oportmo	(.0)	0	(.0)	0	(.0)	0	(.0)				
Oseu an Ni 5 anu presen				(())	0	(0)	0	(0)	0	(0)				
Have used on NPS but hi	story of h	(.0)	u ieit ie ur	(.U)	0	(.0)	0	(.0)	0	(.0)				
maye used an INI B but III		(N)	15 UI. N	(U)	0	(0)	Ο	(0)	Ο	(0)				
No response/unknown	0	(.0)	0	(.0)	0	(.0)	0	(.0)	0	(.0)				
	10	(4 0)	31	(2, 2)	11	(2.8)	6	(2.2)	10	(2, 3)				
	10	(1.0)	01	(/	* *		0	·-·-/	10	\ <u>_</u> .0/				

Table 45. NPS Use and Other Related Items by Occupation (n=3076)

For the type of NPSs used, all the responses of "form unknown" fell under the category of "No response/unknown," and no test was therefore performed.

	Itelatea		occupat		Occupation	1			
	Unemi	ployed	Oth	er	Unkno	wn	Tot	al	
	enem	510900	0 11	.01	Chinic		100	, ar	
	n=1	79	n=1	38	n=4	Ļ	n=30	076	p-value
	n	(%)	n	(%)	n	(%)	n	(%)	-
Harmful effects of NPSs									0.007
Know	137	(76.5)	109	(79.0)	4	(100.0)	2,639	(85.8)	
Do not know	42	(23.5)	27	(19.6)	0	(.0)	424	(13.8)	
No response/unknown	0	(.0)	2	(1.4)	0	(.0)	13	(.4)	
Japan's regulation for designation	ated substa	ances							0.003
Know	97	(54.2)	73	(52.9)	4	(100.0)	1,749	(56.9)	
Do not know	82	(45.8)	64	(46.4)	0	(.0)	1,316	(42.8)	
No response/unknown	0	(.0)	1	(.7)	0	(.0)	11	(.4)	
The perceived number of NPS	Susers								0.002
Increasing	100	(55.9)	79	(57.2)	3	(75.0)	1,761	(57.2)	
Not changing	10	(5.6)	8	(5.8)	0	(.0)	179	(5.8)	
Decreasing	2	(1.1)	1	(.7)	0	(.0)	33	(1.1)	
Do not know	66	(36.9)	50	(36.2)	1	(25.0)	1,092	(35.5)	
No response/unknown	1	(.6)	0	(.0)	0	(.0)	11	(.4)	
Experience of NPS use (lifeting	ne)								0.809
Never used	176	(98.3)	133	(96.4)	4	(100.0)	3,022	(98.2)	
Have used	0	(.0)	1	(.7)	0	(.0)	11	(.4)	
No response/unknown	3	(1.7)	4	(2.9)	0	(.0)	43	(1.4)	
Experience of NPS use (withi	n the past	year)							0.533
Never used	176	(98.3)	134	(97.1)	4	(100.0)	3,033	(98.6)	
Have used	0	(.0)	0	(.0)	0	(.0)	0	(.0)	
No response/unknown	3	(1.7)	4	(2.9)	0	(.0)	43	(1.4)	
Type of NPSs used									
Never used	165	(92.2)	130	(94.2)	3	(75.0)	2,881	(93.7)	0.688
Herbal	0	(.0)	1	(.7)	0	(.0)	8	(.3)	0.674
Liquid	0	(.0)	0	(.0)	0	(.0)	4	(.1)	0.570
Powder	0	(.0)	0	(.0)	0	(.0)	6	(.2)	0.531
Other	0	(.0)	0	(.0)	0	(.0)	0	(.0)	0.357
Form unknown	0	(.0)	0	(.0)	0	(.0)	0	(.0)	-
No response/unknown	14	(7.8)	7	(5.1)	1	(25.0)	184	(6.0)	0.357
Hospital visit associated with	NPS use								
None									
	175	(97.8)	134	(97.1)	3	(75.0)	2,989	(97.2)	-
Have used an NPS but no I	hospital vi	sit associ	ated wit	h NPS	use				
	0	(.0)	1	(.7)	0	(.0)	11	(.4)	-
Used an NPS and was take	en to hospi	tal by an	nbulanc	е					
	0	(.0)	0	(.0)	0	(.0)	0	(.0)	-
Used an NPS and presente	d to a psyc	ehiatric d	epartm	ent					
	0	(.0)	0	(.0)	0	(.0)	0	(.0)	-
Used an NPS and presente	d to a depa	artment	of inter	nal med	icine				
	0	(.0)	0	(.0)	0	(.0)	0	(.0)	-
Used an NPS and presente	d to a trau	ıma depa	rtment						
	0	(.0)	0	(.0)	0	(.0)	0	(.0)	-
Used an NPS and presente	d to any o	ther depa	artment	5					
	0	(.0)	0	(.0)	0	(.0)	0	(.0)	-
Have used an NPS but hist	ory of hos	pital visit	t is unk	nown					
	0	(.0)	0	(.0)	0	(.0)	0	(.0)	-
No response/unknown									
	4	(2.2)	3	(2.2)	1	(25.0)	76	(2.5)	-

Table 45. NPS Use and Other Related Items by Occupation (n=3076) continued

For the type of NPSs used, all the responses of "form unknown" fell under the category of "No response/unknown," and no test was therefore performed.

Table 46.	NPS Use	e and Other	Related 1	ltems by	Drug u	use experience	(n=3076)
-----------	---------	-------------	-----------	----------	--------	----------------	----------

	Drug use experience								
	Lifet	ime	No life	etime	Unkn	own	Tot	al	
	n=7	78	n=2	940	n=	58	n=30	076	p-value
	n	(%)	n	(%)	n	(%)	n	(%)	
Harmful effects of NPSs									0.005
Know	67	(85.9)	2,527	(86.0)	45	(77.6)	2,639	(85.8)	
Do not know	11	(14.1)	402	(13.7)	11	(19.0)	424	(13.8)	
No response/unknow	0	(.0)	11	(.4)	2	(3.4)	13	(.4)	
Japan's regulation for des	ignate	d substa	nces						0.246
Know	48	(61.5)	1,673	(56.9)	28	(48.3)	1,749	(56.9)	
Do not know	30	(38.5)	1,257	(42.8)	29	(50.0)	1,316	(42.8)	
No response/unknow	0	(.0)	10	(.3)	1	(1.7)	11	(.4)	
The perceived number of	NPS u	sers							0.009
Increasing	41	(52.6)	1,693	(57.6)	27	(46.6)	1,761	(57.2)	
Not changing	12	(15.4)	164	(5.6)	3	(5.2)	179	(5.8)	
Decreasing	1	(1.3)	32	(1.1)	0	(.0)	33	(1.1)	
Do not know	23	(29.5)	1,041	(35.4)	28	(48.3)	1,092	(35.5)	
No response/unknow	1	(1.3)	10	(.3)	0	(.0)	11	(.4)	
Experience of NPS use (li	fetime)							< 0.001
Never used	67	(85.9)	2,940	(100.0)	15	(25.9)	3,022	(98.2)	
Have used	11	(14.1)	0	(.0)	0	(.0)	11	(.4)	
No response/unknow	0	(.0)	0	(.0)	43	(74.1)	43	(1.4)	
Experience of NPS use (w	vithin t	he past	year)						< 0.001
Never used	78	(100.0)	2,940	(100.0)	15	(25.9)	3,033	(98.6)	
Have used	0	(.0)	0	(.0)	0	(.0)	0	(.0)	
No response/unknow	0	(.0)	0	(.0)	43	(74.1)	43	(1.4)	
Type of NPSs used									
Never used	62	(79.5)	2,780	(94.6)	39	(67.2)	2,881	(93.7)	< 0.001
Herbal	8	(10.3)	0	(.0)	0	(.0)	8	(.3)	< 0.001
Liquid	4	(5.1)	0	(.0)	0	(.0)	4	(.1)	< 0.001
Powder	6	(7.7)	0	(.0)	0	(.0)	6	(.2)	< 0.001
Other	0	(.0)	0	(.0)	0	(.0)	0	(.0)	< 0.001
Form unknown	0	(.0)	0	(.0)	0	(.0)	0	(.0)	-
No response/unknow	5	(6.4)	160	(5.4)	19	(32.8)	184	(6.0)	< 0.001
Hospital visit associated w	ith NP	S use							
None									
	63	(80.8)	2,881	(98.0)	45	(77.6)	2,989	(97.2)	-
Have used an NPS but	no hos	pital vis	it assoc	iated wit	h NPS u	se			
	11	(14.1)	0	(.0)	0	(.0)	11	(.4)	-
Used an NPS and was	taken t	o hospit	al by an	nbulance	è.				
	0	(.0)	0	(.0)	0	(.0)	0	(.0)	-
Used an NPS and prese	ented t	o a psyc	hiatric d	departme	ent				
-	0	(.0)	0	(.0)	0	(.0)	0	(.0)	-
Used an NPS and prese	ented t	o a depa	rtment	of interr	nal medi	cine			
	0	(.0)	0	(.0)	0	(.0)	0	(.0)	-
Used an NPS and prese	ented t	o a trau	ma depa	artment					
F	0	(.0)	0	(.0)	0	(.0)	0	(.0)	-
Used an NPS and prese	ented t	o any ot	her dep	artment					
	0	(.0)	0	(.0)	0	(.0)	0	(.0)	-
Have used an NPS but	history	y of hos	oital visi	it is unkr	nown				
	0	(.0)	0	(.0)	0	(.0)	0	(.0)	-
No response/unknown									
	4	(5.1)	59	(2.0)	13	(22.4)	76	(2.5)	-

For the type of NPSs used, all the responses of "form unknown" fell under the category of "No response/unknown," and no test was therefore performed.

_	Residence area											
_	Hokk	aido	Toho	oku	Kar	nto	Hoku	riku	Tous	san	Tok	ai
	n=1	31	n=2	50	n=9	48	n=1	54	n=1	50	n=3	28
	n	(%)	n	(%)	n	(%)	n	(%)	n	(%)	n	(%)
Close drug users (any drug)												
Absent	116	(88.5)	234	(93.6)	875	(92.3)	138	(89.6)	138	(92.0)	300	(91.5)
Present	11	(8.4)	12	(4.8)	56	(5.9)	9	(5.8)	7	(4.7)	25	(7.6)
Close drug users (organic sol	vents)											
Absent	124	(94.7)	236	(94.4)	890	(93.9)	142	(92.2)	141	(94.0)	306	(93.3)
Present	4	(3.1)	11	(4.4)	44	(4.6)	8	(5.2)	4	(2.7)	21	(6.4)
Close drug users (cannabis)												
Absent	119	(90.8)	240	(96.0)	909	(95.9)	145	(94.2)	139	(92.7)	313	(95.4)
Present	8	(6.1)	7	(2.8)	22	(2.3)	4	(2.6)	5	(3.3)	11	(3.4)
Close drug users (methamph	etamin	e)										
Absent	122	(93.1)	240	(96.0)	915	(96.5)	146	(94.8)	138	(92.0)	314	(95.7)
Present	5	(3.8)	6	(2.4)	19	(2.0)	3	(1.9)	5	(3.3)	11	(3.4)
Close drug users (MDMA)												
Absent	123	(93.9)	245	(98.0)	930	(98.1)	148	(96.1)	140	(93.3)	316	(96.3)
Present	4	(3.1)	3	(1.2)	8	(.8)	2	(1.3)	4	(2.7)	8	(2.4)
Close drug users (cocaine)												
Absent	126	(96.2)	241	(96.4)	923	(97.4)	148	(96.1)	139	(92.7)	318	(97.0)
Present	1	(.8)	4	(1.6)	8	(.8)	1	(.6)	4	(2.7)	6	(1.8)
Close drug users (heroin)												
Absent	126	(96.2)	242	(96.8)	921	(97.2)	147	(95.5)	139	(92.7)	319	(97.3)
Present	1	(.8)	3	(1.2)	9	(.9)	1	(.6)	4	(2.7)	5	(1.5)
Close drug users (NPSs)												
Absent	126	(96.2)	240	(96.0)	925	(97.6)	147	(95.5)	140	(93.3)	319	(97.3)
Present	3	(2.3)	5	(2.0)	13	(1.4)	1	(.6)	4	(2.7)	6	(1.8)
Experience of ever having tr	y to ten	npt illegal	drugs	(any dru	g)							
No	118	(90.1)	236	(94.4)	884	(93.2)	148	(96.1)	141	(94.0)	300	(91.5)
Yes	10	(7.6)	10	(4.0)	52	(5.5)	4	(2.6)	4	(2.7)	18	(5.5)
Experience of ever having tr	y to ten	npt illegal	drugs(organic s	solvents	s)						
No	126	(96.2)	242	(96.8)	915	(96.5)	148	(96.1)	145	(96.7)	309	(94.2)
Yes	4	(3.1)	6	(2.4)	29	(3.1)	4	(2.6)	2	(1.3)	14	(4.3)
Experience of ever having tr	y to ten	npt illegal	drugs	(cannabi	s)							
No	125	(95.4)	242	(96.8)	910	(96.0)	152	(98.7)	143		316	(96.3)
Yes	5	(3.8)	6	(2.4)	29	(3.1)	0	(.0)	3	(2.0)	6	(1.8)
Experience of ever having tr	y to ten	npt illegal	drugs	(metham	phetan	nine)						
No	128	(97.7)	247	(98.8)	927	(97.8)	152	(98.7)	145	(96.7)	317	(96.6)
Yes	2	(1.5)	1	(.4)	13	(1.4)	0	(.0)	2	(1.3)	5	(1.5)
Experience of ever having tr	y to ten	npt illegal	drugs	(MDMA)								
No	126	(96.2)	246	(98.4)	932	(98.3)	152	(98.7)	145	(96.7)	319	(97.3)
Yes	3	(2.3)	2	(.8)	7	(.7)	0	(.0)	0	(.0)	2	(.6)
Experience of ever having tr	y to ten	npt illegal	drugs	(cocaine)								
No	128	(97.7)	248	(99.2)	933	(98.4)	152	(98.7)	145	(96.7)	321	(97.9)
Yes	1	(.8)	0	(.0)	5	(.5)	0	(.0)	0	(.0)	0	(.0)
Experience of ever having tr	y to ten	npt illegal	drugs	(heroin)								
No	128	(97.7)	248	(99.2)	934	(98.5)	152	(98.7)	145	(96.7)	322	(98.2)
Yes	0	(.0)	0	(.0)	4	(.4)	0	(.0)	0	(.0)	0	(.0)
Experience of ever having tr	y to ten	npt illegal	drugs	(NPSs)								
No	125	(95.4)	245	(98.0)	931	(98.2)	152	(98.7)	145	(96.7)	320	(97.6)
Yes	4	(3.1)	1	(.4)	7	(.7)	0	(.0)	0	(.0)	0	(.0)

	Residence area												
	Ki	nki	Chu	goku	Sh	ikoku	Kita-K	Kyusyu	Min	ami-	Tot	al	
	n=	442	n=	191	n	=88	n=	229	n=	165	n=30	076	p-value
	n	(%)	n	(%)	n	(%)	n	(%)	n	(%)	n	(%)	
Close drug users (any drug)													0.189
Absent	409	(92.5)	174	(91.1)	77	(87.5)	218	(95.2)	154	(93.3)	2,833	(92.1)	
Present	24	(5.4)	15	(7.9)	10	(11.4)	9	(3.9)	7	(4.2)	185	(6.0)	
Close drug users (organic sol	vents)												0.184
Absent	425	(96.2)	177	(92.7)	79	(89.8)	219	(95.6)	157	(95.2)	2,896	(94.1)	
Present	13	(2.9)	12	(6.3)	8	(9.1)	7	(3.1)	5	(3.0)	137	(4.5)	
Close drug users (cannabis)													0.561
Absent	423	(95.7)	181	(94.8)	85	(96.6)	223	(97.4)	157	(95.2)	2,934	(95.4)	
Present	13	(2.9)	6	(3.1)	2	(2.3)	4	(1.7)	4	(2.4)	86	(2.8)	
Close drug users (methamph	etamin	le)											0.312
Absent	425	(96.2)	180	(94.2)	82	(93.2)	222	(96.9)	158	(95.8)	2.942	(95.6)	
Present	10	(2.3)	7	(3.7)	5	(5.7)	5	(2.2)	3	(1.8)	79	(2.6)	
Close drug users (MDMA)		(,		(011)		(011)		(/		(210)		(,	0 193
Absent	432	(97.7)	184	(96.3)	85	(96-6)	224	(97.8)	161	(97.6)	2,988	(97.1)	0.100
Present	3	(7)	4	(2.1)	2	(2.3)	221	(9)	2	(12)	2,000 42	(1 4)	
Close drug users (cocaine)	0	()	1	(2.1)	-	(2.0)	-	(.0)	-	(1.2)	12	(1.1)	0.358
Absent	432	(97.7)	182	(95.3)	86	(97.7)	225	(98.3)	159	(96.4)	2 979	(96.8)	0.000
Present	-102	(01.1)	5	(2.6)	1	(11)	1	(30.5)	2	(12)	2,010	(1.2)	
Close drug users (heroin)	0	()	0	(2.0)	1	(1.1)	1	(1)	-	(1.2)	50	(1.2)	0.411
Absont	439	(97.7)	189	(95.3)	86	(97.7)	994	(97.8)	160	(97.0)	2 978	(96.8)	0.411
Present	402	(31.1)	5	(30.0)	1	(31.1)	224 9	(91.0)	100	(6)	2,510	(11)	
Class drug usons (NPSs)	J	(.7)	0	(2.0)	1	(1.1)	4	(.3)	1	(.0)	55	(1.1)	0.008
Absont	133	(98.0)	180	(94.9)	87	(08.0)	995	(08.3)	161	(97.6)	2 083	(97.0)	0.050
Present	400	(30.0)	100	(94.2)	07	(30.3)	220 9	(98.3)	101	(97.0)	2,365	(37.0)	
Fresent	0 to to m	(1.1)	0 L dansa	(0.1) a (anu d	1	(1.1)	2	(.9)	1	(.0)	47	(1.5)	0.154
Experience of ever naving tr	y to ter	(04.1)	1 00 100	$(0\pi 2)$	rug)	(05.5)	001	(0C F)	155	(02,0)	0.005	(02.9)	0.104
NO	410	(94.1)	102	(90.0)	04	(90.0)	221	(90.0)	100	(93.9)	2,000	(93.0)	
Tes	14 	(0.2)	o I dana	(2.0)	4	(4.0)	4	(1.1)	0	(5.0)	191	(4.3)	0.910
Experience of ever naving tr	y to ter	(oc a)	1 00 100	s (organ		(OF F)	000	(000)	100	(07.0)	9.004	(0, 0, 1)	0.510
INO Xaa	420	(96.2)	100	(98.4)	84	(95.5)	222	(96.9)	160	(97.0)	2,964	(96.4)	
res	0	(1.8)	2 1 J	(1.0)	4	(4.3)	4	(1.1)	4	(2.4)	81	(2.6)	0.970
Experience of ever naving tr	y to ten	(oc a)	1 urug	(07.0)	101S)	(02.0)	004	(07.9)	1.01		9.079	(0, c, c)	0.579
INO Xaa	420	(96.2)	107	(97.9)	01	(98.9)	224	(97.8)	101	(1 0)	2,972	(96.6)	
res	0	(1.8)	2 1 J	(1.0)	1 1-	(1.1)	2	(.9)	2	(1.2)	64	(2.1)	0 777
Experience of ever naving tr	y to ter	npt mega	u arug	s (meth	ampn	(op o)) 00 7	(00.9)	100	(00.0)	9,000	(07.0)	0.777
INO	431	(97.5)	187	(97.9)	87	(98.9)	225	(98.3)	162	(98.2)	3,008	(97.8)	
res	Z	(.5)	2	(1.0)	1	(1.1)	1	(.4)	Z	(1.2)	31	(1.0)	0.991
Experience of ever having tr	y to ter	npt mega	u arug		A)	(00,0)	004	(07.0)	1.01	$(0 \pi a)$	0.010	$(0, \overline{0}, 0)$	0.321
No	431	(97.5)	189	(99.0)	87	(98.9)	224	(97.8)	161	(97.6)	3,012	(97.9)	
Yes	1	(.2)	0	(.0)	1	(1.1)	2	(.9)	2	(1.2)	20	(.7)	0.445
Experience of ever having tr	y to ter	npt illega	ul drug	s (cocair	ie)					(0 = 0)			0.447
No	431	(97.5)	188	(98.4)	88	(100.0)	225	(98.3)	161	(97.6)	3,020	(98.2)	
Yes	0	(.0)	1	(.5)	0	(.0)	1	(.4)	0	(.0)	8	(.3)	
Experience of ever having tr	y to ter	npt illega	ıl drug	s (heroi	n)	<i>,</i> ,							0.625
No	432	(97.7)	188	(98.4)	88	(100.0)	225	(98.3)	162	(98.2)	3,024	(98.3)	
Yes	0	(.0)	1	(.5)	0	(.0)	1	(.4)	0	(.0)	6	(.2)	
Experience of ever having tr	y to ter	npt illega	ul drug	s (NPSs)	(`		(c = c)			o -	()	0.067
No	432	(97.7)	186	(97.4)	88	(100.0)	224	(97.8)	162	(98.2)	3,010	(97.9)	
Yes	1	(.2)	1	(.5)	0	(.0)	1	(.4)	1	(.6)	16	(.5)	

Table 47. Presence of Close Drug Users and Experience of Ever Having Try to Tempt Illegal Drugs by Residence area (n=3076) continued

	Sex						
=	Me	n	Wome	en	Tota	1	
	n = 14	466	n = 16	510	n = 30	76	P-value
	n	(%)	n	(%)	n	(%)	
Close drug users (any drug)							0.003
Absent	1,331	(90.8)	1,502	(93.3)	2,833	(92.1)	
Present	110	(7.5)	75	(4.7)	185	(6.0)	
Close drug users (organic solv	ents)						0.005
Absent	1,366	(93.2)	1,530	(95.0)	2,896	(94.1)	
Present	83	(5.7)	54	(3.4)	137	(4.5)	
Close drug users (cannabis)							0.004
Absent	1,386	(94.5)	1,548	(96.1)	2,934	(95.4)	
Present	56	(3.8)	30	(1.9)	86	(2.8)	
Close drug users (methamphe	tamine)						0.297
Absent	1,398	(95.4)	1,544	(95.9)	2,942	(95.6)	
Present	44	(3.0)	35	(2.2)	79	(2.6)	
Close drug users (MDMA)							0.089
Absent	1,416	(96.6)	1,572	(97.6)	2,988	(97.1)	
Present	27	(1.8)	15	(.9)	42	(1.4)	
Close drug users (cocaine)							0.069
Absent	1,414	(96.5)	1,565	(97.2)	2,979	(96.8)	
Present	24	(1.6)	12	(.7)	36	(1.2)	
Close drug users (heroin)							0.194
Absent	1,414	(96.5)	1,564	(97.1)	2,978	(96.8)	
Present	22	(1.5)	13	(.8)	35	(1.1)	
Close drug users (NPSs)							0.033
Absent	1,411	(96.2)	1,572	(97.6)	2,983	(97.0)	
Present	31	(2.1)	16	(1.0)	47	(1.5)	
Experience of ever having try	to tempt il	legal drugs	(any drug)			0.006
No	1,356	(92.5)	1,529	(95.0)	2,885	(93.8)	
Yes	80	(5.5)	51	(3.2)	131	(4.3)	
Experience of ever having try	to tempt il	legal drugs	(organic s	olvents)			0.005
No	1,397	(95.3)	1,567	(97.3)	2,964	(96.4)	
Yes	53	(3.6)	28	(1.7)	81	(2.6)	
Experience of ever having try	to tempt il	legal drugs	(cannabis)			0.005
No	1,402	(95.6)	1,570	(97.5)	2,972	(96.6)	
Yes	43	(2.9)	21	(1.3)	64	(2.1)	
Experience of ever having try	to tempt il	legal drugs	(metham)	ohetamine))		0.107
No	1,425	(97.2)	1,583	(98.3)	3,008	(97.8)	
Yes	19	(1.3)	12	(.7)	31	(1.0)	
Experience of ever having try	to tempt il	legal drugs	(MDMA)				0.252
No	1,429	(97.5)	1,583	(98.3)	3,012	(97.9)	
Yes	12	(.8)	8	(.5)	20	(.7)	
Experience of ever having try	to tempt il	legal drugs	(cocaine)				0.144
No	1,433	(97.7)	1,587	(98.6)	3,020	(98.2)	
Yes	6	(.4)	2	(.1)	8	(.3)	
Experience of ever having try	to tempt il	legal drugs	(heroin)				0.068
No	1,434	(97.8)	1,590	(98.8)	3,024	(98.3)	
Yes	5	(.3)	1	(.1)	6	(.2)	
Experience of ever having try	to tempt il	legal drugs	(NPSs)				0.634
No	1,432	(97.7)	1,578	(98.0)	3,010	(97.9)	
Yes	7	(.5)	9	(.6)	16	(.5)	

Table 48.	Presence of	Close Drug	Users and	l Experience	of Ever	Having '	Try to	Tempt Illega	al Drugs
by Sex (n	1 = 3076)								

— 83 —

Table 49. Presence of Close Drug Users and Experience of Ever Having Try to Tempt Illegal Drugs by Age group(n=3076)

_	Age group														
-	1	0s	2	0s	3	0s	4	0s	5	0s	6	0s	Tot	al	
	n=	222	n=	382	n=	553	n=	751	n=	695	n=	473	n=30	076	p-value
	n	(%)	n	(%)	n	(%)	n	(%)	n	(%)	n	(%)	n	(%)	
Close drug users (any	drug)														< 0.001
Absent	212	(95.5)	350	(91.6)	497	(89.9)	695	(92.5)	649	(93.4)	430	(90.9)	2,833	(92.1)	
Present	7	(3.2)	25	(6.5)	50	(9.0)	49	(6.5)	29	(4.2)	25	(5.3)	185	(6.0)	
Close drug users (orga	nic sol	vents)													0.017
Absent	213	(95.9)	362	(94.8)	518	(93.7)	709	(94.4)	654	(94.1)	440	(93.0)	2,896	(94.1)	
Present	6	(2.7)	15	(3.9)	32	(5.8)	38	(5.1)	26	(3.7)	20	(4.2)	137	(4.5)	
Close drug users (can	nabis)														< 0.001
Absent	213	(95.9)	362	(94.8)	522	(94.4)	727	(96.8)	665	(95.7)	445	(94.1)	2,934	(95.4)	
Present	6	(2.7)	15	(3.9)	25	(4.5)	18	(2.4)	13	(1.9)	9	(1.9)	86	(2.8)	
Close drug users (met	hamph	etamine)												0.004
Absent	214	(96.4)	369	(96.6)	533	(96.4)	718	(95.6)	661	(95.1)	447	(94.5)	2,942	(95.6)	
Present	5	(2.3)	8	(2.1)	15	(2.7)	27	(3.6)	16	(2.3)	8	(1.7)	79	(2.6)	
Close drug users (MDI	MA)														0.152
Absent	214	(96.4)	372	(97.4)	536	(96.9)	738	(98.3)	671	(96.5)	457	(96.6)	2,988	(97.1)	
Present	5	(2.3)	5	(1.3)	12	(2.2)	6	(.8)	10	(1.4)	4	(.8)	42	(1.4)	
Close drug users (coca	ine)	,		,		,		()						,	0.014
Absent	214	(96.4)	372	(97.4)	539	(97.5)	738	(98.3)	667	(96.0)	449	(94,9)	2.979	(96.8)	
Present	5	(2.3)	5	(1.3)	7	(1.3)	5	(.7)	9	(1.3)	5	(1.1)	36	(1.2)	
Close drug users (here	in)	(,		(((,		(110)		(/		()	0.018
Absent	215	(96.8)	372	(97.4)	539	(97.5)	737	(98.1)	667	(96.0)	448	(94.7)	2.978	(96.8)	
Present	4	(1.8)	5	(1.3)	7	(1.3)	5	(7)	9	(1.3)	5	(1 1)	35	(1 1)	
Close drug users (NPS	s)	(,		((, in the second s	(,	÷	(110)		(/		()	0.077
Absent	215	(96.8)	370	(96.9)	533	(96.4)	736	(98.0)	674	(97.0)	455	(96.2)	2.983	(97.0)	
Present	4	(1.8)	9	(2.4)	13	(2.4)	7	(9)	10	(1 4)	4	(8)	47	(1.5)	
Experience of ever ha	ving tr	v to tem	nt illes	val drugs	(any o	drug)		(,		(====)	-	((()))		(110)	<0.001
No	218	(98.2)	353	(92.4)	500	(90.4)	706	(94.0)	657	(94 5)	451	(95.3)	2 885	(93.8)	0.001
Yes	0	(0)	23	(6.0)	44	(8.0)	35	(47)	21	(3 0)	8	(17)	131	(4.3)	
Experience of ever ha	ving tr	v to tem	nt illes	val drugs	(orga	nic solve	ents)	(111)		(0.0)	0	(117)	101	(110)	<0.001
No	219	(98.6)	366	(95.8)	518	(93.7)	723	(96.3)	675	(97.1)	463	(97.9)	2.964	(96.4)	0.001
Yes	0	(00.0)	10	(2.6)	28	(5.1)	26	(3.5)	13	(1.1)	4	(8)	2,001 81	(2.6)	
Experience of ever ha	ving tr	v to tem	nt illec	al drugs	(cann	ahis)	-0	(0.0)	10	(110)	-	()	01	(1.0)	<0.001
No	219	(98 G)	366	(95.8)	518	(93.7)	728	(96.9)	678		463	(97.9)	2 972	(96.6)	-0.001
Yes	0	(00.0)	12	(3.1)	27	(30.1)	17	(2.3)	7	(1 0)	100	(2)	64	(2.1)	
Experience of ever has	ving tr	v to tem	nt illec	(0.1) ral drugs	(meth	amnhet	amine)	•	(1.0)	1	()	01	(2.1)	0.035
No	220	(99.1)	374	(97 9)	531	(96 0)	739	, (98.4)	681	(98.0)	463	(97.9)	3 008	(97.8)	0.000
Voe	0	(00.1)	9	(5)	14	(2.5)	6	(8)	6	(0.0)	400 2	(61.6)	9,000	(01.0)	
Experience of ever ha	ving tr	v to tem	nt iller	(.0) ral drugs	(MDN	(2.0) (A)	0	(.0)	0	(.0)	0	(.0)	01	(1.0)	0.006
No	910	(98 G)	974	(97.9)	534	(96 6)	740	(98.5)	683	(98.3)	462	(97.7)	3 019	(97.9)	0.000
Voe	213	(38.0)	914	(31.3)	11	(30.0)	740	(33.3)	1	(30.3)	402	(31.1)	5,012 20	(31.3)	
Experience of over her	ving tr	v to tom	nt illoc	(U.)	(0000)	(2.0)	0	(.1)	T	(,1)	1	(.2)	20	(.1)	0.740
No	910	(08 G)	974	(07 0)	544	(08.4)	740	(08.5)	681	(08.0)	469	(07.7)	3 090	(08.9)	0.740
Voe	213 0	(00.0)	1	(31.3)	1	(9)	140	(50.5)	1	(1)	402	(9)	0,020 Q	(00.2) (9)	
Experience of over her	ving to	v to tom	1 nt illoc	(G.) courdo fer	1 (hore	(. <i>2)</i>	4	(.0)	1	(.1)	1	(.4)	0	()	0.514
No	910		оте 276	(02 1)	544	(02 1)	790	(98.4)	681	(02 4)	169	(07.7)	3 094	(08 a)	0.014
Voe	219 0	(0.00)	010	(00.4)	1	(30.4)	109	(30.4)	004	(00.4)	402	(91.1) (9)	0,024 C	(00.0) (9)	
Tes Evnominance of over her	uing to	(.U)	u nt illoc	(.U)	I (NDC)	(. <i>2)</i>	4	(.0)	0	(.0)	1	(.4)	U	(.4)	0.051
No	91Q	y 10 tem (98 9)	одо Pr шеб	(97 G)	598	(97.9)	740	(98.5)	670	(97.7)	169	(97.7)	3 010	(07 0)	0.001
Voe	<u>10</u>	(00.2)	010	(01.0)	000	(1 4)	140 9	(30.0)	<i>งเฮ</i> จ	(01.1)	402 A	(01.1)	10	(51.5)	
162	U	(.0)	ა	(.0)	0	(1.4)	ა	(.4)	4	()	U	(.0)	10	(.0)	

"10s" refers to those aged 15 to 19, and "60s" refers to those aged 60 to 64.

					Occup	ation					
	Self-em	ployed	Full-	time	Non-fu	ll-time	Stud	lent	Housewife		
	n=2	48	n=1	406	n=3	94	n=2	271	n=4	36	
	n	(%)	n	(%)	n	(%)	n	(%)	n	(%)	
Close drug users (any drug	<u>(</u>)										
Absent	219	(88.3)	1,296	(92.2)	357	(90.6)	259	(95.6)	409	(93.8)	
Present	27	(10.9)	89	(6.3)	26	(6.6)	10	(3.7)	17	(3.9)	
Close drug users (organic s	olvents)										
Absent	224	(90.3)	1,324	(94.2)	367	(93.1)	261	(96.3)	417	(95.6)	
Present	22	(8.9)	70	(5.0)	17	(4.3)	8	(3.0)	11	(2.5)	
Close drug users (cannabis)										
Absent	228	(91.9)	1,351	(96.1)	371	(94.2)	260	(95.9)	423	(97.0)	
Present	18	(7.3)	35	(2.5)	12	(3.0)	9	(3.3)	4	(.9)	
Close drug users (metham)	phetamin	e)									
Absent	235	(94.8)	1,354	(96.3)	370	(93.9)	262	(96.7)	421	(96.6)	
Present	10	(4.0)	33	(2.3)	12	(3.0)	7	(2.6)	7	(1.6)	
Close drug users (MDMA)											
Absent	238	(96.0)	1,370	(97.4)	381	(96.7)	262	(96.7)	428	(98.2)	
Present	7	(2.8)	18	(1.3)	5	(1.3)	7	(2.6)	3	(.7)	
Close drug users (cocaine)											
Absent	239	(96.4)	1,370	(97.4)	377	(95.7)	262	(96.7)	425	(97.5)	
Present	6	(2.4)	14	(1.0)	5	(1.3)	7	(2.6)	1	(.2)	
Close drug users (heroin)											
Absent	240	(96.8)	1,369	(97.4)	375	(95.2)	263	(97.0)	425	(97.5)	
Present	5	(2.0)	13	(.9)	7	(1.8)	6	(2.2)	1	(.2)	
Close drug users (NPSs)											
Absent	241	(97.2)	1,362	(96.9)	381	(96.7)	263	(97.0)	425	(97.5)	
Present	6	(2.4)	24	(1.7)	6	(1.5)	6	(2.2)	3	(.7)	
Experience of ever having	try to ten	npt illega	l drugs	(any dr	ug)						
No	233	(94.0)	1,312	(93.3)	365	(92.6)	266	(98.2)	413	(94.7)	
Yes	13	(5.2)	66	(4.7)	21	(5.3)	1	(.4)	14	(3.2)	
Experience of ever having	try to ten	npt illega	l drugs	(organi	e solvent	s)					
No	236	(95.2)	1.344	(95.6)	383	(97.2)	268	(98.9)	426	(97.7)	
Yes	10	(4.0)	48	(3.4)	8	(2.0)	0	(.0)	5	(1.1)	
Experience of ever having	trv to ten	npt illega	l drugs	(cannat	ois)	,				,	
No	238	(96.0)	1.356	(96.4)	376	(95.4)	267	(98.5)	427		
Yes	-00	(3.2)	30	(2.1)	14	(3.6)	1	(.4)	4	(.9)	
Experience of ever having	trv to ten	npt illega	l drugs	(metha	mphetan	nine)	-	(* -)	-	(10)	
No	244	(98.4)	1 370	(97.4)	386	(98.0)	269	(99.3)	427	(97 9)	
Yes	2	(8)	18	(1.3)	4	(10)	0	(0)	5	(1 1)	
Experience of ever having	- trv to ten	nnt illegs	l drugs	(MDMA)	(1.0)	0	(.0)	0	(1,1)	
No	244	(98.4)	1 374	(97.7)	388	(98.5)	268	(98.9)	428	(98.2)	
Ves	244	(30.4)	1,074	(91.1)	900	(50.5)	200	(00.0)	420	(50.2)	
Experience of ever baying	try to ton	nt illege	1 druge	(cocaina	.) 	(.0)	0	(.0)	-	(.0)	
No.	944	(98.4)	1 381	(08 9)	386	(98.0)	268	(08.0)	430	(08.6)	
Voc	244	(30.4)	1,001	(30.2)	000	(30.0)	200	(30.3)	400	(0.0)	
I UD	$\frac{2}{1000}$	(.0)	4 drugs	(1.1)	ى 1	(.0)	0	(.0)	0	(.0)	
N _a		(08.4)	1 angs) 900	(09 F)	909	(0,0,0)	490	(00 c)	
INU Voc	244	(98.4)	1,382	(30.3)	506	(38.9)	208	(98.9)	430	(98.6)	
Ies	2	(.8)	1.1.	(1.)	2	(.5)	0	(.0)	0	(.0)	
Experience of ever having	try to ten	npt illega	u arugs	(NPSS)	004		0.05		405	(07.0)	
INO	245	(98.8)	1,375	(97.8)	384	(97.5)	267	(98.5)	427	(97.9)	
Yes	1	(.4)	8	(.6)	4	(1.0)	0	(.0)	2	(.5)	

Table 50. Presence of Close Drug Users and Experience of Ever Having Try to Tempt Illegal Drugs by Occupation (n=3076)

	Occupation								
-	Unemp	oloyed	Oth	er	Unk	nown	Tot	al	
	n=1	79	n=1	38	n	=4	n=30	076	p-value
	n	(%)	n	(%)	n	(%)	n	(%)	
Close drug users (any drug)									0.002
Absent	163	(91.1)	127	(92.0)	3	(75.0)	2,833	(92.1)	
Present	10	(5.6)	5	(3.6)	1	(25.0)	185	(6.0)	
Close drug users (organic se	olvents)								< 0.001
Absent	169	(94.4)	131	(94.9)	3	(75.0)	2,896	(94.1)	
Present	6	(3.4)	2	(1.4)	1	(25.0)	137	(4.5)	
Close drug users (cannabis)									< 0.001
Absent	169	(94.4)	128	(92.8)	4	(100.0)	2,934	(95.4)	
Present	4	(2.2)	4	(2.9)	0	(.0)	86	(2.8)	
Close drug users (methamp	hetamii	ne)							0.025
Absent	169	(94.4)	128	(92.8)	3	(75.0)	2,942	(95.6)	
Present	5	(2.8)	4	(2.9)	1	(25.0)	79	(2.6)	
Close drug users (MDMA)									0.107
Absent	174	(97.2)	131	(94.9)	4	(100.0)	2,988	(97.1)	
Present	1	(.6)	1	(.7)	0	(.0)	42	(1.4)	
Close drug users (cocaine)									0.022
Absent	173	(96.6)	129	(93.5)	4	(100.0)	2,979	(96.8)	
Present	1	(.6)	2	(1.4)	0	(.0)	36	(1.2)	
Close drug users (heroin)									0.056
Absent	173	(96.6)	129	(93.5)	4	(100.0)	2,978	(96.8)	
Present	1	(.6)	2	(1.4)	0	(.0)	35	(1.1)	
Close drug users (NPSs)									0.578
Absent	174	(97.2)	133	(96.4)	4	(100.0)	2,983	(97.0)	
Present	1	(.6)	1	(.7)	0	(.0)	47	(1.5)	
Experience of ever having t	ry to te	mpt illeg	al drugs	(any dr	ug)				0.215
No	165	(92.2)	127	(92.0)	4	(100.0)	2,885	(93.8)	
Yes	9	(5.0)	7	(5.1)	0	(.0)	131	(4.3)	
Experience of ever having t	ry to te	mpt illeg	al drugs	(organi	c solve	nts)			0.200
No	171	(95.5)	132	(95.7)	4	(100.0)	2,964	(96.4)	
Yes	6	(3.4)	4	(2.9)	0	(.0)	81	(2.6)	
Experience of ever having t	ry to te	mpt illeg	al drugs	(cannab	ois)				0.391
No	172	(96.1)	132	(95.7)	4	(100.0)	2,972	(96.6)	
Yes	4	(2.2)	3	(2.2)	0	(.0)	64	(2.1)	
Experience of ever having t	ry to te	mpt illeg	al drugs	(metha	mpheta	amine)			0.726
No	174	(97.2)	134	(97.1)	4	(100.0)	3,008	(97.8)	
Yes	2	(1.1)	0	(.0)	0	(.0)	31	(1.0)	
Experience of ever having t	ry to te	mpt illeg	al drugs	(MDMA)				0.637
No	173	(96.6)	133	(96.4)	4	(100.0)	3,012	(97.9)	
Yes	2	(1.1)	0	(.0)	0	(.0)	20	(.7)	
Experience of ever having t	ry to te	mpt illeg	al drugs	(cocaine	e)				0.296
No	174	(97.2)	133	(96.4)	4	(100.0)	3,020	(98.2)	
Yes	1	(.6)	0	(.0)	0	(.0)	8	(.3)	
Experience of ever having t	ry to te	mpt illeg	al drugs	(heroin)				0.259
No	175	(97.8)	133	(96.4)	4	(100.0)	3,024	(98.3)	
Yes	1	(.6)	0	(.0)	0	(.0)	6	(.2)	
Experience of ever having t	ry to te	mpt illeg	al drugs	(NPSs)					0.914
No	175	(97.8)	133	(96.4)	4	(100.0)	3,010	(97.9)	
Yes	0	(.0)	1	(.7)	0	(.0)	16	(.5)	

Table 50. Presence of Close Drug Users and Experience of Ever Having Try to Tempt Illegal Drugs by Occupation (n=3076) continued

				Drug u	se expe	rience			
	Lifet	ime	No life	etime	Unkn	own	Tot	al	
	n='	78	n=29	940	n={	58	n=30	076	p-value
	n	(%)	n	(%)	n	(%)	n	(%)	
Close drug users (any drug)									< 0.001
Absent	50	(64.1)	2,751	(93.6)	32	(55.2)	2,833	(92.1)	
Present	26	(33.3)	154	(5.2)	5	(8.6)	185	(6.0)	
Close drug users (organic sol	vents)								< 0.001
Absent	59	(75.6)	2,799	(95.2)	38	(65.5)	2,896	(94.1)	
Present	16	(20.5)	116	(3.9)	5	(8.6)	137	(4.5)	
Close drug users (cannabis)									< 0.001
Absent	59	(75.6)	2,840	(96.6)	35	(60.3)	2,934	(95.4)	
Present	17	(21.8)	69	(2.3)	0	(.0)	86	(2.8)	
Close drug users (methamph	etamin	e)							< 0.001
Absent	62	(79.5)	2.844	(96.7)	36	(62.1)	2.942	(95.6)	
Present	13	(16.7)	65	(2.2)	1	(1.7)	79	(2.6)	
Close drug users (MDMA)		,				,			< 0.001
Absent	68	$(87\ 2)$	2885	(98.1)	35	(60.3)	2.988	(97.1)	
Present	6	(77)	<u>2,000</u> 36	(1.2)	0	(00.0)	42	(1 4)	
Close drug users (cocaine)	0	()	00	(1.2)	0	(.0)	12	(1.1)	<0.001
Absent	69	(88.5)	2.875	(97.8)	35	(60.3)	2 979	(96.8)	-0.001
Present	5	(6.4)	2,010	(11)	0	(00.0)	2,010	(1.2)	
Close drug users (heroin)	0	(0.4)	01	(1,1)	0	(.0)	00	(1.2)	<0.001
Absont	69	(88.5)	2 874	(97.8)	35	(60.3)	2 978	(96.8)	<0.001
Prosont	5	(6.4)	2,074	(01.0)	0	(00.0)	2,010	(11)	
Close drug users (NPSs)	0	(0.4)	50	(1.0)	0	(.0)	00	(1.1)	<0.001
Absont	67	(85.9)	2 878	(97.9)	38	(65.5)	2 983	(97.0)	<0.001
Dresont	6	(00.9)	2,070	(37.3)	0	(00.0)	2,983	(37.0)	
Fresent	0	(1.1)	41	(1.4)	0	(.0)	47	(1.5)	<0.001
No.	9 to ten	(pt mega	a opi	(any uru)	1g) 07	(AC, C)	0.005	(02.9)	<0.001
NO	21 50	(34.0)	2,001	(90.3)	21	(40.0)	2,000	(95.0)	
	00	(64.1)	80	(2.1)	1	(1.7)	191	(4.3)	<0.001
Experience of ever having try	y to ten	npt mega	al drugs	(organic	solvent	s)	0.004	(00, 1)	< 0.001
INO X	44	(36.4)	2,883	(98.1)	37	(63.8)	2,964	(96.4)	
Yes	33	(42.3)	47	(1.6)	1 · `	(1.7)	81	(2.6)	-0.001
Experience of ever having try	y to ten	npt illega	al drugs	(cannab	18)		0.050	$(\alpha \alpha \alpha)$	< 0.001
No	50	(64.1)	2,892	(98.4)	30	(51.7)	2,972	(96.6)	
Yes .	28	(35.9)	36	(1.2)	0	(.0)	64	(2.1)	.0.001
Experience of ever having try	y to ten	npt illega	al drugs	(methan	nphetan	nine)		(a = a)	< 0.001
No	59	(75.6)	2,919	(99.3)	30	(51.7)	3,008	(97.8)	
Yes	18	(23.1)	13	(.4)	0	(.0)	31	(1.0)	.0.001
Experience of ever having try	y to ten	npt illega	al drugs	(MDMA))	(40.0)	0.010	(0 7 0)	< 0.001
No	67	(85.9)	2,917	(99.2)	28	(48.3)	3,012	(97.9)	
Yes	10	(12.8)	10	(.3)	0	(.0)	20	(.7)	
Experience of ever having try	y to ten	npt illega	al drugs	(cocaine)			(< 0.001
No	69	(88.5)	2,923	(99.4)	28	(48.3)	3,020	(98.2)	
Yes	8	(10.3)	0	(.0)	0	(.0)	8	(.3)	
Experience of ever having try	y to ten	npt illega	al drugs	(heroin)					< 0.001
No	71	(91.0)	2,925	(99.5)	28	(48.3)	3,024	(98.3)	
Yes	6	(7.7)	0	(.0)	0	(.0)	6	(.2)	
Experience of ever having try	y to ten	npt illega	al drugs	(NPSs)		,		,	< 0.001
No	69	(88.5)	2,911	(99.0)	30	(51.7)	3,010	(97.9)	
Yes	7	(9.0)	9	(.3)	0	(.0)	16	(.5)	

Table 51. Presence of Close Drug Users and Experience of Ever Having Try to Tempt Illegal Drugs by Drug use experience (n=3076)

Table 52. I	Drug accessibi	ty by Res	idence area	(n=3076)
-------------	----------------	-----------	-------------	----------

						Residen	ice are	a				
	Hok	kaido	Toh	oku	Ka	nto	Hok	uriku	Tou	ısan	То	kai
	n=	131	n=	250	n=	948	n=	154	n=	150	n=	328
	n	(%)	n	(%)	n	(%)	n	(%)	n	(%)	n	(%)
Drug accessibility												
Any drug	60	(45.8)	124	(49.6)	540	(57.0)	77	(50.0)	70	(46.7)	172	(52.4)
Organic solvents	57	(43.5)	122	(48.8)	530	(55.9)	70	(45.5)	69	(46.0)	170	(51.8)
Cannabis	24	(18.3)	39	(15.6)	169	(17.8)	9	(5.8)	8	(5.3)	42	(12.8)
Methamphetamine	15	(11.5)	35	(14.0)	149	(15.7)	10	(6.5)	8	(5.3)	39	(11.9)
MDMA	16	(12.2)	35	(14.0)	147	(15.5)	10	(6.5)	10	(6.7)	42	(12.8)
Cocaine	13	(9.9)	28	(11.2)	134	(14.1)	8	(5.2)	7	(4.7)	34	(10.4)
Heroin	12	(9.2)	27	(10.8)	131	(13.8)	8	(5.2)	7	(4.7)	32	(9.8)
NPSs	27	(20.6)	47	(18.8)	237	(25.0)	24	(15.6)	12	(8.0)	72	(22.0)
Drug accessibility (organic se	olvent	ts)										
Completely inaccessible	45	(34.4)	92	(36.8)	281	(29.6)	64	(41.6)	57	(38.0)	110	(33.5)
Almost inaccessible	22	(16.8)	24	(9.6)	113	(11.9)	13	(8.4)	19	(12.7)	31	(9.5)
Barely accessible	15	(11.5)	52	(20.8)	198	(20.9)	19	(12.3)	25	(16.7)	66	(20.1)
Easily accessible	42	(32.1)	70	(28.0)	332	(35.0)	51	(33.1)	44	(29.3)	104	(31.7)
Drug accessibility (cannabis)												
Completely inaccessible	84	(64.1)	166	(66.4)	559	(59.0)	108	(70.1)	108	(72.0)	204	(62.2)
Almost inaccessible	17	(13.0)	32	(12.8)	192	(20.3)	29	(18.8)	28	(18.7)	65	(19.8)
Barely accessible	19	(14.5)	31	(12.4)	136	(14.3)	6	(3.9)	6	(4.0)	32	(9.8)
Easily accessible	5	(3.8)	8	(3.2)	33	(3.5)	3	(1.9)	2	(1.3)	10	(3.0)
Drug accessibility (methamp	hetar	nine)										
Completely inaccessible	93	(71.0)	171	(68.4)	572	(60.3)	108	(70.1)	115	(76.7)	212	(64.6)
Almost inaccessible	17	(13.0)	32	(12.8)	200	(21.1)	27	(17.5)	21	(14.0)	59	(18.0)
Barely accessible	13	(9.9)	27	(10.8)	117	(12.3)	8	(5.2)	6	(4.0)	31	(9.5)
Easily accessible	2	(1.5)	8	(3.2)	32	(3.4)	2	(1.3)	2	(1.3)	8	(2.4)
Drug accessibility (MDMA)												
Completely inaccessible	93	(71.0)	173	(69.2)	577	(60.9)	105	(68.2)	112	(74.7)	204	(62.2)
Almost inaccessible	16	(12.2)	29	(11.6)	196	(20.7)	29	(18.8)	21	(14.0)	63	(19.2)
Barely accessible	15	(11.5)	29	(11.6)	119	(12.6)	7	(4.5)	10	(6.7)	33	(10.1)
Easily accessible	1	(.8)	6	(2.4)	28	(3.0)	3	(1.9)	0	(.0)	9	(2.7)
Drug accessibility (cocaine)												
Completely inaccessible	98	(74.8)	176	(70.4)	592	(62.4)	109	(70.8)	113	(75.3)	211	(64.3)
Almost inaccessible	14	(10.7)	33	(13.2)	197	(20.8)	28	(18.2)	24	(16.0)	65	(19.8)
Barely accessible	13	(9.9)	22	(8.8)	109	(11.5)	7	(4.5)	6	(4.0)	27	(8.2)
Easily accessible	0	(.0)	6	(2.4)	25	(2.6)	1	(.6)	1	(.7)	7	(2.1)
Drug accessibility (heroin)												
Completely inaccessible	98	(74.8)	178	(71.2)	595	(62.8)	109	(70.8)	117	(78.0)	212	(64.6)
Almost inaccessible	15	(11.5)	32	(12.8)	197	(20.8)	28	(18.2)	20		66	(20.1)
Barely accessible	12	(9.2)	20	(8.0)	110	(11.6)	7	(4.5)	6	(4.0)	27	(8.2)
Easily accessible	0	(.0)	7	(2.8)	21	(2.2)	1	(.6)	1	(.7)	5	(1.5)
Drug accessibility (NPSs)												
Completely inaccessible	75	(57.3)	164	(65.6)	493	(52.0)	95	(61.7)	98	(65.3)	172	(52.4)
Almost inaccessible	23	(17.6)	26	(10.4)	194	(20.5)	26	(16.9)	33	(22.0)	67	(20.4)
Barely accessible	18	(13.7)	33	(13.2)	165	(17.4)	19	(12.3)	11	(7.3)	50	(15.2)
Easily accessible	9	(6.9)	14	(5.6)	72	(7.6)	5	(3.2)	1	(.7)	22	(6.7)

Table 52. I	Drug accessibility	y by Residence	area(n=3076)	continued
-------------	--------------------	----------------	--------------	-----------

				Residence area									
-	Ki	nki	Chu	goku	Shi	koku	Kita-K	Kyusyu	Min	ami-	Tot	al	
	n=	442	n=	191	n=	=88	n=	229	n=	165	n=30	076	p-value
	n	(%)	n	(%)	n	(%)	n	(%)	n	(%)	n	(%)	
Drug accessibility													
Any drug	232	(52.5)	108	(56.5)	43	(48.9)	110	(48.0)	81	(49.1)	1,617	(52.6)	0.255
Organic solvents	228	(51.6)	107	(56.0)	43	(48.9)	109	(47.6)	79	(47.9)	1,584	(51.5)	0.119
Cannabis	56	(12.7)	24	(12.6)	11	(12.5)	33	(14.4)	18	(10.9)	433	(14.1)	0.003
Methamphetamine	50	(11.3)	27	(14.1)	10	(11.4)	31	(13.5)	17	(10.3)	391	(12.7)	0.049
MDMA	52	(11.8)	22	(11.5)	11	(12.5)	33	(14.4)	17	(10.3)	395	(12.8)	0.102
Cocaine	40	(9.0)	22	(11.5)	8	(9.1)	30	(13.1)	17	(10.3)	341	(11.1)	0.025
Heroin	36	(8.1)	20	(10.5)	8	(9.1)	28	(12.2)	15	(9.1)	324	(10.5)	0.020
NPSs	82	(18.6)	36	(18.8)	17	(19.3)	42	(18.3)	23	(13.9)	619	(20.1)	0.001
Drug accessibility (organic sol	lvents)											0.019
Completely inaccessible	153	(34.6)	63	(33.0)	33	(37.5)	92	(40.2)	60	(36.4)	1,050	(34.1)	
Almost inaccessible	44	(10.0)	18	(9.4)	9	(10.2)	20	(8.7)	18	(10.9)	331	(10.8)	
Barely accessible	105	(23.8)	34	(17.8)	20	(22.7)	34	(14.8)	29	(17.6)	597	(19.4)	
Easily accessible	123	(27.8)	73	(38.2)	23	(26.1)	75	(32.8)	50	(30.3)	987	(32.1)	
Drug accessibility (cannabis)													0.022
Completely inaccessible	299	(67.6)	124	(64.9)	58	(65.9)	149	(65.1)	114	(69.1)	1,973	(64.1)	
Almost inaccessible	68	(15.4)	38	(19.9)	16	(18.2)	39	(17.0)	24	(14.5)	548	(17.8)	
Barely accessible	43	(9.7)	21	(11.0)	9	(10.2)	25	(10.9)	14	(8.5)	342	(11.1)	
Easily accessible	13	(2.9)	3	(1.6)	2	(2.3)	8	(3.5)	4	(2.4)	91	(3.0)	
Drug accessibility (methamph	netami	ine)											0.045
Completely inaccessible	306	(69.2)	126	(66.0)	60	(68.2)	153	(66.8)	115	(69.7)	2,031	(66.0)	
Almost inaccessible	67	(15.2)	33	(17.3)	15	(17.0)	37	(16.2)	24	(14.5)	532	(17.3)	
Barely accessible	42	(9.5)	21	(11.0)	8	(9.1)	24	(10.5)	12	(7.3)	309	(10.0)	
Easily accessible	8	(1.8)	6	(3.1)	2	(2.3)	7	(3.1)	5	(3.0)	82	(2.7)	
Drug accessibility (MDMA)													0.052
Completely inaccessible	304	(68.8)	126	(66.0)	56	(63.6)	150	(65.5)	115	(69.7)	2,015	(65.5)	
Almost inaccessible	67	(15.2)	37	(19.4)	16	(18.2)	38	(16.6)	24	(14.5)	536	(17.4)	
Barely accessible	42	(9.5)	18	(9.4)	9	(10.2)	27	(11.8)	13	(7.9)	322	(10.5)	
Easily accessible	10	(2.3)	4	(2.1)	2	(2.3)	6	(2.6)	4	(2.4)	73	(2.4)	
Drug accessibility (cocaine)													0.024
Completely inaccessible	311	(70.4)	129	(67.5)	60	(68.2)	155	(67.7)	115	(69.7)	2,069	(67.3)	
Almost inaccessible	71	(16.1)	35	(18.3)	17	(19.3)	36	(15.7)	24	(14.5)	544	(17.7)	
Barely accessible	34	(7.7)	19	(9.9)	7	(8.0)	26	(11.4)	14	(8.5)	284	(9.2)	
Easily accessible	6	(1.4)	3	(1.6)	1	(1.1)	4	(1.7)	3	(1.8)	57	(1.9)	
Drug accessibility (heroin)													0.007
Completely inaccessible	314	(71.0)	129	(67.5)	60	(68.2)	156	(68.1)	116	(70.3)	2,084	(67.8)	
Almost inaccessible	70	(15.8)	36	(18.8)	17	(19.3)	37	(16.2)	25		543	(17.7)	
Barely accessible	32	(7.2)	18	(9.4)	8	(9.1)	24	(10.5)	12	(7.3)	276	(9.0)	
Easily accessible	4	(.9)	2	(1.0)	0	(.0)	4	(1.7)	3	(1.8)	48	(1.6)	
Drug accessibility (NPSs)													< 0.001
Completely inaccessible	274	(62.0)	117	(61.3)	53	(60.2)	139	(60.7)	105	(63.6)	1,785	(58.0)	
Almost inaccessible	67	(15.2)	31	(16.2)	15	(17.0)	40	(17.5)	28	(17.0)	550	(17.9)	
Barely accessible	62	(14.0)	27	(14.1)	12	(13.6)	24	(10.5)	15	(9.1)	436	(14.2)	
Easily accessible	20	(4.5)	9	(4.7)	5	(5.7)	18	(7.9)	8	(4.8)	183	(5.9)	

				Sex			
-	Me	en	Won	nen	Tot	al	
	n = 1	466	n = 1	610	n = 3	8076	P-value
	n	(%)	n	(%)	n	(%)	1 vanto
Drug accessibility							
Any drug	920	(62.8)	697	(43.3)	1,617	(52.6)	< 0.001
Organic solvents	906	(61.8)	678	(42.1)	1.584	(51.5)	< 0.001
Cannabis	217	(14.8)	216	(13.4)	433	(14.1)	0.519
Methamphetamine	186	(12.7)	205	(12.7)	391	(12.7)	0.922
MDMA	192	(13.1)	203	(12.6)	395	(12.8)	0.813
Cocaine	162	(11.1)	179	(11.1)	341	(11.1)	0.975
Heroin	158	(10.8)	166	(10.3)	324	(10.5)	0.830
NPSs	326	(22.2)	293	(18.2)	619	(20.1)	0.020
Drug accessibility (organic solv	ents)						< 0.001
Completely inaccessible	368	(25.1)	682	(42.4)	1,050	(34.1)	
Almost inaccessible	144	(9.8)	187	(11.6)	331	(10.8)	
Barely accessible	314	(21.4)	283	(17.6)	597	(19.4)	
Easily accessible	592	(40.4)	395	(24.5)	987	(32.1)	
Drug accessibility (cannabis)							< 0.001
Completely inaccessible	853	(58.2)	1,120	(69.6)	1,973	(64.1)	
Almost inaccessible	340	(23.2)	208	(12.9)	548	(17.8)	
Barely accessible	173	(11.8)	169	(10.5)	342	(11.1)	
Easily accessible	44	(3.0)	47	(2.9)	91	(3.0)	
Drug accessibility (methamphe	tamine)						< 0.001
Completely inaccessible	894	(61.0)	1,137	(70.6)	2,031	(66.0)	
Almost inaccessible	330	(22.5)	202	(12.5)	532	(17.3)	
Barely accessible	155	(10.6)	154	(9.6)	309	(10.0)	
Easily accessible	31	(2.1)	51	(3.2)	82	(2.7)	
Drug accessibility (MDMA)							< 0.001
Completely inaccessible	885	(60.4)	1,130	(70.2)	2,015	(65.5)	
Almost inaccessible	330	(22.5)	206	(12.8)	536	(17.4)	
Barely accessible	163	(11.1)	159	(9.9)	322	(10.5)	
Easily accessible	29	(2.0)	44	(2.7)	73	(2.4)	
Drug accessibility (cocaine)							< 0.001
Completely inaccessible	911	(62.1)	1,158	(71.9)	2,069	(67.3)	
Almost inaccessible	336	(22.9)	208	(12.9)	544	(17.7)	
Barely accessible	137	(9.3)	147	(9.1)	284	(9.2)	
Easily accessible	25	(1.7)	32	(2.0)	57	(1.9)	
Drug accessibility (heroin)							< 0.001
Completely inaccessible	919	(62.7)	1,165	(72.4)	2,084	(67.8)	
Almost inaccessible	332	(22.6)	211	(13.1)	543	(17.7)	
Barely accessible	137	(9.3)	139	(8.6)	276	(9.0)	
Easily accessible	21	(1.4)	27	(1.7)	48	(1.6)	
Drug accessibility (NPSs)							< 0.001
Completely inaccessible	756	(51.6)	1,029	(63.9)	1,785	(58.0)	
Almost inaccessible	327	(22.3)	223	(13.9)	550	(17.9)	
Barely accessible	245	(16.7)	191	(11.9)	436	(14.2)	
Easily accessible	81	(5 5)	102	(6.3)	183	(5.9)	

Table 53. Drug accessibility by sex(n=3076)

Table 54. Drug accessibility by Age group(n=3076)

								Age gro	oup						
	1	0s	2	0s	3	0s	4)s	5	0s	6	0s	То	tal	
	n=	222	n=	382	n=	553	n=	751	n=	695	n=	473	n=3	076	p-value
	n	(%)	n	(%)	n	(%)	n	(%)	n	(%)	n	(%)	n	(%)	
Drug accessibility															
Any drug	75	(33.8)	173	(45.3)	292	(52.8)	447	(59.5)	393	(56.5)	237	(50.1)	1,617	(52.6)	< 0.001
Organic solvents	72	(32.4)	166	(43.5)	284	(51.4)	440	(58.6)	386	(55.5)	236	(49.9)	1,584	(51.5)	< 0.001
Cannabis	41	(18.5)	78	(20.4)	105	(19.0)	102	(13.6)	74	(10.6)	33	(7.0)	433	(14.1)	< 0.001
Methamphetamine	39	(17.6)	68	(17.8)	91	(16.5)	95	(12.6)	70	(10.1)	28	(5.9)	391	(12.7)	< 0.001
MDMA	34	(15.3)	61	(16.0)	95	(17.2)	106	(14.1)	71	(10.2)	28	(5.9)	395	(12.8)	< 0.001
Cocaine	36	(16.2)	62	(16.2)	76	(13.7)	82	(10.9)	62	(8.9)	23	(4.9)	341	(11.1)	< 0.001
Heroin	35	(15.8)	58	(15.2)	73	(13.2)	79	(10.5)	56	(8.1)	23	(4.9)	324	(10.5)	< 0.001
NPSs	45	(20.3)	88	(23.0)	133	(24.1)	168	(22.4)	132	(19.0)	53	(11.2)	619	(20.1)	< 0.001
Drug accessibility (organic s	olvents	3)													< 0.001
Completely inaccessible	117	(52.7)	169	(44.2)	192	(34.7)	215	(28.6)	205	(29.5)	152	(32.1)	1,050	(34.1)	
Almost inaccessible	25	(11.3)	36	(9.4)	56	(10.1)	79	(10.5)	75	(10.8)	60	(12.7)	331	(10.8)	
Barely accessible	38	(17.1)	50	(13.1)	109	(19.7)	147	(19.6)	157	(22.6)	96	(20.3)	597	(19.4)	
Easily accessible	34	(15.3)	116	(30.4)	175	(31.6)	293	(39.0)	229	(32.9)	140	(29.6)	987	(32.1)	
Drug accessibility (cannabis))														< 0.001
Completely inaccessible	145	(65.3)	230	(60.2)	327	(59.1)	471	(62.7)	467	(67.2)	333	(70.4)	1,973	(64.1)	
Almost inaccessible	28	(12.6)	61	(16.0)	98	(17.7)	156	(20.8)	125	(18.0)	80	(16.9)	548	(17.8)	
Barely accessible	30	(13.5)	57	(14.9)	86	(15.6)	80	(10.7)	62	(8.9)	27	(5.7)	342	(11.1)	
Easily accessible	11	(5.0)	21	(5.5)	19	(3.4)	22	(2.9)	12	(1.7)	6	(1.3)	91	(3.0)	
Drug accessibility (methamp	hetam	ine)													< 0.001
Completely inaccessible	147	(66.2)	238	(62.3)	339	(61.3)	491	(65.4)	480	(69.1)	336	(71.0)	2,031	(66.0)	
Almost inaccessible	28	(12.6)	61	(16.0)	99	(17.9)	143	(19.0)	120	(17.3)	81	(17.1)	532	(17.3)	
Barely accessible	29	(13.1)	47	(12.3)	78	(14.1)	74	(9.9)	58	(8.3)	23	(4.9)	309	(10.0)	
Easily accessible	10	(4.5)	21	(5.5)	13	(2.4)	21	(2.8)	12	(1.7)	5	(1.1)	82	(2.7)	
Drug accessibility (MDMA)															< 0.001
Completely inaccessible	146	(65.8)	244	(63.9)	338	(61.1)	476	(63.4)	474	(68.2)	337	(71.2)	2,015	(65.5)	
Almost inaccessible	34	(15.3)	63	(16.5)	97	(17.5)	142	(18.9)	119	(17.1)	81	(17.1)	536	(17.4)	
Barely accessible	28	(12.6)	46	(12.0)	83	(15.0)	81	(10.8)	60	(8.6)	24	(5.1)	322	(10.5)	
Easily accessible	6	(2.7)	15	(3.9)	12	(2.2)	25	(3.3)	11	(1.6)	4	(.8)	73	(2.4)	
Drug accessibility (cocaine)															< 0.001
Completely inaccessible	147	(66.2)	242	(63.4)	349	(63.1)	502	(66.8)	490	(70.5)	339	(71.7)	2,069	(67.3)	
Almost inaccessible	31	(14.0)	64	(16.8)	104	(18.8)	145	(19.3)	117	(16.8)	83	(17.5)	544	(17.7)	
Barely accessible	29	(13.1)	49	(12.8)	66	(11.9)	67	(8.9)	53	(7.6)	20	(4.2)	284	(9.2)	
Easily accessible	7	(3.2)	13	(3.4)	10	(1.8)	15	(2.0)	9	(1.3)	3	(.6)	57	(1.9)	
Drug accessibility (heroin)															< 0.001
Completely inaccessible	148	(66.7)	245	(64.1)	352	(63.7)	503	(67.0)	492	(70.8)	344	(72.7)	2,084	(67.8)	
Almost inaccessible	31	(14.0)	65	(17.0)	104	(18.8)	147	(19.6)	118		78	(16.5)	543	(17.7)	
Barely accessible	29	(13.1)	45	(11.8)	62	(11.2)	68	(9.1)	51	(7.3)	21	(4.4)	276	(9.0)	
Easily accessible	6	(2.7)	13	(3.4)	11	(2.0)	11	(1.5)	5	(.7)	2	(.4)	48	(1.6)	
Drug accessibility (NPSs)															< 0.001
Completely inaccessible	139	(62.6)	224	(58.6)	303	(54.8)	399	(53.1)	409	(58.8)	311	(65.8)	1,785	(58.0)	
Almost inaccessible	30	(13.5)	56	(14.7)	94	(17.0)	161	(21.4)	127	(18.3)	82	(17.3)	550	(17.9)	
Barely accessible	31	(14.0)	56	(14.7)	97	(17.5)	112	(14.9)	99	(14.2)	41	(8.7)	436	(14.2)	
Easily accessible	14	(6.3)	32	(8.4)	36	(6.5)	56	(7.5)	33	(4.7)	12	(2.5)	183	(5.9)	

"10s" refers to those aged 15 to 19, and "60s" refers to those aged 60 to 64.

	U 1				Occupation					
	Se	elf-	Full	time	Non	-full-	Stu	dent	Hous	ewife
	n=	248	n=1	406	n=	394	n=	271	n=	436
	n	(%)	n	(%)	n	(%)	n	(%)	n	(%)
Drug accessibility										
Any drug	160	(64.5)	827	(58.8)	196	(49.7)	101	(37.3)	186	(42.7)
Organic solvents	159	(64.1)	813	(57.8)	189	(48.0)	97	(35.8)	182	(41.7)
Cannabis	32	(12.9)	205	(14.6)	66	(16.8)	54	(19.9)	41	(9.4)
Methamphetamine	29	(11.7)	174	(12.4)	63	(16.0)	51	(18.8)	38	(8.7)
MDMA	32	(12.9)	179	(12.7)	67	(17.0)	44	(16.2)	40	(9.2)
Cocaine	25	(10.1)	153	(10.9)	53	(13.5)	49	(18.1)	30	(6.9)
Heroin	25	(10.1)	146	(10.4)	51	(12.9)	47	(17.3)	26	(6.0)
NPSs	51	(20.6)	305	(21.7)	91	(23.1)	63	(23.2)	59	(13.5)
Drug accessibility (organic so	lvents)								
Completely inaccessible	63	(25.4)	406	(28.9)	141	(35.8)	134	(49.4)	180	(41.3)
Almost inaccessible	18	(7.3)	142	(10.1)	50	(12.7)	31	(11.4)	54	(12.4)
Barely accessible	61	(24.6)	291	(20.7)	73	(18.5)	43	(15.9)	77	(17.7)
Easily accessible	98	(39.5)	522	(37.1)	116	(29.4)	54	(19.9)	105	(24.1)
Drug accessibility (cannabis)										
Completely inaccessible	149	(60.1)	867	(61.7)	242	(61.4)	171	(63.1)	325	(74.5)
Almost inaccessible	58	(23.4)	285	(20.3)	69	(17.5)	37	(13.7)	50	(11.5)
Barely accessible	18	(7.3)	171	(12.2)	54	(13.7)	37	(13.7)	32	(7.3)
Easily accessible	14	(5.6)	34	(2.4)	12	(3.0)	17	(6.3)	9	(2.1)
Drug accessibility (methamp	hetami	ine)								
Completely inaccessible	159	(64.1)	898	(63.9)	246	(62.4)	173	(63.8)	331	(75.9)
Almost inaccessible	51	(20.6)	284	(20.2)	66	(16.8)	38	(14.0)	48	(11.0)
Barely accessible	20	(8.1)	143	(10.2)	54	(13.7)	35	(12.9)	29	(6.7)
Easily accessible	9	(3.6)	31	(2.2)	9	(2.3)	16	(5.9)	9	(2.1)
Drug accessibility (MDMA)										
Completely inaccessible	155	(62.5)	892	(63.4)	248	(62.9)	173	(63.8)	327	(75.0)
Almost inaccessible	51	(20.6)	280	(19.9)	61	(15.5)	45	(16.6)	50	(11.5)
Barely accessible	23	(9.3)	152	(10.8)	58	(14.7)	32	(11.8)	31	(7.1)
Easily accessible		(3.6)	27	(1.9)	9	(2.3)	12	(4.4)	9	(2.1)
Drug accessibility (cocaine)		(0.0)		(,		(,		()		(
Completely inaccessible	162	(65.3)	920	(65.4)	256	(65.0)	173	(63.8)	332	(76.1)
Almost inaccessible	52	(21.0)	283	(20.1)	67	(17.0)	40	(14.8)	55	(12.6)
Barely accessible	19	(77)	132	(9.4)	46	(11.7)	37	(13.7)	22	(5.0)
Easily accessible	6	(2.4)	21	(1.5)	7	(1.8)	12	(4 4)	8	(1.8)
Drug accessibility (heroin)	Ŭ	(=: :)		(110)		(110)		(111)	0	(110)
Completely inaccessible	164	(66.1)	925	(65.8)	259	(65 7)	175	(64.6)	333	(76.4)
Almost inaccessible	50	(20.2)	285	(20.3)	65	(16.5)	40	(14.8)	56	(10.1)
Barely accessible	19	(20.2)	128	(9.1)	46	(11.7)	37	(13.7)	20	(4.6)
Easily accessible	6	(2, 4)	18	(1.3)	5	(1.3)	10	(37)	-0 6	(1.4)
Drug accessibility (NPSs)	0	(2.1)	10	(1.0)	0	(1.0)	10	(0.1)	0	(1.4)
Completely inaccessible	139	(56.0)	761	$(54\ 1)$	223	(56-6)	163	(60.1)	293	(67.2)
Almost inaccessible	49	(19.8)	289	(20.6)	61	(15.5)	36	(13.3)	200 88	(15.1)
Barely accessible	36	(14.5)	219	(15.6)	65	(16.5)	<u>⊿</u> 1	(15.0)	30	(8 0)
Easily accessible	15	(0.3)	210	(6.1)	96	(10.0)	 99	(8.1)	90 20	(0.0) (4 G)

Table 55.	Drug	accessibility	by	Occupation	(n=3076)
-----------	------	---------------	----	------------	----------

	Occupation								
	Unem	ployed	Oth	ier	Unkn	own	Tot	al	
	n=1	79	n=1	.38	n=	4	n=3	076	p-value
	n	(%)	n	(%)	n	(%)	n	(%)	
Drug accessibility									
Any drug	82	(45.8)	63	(45.7)	2	(50.0)	1,617	(52.6)	< 0.001
Organic solvents	80	(44.7)	62	(44.9)	2	(50.0)	1,584	(51.5)	< 0.001
Cannabis	18	(10.1)	17	(12.3)	0	(.0)	433	(14.1)	< 0.001
Methamphetamine	19	(10.6)	16	(11.6)	1	(25.0)	391	(12.7)	0.010
MDMA	17	(9.5)	16	(11.6)	0	(.0)	395	(12.8)	< 0.001
Cocaine	15	(8.4)	16	(11.6)	0	(.0)	341	(11.1)	< 0.001
Heroin	14	(7.8)	15	(10.9)	0	(.0)	324	(10.5)	< 0.001
NPSs	24	(13.4)	26	(18.8)	0	(.0)	619	(20.1)	< 0.001
Drug accessibility (organic solv	vents)								< 0.001
Completely inaccessible	68	(38.0)	57	(41.3)	1	(25.0)	1,050	(34.1)	
Almost inaccessible	25	(14.0)	11	(8.0)	0	(.0)	331	(10.8)	
Barely accessible	27	(15.1)	25	(18.1)	0	(.0)	597	(19.4)	
Easily accessible	53	(29.6)	37	(26.8)	2	(50.0)	987	(32.1)	
Drug accessibility (cannabis)									< 0.001
Completely inaccessible	120	(67.0)	98	(71.0)	1	(25.0)	1,973	(64.1)	
Almost inaccessible	32	(17.9)	16	(11.6)	1	(25.0)	548	(17.8)	
Barely accessible	15	(8.4)	15	(10.9)	0	(.0)	342	(11.1)	
Easily accessible	3	(1.7)	2	(1.4)	0	(.0)	91	(3.0)	
Drug accessibility (methamphe	etamine)								< 0.001
Completely inaccessible	123	(68.7)	100	(72.5)	1	(25.0)	2,031	(66.0)	
Almost inaccessible	30	(16.8)	14	(10.1)	1	(25.0)	532	(17.3)	
Barely accessible	14	(7.8)	13	(9.4)	1	(25.0)	309	(10.0)	
Easily accessible	5	(2.8)	3	(2.2)	0	(.0)	82	(2.7)	
Drug accessibility (MDMA)									< 0.001
Completely inaccessible	120	(67.0)	99	(71.7)	1	(25.0)	2,015	(65.5)	
Almost inaccessible	32	(17.9)	16	(11.6)	1	(25.0)	536	(17.4)	
Barely accessible	13	(7.3)	13	(9.4)	0	(.0)	322	(10.5)	
Easily accessible	4	(2.2)	3	(2.2)	0	(.0)	73	(2.4)	
Drug accessibility (cocaine)									< 0.001
Completely inaccessible	122	(68.2)	103	(74.6)	1	(25.0)	2,069	(67.3)	
Almost inaccessible	34	(19.0)	12	(8.7)	1	(25.0)	544	(17.7)	
Barely accessible	13	(7.3)	15	(10.9)	0	(.0)	284	(9.2)	
Easily accessible	2	(1.1)	1	(.7)	0	(.0)	57	(1.9)	
Drug accessibility (heroin)									< 0.001
Completely inaccessible	123	(68.7)	104	(75.4)	1	(25.0)	2,084	(67.8)	
Almost inaccessible	34	(19.0)	12	(8.7)	1	(25.0)	543	(17.7)	
Barely accessible	12	(6.7)	14	(10.1)	0	(.0)	276	(9.0)	
Easily accessible	2	(1.1)	1	(.7)	0	(.0)	48	(1.6)	
Drug accessibility (NPSs)	-	/	-		-			/	< 0.001
Completely inaccessible	113	(63.1)	92	(66.7)	1	(25.0)	1.785	(58.0)	
Almost inaccessible	34	(19.0)	14	(10.1)	1	(25.0)	550	(17.9)	
Barely accessible	18	(10.1)	18	(13.0)	0	(0)	436	(14.2)	
Easily accessible	6	(3.4)	8	(5.8)	0	(0)	183	(5.9)	

Table 55.	Drug accessibility	by Occupation	(n=3076)	continued

Table 56.	Drug accessibility	by Drug u	se experience	(n=3076)
Table 50.	Drug accessionity	by Diug u	be experience	(11-3010)

	Drug use experience								
	Lifet	ime	No life	etime	Unkn	own	Tot	al	
	n='	78	n=29	940	n={	58	n=30	076	p-value
	n	(%)	n	(%)	n	(%)	n	(%)	
Drug accessibility									
Any drug	67	(85.9)	1,534	(52.2)	16	(27.6)	1,617	(52.6)	< 0.001
Organic solvents	65	(83.3)	1,504	(51.2)	15	(25.9)	1,584	(51.5)	< 0.001
Cannabis	36	(46.2)	394	(13.4)	3	(5.2)	433	(14.1)	< 0.001
Methamphetamine	33	(42.3)	355	(12.1)	3	(5.2)	391	(12.7)	< 0.001
MDMA	34	(43.6)	358	(12.2)	3	(5.2)	395	(12.8)	< 0.001
Cocaine	25	(32.1)	313	(10.6)	3	(5.2)	341	(11.1)	< 0.001
Heroin	23	(29.5)	298	(10.1)	3	(5.2)	324	(10.5)	< 0.001
NPSs	39	(50.0)	576	(19.6)	4	(6.9)	619	(20.1)	< 0.001
Drug accessibility (organic solv	rents)								< 0.001
Completely inaccessible	5	(6.4)	1,030	(35.0)	15	(25.9)	1,050	(34.1)	
Almost inaccessible	7	(9.0)	318	(10.8)	6	(10.3)	331	(10.8)	
Barely accessible	18	(23.1)	574	(19.5)	5	(8.6)	597	(19.4)	
Easily accessible	47	(60.3)	930	(31.6)	10	(17.2)	987	(32.1)	
Drug accessibility (cannabis)									< 0.001
Completely inaccessible	20	(25.6)	1,931	(65.7)	22	(37.9)	1,973	(64.1)	
Almost inaccessible	20	(25.6)	524	(17.8)	4	(6.9)	548	(17.8)	
Barely accessible	27	(34.6)	312	(10.6)	3	(5.2)	342	(11.1)	
Easily accessible	9	(11.5)	82	(2.8)	0	(.0)	91	(3.0)	
Drug accessibility (methamphe	etamin	e)							< 0.001
Completely inaccessible	23	(29.5)	1,986	(67.6)	22	(37.9)	2,031	(66.0)	
Almost inaccessible	20	(25.6)	509	(17.3)	3	(5.2)	532	(17.3)	
Barely accessible	23	(29.5)	283	(9.6)	3	(5.2)	309	(10.0)	
Easily accessible	10	(12.8)	72	(2.4)	0	(.0)	82	(2.7)	
Drug accessibility (MDMA)									< 0.001
Completely inaccessible	23	(29.5)	1,970	(67.0)	22	(37.9)	2,015	(65.5)	
Almost inaccessible	19	(24.4)	513	(17.4)	4	(6.9)	536	(17.4)	
Barely accessible	26	(33.3)	293	(10.0)	3	(5.2)	322	(10.5)	
Easily accessible	8	(10.3)	65	(2.2)	0	(.0)	73	(2.4)	
Drug accessibility (cocaine)									< 0.001
Completely inaccessible	24	(30.8)	2,024	(68.8)	21	(36.2)	2,069	(67.3)	
Almost inaccessible	27	(34.6)	514	(17.5)	3	(5.2)	544	(17.7)	
Barely accessible	20	(25.6)	261	(8.9)	3	(5.2)	284	(9.2)	
Easily accessible	5	(6.4)	52	(1.8)	0	(.0)	57	(1.9)	
Drug accessibility (heroin)									< 0.001
Completely inaccessible	26	(33.3)	2,036	(69.3)	22	(37.9)	2,084	(67.8)	
Almost inaccessible	27	(34.6)	514	(17.5)	2	(3.4)	543	(17.7)	
Barely accessible	19	(24.4)	254	(8.6)	3	(5.2)	276	(9.0)	
Easily accessible	4	(5.1)	44	(1.5)	0	(.0)	48	(1.6)	
Drug accessibility (NPSs)									< 0.001
Completely inaccessible	17	(21.8)	1,746	(59.4)	22	(37.9)	1,785	(58.0)	
Almost inaccessible	20	(25.6)	526	(17.9)	4	(6.9)	550	(17.9)	
Barely accessible	27	(34.6)	405	(13.8)	4	(6.9)	436	(14.2)	
Easily accessible	12	(15.4)	171	(5.8)	0	(.0)	183	(5.9)	

Table 57.	Drug Use	Experience	by	Residence area	(n = 3076)	3)
-----------	----------	------------	----	----------------	------------	----

_						Residen	ce area	ı				
	Hok	kaido	Toh	oku	Ka	nto	Hoku	uriku	Tou	Isan	То	kai
	n=	131	n=	250	n=	948	n=	154	n=	150	n=	328
	n	(%)	n	(%)	n	(%)	n	(%)	n	(%)	n	(%)
Lifetime experience (any drug)												
No	120	(91.6)	239	(95.6)	909	(95.9)	149	(96.8)	144	(96.0)	312	(95.1)
Yes	6	(4.6)	4	(1.6)	25	(2.6)	3	(1.9)	2	(1.3)	10	(3.0)
Lifetime experience (organic sol	vents)											
No	128	(97.7)	244	(97.6)	930	(98.1)	149	(96.8)	147	(98.0)	317	(96.6)
Yes	2	(1.5)	3	(1.2)	14	(1.5)	3	(1.9)	1	(.7)	9	(2.7)
Lifetime experience (cannabis)												
No	126	(96.2)	246	(98.4)	925	(97.6)	152	(98.7)	145	(96.7)	319	(97.3)
Yes	4	(3.1)	1	(.4)	15	(1.6)	0	(.0)	2	(1.3)	4	(1.2)
Lifetime experience (methamphe	etamir	ne)										
No	128	(97.7)	247	(98.8)	934	(98.5)	152	(98.7)	146	(97.3)	321	(97.9)
Yes	2	(1.5)	0	(.0)	7	(.7)	0	(.0)	1	(.7)	3	(.9)
Lifetime experience (MDMA)												
No	129	(98.5)	247	(98.8)	938	(98.9)	152	(98.7)	146	(97.3)	324	(98.8)
Yes	1	(.8)	0	(.0)	1	(.1)	0	(.0)	0	(.0)	0	(.0)
Lifetime experience (cocaine)												
No	128	(97.7)	247	(98.8)	935	(98.6)	152	(98.7)	146	(97.3)	323	(98.5)
Yes	1	(.8)	0	(.0)	3	(.3)	0	(.0)	0	(.0)	1	(.3)
Lifetime experience (heroin)												
No	129	(98.5)	244	(97.6)	933	(98.4)	152	(98.7)	146	(97.3)	323	(98.5)
Yes	0	(.0)	0	(.0)	3	(.3)	0	(.0)	0	(.0)	0	(.0)
Lifetime experience (NPSs)												
No	126	(96.2)	246	(98.4)	935	(98.6)	152	(98.7)	146	(97.3)	324	(98.8)
Yes	2	(1.5)	0	(.0)	2	(.2)	0	(.0)	0	(.0)	1	(.3)
Past-year experience (any drug)												
No	126	(96.2)	242	(96.8)	932	(98.3)	152	(98.7)	146	(97.3)	321	(97.9)
Yes	0	(.0)	1	(.4)	2	(.2)	0	(.0)	0	(.0)	1	(.3)
Past-year experience (organic so	lvents)										
No	130	(99.2)	246	(98.4)	943	(99.5)	152	(98.7)	148	(98.7)	326	(99.4)
Yes	0	(.0)	1	(.4)	1	(.1)	0	(.0)	0	(.0)	0	(.0)
Past-year experience (cannabis)												
No	130	(99.2)	247	(98.8)	939	(99.1)	152	(98.7)	147		322	(98.2)
Yes	0	(.0)	0	(.0)	1	(.1)	0	(.0)	0	(.0)	1	(.3)
Past-year experience (methamp	hetami	ine)										
No	130	(99.2)	247	(98.8)	941	(99.3)	152	(98.7)	147	(98.0)	324	(98.8)
Yes	0	(.0)	0	(.0)	0	(.0)	0	(.0)	0	(.0)	0	(.0)
Past-vear experience (MDMA)												
No	130	(99.2)	247	(98.8)	939	(99.1)	152	(98.7)	146	(97.3)	324	(98.8)
Yes	0	(.0)	0	(.0)	0	(.0)	0	(.0)	0	(.0)	0	(.0)
Past-vear experience (cocaine)												
No	129	(98.5)	247	(98.8)	938	(98.9)	152	(98.7)	146	(97.3)	324	(98.8)
Yes	0	(.0)	0	(.0)	0	(.0)	0	(.0)	0	(.0)	0	(.0)
Past-year experience (heroin)		((,))		(,		(,		(,		(,		(10)
No	129	(98.5)	244	(97.6)	936	(98.7)	152	(98.7)	146	(97.3)	323	(98.5)
Yes	0	(.0)	0	(.0)	0	(.0)	0	(.0)	0	(.0)	0	(.0)
Past-year experience (NPSs)	Ŭ	()	Ŭ	()	Ŭ		Ŭ	()	Ŭ	()	Ŭ	()
No	128	(97.7)	246	(98.4)	937	(98.8)	152	(98.7)	146	(97.3)	325	(99.1)
Yes	0	(.0)	0	(.0)	0	(.0)	0	(.0)	0	(.0)	0	(.0)

Table 57. Drug Use Experience by Residence area (n = 3076) continued

-						R	lesiden	ce area					
	Ki	nki	Chu	goku	\mathbf{Sh}	ikoku	Kita-K	Xyusyu	Min	ami-	Tot	al	
	n=	442	n=	191	n	=88	n=	229	n=	165	n=30	076	p-value
	n	(%)	n	(%)	n	(%)	n	(%)	n	(%)	n	(%)	
Lifetime experience (any o	drug)												0.798
No	420	(95.0)	180	(94.2)	86	(97.7)	223	(97.4)	158	(95.8)	2,940	(95.6)	
Yes	13	(2.9)	6	(3.1)	1	(1.1)	3	(1.3)	5	(3.0)	78	(2.5)	
Lifetime experience (organ	nic solv	vents)											0.894
No	431	(97.5)	186	(97.4)	88	(100.0)	223	(97.4)	160	(97.0)	3,003	(97.6)	
Yes	6	(1.4)	4	(2.1)	0	(.0)	3	(1.3)	4	(2.4)	49	(1.6)	
Lifetime experience (cann	abis)												0.660
No	432	(97.7)	187	(97.9)	88	(100.0)	224	(97.8)	163	(98.8)	3,007	(97.8)	
Yes	6	(1.4)	1	(.5)	0	(.0)	2	(.9)	0	(.0)	35	(1.1)	
Lifetime experience (meth	amphe	etamine)											0.831
No	436	(98.6)	186	(97.4)	88	(100.0)	225	(98.3)	163	(98.8)	3,026	(98.4)	
Yes	1	(.2)	1	(.5)	0	(.0)	1	(.4)	0	(.0)	16	(.5)	
Lifetime experience (MDN	IA)												0.870
No	433	(98.0)	187	(97.9)	88	(100.0)	225	(98.3)	163	(98.8)	3,032	(98.6)	
Yes	2	(.5)	1	(.5)	0	(.0)	1	(.4)	0	(.0)	6	(.2)	
Lifetime experience (cocai	ne)												0.911
No	434	(98.2)	188	(98.4)	88	(100.0)	226	(98.7)	163	(98.8)	3.030	(98.5)	
Yes	0	(.0)	0	(.0)	0	(.0)	0	(.0)	0	(.0)	5	(.2)	
Lifetime experience (hero	in)	(,		(,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,		(,		(,		((,))		(/	0.925
No	435	(98.4)	187	(97 9)	88	(100.0)	226	(98.7)	163	(98.8)	3.026	(98.4)	
Yes	0	(0)	0	(0)	0	(0)	0	(0)	0	(0)	3	(1)	
Lifetime experience (NPS	z)	(10)	0	(10)	0	()	Ũ	(10)	0	(10)	0	(11)	0.829
No	434	(98.2)	186	(974)	86	(97.7)	225	(98.3)	162	(98.2)	3.022	(98.2)	0.020
Ves	2	(5)	100	(5)	1	(1 1)	1	(14)	102	(6)	11	(00. <u></u>)	
Past-year experience (any	drug)	(.0)	1	(.0)	1	(1.1)	1	(.1)	1	(.0)		(. 1)	0.919
No	432	(977)	186	(974)	87	(98.9)	226	(98.7)	163	(98.8)	3 013	(98.0)	0.010
Ves	0	(01.1)	0	(01.1)	0	(0)	0	(00.1)	0	(00.0)	4	(1)	
Past-year experience (org	anic so	(.0) lvents)	0	(.0)	0	(.0)	0	(.0)	0	(.0)	1	(,1)	0.928
No	437	(98.9)	190	(99.5)	88	(100.0)	226	(98.7)	164	(99.4)	3 050	(99.2)	0.020
Ves	101	(00.0)	100	(00.0)	00	(100.0)	0	(00.1)	0	(00.4)	2	(1)	
Past-year experience (can	nahie)	(.0)	0	(.0)	0	(.0)	0	(.0)	0	(.0)	-	(,1)	0 989
No	/138	(99.1)	188	(98.4)	88	(100.0)	226	(98.7)	163		3 040	(98.8)	0.000
Ves	100	(00.1)	0	(00.4)	00	(100.0)	0	(00.1)	105	(0)	9,040	(1)	
Post-voor ovnorioneo (mot	hamp	(.0)	3	(.0)	0	(.0)	0	(.0)	0	(.0)	2	(,1)	0.869
No	137	(08.0)	187	(97.9)	88	(100.0)	99G	(98.7)	163	(08.8)	3 049	(080)	0.005
Vos	104	(30.3)	107	(31.3)	00	(100.0)	220	(30.1)	105	(30.0)	0,042	(30.3)	
Post-yoor ovnorionco (MD	MA)	(.0)	0	(.0)	0	(.0)	0	(.0)	0	(.0)	0	(.0)	0.882
No	495	(08.4)	100	(08.4)	00	(100.0)	996	(08.7)	169	(00 0)	2 0 2 0	$(0 \otimes \otimes)$	0.002
NO	455	(90.4)	100	(96.4)	00	(100.0)	220	(90.1)	105	(90.0)	5,050	(90.0)	
Tes Destaura en enconier en (enco	0 ((.0)	0	(.0)	0	(.0)	0	(.0)	0	(.0)	0	(.0)	0.009
Past-year experience (coca	ame)	(00.0)	100	(02.4)	00	(100.0)	000	(08.7)	1.00	(00.0)	2.025	(09.7)	0.908
NO	434	(98.2)	188	(98.4)	88	(100.0)	226	(98.7)	163	(98.8)	3,035	(98.7)	
res (1	• \	(.0)	0	(.0)	0	(.0)	0	(.0)	0	(.0)	0	(.0)	0.001
rast-year experience (her	01n)	(00, 1)	105	(07.0)	00	(100.0)	000	$(0, \overline{n})$	1.00	(00,0)	9,020		0.891
INO X	435	(98.4)	187	(97.9)	88	(100.0)	226	(98.7)	163	(98.8)	3,029	(98.5)	
Tes (TD)	0	(.0)	0	(.0)	0	(.0)	0	(.0)	0	(.0)	0	(.0)	0.000
Past-year experience (NPS	58/	(0, c, c)	105	$(0, \overline{0}, 0)$	~-	(0,2,1)	000	$(0, \overline{n})$	1.00	(0, 0, 0)	0.000	(0, 0, 0)	0.932
N0	436	(98.6)	187	(97.9)	87	(98.9)	226	(98.7)	163	(98.8)	3,033	(98.6)	
Yes	0	(.0)	0	(.0)	0	(.0)	0	(.0)	0	(.0)	0	(.0)	

Table 58.	Drug Use	Experience	by Sex	(n = 3076)
-----------	----------	------------	--------	------------

	Sex						
	Me	en	Won	nen	Tot	al	
	n = 1	466	n = 1	610	n = 3	076	P-value
	n	(%)	n	(%)	n	(%)	
Lifetime experience (any dr	ug)						< 0.001
No	1,374	(93.7)	1,566	(97.3)	2,940	(95.6)	
Yes	58	(4.0)	20	(1.2)	78	(2.5)	
Lifetime experience (organi	ic solven	ts)					0.003
No	1,417	(96.7)	1,586	(98.5)	3,003	(97.6)	
Yes	34	(2.3)	15	(.9)	49	(1.6)	
Lifetime experience (canna	bis)						< 0.001
No	1,416	(96.6)	1,591	(98.8)	3,007	(97.8)	
Yes	28	(1.9)	7	(.4)	35	(1.1)	
Lifetime experience (metha	mpheta	mine)					< 0.001
No	1,429	(97.5)	1,597	(99.2)	3,026	(98.4)	
Yes	14	(1.0)	2	(.1)	16	(.5)	
Lifetime experience (MDMA	4)						0.059
No	1,438	(98.1)	1,594	(99.0)	3,032	(98.6)	
Yes	5	(.3)	1	(.1)	6	(.2)	
Lifetime experience (cocain	e)						0.023
No	1,437	(98.0)	1,593	(98.9)	3,030	(98.5)	
Yes	5	(.3)	0	(.0)	5	(.2)	
Lifetime experience (heroin	1)						0.016
No	1,433	(97.7)	1,593	(98.9)	3,026	(98.4)	
Yes	3	(.2)	0	(.0)	3	(.1)	
Lifetime experience (NPSs)							0.137
No	1,434	(97.8)	1,588	(98.6)	3,022	(98.2)	
Yes	8	(.5)	3	(.2)	11	(.4)	
Past-year experience (any d	lrug)						0.193
No	1,429	(97.5)	1,584	(98.4)	3,013	(98.0)	
Yes	2	(.1)	2	(.1)	4	(.1)	
Past-year experience (organ	nic solve	nts)					0.114
No	1,449	(98.8)	1,601	(99.4)	3,050	(99.2)	
Yes	2	(.1)	0	(.0)	2	(.1)	
Past-year experience (cann	abis)						0.055
No	1,444	(98.5)	1,596	(99.1)	3,040	(98.8)	
Yes	0	(.0)	2	(.1)	2	(.1)	
Past-year experience (meth	amphet	amine)					0.019
No	1,443	(98.4)	1,599	(99.3)	3,042	(98.9)	
Yes	0	(.0)	0	(.0)	0	(.0)	
Past-year experience (MDM	IA)						0.110
No	1,443	(98.4)	1,595	(99.1)	3,038	(98.8)	
Yes	0	(.0)	0	(.0)	0	(.0)	
Past-year experience (cocai	ne)						0.160
No	1,442	(98.4)	1,593	(98.9)	3,035	(98.7)	
Yes	0	(.0)	0	(.0)	0	(.0)	
Past-year experience (heroi	in)						0.025
No	1,436	(98.0)	1,593	(98.9)	3,029	(98.5)	
Yes	0	(.0)	0	(.0)	0	(.0)	
Past-year experience (NPSs	3)						0.281
No	1,442	(98.4)	1,591	(98.8)	3,033	(98.6)	
Yes	0	(.0)	0	(.0)	0	(.0)	

Table 59.	Drug Use	Experience	by Age	group	(n =	3076)
-----------	----------	------------	--------	-------	------	-------

Interpart Interpart <	_								Age gr	oup												
n=222 n=382 n=382 n=573 n=4953 n=4973 n=3076 prvalue Lifetime experience (any drug) Image (any drug) <t< td=""><td></td><td>10</td><td>0s</td><td>2</td><td>0s</td><td>3</td><td>0s</td><td>4</td><td>0s</td><td>5</td><td>0s</td><td>6</td><td>0s</td><td>Tot</td><td>al</td><td></td></t<>		10	0s	2	0s	3	0s	4	0s	5	0s	6	0s	Tot	al							
n (%) n (%)<		n=	222	n=	382	n=	553	n=	751	n=	695	n=	473	n=30	076	p-value						
11 define experience (ny ±up)10. 10.10. 10.10. 10.10. 10.10. 10.10. 10.10. 10.10. 10.10. 10.10. 10.10. 10.10. 10.10. 10.10. 10.10. 10.10. 10.10. 10.10. 10.10. 10.10. 10.10. 10.10. 10.10. 10.10. 10.10. 10.10. 10.10. 10.10. 10.10. 10.10. 10.10. 10.10. 10.10. 10.10. 10.10. 10.10. 10.10. 10.10. 10.10. 10.10. 10.10. 10.10. 10.10. 10.10. 10.10. 10.10. 10. 10.10. 10. 10.10. 10. 10.10. 10. 10.10. 10. 10.10. 10. 10. 10.10. 10. 10. 10. 10. 10.10. 10. 10. 10. 10. 10. 10. 10. 10. 10.		n	(%)	n	(%)	n	(%)	n	(%)	n	(%)	n	(%)	n	(%)							
No 19 (98.4) 368 (96.2) 718 (35.4) 65.5 (94.2) (35.0) (55.0) (35.0) (55.0) (35.0) (55.0) (35.0) (55.0) (35.0) (55.0) (37.0) (37.0) (37.0) (37.0) (37.0) (37.0) (37.0) (37.0) (37.0) (37.0) (37.0) (37.0) (37.0) (37.0) (37.0) (37.0) (37.0) (37.0) (37.0) (37.0) (37.0) (37.0) (37.0) (37.0) (37.0) (37.0) (37.0) (37.0) (37.0) (37.0) (37.0) (37.0) (37.0) (37.0) (37.0) (37.0) (37.0) (37.0) (37.0) (37.0) (37.0) (37.0) (37.0) (37.0) (37.0) (37.0) (37.0) (37.0) (37.0) (37.0) (37.0) (37.0) (37.0) (37.0) (37.0) (37.0) (37.0) (37.0) (37.0) (37.0) (37.0) (37.0) (37.0) (37.0) (37.0) (37.0) <th< td=""><td>Lifetime experience (an</td><td>y drug</td><td>g)</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td>0.101</td></th<>	Lifetime experience (an	y drug	g)													0.101						
Yee 0 (.0) 8 (2.1) 15 (2.7) 23 (3.1) 29 (1.3) 9 (1.9) 78 (2.5) Lifetime experience forganica Solventis 0 (0) 3 (8.6) 544 (98.4) 732 (97.5) 674 (97.0) 458 (96.8) 30.03 (97.6) 10 10 10 11 (2.0) 11 (2.0) 11 (2.0) 11 (2.0) 11 (2.0) 11 (2.0) 11 (2.0) 11 (2.0) 11 (2.0) 11 (2.0) 13 (4.0) (3.0) (3.0) (3.0) (3.0) (3.0) (3.0) (3.0) (3.0) (3.0) (3.0) (3.0) (3.0) (3.0) (3.0) (3.0) (3.0) (3.0) (3.0) (3.0) (3.0) (3.0) (3.0) (3.0) (3.0) (3.0) (3.0) (3.0) (3.0) (3.0) (3.0) (3.0) (3.0) (3.0) (3.0) (3.0)	No	219	(98.6)	368	(96.3)	530	(95.8)	718	(95.6)	655	(94.2)	450	(95.1)	2,940	(95.6)							
Lifetime experience (spanie selvents) vs 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0	Yes	0	(.0)	8	(2.1)	15	(2.7)	23	(3.1)	23	(3.3)	9	(1.9)	78	(2.5)							
No 219 (9.8) 374 (9.4) 3 (9.7) 674 (97.0) 678 (97.0) 480 (9.0) (9.0) (9.0) (9.0) (9.0) (9.0) (9.0) (9.0) (9.0) (9.0) (9.0) (9.0) (9.0) (9.0) (9.0) (9.0) (1.0) (1.0) (1.0) (1.0) (1.0) (1.0) (1.0) (1.0) (1.0) (1.0) (1.0) (1.0) (1.0) (1.0) (1.0) (1.0) (1.0) (1.0) (1.0) (1.0) (1.0) (1.0) (1.0) (1.0) (1.0) (1.0) (1.0) (1.0) (1.0) (1.0) (1.0) (1.0) (1.0) (1.0) (1.0) (1.0) (1.0) (1.0) (1.0) (1.0) (1.0) (1.0) (1.0) (1.0) (1.0) (1.0) (1.0) (1.0) (1.0) (1.0) (1.0) (1.0) (1.0) (1.0) (1.0) (1.0) (1.0) (1.0) (1.0) (1.0) (1.0)	Lifetime experience (or	ganic	solvents	3)												0.058						
Yes 0 (.0) 3 (.8) 6 (.1) 18 (2.4) 13 (1.9) 9 (1.9) 49 (1.6) Lifetime experience (cannubis) 0 (.0) 4 (1.0) 11 (2.0) 11 (1.5) 9 (1.3) 0 (.0) 3.5 (1.1) Lifetime experience (methammpethamine) 10 (.0) 0 (.0) 51 (9.8, 0) 741 (9.8, 7) 682 (9.8, 1) 463 (9.7) 3.026 (9.8, 1) Lifetime experience (MDMA) 10 (.0) 0 (.0) 3 (5.1) 745 (9.2) 683 (9.8, 1) 463 (9.7) 3.026 (9.8, 1) Lifetime experience (cocanice) 0 (.0) 1 (.2) 3 (.4) 1 1 10 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0	No	219	(98.6)	376	(98.4)	544	(98.4)	732	(97.5)	674	(97.0)	458	(96.8)	3,003	(97.6)							
Lifetime experience (nambis) visite 98.6 97.8 97.0 17 120 11 1.10 15 9 1.30 140 98.10 3.007 97.08 97.08 100 10 100 10 100 10 100 10 100 10 100 10 100 10 100 10 100 10 100 10 100 10 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100	Yes	0	(.0)	3	(.8)	6	(1.1)	18	(2.4)	13	(1.9)	9	(1.9)	49	(1.6)							
No 19 08.6 375 08.21 371 07.10 736 08.00 676 07.30 04.4 08.10 03.00 07.00 37.00 07.00 37.00 07.00 37.00 07.00 37.00 07.00 37.00 07.00 37.00 07.00 37.00 07.00 37.00 07.00 37.00 07.00 37.00 07.00 37.00 08.70 37.00 08.70 37.00 08.70 37.00 08.70 37.00 08.70 37.00 08.70 37.00 08.70 37.00 08.70 37.00 08.70 37.00 08.70 37.00 08.70 37.00 08.70 37.00 08.70 37.00 08.70 37.00 08.70 37.00 08.70 37.00 08.70 37.00 08.70 37.00 08.70 37.00 08.70 37.00 08.70 37.00 08.70 37.00 08.70 37.00 08.70 37.00 08.70 37.00 08.70 37.00 08.70 37.00 08.70 37.00 08.70 37.00 08.70 37.00 08.70	Lifetime experience (ca	nnabi	s)													0.044						
Yes 0 (.0) 4 (.10) 11 (.20) 11 (.15) 9 (.13) 0 (.0) 35 (.1) Lifetime experience (member) 0 (.0) 0 (.0) 0 (.0) 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0	No	219	(98.6)	375	(98.2)	537	(97.1)	736	(98.0)	676	(97.3)	464	(98.1)	3,007	(97.8)							
Lifetime experience (methany-betawne) 0.8.0 378 69.00 5.43 69.20 7.4 68.7 68.7 68.1 63 69.1 63 69.61 1 62.0 6 7.8 69.2 63.0 63 99.2 63.0 83 98.3 463 67.0 30.2 98.61 No 219 98.61 377 69.7 545 69.20 63.0 83.9 463 67.09 0.0 6 23 Ves 0.0 0.00 0.0 7.0 7.45 59.2 63.0 83.9 46.3 67.09 0.0 6 23 Ves 0.0 0.00 0.0 1 12.2 3 1.40 1.0 0.0 55 69.2 Ves 0.00 0.00 0.00 0.00 1.02 3.1 1.40 1.0 0.0 0.0 3.02 98.4 Ves 0.00 0.00 0.00 0.00 1.02 3.01 98.9 6.0 1.0 1.0 1.0 0.0 0.0 0.0 0	Yes	0	(.0)	4	(1.0)	11	(2.0)	11	(1.5)	9	(1.3)	0	(.0)	35	(1.1)							
No 210 08.60 378 09.00 543 98.20 741 08.20 68.2 08.10 68.3 07.00 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 <td>Lifetime experience (me</td> <td>etham</td> <td>phetam</td> <td>ine)</td> <td></td> <td>0.266</td>	Lifetime experience (me	etham	phetam	ine)												0.266						
Yes 0 (.0) 0 (.0) 5 (.0) 6 (.8) 4 (.6) 1 (.2) 16 (.5) Lifetime experience (002110) No (.0) 0 (.0) 3 (.5) 2 (.3) 1 (.1) 0 (.0) 0 (.2) 0.21 0.21 0.21 0.21 0.21 0.21 0.21 0.21 0.21 0.21 0.21 0.21 0.21 0.21 0.21 0.21 0.21 0.21 0.21 0.21 0.21 0.21 0.21 0.21 0.21 0.21 0.21 0.21 0.21 0.21 0.21 0.21 0.21 0.21 0.21 0.21 0.21 0.21 0.21 0.21 0.21 0.21 0.21 0.21 0.21 0.21 0.21 0.21 0.21 0.21 0.21 0.21 0.21 0.21 0.21 0.21 0.21 0.21 0.21 0.21 0.21 0.21 0.21 0.21 0.21 0.21 0.21 0.21 0.21 0.21 0.21	No	219	(98.6)	378	(99.0)	543	(98.2)	741	(98.7)	682	(98.1)	463	(97.9)	3,026	(98.4)							
Lifetime experience (MDMA) 219 98.6 377 (98.7) 545 (98.6) 745 (99.2) 683 (98.3) 463 (97.9) 3.032 (98.6) 773 No 219 (98.6) 376 (98.4) 547 (98.9) 743 (98.9) 682 (98.1) 463 (97.9) 3.032 (98.6) 773 (98.7) 743 (98.9) 682 (98.1) 463 (97.9) 3.032 (98.4) 743 (98.9) 681 98.0 681 98.0 460 (97.3) 3.026 (98.4) 743 (98.9) 681 98.0 681 98.0 681 98.0 681 98.0 680 97.0 680 680 97.0 680 680 97.0 3.026 68.4 743 748 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 00	Yes	0	(.0)	0	(.0)	5	(.9)	6	(.8)	4	(.6)	1	(.2)	16	(.5)							
No 219 (98.6) 377 (98.7) 645 (98.6) 745 (99.2) 683 (98.3) 463 (97.9) 3,032 (98.6) Yes 0 (.0) 0 (.0) 3 (.5) 2 (.3) 1 (.1) 0 (.0) 3,032 (98.6) Yes 0 (.0) 0 (.0) 1 (.2) 3 (.4) 1 (.1) 0 (.0) 3,032 (98.6) Yes 0 (.0) 0 (.0) 1 (.2) 3 (.4) 1 (.1) 0 (.6) 3,032 (98.6) Yes 0 (.0) 377 (98.7) 7.45 (98.7) 7.43 (.8) 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0	Lifetime experience (M	DMA)														0.221						
Yes 0 (.0) 0 (.0) 3 (.5) 2 (.3) 1 (.1) 0 (.0) 6 (.2) Lifetime experience (occaine) 376 (98.6) 376 (98.6) 547 (98.9) 68.2 98.1 463 (97.9) 3,030 (98.5) (2) Yes 0 (.0) 0 (.0) 743 (98.9) 681 (98.0) 460 (97.3) 3,026 (98.4) (36.7) No 219 (98.6) 377 (98.7) 546 (98.7) 743 (98.0) 681 (98.0) 60 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 <	No	219	(98.6)	377	(98.7)	545	(98.6)	745	(99.2)	683	(98.3)	463	(97.9)	3,032	(98.6)							
Lifetime experience (scaling)0.810.820.820.810.630.97.90.80.90.820.810.630.97.90.80.90.85.90.820.810.810.810.810.810.810.810.810.810.810.810.810.810.810.810.810.810.810.810.810.810.810.810.810.810.810.810.810.810.810.810.810.810.810.810.810.810.810.810.810.810.810.810.810.810.810.810.810.810.810.810.810.810.810.810.810.810.810.810.810.810.810.810.810.810.810.810.810.810.810.810.810.810.810.810.810.810.810.810.810.810.810.810.810.810.810.810.810.810.810.810.810.810.810.810.810.810.810.810.810.810.810.810.810.810.810.810.810.810.810.810.810.810.810.810.810.810.810.810.810.810.810.810.810.810.810.810.810.810.810.810.810.810.810.810.81 <th0.81< th="">0.81</th0.81<>	Yes	0	(.0)	0	(.0)	3	(.5)	2	(.3)	1	(.1)	0	(.0)	6	(.2)							
No219(98.6)376(98.4)(98.7)(98.7)(98.2)(98.1)(43(97.9)3,030(98.5)(0.3)Yes0(0.0)0(0.0)1(2.0)3(4.1)1(1.1)0(0.0)5(2.0)No219(98.6)377(98.7)546(98.7)743(98.0)681(98.0)(60)(0.0)33,026(98.7)No219(98.6)377(98.7)546(98.7)743(98.7)681(98.0)460(7.3)3,026(98.7)No219(98.6)377(98.7)546(98.7)741(98.7)681(98.0)62(97.7)3,026(98.7)Yes0(0.0)2(5.0)44(7.1)(98.7)687(97.6)458(96.8)3,013(8.0)Pastycar experience(77.7)(98.6)374(97.9)544(98.4)(98.7)(97.6)687(98.8)(66)(98.5)3,013(98.0)Pastycar experience(77.7)(98.7)687(98.7)687(98.8)(66)(98.7)3,050(99.2)Yes0(0.0)1(3.0)(9.2)57(9.2)747(9.2)687(9.4)(66(9.8)3,050(9.2)Yes0(0.0)1(3.0)1(2.0)0(0.0)0(0.0)0(0.0)(0.0)(0.0) <td>Lifetime experience (co</td> <td>caine)</td> <td></td> <td>0.371</td>	Lifetime experience (co	caine)														0.371						
Yes 0 (.0) 0 (.0) 1 (.2) 3 (.4) 1 (.1) 0 (.0) 5 (.2) Lifetime experience (heroin) 219 (98.6) 377 (98.7) 546 (98.7) 73 (98.9) 681 (98.0) 460 (97.3) 30.26 (98.4) (98.6) 37 (98.7) 681 (98.0) 462 (97.7) 3.022 (98.2) (98.7) (98.7) (98.7) (98.7) (98.7) 681 (98.0) 462 (97.7) 3.022 (98.2) (98.7) (98.7) (98.7) (98.7) 681 (98.0) 681 (98.7) 3.013 (98.0) (98.7) (98.7) (98.7) 681 (98.7) 681 (98.7) 681 (98.7) 681 (98.7) 681 (98.7) 681 (98.7) 681 (98.7) 681 (98.7) 681 (98.7) 681 (98.7) 681 (98.7) 681 (98.7) 681 (98.7) 681 (98.7) 681 (98.7) 681 (98.7) 681 (98.7) <td>No</td> <td>219</td> <td>(98.6)</td> <td>376</td> <td>(98.4)</td> <td>547</td> <td>(98.9)</td> <td>743</td> <td>(98.9)</td> <td>682</td> <td>(98.1)</td> <td>463</td> <td>(97.9)</td> <td>3,030</td> <td>(98.5)</td> <td></td>	No	219	(98.6)	376	(98.4)	547	(98.9)	743	(98.9)	682	(98.1)	463	(97.9)	3,030	(98.5)							
Lifetime experience (heroin) 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 <td< td=""><td>Yes</td><td>0</td><td>(.0)</td><td>0</td><td>(.0)</td><td>1</td><td>(.2)</td><td>3</td><td>(.4)</td><td>1</td><td>(.1)</td><td>0</td><td>(.0)</td><td>5</td><td>(.2)</td><td></td></td<>	Yes	0	(.0)	0	(.0)	1	(.2)	3	(.4)	1	(.1)	0	(.0)	5	(.2)							
No 219 98.61 377 98.71 546 (98.7) 743 (98.0) 681 (98.0) 460 (97.3) 30.26 (98.4) Lifetime experience (NPSs)	Lifetime experience (he	roin)														0.038						
Yes 0 (.0) 0 (.0) 3 (.4) 0 (.0) 0 (.0) 3 (.1) Lifetime experience (NPSs) 19 98.6) 375 98.2) 544 98.4) 741 (98.7) 681 (98.0) 462 (97.7) 3.022 (98.2) (98.6) 376 (98.2) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) <	No	219	(98.6)	377	(98.7)	546	(98.7)	743	(98.9)	681	(98.0)	460	(97.3)	3,026	(98.4)							
Lifetime experience (NPSs) 0 219 98.60 375 98.20 544 98.40 741 98.70 681 98.00 462 97.70 3,022 98.20 Yes 0 (.0) 2 (.5) 4 (.7) 2 (.3) 3 (.4) 0 (.0) 11 (.4) Past-year experience (any drug) Ves 0 (.0) 1 (.2) 14 (.98.7) 684 (.96.7) 10 458 (.96.8) 30.01 (.90.0) Yes 0 (.0) 1 (.2) 1 (.1) 0 (.0) 1 (.2) 14 (.1) Past-year experience (organic solvents) Ves 0 (.0) 0 (.0) 1 (.2) 1 (.2) 4 (.1) Past-year experience (cannabis) Ves 0 (.0) 1 (.3) 1 (.2) 0 (.0) 0 (.0) 0 (.0) 0 (.0) 0 (.0) 0 (.0) 0 (.0) 0 (.0) <td< td=""><td>Yes</td><td>0</td><td>(.0)</td><td>0</td><td>(.0)</td><td>0</td><td>(.0)</td><td>3</td><td>(.4)</td><td>0</td><td>(.0)</td><td>0</td><td>(.0)</td><td>3</td><td>(.1)</td><td></td></td<>	Yes	0	(.0)	0	(.0)	0	(.0)	3	(.4)	0	(.0)	0	(.0)	3	(.1)							
No 219 98.61 375 98.20 544 (98.4) 741 (98.7) 681 (98.0) 462 (97.7) 3,022 (98.2) Yes 0 (.0) 2 (.5) 4 (.7) 2 (.3) 3 (.4) 0 (.0) 11 (.4) Past-year experience (any drug)	Lifetime experience (NI	PSs)														0.455						
Yes 0 0.0 2 0.5 4 0.7 2 0.3 3 0.4 0 0.0 11 0.4 Past-year experience (any drug) 219 08.60 374 09.0 544 08.40 70 08.50 678 07.6 458 96.80 3,013 08.00 Yes 0 0 0 0 1 0.2 1 0.0 0 0 0.328 No 219 08.60 379 09.2 550 09.57 749 09.70 687 08.80 466 08.50 3,050 09.2 0.328 No 219 08.60 379 09.20 550 09.57 749 09.50 685 464 08.10 3,040 08.20 (1) Past-year experience (cannabis) Ves 0 0.0 0 0.00 0 0.00 0 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 <t< td=""><td>No</td><td>219</td><td>(98.6)</td><td>375</td><td>(98.2)</td><td>544</td><td>(98.4)</td><td>741</td><td>(98.7)</td><td>681</td><td>(98.0)</td><td>462</td><td>(97.7)</td><td>3,022</td><td>(98.2)</td><td></td></t<>	No	219	(98.6)	375	(98.2)	544	(98.4)	741	(98.7)	681	(98.0)	462	(97.7)	3,022	(98.2)							
Past-year experience (any drug) 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0	Yes	0	(.0)	2	(.5)	4	(.7)	2	(.3)	3	(.4)	0	(.0)	11	(.4)							
No 219 98.6 374 97.9 544 98.4 740 98.5 678 97.6 458 96.8 3,013 98.0 Yes 0 (.0) 1 (.3) 1 (.2) 1 (.1) 0 (.0) 1 (.2) 4 (.1) Past-year experience (organic solvents) 0 0.0 0 0.0 0 0.0 1 (.1) 0 (.0) 1 (.2) 4 (.1) Past-year experience (organic solvents) 0 0.0 0 0.0 1 (.1) 0 (.0) 1 (.2) 2 (.1) Past-year experience (cannabis) 0 0.0 0 0.0 1 0.1 0 0.0 0 0.322 0.342 0.343 0.888 3.040 98.89 3.04 98.9 747 09.50 685 464 08.10 3.042 08.89 0.303 0.888 98.9 0 0.0 0 0.0 0 0.0 0.0 0.0 0.0 0.0 0.0 0.	Past-year experience (a	ny dru	lg)													0.606						
Yes 0 (.0) 1 (.3) 1 (.2) 1 (.1) 0 (.0) 1 (.2) 4 (.1) Past-year experience (organic suburs) 219 (98.6) 379 (99.2) 550 (99.7) 687 (98.8) 466 (98.5) 3,050 (99.2) 2 (.1) (.1) 0 (.0) 1 (.2) 2 (.1) Yes 0 (.0) 0 (.0) 0 (.0) 1 (.1) 0 (.0) 1 (.2) 2 (.1) Past-year experience (cannabis) 0 (.0) 1 (.3) 1 (.2) 0 (.0) 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0	No	219	(98.6)	374	(97.9)	544	(98.4)	740	(98.5)	678	(97.6)	458	(96.8)	3,013	(98.0)							
Past-year experience (organic solvents) 0 0.92.0 550 09.50 749 09.70 687 08.80 466 08.50 3,050 09.20 0 Yes 0 (.0) 0 (.0) 0 (.0) 1 (.1) 0 0.0 1 0.22 2 0.10 Past-year experience (cannabis) Ves 0 (.0) 1 (.2) 0 0.0 0 0.02 0.342 No 219 98.60 378 (99.0) 547 (98.9) 747 (99.5) 685 464 (98.1) 3,040 (98.8) Yes 0 (.0) 1 (.3) 1 (.2) 0 (.0) 0 (.0) 29 (98.0) 548 (99.1) 747 (99.5) 686 (98.7) 464 (98.1) 3,042 (98.9) 949 946 (.0) 0 (.0) 0 (.0) 0 (.0) 0 (.0) 0 (.0) 0 (.0) 0 (.0) 0 (.0) 0 (.0)	Yes	0	(.0)	1	(.3)	1	(.2)	1	(.1)	0	(.0)	1	(.2)	4	(.1)							
No 219 (98.6) 379 (99.2) 550 (99.5) 749 (99.7) 687 (98.8) 466 (98.5) 3,050 (99.2) Yes 0 (.0) 0 (.0) 0 (.0) 1 (.1) 0 (.0) 1 (.2) 2 (.1) Past-year experience (cannabis) 0 0.342 No 219 (98.6) 378 (99.0) 547 (98.9) 747 (99.5) 685 464 (98.1) 3,040 (98.8) Yes 0 (.0) 1 (.3) 1 (.2) 0 (.0) 0 (.0) 2 (.1) Past-year experience (methamphetamine) 0 (.0) 0 No 219 (98.6) 377 (98.7) 548 (99.1) 747 (99.5) 686 (98.7) 464 (98.1) 3,042 (98.9) (.0) Yes 0 (.0) 0 (.0) 0 (.0) 0 (.0) 0 (.0) </td <td>Past-year experience (o</td> <td>rganio</td> <td>solven</td> <td>ts)</td> <td></td> <td>0.328</td>	Past-year experience (o	rganio	solven	ts)												0.328						
Yes 0 (.0) 0 (.0) 0 (.0) 1 (.1) 0 (.0) 1 (.2) 2 (.1) Past-year experience (cannabis) 219 (98.6) 378 (99.0) 547 (98.9) 747 (99.5) 685 464 (98.1) 3,040 (98.8) Yes 0 (.0) 1 (.3) 1 (.2) 0 (.0) 0 (.0) 2 (.1) Past-year experience (methampterametametametametametametametametametamet	No	219	(98.6)	379	(99.2)	550	(99.5)	749	(99.7)	687	(98.8)	466	(98.5)	3,050	(99.2)							
Past-year experience (canabis) No 219 98.60 378 99.00 547 98.90 747 99.50 685 464 98.10 3,040 98.80 Yes 0 (.0) 1 (.3) 1 (.2) 0 (.0) 0 (.0) 2 (.1) Past-year experience (methamphetammetric methods) Xes 99.86 378 99.00 548 99.11 747 99.50 686 98.71 464 98.10 3,042 98.90 760 760 760 0 0.00 0 0.00 0 0.00 0 0.00 0 0.00 0 0.00 0 0.00 0 0.00 0 0.00 0 0.00 0 0.00 0 0.00 0 0.00 0 0.00 0 0.00 0 0.00 0 0.00 0 0.00 0 0.00 0 0.00 0 0.00 0 0.00 0 0.00 0 0.00 0 0.00 0 0.00 0.00 0.00 0.00<	Yes	0	(.0)	0	(.0)	0	(.0)	1	(.1)	0	(.0)	1	(.2)	2	(.1)							
No 219 (98.6) 378 (99.0) 547 (98.9) 747 (99.5) 685 464 (98.1) 3,040 (98.8) Yes 0 (.0) 1 (.3) 1 (.2) 0 (.0) 0 (.0) 2 (.1) Past-year experience (methamphetamine) 0 No 219 (98.6) 378 (99.0) 548 (99.1) 747 (99.5) 686 (98.7) 464 (98.1) 3,042 (98.9) Yes 0 (.0) 0 (.0) 0 (.0) 0 (.0) 0 (.0) 0 (.0) 0 (.0) 0 (.0) 0 (.0) 0 (.0) 0 (.0) 0 (.0) 0 (.0) 0 (.0) 0 (.0) 0 (.0) 0 (.0) 0 (.0) 0 (.0) 0 (.0) 0 (.0) 0 (.0) 0 (.0) 0 (.0) 0 (.0) 0 (.0) 0 0 0	Past-year experience (c	annab	ois)													0.342						
Yes 0 (.0) 1 (.3) 1 (.2) 0 (.0) 0 (.0) 0 (.0) 2 (.1) Past-year experience (methamphetamme) 0 219 98.60 378 (99.0) 548 (99.1) 747 (99.5) 686 (98.7) 464 (98.1) 3,042 (98.9) (98.9) Yes 0 (.0) 0 (.0) 0 (.0) 0 (.0) 0 (.0) 0 (.0) 0 (.0) 0 (.0) 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 </td <td>No</td> <td>219</td> <td>(98.6)</td> <td>378</td> <td>(99.0)</td> <td>547</td> <td>(98.9)</td> <td>747</td> <td>(99.5)</td> <td>685</td> <td></td> <td>464</td> <td>(98.1)</td> <td>3,040</td> <td>(98.8)</td> <td></td>	No	219	(98.6)	378	(99.0)	547	(98.9)	747	(99.5)	685		464	(98.1)	3,040	(98.8)							
Past-year experience (methamphetamine)0.350No219(98.6)378(99.0)548(99.1)747(99.5)686(98.7)464(98.1) $3,042$ (98.9)Yes0(.0)0(.0)0(.0)0(.0)0(.0)0(.0)00000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000<	Yes	0	(.0)	1	(.3)	1	(.2)	0	(.0)	0	(.0)	0	(.0)	2	(.1)							
No219 (98.6)378 (99.0)548 (99.1)747 (99.5)686 (98.7)464 (98.1)3,042 (98.9)Yes0(.0)0(.0)0(.0)0(.0)0(.0)0(.0)Past-year experience (MDMA)0.202No219 (98.6)377 (98.7)548 (99.1)747 (99.5)684 (98.4)463 (97.9)3,038 (98.8)Yes0(.0)0(.0)0(.0)0(.0)000.202No219 (98.6)376 (98.4)548 (99.1)747 (99.5)684 (98.3)463 (97.9)3,038 (98.8)0.201No219 (98.6)376 (98.4)548 (99.1)746 (99.3)683 (98.3)463 (97.9)3,035 (98.7)0.261No219 (98.6)377 (98.7)546 (98.7)746 (99.3)683 (98.3)463 (97.9)3,035 (98.7)0.078No219 (98.6)377 (98.7)546 (98.7)746 (99.3)681 (98.0)460 (97.3)3,029 (98.5)0.078No219 (98.6)377 (98.7)546 (98.7)746 (99.3)681 (98.0)460 (97.3)3,032 (98.5)0.449No219 (98.6)377 (98.7)548 (99.1)743 (98.9)684 (98.4)462 (97.7)3,033 (98.6)No219 (98.6)377 (98.7)548 (99.1)743 (98.9)684 (98.4)462 (97.7)3,033 (98.6)No219 (98.6)377 (98.7)548 (99.1)743 (98.9)684 (98.4)462 (97.7)3,033 (98.6)No219 (98.6)37	Past-year experience (n	nethai	nphetai	mine)												0.350						
Yes0(.0)0(.0)0(.0)0(.0)0(.0)0(.0)0(.0)0(.0)0(.0)Past-year experience (MDMA) $X19$ (98.6)377(98.7)548(99.1)747(99.5)684(98.4)463(97.9)3,038(98.8)(.0)0(.0)0(.0)0(.0)0(.0)0(.0)0(.0)0(.0)0(.0)0(.0)0(.0)0(.0)0(.0)0(.0)0(.0)0(.0)0(.0)0(.0)0(.0)0(.0)0(.0)0(.0)0(.0)0(.0)0(.0)0(.0)0(.0)0(.0)0(.0)0(.0)0(.0)0(.0)0(.0)0(.0)0(.0)0(.0)0(.0)0(.0)0(.0)0(.0)0(.0)0(.0)0(.0)0(.0)0(.0)0(.0)0(.0)0(.0)0(.0)0(.0)0(.0)0(.0)0(.0)0(.0)0(.0)0(.0)000000000000000000000000000000 <td>No</td> <td>219</td> <td>(98.6)</td> <td>378</td> <td>(99.0)</td> <td>548</td> <td>(99.1)</td> <td>747</td> <td>(99.5)</td> <td>686</td> <td>(98.7)</td> <td>464</td> <td>(98.1)</td> <td>3,042</td> <td>(98.9)</td> <td></td>	No	219	(98.6)	378	(99.0)	548	(99.1)	747	(99.5)	686	(98.7)	464	(98.1)	3,042	(98.9)							
$ \begin{array}{c c c c c c c c c c c c c c c c c c c $	Yes	0	(.0)	0	(.0)	0	(.0)	0	(.0)	0	(.0)	0	(.0)	0	(.0)							
No 219 (98.6) 377 (98.7) 548 (99.1) 747 (99.5) 684 (98.4) 463 (97.9) $3,038$ (98.8)Yes0(.0)0(.0)0(.0)0(.0)0(.0)0(.0)Past-year experience (cocaine)0.261No 219 (98.6) 376 (98.4) 548 (99.1) 746 (99.3) 683 (98.3) 463 (97.9) $3,035$ (98.7)Yes0(.0)0(.0)0(.0)0(.0)0(.0)0Past-year experience (heroin)0.078No 219 (98.6) 377 (98.7) 546 (98.7) 746 (99.3) 681 (98.0) 460 (97.3) $3,029$ (98.5)Yes0(.0)0(.0)0(.0)0(.0)0(.0)Past-year experience (NPSs)0.449No 219 (98.6) 377 (98.7) 548 (99.1) 743 (98.9) 684 (98.4) 462 (97.7) $3,033$ (98.6)No 219 (98.6) 377 (98.7) 548 (99.1) 743 (98.9) 684 (98.4) 462 (97.7) $3,033$ (98.6)No 219 (98.6) 377 (98.7) 548 (99.1) 743 (98.9) 684 (98.4) 462 (97.7) $3,033$ (98.6)	Past-vear experience (N	/IDMA)													0.202						
Yes0(.0)0(.0)0(.0)0(.0)0(.0)0(.0)0(.0)Past-year experience (cocaine) 219 (98.6)376(98.4)548(99.1)746(99.3)683(98.3)463(97.9)3,035(98.7)Yes0(.0)0(.0)0(.0)0(.0)0(.0)0(.0)Past-year experience (heroin) 377 (98.7)546(98.7)746(99.3)681(98.0)460(97.3)3,029(98.5)Yes0(.0)0(.0)0(.0)0(.0)0(.0)0(.0)Past-year experience (NPSs) 0 (.0)0(.0)0(.0)0(.0)00(.0)No219(98.6)377(98.7)548(99.1)743(98.9)684(98.4)462(97.7)3,033(98.6)No219(98.6)377(98.7)548(99.1)743(98.9)684(98.4)462(97.7)3,033(98.6)No219(98.6)377(98.7)548(99.1)743(98.9)684(98.4)462(97.7)3,033(98.6)Yes0(.0)0(.0)0(.0)0(.0)0(.0)0(.0)	No	219	(98.6)	377	(98.7)	548	(99.1)	747	(99.5)	684	(98.4)	463	(97.9)	3.038	(98.8)							
Past-year experience (cocaine) 0,261 No 219 (98.6) 376 (98.4) 548 (99.1) 746 (99.3) 683 (98.3) 463 (97.9) 3,035 (98.7) Yes 0 (.0) 0 (.0) 0 (.0) 0 (.0) 0 (.0) 0 (.0) 0 (.0) 0 (.0) Past-year experience (heroin) 0.078 No 219 (98.6) 377 (98.7) 546 (98.7) 746 (99.3) 681 (98.0) 460 (97.3) 3,029 (98.5) Yes 0 (.0) 0 (.0) 0 (.0) 0 (.0) 0 (.0) 0 (.0) 0 (.0) 0 (.0) Past-year experience (NPSs) 0.449 No 219 (98.6) 377 (98.7) 548 (99.1) 743 (98.9) 684 (98.4) 462 (97.7) 3,033 (98.6) Yes 0 (.0) 0 (.0) 0 (.0) 0 (.0) 0 (.0) 0 (.0) 0 (.0) 0 (.0)	Yes	0	(.0)	0	(.0)	0	(.0)	0	(.0)	0	(.0)	0	(.0)	0,000	(.0)							
No219 (98.6)376 (98.4)548 (99.1)746 (99.3)683 (98.3)463 (97.9)3,035 (98.7)Yes0 (.0)0 (.0)0 (.0)0 (.0)0 (.0)0 (.0)0 (.0)0 (.0)Past-year experience (heroin)0.078No219 (98.6)377 (98.7)546 (98.7)746 (99.3)681 (98.0)460 (97.3)3,029 (98.5)Yes0 (.0)0 (.0)0 (.0)0 (.0)0 (.0)0 (.0)0 (.0)0 (.0)Past-year experience (NPSs)0.0449No219 (98.6)377 (98.7)548 (99.1)743 (98.9)684 (98.4)462 (97.7)3,033 (98.6)Ves0 (.0)0 (.0)0 (.0)0 (.0)0 (.0)0 (.0)0 (.0)	Past-year experience (c	ocaine	a)		(,		(10)		(,		(,		(,		(10)	0 261						
Yes 0 (.0) 0 (.0) 0 (.0) 0 (.0) 0 (.0) 0 (.0) 0 (.0) 0 (.0) 0 (.0) 0 (.0) 0 (.0) 0 (.0) 0 (.0) 0 (.0) 0 (.0) 0 (.0) 0 (.0) 0 (.0) 0 (.0) 0 (.0) 0 (.0) 0 (.0) 0 (.0) 0 (.0) 0 (.0) 0 (.0) 0 (.0) 0 (.0) 0 (.0) 0 (.0) 0 (.0) 0 (.0) 0 (.0) 0 (.0) 0 (.0) 0 (.0) 0 (.0) 0 (.0) 0 (.0) 0 (.0) 0 (.0) 0 (.0) 0 (.0) 0 (.0) 0 (.0) 0 (.0) 0 (.0) 0 (.0) 0 (.0) 0 (.0) 0 (.0) 0 (.0) 0 (.0) 0 (.0) <	No	219	(98.6)	376	(98.4)	548	(99.1)	746	(99.3)	683	(98.3)	463	(97.9)	3.035	(98.7)	0.201						
(10) (10) (10) (10) (10) (10) (10) (10) (10) (10) (10) (10) (10) (10) (10) (10) (10) (10) (10) (10) (10) (10) (10) (10) (10) (10) (10) (10) (10) (10) (10) (10) (10) (10) (10) (10) (10) (10) (10) (10) (10) (10) (10) (10) (10) (10) (10) (10) (10) (10) (10) (10) (10) (10) (10) (10) (10) (10) (10) <th <="" colspan="6" td=""><td>Yes</td><td>0</td><td>(0)</td><td>0</td><td>(0)</td><td>0</td><td>(0)</td><td>0</td><td>(0)</td><td>0</td><td>(0)</td><td>0</td><td>(0)</td><td>0,000</td><td>(0)</td><td></td></th>	<td>Yes</td> <td>0</td> <td>(0)</td> <td>0</td> <td>(0)</td> <td>0</td> <td>(0)</td> <td>0</td> <td>(0)</td> <td>0</td> <td>(0)</td> <td>0</td> <td>(0)</td> <td>0,000</td> <td>(0)</td> <td></td>						Yes	0	(0)	0	(0)	0	(0)	0	(0)	0	(0)	0	(0)	0,000	(0)	
No 219 (98.6) 377 (98.7) 546 (98.7) 746 (99.3) 681 (98.0) 460 (97.3) 3,029 (98.5) Yes 0 (.0) 0 (.0) 0 (.0) 0 (.0) 0 (.0) 0 (.0) 0 (.0) Past-year experience (NPSs) 0.449 No 219 (98.6) 377 (98.7) 548 (99.1) 743 (98.9) 684 (98.4) 462 (97.7) 3,033 (98.6) Ves 0 (0) 0 (0) 0 (0) 0 (0) 0 (0)	Past-vear experience (h	eroin)	0	(10)	0	(10)	0	(.0)	0	(10)	0	(10)	0	(10)	0.078						
Yes 0 (.0) 0 (.0) 0 (.0) 0 (.0) 0 (.0) 0 (.0) 0 (.0) 0 (.0) 0 (.0) 0 (.0) 0 (.0) 0 (.0) 0 (.0) 0 (.0) 0 (.0) 0 (.0) 0 (.0) 0 (.0) 0 (.0) 0 (.0) 0 (.0) 0 (.0) 0 (.0) 0 (.0) 0 (.0) 0 (.0) 0 (.0) 0 (.0) 0 (.0) 0 (.0) 0 (.0) 0 (.0) 0 (.0) 0 (.0) 0 (.0) 0 (.0) 0 (.0) 0 (.0) 0 (.0) 0 (.0) 0 (.0) 0 (.0) 0 (.0) 0 (.0) 0 (.0) 0 (.0) 0 (.0) 0 (.0) 0 (.0) 0 (.0) 0 (.0) 0 (.0) 0 (.0) 0 (.0) <	No	219	(98.6)	377	(98.7)	546	(98.7)	746	(99.3)	681	(98.0)	460	(97.3)	3 029	(98.5)	0.010						
Past-year experience (NPSs) 0.449 No 219 (98.6) 377 (98.7) 548 (99.1) 743 (98.9) 684 (98.4) 462 (97.7) 3,033 (98.6) Ves 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0)	Yes	0	(0)	0	(0)	0	(0)	0	(0)	0	(0)	0	(0)	0,010	(0)							
No 219 (98.6) 377 (98.7) 548 (99.1) 743 (98.9) 684 (98.4) 462 (97.7) 3,033 (98.6) Ves 0 (0) 0 (0) 0 (0) 0 (0)	Past-year experience (N	JPSs)	(.0)	0	(.0)	0	(.0)	0	(.0)	0	(.0)	0	(.0)	0	(.0)	0.449						
$V_{\text{Rg}} = \begin{pmatrix} 0 & 0 \\ 0 & 0 \\ 0 & 0 \\ 0 & 0 \\ 0 & 0 \\ 0 & 0 \\ 0 & 0 \\ 0 & 0 \\ 0 & 0 \\ 0 & 0 \\ 0 & 0 \\ 0 & 0 \\ 0 & 0 \\ 0 & 0 \\ 0 & 0 \\ 0 & 0 \\ 0 & 0 \\ 0 & 0 \\ 0 & 0 \\ 0 & 0 \\ 0 & 0 \\ 0 & 0 \\ 0 & 0 \\ 0 & 0 \\ 0 & 0 \\ 0 & 0 \\ 0 & 0 \\ 0 & 0 \\ 0 & 0 \\ 0 & 0 \\ 0 & 0 \\ 0 & 0 \\ 0 & 0 \\ 0 & 0 \\ 0 & 0 \\ 0 & 0 \\ 0 & 0 \\ 0 & 0 \\ 0 & 0 \\ 0 & 0 \\ 0 & 0 \\ 0 & 0 \\ 0 & 0 \\ 0 & 0 \\ 0 & 0 \\ 0 & 0 \\ 0 & 0 \\ 0 & 0 \\ 0 & 0 \\ 0 & 0 \\ 0 & 0 \\ 0 & 0 \\ 0 & 0 \\ 0 & 0 \\ 0 & 0 \\ 0 & 0 \\ 0 & 0 \\ 0 & 0 \\ 0 & 0 \\ 0 & 0 \\ 0 & 0 \\ 0 & 0 \\ 0 & 0 \\ 0 & 0 \\ 0 & 0 \\ 0 & 0 \\ 0 & 0 \\ 0 & 0 \\ 0 & 0 \\ 0 & 0 \\ 0 & 0 \\ 0 & 0 \\ 0 & 0 \\ 0 & 0 \\ 0 & 0 \\ 0 & 0 \\ 0 & 0 \\ 0 & 0 \\ 0 & 0 \\ 0 & 0 \\ 0 & 0 \\ 0 & 0 \\ 0 & 0 \\ 0 & 0 \\ 0 & 0 \\ 0 & 0 \\ 0 & 0 \\ 0 & 0 \\ 0 & 0 \\ 0 & 0 \\ 0 & 0 \\ 0 & 0 \\ 0 & 0 \\ 0 & 0 \\ 0 & 0 \\ 0 & 0 \\ 0 & 0 \\ 0 & 0 \\ 0 & 0 \\ 0 & 0 \\ 0 & 0 \\ 0 & 0 \\ 0 & 0 \\ 0 & 0 \\ 0 & 0 \\ 0 & 0 \\ 0 & 0 \\ 0 & 0 \\ 0 & 0 \\ 0 & 0 \\ 0 & 0 \\ 0 & 0 \\ 0 & 0 \\ 0 & 0 \\ 0 & 0 \\ 0 & 0 \\ 0 & 0 \\ 0 & 0 \\ 0 & 0 \\ 0 & 0 \\ 0 & 0 \\ 0 & 0 \\ 0 & 0 \\ 0 & 0 \\ 0 & 0 \\ 0 & 0 \\ 0 & 0 \\ 0 & 0 \\ 0 & 0 \\ 0 & 0 \\ 0 & 0 \\ 0 & 0 \\ 0 & 0 \\ 0 & 0 \\ 0 & 0 \\ 0 & 0 \\ 0 & 0 \\ 0 & 0 \\ 0 & 0 \\ 0 & 0 \\ 0 & 0 \\ 0 & 0 \\ 0 & 0 \\ 0 & 0 \\ 0 & 0 \\ 0 & 0 \\ 0 & 0 \\ 0 & 0 \\ 0 & 0 \\ 0 & 0 \\ 0 & 0 \\ 0 & 0 \\ 0 & 0 \\ 0 & 0 \\ 0 & 0 \\ 0 & 0 \\ 0 & 0 \\ 0 & 0 \\ 0 & 0 \\ 0 & 0 \\ 0 & 0 \\ 0 & 0 \\ 0 & 0 \\ 0 & 0 \\ 0 & 0 \\ 0 & 0 \\ 0 & 0 \\ 0 & 0 \\ 0 & 0 \\ 0 & 0 \\ 0 & 0 \\ 0 & 0 \\ 0 & 0 \\ 0 & 0 \\ 0 & 0 \\ 0 & 0 \\ 0 & 0 \\ 0 & 0 \\ 0 & 0 \\ 0 & 0 \\ 0 & 0 \\ 0 & 0 \\ 0 & 0 \\ 0 & 0 \\ 0 & 0 \\ 0 & 0 \\ 0 & 0 \\ 0 & 0 \\ 0 & 0 \\ 0 & 0 \\ 0 & 0 \\ 0 & 0 \\ 0 & 0 \\ 0 & 0 \\ 0 & 0 \\ 0 & 0 \\ 0 & 0 \\ 0 & 0 \\ 0 & 0 \\ 0 & 0 \\ 0 & 0 \\ 0 & 0 \\ 0 & 0 \\ 0 & 0 \\ 0 & 0 \\ 0 & 0 \\ 0 & 0 \\ 0 & 0 \\ 0 & 0 \\ 0 & 0 \\ 0 & 0 \\ 0 & 0 \\ 0 & 0 \\ 0 & 0 \\ 0 & 0 \\ 0 & 0 \\ 0 & 0 \\ 0 & 0 \\ 0 & 0 \\ 0 & 0 \\ 0 & 0 \\ 0 & 0 \\ 0 & 0 \\ 0 & 0 \\ 0 & 0 \\ 0 & 0 \\ 0 & 0 \\ 0 & 0 \\ 0 & 0 \\ 0 & 0 \\ 0 & 0 \\ 0 & 0 \\ 0 & 0 \\ 0 & 0 \\ 0 & 0 \\ 0 & 0 \\ 0 & 0 \\ 0 & 0 \\ 0 & 0 \\ 0 & 0 \\ 0 & 0 \\ 0 & 0 \\ 0 & 0 \\ 0 & 0 \\ 0 & 0 \\ 0 & 0 \\ 0 & 0 \\ 0 & 0 \\ 0 & 0 \\ 0 & 0 \\ 0 & 0 \\ 0 & 0 \\ 0 & 0 \\ 0 & 0 $	No	219	(98.6)	377	(987)	548	(99 1)	743	(98.9)	684	(98.4)	462	(977)	3 033	(98 6)	0.110						
	Yes	0	())	0	())	0+0	())	0	())	0	())	0	())	0,000	(0)							

"10s" refers to those aged 15 to 19, and "60s" refers to those aged 60 to 64.

Table 60 Dru	ıg Use	Experience	by (Occupation	(n =	3076)
--------------	--------	------------	------	------------	------	-------

_					Occup	ation				
	Se	elf-	Full-t	time	Non	-full-	Stu	dent	Hous	ewife
	n=	248	n=14	406	n=	394	n=	271	n=	436
	n	(%)	n	(%)	n	(%)	n	(%)	n	(%)
Lifetime experience (any dru	ıg)									
No	227	(91.5)	1,345	(95.7)	375	(95.2)	268	(98.9)	422	(96.8)
Yes	14	(5.6)	36	(2.6)	14	(3.6)	0	(.0)	5	(1.1)
Lifetime experience (organic	solve	nts)								
No	236	(95.2)	1,375	(97.8)	385	(97.7)	269	(99.3)	429	(98.4)
Yes	7	(2.8)	23	(1.6)	8	(2.0)	0	(.0)	3	(.7)
Lifetime experience (cannab	is)									
No	236	(95.2)	1,376	(97.9)	383	(97.2)	269	(99.3)	431	(98.9)
Yes	7	(2.8)	15	(1.1)	8	(2.0)	0	(.0)	0	(.0)
Lifetime experience (methan	nphet	amine)								
No	241	(97.2)	1,381	(98.2)	391	(99.2)	269	(99.3)	432	(99.1)
Yes	3	(1.2)	9	(.6)	0	(.0)	0	(.0)	0	(.0)
Lifetime experience (MDMA)									
No	243	(98.0)	1,389	(98.8)	392	(99.5)	269	(99.3)	428	(98.2)
Yes	1	(.4)	2	(.1)	0	(.0)	0	(.0)	1	(.2)
Lifetime experience (cocaine)									
No	243	(98.0)	1.387	(98.6)	391	(99.2)	268	(98.9)	429	(98.4)
Yes	1	(4)	3	(2)	0	(0)	0	(0)	0	(0)
Lifetime experience (heroin)	-	(• 1)	0	()	Ũ	(10)	Ũ	(10)	0	(10)
No	242	(97.6)	1 385	(98 5)	390	(99.0)	269	(99.3)	429	(98.4)
Ves	1	(4)	1,000	(1)	0	(00.0)	0	(00.0)	0	(00,1)
Lifetime experience (NPSs)	1	(. 1)	1	(.1)	0	(.0)	0	(.0)	0	(.0)
No	243	(98.0)	1 381	(98.2)	390	(99.0)	269	(99.3)	426	(97.7)
Vos	240 1	(30.0)	1,001	(50.2)	1	(3)	200	(00.0)	1	(31.1)
Past-year experience (any di	1 (1)	(1)	'	(.0)	T	(.0)	0	(.0)	T	(.2)
No	9/1	(97.2)	1 380	(98.2)	388	(98.5)	268	(98.9)	497	(97.9)
Vos	241	(01.2)	1,000	(1)	1	(30.0)	200	(00.0)	141	(01.0)
Past-year experience (organ	ic solv	(.0)	1	(.1)	T	(.0)	0	(.0)	0	(.0)
No	243	(98.0)	1 397	(99.4)	303	(99.7)	269	(99.3)	132	(99.1)
Vos	240	(30.0)	1,557	(1)	000	(33.1)	203	(33.3)	402	(00.1)
Past-year experience (canno	bie)	(.0)	1	(.1)	0	(.0)	0	(.0)	0	(.0)
No	949	(080)	1 201	(08.0)	200	(00,0)	960	(00.3)	491	
No	240	(30.0)	1,391	(30.3)	1	(33.0)	209	(99.3)	401	(0)
Tes Destrucen ernenienee (methe	U	(.0)	0	(.0)	1	(.5)	0	(.0)	0	(.0)
rast-year experience (metha	944	(08.4)	1 200	(080)	901	(00.9)	960	(00.2)	499	(00.1)
NO	244	(90.4)	1,590	(96.9)	391	(99.2)	209	(99.5)	452	(99.1)
res Destaura amarica as (MDM) ()	(.0)	0	(.0)	0	(.0)	0	(.0)	0	(.0)
Past-year experience (MDMA	-1)	(00, 4)	1 901	(00,0)	202	(00 5)	000	(00, 0)	490	(00, 4)
NO	244	(98.4)	1,391	(98.9)	392	(99.5)	269	(99.3)	429	(98.4)
ies . (·	, 0	(.0)	0	(.0)	0	(.0)	0	(.0)	0	(.0)
Past-year experience (cocain	.e)		1 000	$(\alpha \alpha \alpha)$	0.01	(00, 0)	0.00	(00,0)	100	
No	244	(98.4)	1,390	(98.9)	391	(99.2)	268	(98.9)	429	(98.4)
Yes	0	(.0)	0	(.0)	0	(.0)	0	(.0)	0	(.0)
Past-year experience (heroir	1)									
No	243	(98.0)	1,386	(98.6)	390	(99.0)	269	(99.3)	429	(98.4)
Yes	0	(.0)	0	(.0)	0	(.0)	0	(.0)	0	(.0)
Past-year experience (NPSs)				(
No	244	(98.4)	1,388	(98.7)	391	(99.2)	269	(99.3)	427	(97.9)
Yes	0	(.0)	0	(.0)	0	(.0)	0	(.0)	0	(.0)

				00	ccupatio	n			
-	Unem	oloyed	Oth	ier	Unkr	nown	Tot	al	
	n=1	79	n=1	.38	n=	=4	n=3	076	p-value
	n	(%)	n	(%)	n	(%)	n	(%)	
Lifetime experience (any drug)									0.014
No	169	(94.4)	130	(94.2)	4	(100.0)	2,940	(95.6)	
Yes	6	(3.4)	3	(2.2)	0	(.0)	78	(2.5)	
Lifetime experience (organic so	olvents)								0.088
No	171	(95.5)	134	(97.1)	4	(100.0)	3,003	(97.6)	
Yes	6	(3.4)	2	(1.4)	0	(.0)	49	(1.6)	
Lifetime experience (cannabis)									0.106
No	174	(97.2)	134	(97.1)	4	(100.0)	3,007	(97.8)	
Yes	3	(1.7)	2	(1.4)	0	(.0)	35	(1.1)	
Lifetime experience (methamp	hetamir	le)							0.300
No	174	(97.2)	134	(97.1)	4	(100.0)	3,026	(98.4)	
Yes	3	(1.7)	1	(.7)	0	(.0)	16	(.5)	
Lifetime experience (MDMA)									0.344
No	175	(97.8)	132	(95.7)	4	(100.0)	3,032	(98.6)	
Yes	1	(.6)	1	(.7)	0	(.0)	6	(.2)	
Lifetime experience (cocaine)									0.569
No	175	(97.8)	133	(96.4)	4	(100.0)	3,030	(98.5)	
Yes	1	(.6)	0	(.0)	0	(.0)	5	(.2)	
Lifetime experience (heroin)									0.404
No	174	(97.2)	133	(96.4)	4	(100.0)	3,026	(98.4)	
Yes	1	(.6)	0	(.0)	0	(.0)	3	(.1)	
Lifetime experience (NPSs)									0.809
No	176	(98.3)	133	(96.4)	4	(100.0)	3,022	(98.2)	
Yes	0	(.0)	1	(.7)	0	(.0)	11	(.4)	
Past-year experience (any drug	g)								0.055
No	173	(96.6)	132	(95.7)	4	(100.0)	3,013	(98.0)	
Yes	2	(1.1)	0	(.0)	0	(.0)	4	(.1)	
Past-year experience (organic	solvents)							0.313
No	176	(98.3)	136	(98.6)	4	(100.0)	3,050	(99.2)	
Yes	1	(.6)	0	(.0)	0	(.0)	2	(.1)	
Past-year experience (cannabis	3)								0.498
No	176	(98.3)	136	(98.6)	4	(100.0)	3,040	(98.8)	
Yes	1	(.6)	0	(.0)	0	(.0)	2	(.1)	
Past-year experience (metham	phetami	ine)							0.886
No	177	(98.9)	135	(97.8)	4	(100.0)	3,042	(98.9)	
Yes	0	(.0)	0	(.0)	0	(.0)	0	(.0)	
Past-year experience (MDMA)									0.180
No	176	(98.3)	133	(96.4)	4	(100.0)	3,038	(98.8)	
Yes	0	(.0)	0	(.0)	0	(.0)	0	(.0)	
Past-year experience (cocaine)									0.369
No	176	(98.3)	133	(96.4)	4	(100.0)	3,035	(98.7)	
Yes	0	(.0)	0	(.0)	0	(.0)	0	(.0)	
Past-year experience (heroin)									0.428
No	175	(97.8)	133	(96.4)	4	(100.0)	3,029	(98.5)	
Yes	0	(.0)	0	(.0)	0	(.0)	0	(.0)	
Past-year experience (NPSs)									0.533
No	176	(98.3)	134	(97.1)	4	(100.0)	3,033	(98.6)	
Yes	0	(.0)	0	(.0)	0	(.0)	0	(.0)	

				Drug u	se expei				
—	Lifet	time	No lif	etime	Unkn	own	Tot	al	
	n=	78	n=2	940	n=	58	n=3	076	p-value
	n	(%)	n	(%)	n	(%)	n	(%)	
Lifetime experience (organic sol	vents)								< 0.001
No	28	(35.9)	2,940	(100.0)	35	(60.3)	3,003	(97.6)	
Yes	49	(62.8)	0	(.0)	0	(.0)	49	(1.6)	
Lifetime experience (cannabis)									< 0.001
No	43	(55.1)	2,940	(100.0)	24	(41.4)	3,007	(97.8)	
Yes	35	(44.9)	0	(.0)	0	(.0)	35	(1.1)	
Lifetime experience (methamph	etamin	ie)							< 0.001
No	61	(78.2)	2,940	(100.0)	25	(43.1)	3,026	(98.4)	
Yes	16	(20.5)	0	(.0)	0	(.0)	16	(.5)	
Lifetime experience (MDMA)									< 0.001
No	71	(91.0)	2,940	(100.0)	21	(36.2)	3,032	(98.6)	
Yes	6	(7.7)	0	(.0)	0	(.0)	6	(.2)	
Lifetime experience (cocaine)									< 0.001
No	72	(92.3)	2,940	(100.0)	18	(31.0)	3,030	(98.5)	
Yes	5	(6.4)	0	(.0)	0	(.0)	5	(.2)	
Lifetime experience (heroin)									< 0.001
No	74	(94.9)	2,940	(100.0)	12	(20.7)	3,026	(98.4)	
Yes	3	(3.8)	0	(.0)	0	(.0)	3	(.1)	
Lifetime experience (NPSs)									< 0.001
No	67	(85.9)	2,940	(100.0)	15	(25.9)	3,022	(98.2)	
Yes	11	(14.1)	0	(.0)	0	(.0)	11	(.4)	
Past-year experience (any drug)	1								< 0.001
No	73	(93.6)	2,940	(100.0)	0	(.0)	3,013	(98.0)	
Yes	4	(5.1)	0	(.0)	0	(.0)	4	(.1)	
Past-year experience (organic se	olvents)							< 0.001
No	75	(96.2)	2,940	(100.0)	35	(60.3)	3,050	(99.2)	
Yes	2	(2.6)	0	(.0)	0	(.0)	2	(.1)	
Past-year experience (cannabis)									< 0.001
No	76	(97.4)	2,940	(100.0)	24	(41.4)	3,040	(98.8)	
Yes	2	(2.6)	0	(.0)	0	(.0)	2	(.1)	
Past-year experience (methamp	hetami	ine)							< 0.001
No	77	(98.7)	2,940	(100.0)	25	(43.1)	3,042	(98.9)	
Yes	0	(.0)	0	(.0)	0	(.0)	0	(.0)	
Past-year experience (MDMA)									< 0.001
No	77	(98.7)	2,940	(100.0)	21	(36.2)	3,038	(98.8)	
Yes	0	(.0)	0	(.0)	0	(.0)	0	(.0)	
Past-year experience (cocaine)									< 0.001
No	77	(98.7)	2,940	(100.0)	18	(31.0)	3,035	(98.7)	
Yes	0	(.0)	0	(.0)	0	(.0)	0	(.0)	
Past-year experience (heroin)									< 0.001
No	77	(98.7)	2,940	(100.0)	12	(20.7)	3,029	(98.5)	
Yes	0	(.0)	0	(.0)	0	(.0)	0	(.0)	
Past-year experience (NPSs)									< 0.001
No	78	(100.0)	2,940	(100.0)	15	(25.9)	3,033	(98.6)	
Yes	0	(.0)	0	(.0)	0	(.0)	0	(.0)	

Table 61. Drug Us	e Experience	by Drug us	e experie	nce(n =	3076)



Fig.2 Changes in the Past-Year Prevalence of Alcohol Use (Overall:2005-2015)



Fig.3 Changes in the Past-Year Prevalence of Alcohol Use by Age Group (2005-2015)



Fig.4 Changes in the Lifetime Prevalence of Tabacco Use (Overall: 1999-2015)



Fig.5 Changes in the Lifetime Prevalence of Tabacco Use Over Time by Age Group (1999-2015)



Fig.6 Changes in the Past-Year Prevalence of Tobacco Use (Overall:2001-2015)



Fig.7 Changes in the Past-Year Prevalence of Tabacco Use by Age Group (2001-2015)

Table 62 Estimated Past-Year Prevalence of Alcohol/Tobacco Use by Sex (%)

	Alcohol use			Tobacco use		
	Overall	Men	Women	Overall	Men	Women
2003	85.1	89.2	81.3	32.8	49.5	17.2
	(84.5)	(89.0)	(80.3)	(32.9)	(49.2)	(17.5)
2005	84.2	88.9	79.9	33.3	48.3	19.5
	(84.0)	(88.9)	(79.2)	(34.6)	(49.1)	(20.3)
2007	83.8	88.8	79.3	30.4	44.6	17.3
	(83.6)	(88.5)	(79.1)	(30.3)	(44.8)	(17.0)
2009	83.7	88.5	79.2	32.1	48.9	16.1
	(83.8)	(88.5)	(79.4)	(32.2)	(48.9)	(16.4)
2011	85.3	88.9	81.9	29.3	43.4	16.2
	(85.0)	(88.6)	(81.7)	(29.1)	(43.5)	(15.8)
2013	82.2	85.7	79.1	27.2	39.4	16.5
	(81.9)	(85.5)	(78.7)	(28.0)	(40.9)	(16.6)
2015	80.2	84.6	76.1	26.2	40.2	13.3
	(79.8)	(84.4)	(75.6)	(26.9)	(40.9)	(14.1)

The values in the parentheses are unadjusted.

Table 63 Estimated Past-Year Prevalence of Analgesic/Tranquilizer/Hypnotic Use by Sex (%)

	Analgesics				
	Overall	Men	Women		
2003	55.2	47.1	62.8		
2005	55.1	48.9	60.8		
2007	55.3	47.0	63.0		
2009	58.1	49.0	66.8		
2011	58.6	46.4	69.9		
2013	61.4	50.6	70.9		
2015	62.9	53.1	71.9		
	Tranquilizers				
	Overall	Men	Women		
2003	7.4	5.6	9.1		
2005	8.1	6.4	9.7		
2007	8.1	6.2	9.9		
2009	7.1	6.1	8.1		
2011	5.6	4.8	6.3		
2013	6.2	5.7	6.6		
2015	5.6	4.2	6.9		
	Hypnotics				
	Overall	Men	Women		
2003	6.2	6.0	6.3		
2005	6.2	4.7	7.6		
2007	7.7	6.5	8.7		
2009	6.5	5.5	7.4		
2011	5.6	4.9	6.3		
2013	5.6	5.6	5.6		
2015	6.1	5.2	7.0		



Fig.8 Changes in the Past-Year Prevalence of Analgesic Use (1995-2015)



Fig.9 Changes in the Chronic use of Analgesic (1999-2015) Chronic use: defined as ≥three times a week


Fig.10 Changes in the Past-Year Prevalence of Tranquilizer Use (1995-2015)



Fig.11 Changes in the Chronic use of Tranquilizer (1999-2015) Chronic use: defined as ≥three times a week



Fig.12 Changes in the Past-Year Prevalence of Hypnotic Use (1995-2015)



Fig.13 Changes in the Chronic use of Hypnotic (1999-2015) Chronic use: defined as ≥three times a week



Fig.14 Changes in views on cannabis use (Overall: 1999-2015) Sum of "Individual Freedom" + "A Little Use Should Be Allowed"



Fig.15 Changes in views on cannabis use (by age group: 1999-2015) Sum of "Individual Freedom" + "A Little Use Should Be Allowed"



Fig.16 Changes in views on methamphetamine use (Overall: 1999-2015) Sum of "Individual Freedom" + "A Little Use Should Be Allowed"



Fig.17 Changes in views on methamphetamine use (by age group: 1999-2015) Sum of "Individual Freedom" + "A Little Use Should Be Allowed"



Fig.18 Changes in the proportion of respondents with a peer drug abuser within the past year (1995-2015)



Fig.19 Changes in drug accessibility (1999-2015) Sum of "Easily Accessible" + "Barely Accessible"







Fig.21 Changes in drug accessibility by age group (Organic solvents: 1999-2015) Sum of "Easily Accessible" + "Barely Accessible"



Fig.22 Changes in drug accessibility (Cannabis: 1999-2015) Sum of "Easily Accessible" + "Barely Accessible"



Fig.23 Changes in drug accessibility by age group (Cannabis: 1999-2015) Sum of "Easily Accessible" + "Barely Accessible"



Fig.24 Changes in drug accessibility (Methamphetamine: 1999-2015) Sum of "Easily Accessible" + "Barely Accessible"



Fig.25 Changes in drug accessibility by age group (Methamphetamine: 1999-2015) Sum of "Easily Accessible" + "Barely Accessible"



Fig.26 Changes in drug accessibility (Heroin: 1999-2015) Sum of "Easily Accessible" + "Barely Accessible"



Fig.27 Changes in drug accessibility by age group (Heroin: 1999-2015) Sum of "Easily Accessible" + "Barely Accessible"



Fig.28 Changes in drug accessibility (Cocaine: 1999-2015) Sum of "Easily Accessible" + "Barely Accessible"



Fig.29 Changes in drug accessibility by age group (Cocaine: 1999-2015) Sum of "Easily Accessible" + "Barely Accessible"



Fig.30 Changes in drug accessibility (MDMA: 1999-2015) Sum of "Easily Accessible" + "Barely Accessible"



Fig.31 Changes in drug accessibility by age group (MDMA: 1999-2015) Sum of "Easily Accessible" + "Barely Accessible"

(1990-201)))							(%)
	Organic	Cannabis	Methamp	Cocaine	Heroin	MDMA	NPSs	Any drug
	solvents		hetamine					
1995	2.0	1.3	0.7	0.2	0.2	-	-	2.9
1997	1.7	1.6	0.4	0.1	0.2	-	-	3.2
1999	2.9	1.6	1.0	0.5	0.2	-	-	4.1
2001	3.9	2.1	1.1	0.3	0.2	-	-	5.0
2003	2.7	1.4	0.9	0.3	0.2	0.2	-	3.8
2005	2.7	2.0	0.9	0.4	0.2	0.2	-	4.0
2007	3.0	1.8	1.0	0.3	0.2	0.4	-	4.4
2009	3.6	2.8	1.2	0.4	0.1	0.6	-	6.4
2011	2.9	2.0	0.9	0.2	0.2	0.2	-	4.6
2013	2.6	2.7	0.9	0.3	*	0.4	-	4.8
2015	2.4	2.0	1.0	0.2	0.2	0.6	0.6	4.1

Table 64 Estimated Prevalence of Experience of Ever Having Try to Tempt Illegal Drugs (1995–2015)

*:Within the range of statistical errors



Fig.32 Estimated Lifetime Prevalence of Experience of Ever Having Try to Tempt Illegal Drugs (1995-2015)

Number of exercised langest Number of even having top to tenner likest Number of even having top top tenner likest Number of tenner likest Number o			Overall			Men			Women	
Inderstands and experimentor experimentor to tempt likes Lower limit programmentor to tempt		Number of	Overan		Number of	men		Number of	Women	
Hertime very laving to over		individuals with			individuals with			individuals with		
Lower limit Upper limit experiment line line line line line line line line		lifetime			lifetime			lifetime		
over-baring tripset core remain tripset core c		experience of	Lower limit	Upper limit	experience of	Lower limit	Upper limit	experience of	Lower limit	Upper limit
is tengrillegi to tengrillegi to tengrillegi to tengrillegi 2003 3.220.448 2.585.285 3.685.012 2.102.885 3.685.102 2.402.485 3.685.102 2.402.485 1.845.670 9.645.501 1.245.672 2007 3.578.721 2.814.770 2.484.740 2.489.682 1.855.480 1.895.387 2.801.881 1.089.807 645.151 1.1383.868 2009 3.41.011 1.090.800 8.11.10.11 1.652.477 1.118.062 2.122.901 8.47.561 1.221.74 2013 2.288.585 1.705.676 2.817.493 1.052.477 1.118.0164 2.88.525 1.073.584 2015 2.489.585 1.705.767 1.067.790 1.045.813 1.988.41 500.544 1.80.144 7.803.11.228.78 2010 2.663.867 2.031.10 3.767.94 1.907.716 0.904.000 1.901.824 407.055 1.028.185 2010 2.663.867 2.031.10 3.617.162 2.441.44 1.241.02 1.011.717 1.755.567 608.195		ever having try			ever having try			ever having try		
Organic systems Organic systems Open systems Open systems 2006 3.2263.04 2.563.65 4.070.916 1.880.665 1.500.516 2.445.413 1.446.670 9.06.061 1.125.076 2007 3.577.312 2.81.702 2.407.102 2.471.902 2.471.901 2.700.903 1.888.876 2.901.401 1.090.096 6.04.905 1.125.076 2011 2.707.312 2.111.04 3.030.860 1.112.101 1.652.670 1.122.506 1.025.705 1.070.576 2.817.571 2015 2.288.535 1.700.576 2.817.704 1.025.747 1.181.065 1.025.705 1.055.707 2005 2.400.011 1.22.183 3.116.620 1.067.724 1.045.61 9.012.00 470.707 1.185.577 2005 2.400.011 1.26.18 3.116.620 1.067.724 1.045.61 9.002.44 7.00.724 1.055.577 2005 1.052.065 2.01.082 1.060.649 9.01.282 376.072 1.055.858 2005 1.071.721		to tempt illegal			to tempt illegal			to tempt illegal		
2006 3.228,940 2.58,828 3.896,612 2.102,835 1.612,304 2.50,847 1.124,063 400,605 2007 3.777,721 2.814,770 4.387,748 1.849,064 3.124,668 3.124,668 1.089,397 461,519 2007 3.777,721 2.814,770 4.387,748 2.339,358 1.971,377 1.450,868 2.312,458 1.089,355 447,663 1.022,174 2.011 2.238,555 1.706,876 2.817,187 1.450,868 2.122,568 857,553 447,667 1.073,854 2.003 1.623,669 1.111,118 1.652,477 1.050,414 1.506,141 750,853 376,074 1.185,577 2003 1.623,669 1.111,178 2.114,107 2.414,414 600,544 1.501,144 750,823 376,074 1.185,577 2005 2.633,077 2.033,101 3.33,410 1.352,640 1.286,477 2.304,302 888,547 541,111 1.228,477 2005 2.663,307 2.033,810 1.314,134 1.444,074 4.344,721<					Organic s	olvents				
2006 3.327.335 2.575.085 4.079.015 1.880.065 1.300.510 2.4.463.701 4.446.670 94.680 1.985.085 31.2.588 1.083.073 045.159 1.533.685 2009 3.310.271 2.749.002 4.071.401 2.379.483 1.889.276 2.330.449 1.030.909 64.929 1.022.174 2011 2.707.312 2.111.41 1.043.030.850 1.245.087 1.985.085 1.22.956 857.053 497.056 1.918.757 2003 1.022.660 1.110.718 2.141.161 1.522.820 1.048.06 900.290 473.766 1.928.754 2000 2.648.019 1.81.118 3.116.200 1.057.214 1.044.808 2.000.646 901.290 473.766 1.928.751 2001 2.648.019 1.381.161 3.116.201 1.057.714 1.044.802 2.006.441 1.804.228 857.853 1.978.040 1.986.422 484.8116 1.928.478 2001 2.668.019 1.381.640 1.204.642 1.066.378 0.208.423 3.89.499	2003	3,226,949	2,558,285	3,895,612	2,102,885	1,612,304	2,593,467	1,124,063	690,698	1,557,429
2007 3.078.751 2.814.702 4.249.740 2.439.324 1.855.08 3.122.568 1.089.337 46.199 1.633.636 2001 3.2107.312 2.111.043 3.303.580 1.971.377 1.455.866 2.409.449 1.030.999 649.200 1.122.567 2015 2.285.535 1.759.675 2.817.433 1.625.457 1.085.131 763.141 462.673 1.073.864 2015 2.285.535 1.759.675 2.817.433 1.525.205 1.857.75 407.656 1.218.507 2004 2.460.019 1.821.518 3.116.520 1.467.729 1.044.808 2.400.649 901.200 473.705 1.058.118 2004 2.460.019 1.821.518 3.314.810 1.326.427 2.304.329 885.847 548.101 1.285.977 949.083 2015 1.017.045 3.334.810 1.324.402 2.401.408 80.9001 1.637.555 600.632 316.949 976.333 2015 1.017.045 5.833.81.81 1.648.071 4.31.4418 487.271	2005	3,327,335	2,575,055	4,079,615	1,880,665	1,306,516	2,454,813	1,446,670	946,809	1,946,532
2009 3.10.271 2.749.002 4.071.401 2.373.833 1.828.276 2.430.449 1.030.909 642.905 1.042.571 2011 2.071.312 2.111.411 1.906.630 3.111.191 1.652.457 1.181.965 2.122.980 857.953 449.655 1.218.250 2015 2.288.5.35 1.769.676 2.217.463 1.625.269 1.607.251 1.044.808 2.066.49 90.12.907 4.366.074 1.185.877 2005 2.460.19 1.521.518 3.116.520 1.567.729 1.044.808 2.066.49 90.12.904 473.796 1.938.74 2007 2.460.19 1.521.518 3.116.520 1.567.729 1.044.802 2.066.49 90.12.904 473.796 1.938.792 916.933 2011 1.907.924 1.361.705 2.451.144 1.254.902 1.968.423 3.378.361 976.633 2001 1.3012.065 1.354.950 1.364.950 1.364.950 1.364.950 1.364.948 884.355 2001 1.304.303 1.652.841 2.448.	2007	3,578,721	2,814,702	4,342,740	2,489,324	1,855,080	3,123,568	1,089,397	645,159	1,533,636
2011 2,07,312 2,110,43 3,303,580 1,469,487 1,450,467 1,118,1865 2,2296 857,355 497,666 1,218,250 2013 2,286,535 1,759,576 2,817,493 1,525,320 1,092,500 1,555,513 763,215 452,575 1,073,854 2003 1,625,660 1,110,178 2,141,161 84,4344 500,544 1,180,144 780,825 376,074 1,185,577 2005 2,460,019 1,821,518 3,116,530 1,007,224 1,044,080 2,004,064 901,204 753,012 407,095 1,088,118 20007 2,460,019 1,823,714 1,405,104 2,804,024 2,304,302 885,147 548,115 1,282,978 2011 1,007,944 1,361,705 2,461,408 1,311,431 817,221 1,775,65 600,062 316,949 844,353 2015 1,078,048 680,743 1,442,074 441,658 423,077 81,27871 1,776,355 600,00,622 316,949 844,353 565,840 0,223,077	2009	3,410,271	2,749,052	4,071,491	2,379,363	1,828,276	2,930,449	1,030,909	649,260	1,412,557
2013 2.510.411 1.909.600 3.111.191 1.652.467 1.181.905 2.122.900 857.953 497.666 1.218.200 2015 2.288.535 1.769.676 2.817.493 1.622.509 1.968.131 763.215 452.675 1.073.854 2003 1.625.669 1.110.178 2.141.161 844.844 509.644 1.180.144 780.825 376.074 1.85.777 2006 2.460.019 1.82.138 3.116.520 1.767.101 1.901.244 783.012 477.905 1.382.784 2007 2.160.162 1.662.019 2.757.704 1.407.150 90.0628 30.328.847 797.66.33 228.978 2011 1.907.924 1.361.705 2.451.144 1.254.072 2.90.321.876 653.832 316.949 884.355 2013 1.971.872 1.625.848 3.71.818 2.01.688 287.770 338.947 796.633 2006 1.078.681 588.153 1.566.086 503.919 2.23.707 784.275 574.102 574.290 <tr< td=""><td>2011</td><td>2,707,312</td><td>2,111,043</td><td>3,303,580</td><td>1,971,377</td><td>1,450,806</td><td>2,491,948</td><td>735,935</td><td>449,695</td><td>1,022,174</td></tr<>	2011	2,707,312	2,111,043	3,303,580	1,971,377	1,450,806	2,491,948	735,935	449,695	1,022,174
$\begin{array}{c c c c c c c c c c c c c c c c c c c $	2013	2,510,411	1,909,630	3.111.191	1.652.457	1.181.965	2,122,950	857,953	497,656	1.218.250
$ \begin{array}{ c c c c c c c c c c c c c c c c c c c$	2015	2.288.535	1.759.576	2.817.493	1.525.320	1.092.509	1.958.131	763.215	452,575	1.073.854
$\begin{array}{c c c c c c c c c c c c c c c c c c c $		_,,	-,,	_,,	Canna	abis	1,000,101	,	,	2,010,000
$\begin{array}{c c c c c c c c c c c c c c c c c c c $	2003	1.625.669	1 110 178	2 141 161	844 844	509 544	1 180 144	780 825	376.074	1 185 577
$ \begin{array}{c c c c c c c c c c c c c c c c c c c $	2005	2 469 019	1 821 518	3 116 520	1 567 729	1 044 808	2 090 649	901 290	473 796	1 328 784
2009 2.683,057 2.033,101 3.334,810 1.725,410 4.2864,27 2.304,392 504,101 1.283,975 2011 1.907,924 1.361,705 2.444,144 1.254,092 880,903 1.687,281 653,832 37,972 449,693 2013 2.671,872 1.625,383 3.718,83 2.014,802 1.006,783 3021,787 663,732 316,949 884,355 2003 1.036,408 630,743 1.442,074 461,636 225,078 698,195 574,772 224,185 925,358 2007 1.203,439 753,328 1.653,008 600,391 223,077 784,273 574,690 224,185 925,258 2007 1.203,439 753,328 1.653,008 800,217 449,257 803,683 303,558 125,956 481,161 2010 130,029 50,108 1.544,947 1.307,682 582,003 271,613 892,933 346,578 118,935 574,220 2011 193,044 324,663 342,320 *	2007	2,160,162	1 562 619	2 757 704	1,007,150	904.006	1 910 294	753.012	407 905	1,028,101
2000 2000,7924 1,301,70 2,444,14 1,254,1092 820,003 1,687,281 653,832 357,877 742,178 2013 2,671,872 1,625,583 3,718,361 2,014,082 1,006,378 3,021,787 667,790 338,947 976,633 2003 1,032,605 1,332,664 2,411,661 1,311,41 847,271 1,775,555 600,052 316,949 884,553 2003 1,036,408 630,743 1,442,046 1,311,41 847,271 7784,275 574,000 253,558 894,622 2007 1,203,430 753,280 1,653,690 861,915 488,901 1,234,930 341,524 109,808 573,240 2006 1170101.0 734,182 1,607,862 582,003 271,613 892,393 346,578 118,895 574,220 2015 937,384 527,874 1,346,894 529,487 250,999 807,975 407,897 144,120 671,674 2007 245,514 247,814 446 352,570	2001	2,100,102	2 033 104	3 334 810	1 795 410	1 286 427	2 304 392	888 547	548 116	1 228 978
	2003	1 907 924	1 361 705	2 454 144	1,755,410	820 003	1 687 281	653 832	357 072	949 693
$ \begin{array}{c c c c c c c c c c c c c c c c c c c $	2011	2,671,924	1,001,700	2,404,144	2 014 082	1 006 278	2 021 787	657 700	228 047	076 622
	2015	1,012,065	1,020,000	2 401 466	1 911 419	947.971	1 775 555	600.652	216 040	970,055
$\begin{array}{c c c c c c c c c c c c c c c c c c c $	2015	1,912,005	1,352,004	2,491,400	1,511,415 Mothemph	047,271	1,775,555	000,052	510,949	004,000
$ \begin{array}{c c c c c c c c c c c c c c c c c c c $	2002	1 026 408	620 742	1 449 074	461 626	225.078	608 105	574 779	994 195	025 259
$ \begin{array}{c c c c c c c c c c c c c c c c c c c $	2005	1,030,408	599 159	1,442,074	502.001	223,018	784 975	574,000	224,100	920,000 804 699
$ \begin{array}{c c c c c c c c c c c c c c c c c c c $	2003	1,070,001	752.280	1,508,008	961.015	488.001	1 994 020	241 594	100 808	572 240
$ \begin{array}{c c c c c c c c c c c c c c c c c c c $	2007	1,205,455	794 199	1,005,000	602.661	221 784	999 599	568 240	244 158	802 522
$\begin{array}{c c c c c c c c c c c c c c c c c c c $	2003	820.020	505 108	1,007,021	526 470	240.257	802.682	202 559	125.056	481 161
$ \begin{array}{c c c c c c c c c c c c c c c c c c c $	2011	028 581	540,470	1,104,500	582.002	243,237	802,003	246 578	118 025	574 220
$\begin{array}{c c c c c c c c c c c c c c c c c c c $	2015	920,001	597 874	1,307,002	529.487	271,013	807.975	407 897	144 120	671.674
$\begin{array}{c c c c c c c c c c c c c c c c c c c $	2015	337,304	521,614	1,040,004	525,407 Horo	200,999	801,915	407,837	144,120	071,074
$\begin{array}{c c c c c c c c c c c c c c c c c c c $	2003	250 292	46 103	454 481	*	*	*	*	*	*
$\begin{array}{c c c c c c c c c c c c c c c c c c c $	2005	187.947	32 663	343 230	*	*	*	*	*	*
$\begin{array}{c c c c c c c c c c c c c c c c c c c $	2005	245 514	24 782	466 245	203 468	35 570	371 367	*	*	*
$\begin{array}{c c c c c c c c c c c c c c c c c c c $	2007	139 300	13 092	265 509	99 561	502	198 621	*	*	*
$\begin{array}{c c c c c c c c c c c c c c c c c c c $	2003	148 309	26 256	270,363	*	*	*	117 023	8 842	225 204
$\begin{array}{c c c c c c c c c c c c c c c c c c c $	2011	*	*	*	*	*	*	*	*	*
$\begin{array}{c c c c c c c c c c c c c c c c c c c $	2015	156 910	21 955	291 864	143 305	11.033	275 577	*	*	*
$\begin{array}{c ccccccccccccccccccccccccccccccccccc$	2010	100,010	1,000	201,001	Cocai	ne	210,011			
$\begin{array}{c c c c c c c c c c c c c c c c c c c $	2003	343.025	101 546	$584\ 504$	227 511	47 742	407 280	*	*	*
$\begin{array}{c c c c c c c c c c c c c c c c c c c $	2005	445.093	163 654	726 532	298.031	56 370	539 693	147.062	1 406	292 717
$\begin{array}{c c c c c c c c c c c c c c c c c c c $	2007	408 925	127 275	690 575	249 214	38.013	460 415	*	*	*
$\begin{array}{c c c c c c c c c c c c c c c c c c c $	2001	400,520	138 889	712 245	171.807	21 630	321 984	253 760	39 906	467 614
$\begin{array}{c c c c c c c c c c c c c c c c c c c $	2003	228,307	79 568	377.070	*	*	*	160.824	34 994	286 654
$\begin{array}{c c c c c c c c c c c c c c c c c c c $	2011	319 198	116 423	521 973	168 863	19 550	318 176	150 335	12 551	288,120
$\begin{array}{c c c c c c c c c c c c c c c c c c c $	2015	204 813	53 320	356 305	173 398	28 470	318 326	*	*	*
2003284,15789,892478,422***156,65910,259303,0582005199,47021,993376,947*********2007500,445213,622787,269337,08897,954576,222****2009571,689269,053874,324169,46118,247320,676402,227165,065639,3902011226,18773,289379,086120,73910,157231,320105,4497,335203,5632013421,940161,430682,449246,87861,407432,350****2015583,660275,375891,946323,954126,794521,114259,70768,133451,280NPSs2015520,545190,934850,155294,740972588,508225,80470,100381,509Any drug20034,496,2713,685,9645,306,5772,686,6302,157,9713,215,2901,809,6401,219,3912,399,89020054,854,5693,934,0995,775,0392,737,9552,058,1963,417,7142,116,6141,496,5842,736,64420075,299,1424,372,9916,225,2933,455,3082,694,4454,216,1701,843,8341,297,6202,390,04820096,114,8925,211,8897,017,8943,912,5213,228,7074,596,3362,202,371 <td>2010</td> <td>201,010</td> <td>55,620</td> <td>550,000</td> <td>MDN</td> <td>1A</td> <td>010,020</td> <td></td> <td>L</td> <td></td>	2010	201,010	55,620	550,000	MDN	1A	010,020		L	
2005 $199,470$ $21,993$ $376,947$ ******* 2007 $500,445$ $213,622$ $787,269$ $337,088$ $97,954$ $576,222$ **** 2009 $571,689$ $269,053$ $874,324$ $169,461$ $18,247$ $320,676$ $402,227$ $165,065$ $639,390$ 2011 $226,187$ $73,289$ $379,086$ $120,739$ $10,157$ $231,320$ $105,449$ $7,335$ $203,563$ 2013 $421,940$ $161,430$ $682,449$ $246,878$ $61,407$ $432,350$ *** 2015 $583,660$ $275,375$ $891,946$ $323,954$ $126,794$ $521,114$ $259,707$ $68,133$ $451,280$ 2015 $520,545$ $190,934$ $850,155$ $294,740$ 972 $588,508$ $225,804$ $70,100$ $381,509$ 2015 $520,545$ $190,934$ $850,155$ $294,740$ 972 $588,508$ $225,804$ $70,100$ $381,509$ 2003 $4,496,271$ $3,685,964$ $5,306,577$ $2,686,630$ $2,157,971$ $3,215,290$ $1,809,640$ $1,219,391$ $2,399,890$ 2005 $4,854,569$ $3,934,099$ $5,775,039$ $2,737,955$ $2,058,196$ $3,417,714$ $2,116,614$ $1,496,584$ $2,736,644$ 2007 $5,299,142$ $4,372,991$ $6,225,293$ $3,455,308$ $2,694,445$ $4,216,170$ $1,843,834$ $1,297,620$ $2,390,048$ 2009 $6,114,89$	2003	284 157	89 892	478 422	*	*	*	156 659	10 259	303 058
$\begin{array}{c c c c c c c c c c c c c c c c c c c $	2005	199 470	21 993	376 947	*	*	*	*	*	*
2009571,689269,053874,324169,46118,247320,676402,227165,065639,3902011226,18773,289379,086120,73910,157231,320105,4497,335203,5632013421,940161,430682,449246,87861,407432,350****2015583,660275,375891,946323,954126,794521,114259,70768,133451,280NPSs2015520,545190,934850,155294,740972588,508225,80470,100381,509Number of the second seco	2007	500 445	213 622	787 269	337 088	97 954	576 222	*	*	*
$\begin{array}{c c c c c c c c c c c c c c c c c c c $	2009	571 689	269.053	874 324	169 461	18 247	320 676	402 227	165 065	639 390
$\begin{array}{c c c c c c c c c c c c c c c c c c c $	2011	226 187	73 289	379.086	120 739	10.157	231 320	105 449	7 335	203 563
$\begin{array}{c c c c c c c c c c c c c c c c c c c $	2013	421 940	161 430	682 449	246 878	61 407	432 350	*	*	*
2010 300,000 210,010 601,010 612,011 120,011 612,011 600,100 101,200 NPSs 2015 520,545 190,934 850,155 294,740 972 588,508 225,804 70,100 381,509 Any drug 2003 4,496,271 3,685,964 5,306,577 2,686,630 2,157,971 3,215,290 1,809,640 1,219,391 2,399,890 2005 4,854,569 3,934,099 5,775,039 2,737,955 2,058,196 3,417,714 2,116,614 1,496,584 2,736,644 2007 5,299,142 4,372,991 6,225,293 3,455,308 2,694,445 4,216,170 1,843,834 1,297,620 2,390,048 2009 6,114,892 5,211,889 7,017,894 3,912,521 3,228,707 4,596,336 2,202,371 1,587,472 2,817,269 2011 4,345,720 3,537,799 5,153,642 2,947,843 2,272,755 3,622,931 1,397,877 969,168 1,826,587	2015	583 660	275 375	891 946	323 954	126 794	521 114	259 707	68 133	451 280
2015520,545190,934850,155294,740972588,508225,80470,100381,509Any drug20034,496,2713,685,9645,306,5772,686,6302,157,9713,215,2901,809,6401,219,3912,399,89020054,854,5693,934,0995,775,0392,737,9552,058,1963,417,7142,116,6141,496,5842,736,64420075,299,1424,372,9916,225,2933,455,3082,694,4454,216,1701,843,8341,297,6202,390,04820096,114,8925,211,8897,017,8943,912,5213,228,7074,596,3362,202,3711,587,4722,817,26920114,345,7203,537,7995,153,6422,947,8432,272,7553,622,9311,397,877969,1681,826,58720134,644,8703,461,8375,827,9043,145,6872,061,8274,229,5481,499,1831,039,0051,959,36220153,827,3743,062,4224,592,3272,329,7361,771,8972,887,5741,497,6381,039,7391,955,537*:Within the range of statistical errors: The lower limit of confidence interval is <0.	2010		,010	001,010		is	~ - 1,117		00,100	101,200
2016 316,010 100,001 201,110 012 012 000,000 122,001 100,000 Any drug 2003 4,496,271 3,685,964 5,306,577 2,686,630 2,157,971 3,215,290 1,809,640 1,219,391 2,399,890 2005 4,854,569 3,934,099 5,775,039 2,737,955 2,058,196 3,417,714 2,116,614 1,496,584 2,736,644 2007 5,299,142 4,372,991 6,225,293 3,455,308 2,694,445 4,216,170 1,843,834 1,297,620 2,390,048 2009 6,114,892 5,211,889 7,017,894 3,912,521 3,228,707 4,596,336 2,202,371 1,587,472 2,817,269 2011 4,345,720 3,537,799 5,153,642 2,947,843 2,272,755 3,622,931 1,397,877 969,168 1,826,587 2013 4,644,870 3,461,837 5,827,904 3,145,687 2,061,827 4,229,548 1,499,183 1,039,005 1,959,362 2015 3,827,374	2015	520 545	190 934	850 155	294 740	972	588 508	225 804	70 100	381 509
20034,496,2713,685,9645,306,5772,686,6302,157,9713,215,2901,809,6401,219,3912,399,89020054,854,5693,934,0995,775,0392,737,9552,058,1963,417,7142,116,6141,496,5842,736,64420075,299,1424,372,9916,225,2933,455,3082,694,4454,216,1701,843,8341,297,6202,390,04820096,114,8925,211,8897,017,8943,912,5213,228,7074,596,3362,202,3711,587,4722,817,26920114,345,7203,537,7995,153,6422,947,8432,272,7553,622,9311,397,877969,1681,826,58720134,644,8703,461,8375,827,9043,145,6872,061,8274,229,5481,499,1831,039,0051,959,36220153,827,3743,062,4224,592,3272,329,7361,771,8972,887,5741,497,6381,039,7391,955,537*Within the range of statistical errors: The lower limit of confidence interval is <0.	2010	0-0,010	100,001	000,100	Anv_d	rug	000,000	0,004		001,000
$\begin{array}{c c c c c c c c c c c c c c c c c c c $	2003	4,496.271	3,685.964	5,306.577	2,686.630	2,157.971	3,215.290	1,809.640	1,219.391	2,399.890
$\begin{array}{c c c c c c c c c c c c c c c c c c c $	2005	4,854,569	3,934,099	5,775.039	2,737,955	2,058,196	3,417.714	2,116.614	1,496.584	2,736.644
$\begin{array}{c c c c c c c c c c c c c c c c c c c $	2007	5,299,142	4,372,991	6,225,293	3,455,308	2,694,445	4,216,170	1.843.834	1,297.620	2,390.048
2011 4,345,720 3,537,799 5,153,642 2,947,843 2,272,755 3,622,931 1,397,877 969,168 1,826,587 2013 4,644,870 3,461,837 5,827,904 3,145,687 2,061,827 4,229,548 1,499,183 1,039,005 1,959,362 2015 3,827,374 3,062,422 4,592,327 2,329,736 1,771,897 2,887,574 1,497,638 1,039,739 1,955,537 *Within the range of statistical errors: The lower limit of confidence interval is <0.	2009	6,114.892	5,211.889	7,017.894	3,912.521	3,228.707	4,596.336	2,202.371	1,587.472	2,817.269
$\begin{array}{c ccccccccccccccccccccccccccccccccccc$	2011	4,345.720	3,537.799	5,153.642	2,947.843	2,272.755	3,622.931	1,397.877	969.168	1,826.587
$\begin{array}{c ccccccccccccccccccccccccccccccccccc$	2013	4,644.870	3,461.837	5,827.904	3,145.687	2,061.827	4,229.548	1,499.183	1,039.005	1,959.362
*:Within the range of statistical errors: The lower limit of confidence interval is <0.	2015	3,827,374	3,062,422	4,592,327	2,329,736	1,771,897	2,887,574	1,497,638	1,039,739	1,955,537
	*:Within t	he range of st	atistical er	rors: The lo	wer limit of co	onfidence ir	nterval is <	0.		

Table 65 Estimated Number of Individuals with Lifetime Experience of Ever Having Try to Tempt Illegal Drugs (Lower Limit–Upper Limit)

	Organic	Cannabis	Metham	Heroin	Cocaine	MDMA	NPSs	Any drug
	solvents		phetami					
			ne					
1995	0.16%	0.25%	0.07%	0.00%	0.05%	-	-	0.43%
1997	0.09%	0.26%	0.00%	0.13%	0.03%	-	-	0.42%
1999	0.04%	0.12%	0.10%	0.03%	0.03%	-	-	0.20%
2001	0.03%	0.30%	0.07%	0.03%	0.03%	-	-	0.30%
2003	0.04%	0.12%	0.07%	0.00%	0.00%	0.00%	-	0.23%
2005	0.06%	0.15%	0.00%	0.00%	0.00%	0.06%	-	0.20%
2007	0.07%	0.20%	0.18%	0.03%	0.07%	0.13%	-	0.47%
2009	0.00%	0.12%	0.03%	0.03%	0.00%	0.03%	-	0.19%
2011	0.00%	0.10%	0.00%	0.00%	0.00%	0.00%	-	0.20%
2015	0.10%	0.03%	0.00%	0.00%	0.03%	0.00%	0.07%	0.20%

Table 66 Changes in the Past-Year Prevalence of xperience of Ever Having Try to Tempt Illegal Drugs (1995–2015) No data for 2013

Table 67Changes in the Lifetime Prevalence of Drug Use (1995–2015)

	Organic	Cannabis	Metham	Cocaine	Heroin	MDMA	NPSs	Any drug
	solvents		phetami					
			ne					
1995	1.7%	0.5%	0.3%	*	*	-	-	2.2%
1997	1.9%	0.6%	0.3%	*	*	-	-	2.5%
1999	1.7%	1.0%	0.4%	0.2%	*	-	-	2.6%
2001	2.0%	1.1%	0.3%	0.1%	*	-	-	2.7%
2003	1.5%	0.5%	0.4%	0.1%	*	*	-	2.0%
2005	1.3%	1.2%	0.3%	*	*	*	-	2.2%
2007	2.0%	0.8%	0.4%	*	*	0.2%	-	2.6%
2009	1.9%	1.4%	0.3%	*	*	0.2%	-	2.9%
2011	1.6%	1.2%	0.4%	*	*	0.1%	-	2.7%
2013	1.9%	1.1%	0.5%	*	*	0.3%	0.4%	2.5%
2015	1.5%	1.0%	0.5%	0.1%	*	0.1%	0.3%	2.4%

*:Within the range of statistical errors



Fig.33 Estimated Lifetime Prevalence of Drug use (1995-2015)

Table 68 Estimated Number of Individuals with Lifetime Experience of Drug Use (Lower Limit–Upper Limit)

		Overall			Men		Women		
	Number of individuals with lifetime experience	Lower limit	Upper limit	Number of individuals with lifetime experience	Lower limit	Upper limit	Number of individuals with lifetime experience	Lower limit	Upper limit
	experience			Owner			experience		
2002	1 504 001	1 000 000	2 240 005	Organic	solvents	1 414 001	555.000	050.005	000 00 1
2003	1,764,691	1,260,296	2,269,087	1,206,730	799,180	1,614,281	557,960	279,227	836,694
2005	1,560,170	1,047,149	2,073,191	896,139	514,780	1,277,498	664,031	306,047	1,022,015
2007	2,444,351	1,822,901	3,065,802	1,770,256	1,243,471	2,297,040	674,095	323,374	1,024,817
2009	1,798,329	1,299,177	2,297,482	1,412,115	983,657	1,840,572	386,214	146,849	625,580
2011	1,477,421	1,022,845	1,931,998	1,104,593	677,149	1,032,036	372,828	197,859	020,200
2013	1,825,432	1,279,188	2,371,675	1,217,329	799,429	1,635,229	608,103	283,883	932,322
2015	1,381,847	936,570	1,827,123	967,540	591,199	1,343,881	414,307	190,067	638,546
2002	FF0 202	271 100	220 410	299.190	142.014	699.969	100 114	0.909	220.200
2005	1 416 502	271,190	1 041 167	079,619	522.460	022,303	100,114	0,005	529,500
2005	1,410,595	500.082	1,941,107	780.408	020,400 411,699	1,421,775	445,975	140,755	147,195
2007	1,014,207	000 897	1,450,550	1 070 441	411,002	1,107,155	224,790	41,207	408,390
2009	1,303,903	909,827 601.848	1,010,102	759 250	270,512	1,455,672	295,524	92,500 145.720	494,402
2011	1,130,402	667.074	1,004,900	797,070	379,010	1,137,204	005 040	145,750 60,470	501.014
2015	1,075,212	596 147	1,479,550	796 455	442,240	1,155,095	200,242	09,470 26.546	280 502
2015	945,024	560,147	1,505,901	Mothemn	440,709	1,027,132	208,509	30,340	380,392
2003	108 0 18	222 751	764 145	237 800	110 491	565 378	161.049	4.956	21 714
2005	315 989	200,849	600 722	*	*	*	202 512	4,550	402.211
2005	527.400	20,842	848 640	2/1 882	70.828	603 030	203,513	4,014	402,211
2007	327,409	192.634	522 278	212 022	19,020	377.655	*	*	*
2003	323,000	145 017	616 697	212,023	40,331	405 741	160 558	24.027	204 178
2011	510 721	236 800	802.642	211,714	107 800	529 952	201.346	10.516	304,175
2015	501 556	235,566	767 545	138 853	107,855	682 255	*	*	\$
2015	301,330	235,500	707,545	438,833 Hor	190,402	082,200			
2003	*	*	*	*	*	*	180 206	16 296	344 116
2005	*	*	*	*	*	*	#	#	#
2007	*	*	*	*	*	*	#	#	#
2009	#	#	#	#	#	#	#	#	#
2000	#	#	#	#	#	#	#	#	#
2013	*	*	*	*	*	*	*	*	*
2015	*	*	*	*	*	*	#	#	#
				Coc	aine				
2003	*	*	*	*	*	*	#	#	#
2005	*	*	*	*	*	*	#	#	#
2007	*	*	*	*	*	*	*	*	*
2009	215,032	13,751	416,312	*	*	*	*	*	*
2011	*	*	*	*	*	*	#	#	#
2013	*	*	*	*	*	*	*	*	*
2015	118,177	11,248	225,106	118,177	11,248	225,106	#	#	#
				MD	MA				
2003	*	*	*	#	#	#	*	*	*
2005	*	*	*	*	*	*	*	*	*
2007	232,984	24,111	441,857	*	*	*	*	*	*
2009	207,868	35,795	379,942	*	*	*	138,278	1,844	274,711
2011	140,042	18,831	261,252	*	*	*	*	*	*
2013	260,762	45,744	475,780	160,167	5,822	314,511	*	*	*
2015	117,550	17,683	217,417	88,694	6,551	170,838	*	*	*
				NF	Ss				
2013	399,773	168,771	630,774	299,080	91,609	506,551	*	*	*
2015	309,735	109,761	509,709	216,976	52,866	381,087	*	*	*
				Any	drug				
2003	2,373,965	1,769,084	2,978,845	$1,5\overline{52,576}$	1,081,467	2,023,685	821,389	462,480	1,180,298
2005	2,663,656	1,929,692	3,397,619	1,600,222	1,036,384	2,164,059	1,063,434	603,972	1,522,896
2007	3,086,607	2,400,434	3,772,780	2,114,588	1,544,277	2,684,899	972,019	571,793	1,372,245
2009	2,768,501	2,127,456	3,409,546	2,081,449	1,573,077	2,589,522	687,052	358,204	1,015,899
2011	2,510,211	1,896,082	3,124,340	1,830,861	1,280,232	2,381,489	679,350	398,721	959,980
2013	2,489,112	1,830,464	3,147,760	1,699,196	1,186,374	2,212,018	789,916	440,585	1,139,246
2015	2,225,266	1,652,598	2,797,934	1,636,768	1,164,391	2,109,145	588,498	313,346	863,649

*:Within the range of statistical errors: The lower limit of confidence interval is <0.

#:No respondent: No estimates could be calculated due to the absence of respondents.

	Organic	Cannabis	Metham	Heroin	Cocaine	MDMA	NPSs	Any drug
	solvents		phetami					
			ne					
1995	0.08%	0.07%	0.06%	0.00%	0.06%	-	-	0.16%
1997	0.02%	0.10%	0.06%	0.02%	0.02%	-	-	0.14%
1999	0.04%	0.04%	0.07%	0.03%	0.03%	-	-	0.13%
2001	0.00%	0.11%	0.00%	0.00%	0.03%	-	-	0.16%
2003	0.07%	0.00%	0.00%	0.00%	0.00%	0.00%	-	0.07%
2005	0.00%	0.04%	0.00%	0.00%	0.00%	0.00%	-	0.04%
2007	0.00%	0.04%	0.00%	0.00%	0.00%	0.00%	-	0.04%
2009	0.00%	0.03%	0.00%	0.00%	0.00%	0.00%	-	0.03%
2011	0.00%	0.10%	0.00%	0.00%	0.00%	0.00%	-	0.10%
2013	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.10%	0.10%
2015	0.07%	0.07%	0.00%	0.00%	0.00%	0.00%	0.00%	0.13%

Table 69 Changes in the Past-Year Prevalence of Drug Use (1995–2015)

Table E Number and Age(mean,SD) of Individuals with Lifetime Experience of Drug Use

		2015			2013	
drugs	number a	ge(mean)	SD	number	age(mean)	SD
Organic solvents	49	47.9	10.5	54	43.8	9.4
Cannabis	35	41.3	9.8	30	40.7	9.5
Methamphetamine	16	44.1	8.9	14	40.1	9.0
MDMA	6	40.0	9.4	6	40.5	8.1
Cocaine	5	45.4	6.7	2	36.5	
Heroin	3	45.7	4.9	2	43.0	
NPSs	11	40.8	10.4	12	33.8	8.1
Any drug	78	45.5	11.1	72	42.5	9.8

